before	IN	O
using	VBG	O
this	DT	O
medication	NN	O
","	","	O
tell	VB	O
your	PRP$	O
doctor	NN	O
or	CC	O
pharmacist	NN	O
of	IN	O
all	DT	O
prescription	NN	O
and	CC	O
nonprescription	NN	O
products	NNS	O
you	PRP	O
may	MD	O
use	VB	O
","	","	O
especially	RB	O
of	IN	O
:	:	O
aminoglycosides	NNS	G
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
gentamicin	NN	D
","	","	O
amikacin	NN	D
-rrb-	-RRB-	O
","	","	O
amphotericin	NN	O
b	NN	O
","	","	O
cyclosporine	NN	D
","	","	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	D
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
ibuprofen	NN	D
-rrb-	-RRB-	O
","	","	O
tacrolimus	NN	D
","	","	O
vancomycin	NN	D
.	.	.
		
do	VB	O
not	RB	O
start	VB	O
or	CC	O
stop	VB	O
any	DT	O
medicine	NN	O
without	IN	O
doctor	NN	O
or	CC	O
pharmacist	NN	O
approval	NN	O
.	.	.
		
intravenous	JJ	O
adenocard	NN	B
-lrb-	-LRB-	O
adenosine	NN	D
-rrb-	-RRB-	O
has	VBZ	O
been	VBN	O
effectively	RB	O
administered	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
other	JJ	O
cardioactive	JJ	O
drugs	NNS	D
","	","	O
such	JJ	O
as	IN	O
quinidine	NN	D
","	","	O
beta-adrenergic	JJ	O
blocking	VBG	O
agents	NNS	O
","	","	O
calcium	NN	D
channel	NN	O
blocking	VBG	O
agents	NNS	O
","	","	O
and	CC	O
angiotensin	NN	O
converting	NN	O
enzyme	NN	O
inhibitors	NNS	O
","	","	O
without	IN	O
any	DT	O
change	NN	O
in	IN	O
the	DT	O
adverse	JJ	O
reaction	NN	O
profile	NN	O
.	.	.
		
digoxin	NN	D
and	CC	O
verapamil	NN	D
use	NN	O
may	MD	O
be	VB	O
rarely	RB	O
associated	VBN	O
with	IN	O
ventricular	JJ	O
fibrillation	NN	O
when	WRB	O
combined	VBN	O
with	IN	O
adenocard	NNP	B
.	.	.
		
because	IN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
additive	JJ	O
or	CC	O
synergistic	JJ	O
depressant	NN	O
effects	NNS	O
on	IN	O
the	DT	O
sa	NNP	O
and	CC	O
av	NNP	O
nodes	NNS	O
","	","	O
however	RB	O
","	","	O
adenocard	NNP	B
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
these	DT	O
agents	NNS	O
.	.	.
		
the	DT	O
use	NN	O
of	IN	O
adenocard	NNP	B
in	IN	O
patients	NNS	O
receiving	VBG	O
digitalis	NN	G
may	MD	O
be	VB	O
rarely	RB	O
associated	VBN	O
with	IN	O
ventricular	JJ	O
fibrillation	NN	O
.	.	.
		
the	DT	O
effects	NNS	O
of	IN	O
adenosine	NN	D
are	VBP	O
antagonized	VBN	O
by	IN	O
methylxanthines	NNS	G
such	JJ	O
as	IN	O
caffeine	NN	D
and	CC	O
theophylline	NN	D
.	.	.
		
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
these	DT	O
methylxanthines	NNS	G
","	","	O
larger	JJR	O
doses	NNS	O
of	IN	O
adenosine	NN	D
may	MD	O
be	VB	O
required	VBN	O
or	CC	O
adenosine	NN	D
may	MD	O
not	RB	O
be	VB	O
effective	JJ	O
.	.	.
		
adenosine	NN	D
effects	NNS	O
are	VBP	O
potentiated	VBN	O
by	IN	O
dipyridamole	NN	D
.	.	.
		
thus	RB	O
","	","	O
smaller	JJR	O
doses	NNS	O
of	IN	O
adenosine	NN	D
may	MD	O
be	VB	O
effective	JJ	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
dipyridamole	NN	D
.	.	.
		
carbamazepine	NNP	D
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
increase	VB	O
the	DT	O
degree	NN	O
of	IN	O
heart	NN	O
block	NN	O
produced	VBN	O
by	IN	O
other	JJ	O
agents	NNS	O
.	.	.
		
as	IN	O
the	DT	O
primary	JJ	O
effect	NN	O
of	IN	O
adenosine	NN	D
is	VBZ	O
to	TO	O
decrease	VB	O
conduction	NN	O
through	IN	O
the	DT	O
a-v	NN	O
node	NN	O
","	","	O
higher	JJR	O
degrees	NNS	O
of	IN	O
heart	NN	O
block	NN	O
may	MD	O
be	VB	O
produced	VBN	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
carbamazepine	NN	D
.	.	.
		
co-administration	NN	O
with	IN	O
antifungal	JJ	O
agents	NNS	O
such	JJ	O
as	IN	O
ketoconazole	NN	D
or	CC	O
itraconazole	NN	D
is	VBZ	O
not	RB	O
recommended	VBN	O
.	.	.
		
nafazodone	NNP	D
","	","	O
fluvoxamine	NN	D
","	","	O
cimetidine	NN	D
-lrb-	-LRB-	O
consider	VB	O
xanax	NNP	B
dose	NN	O
reduction	NN	O
-rrb-	-RRB-	O
.	.	.
		
fluoxetine	NNP	D
","	","	O
ocs	NNP	G
","	","	O
sertraline	NN	D
","	","	O
diltiazem	NN	D
","	","	O
macrolide	NN	O
antibiotics	NNS	G
-lrb-	-LRB-	O
exercise	NN	O
caution	NN	O
-rrb-	-RRB-	O
.	.	.
		
no	DT	O
drug	NN	D
interaction	NN	O
studies	NNS	O
were	VBD	O
performed	VBN	O
.	.	.
		
no	DT	O
in	FW	O
vitro	FW	O
metabolism	NN	O
studies	NNS	O
were	VBD	O
performed	VBN	O
.	.	.
		
dexamethasone	NN	D
:	:	O
steady-state	JJ	O
trough	NN	O
concentrations	NNS	O
of	IN	O
albendazole	NN	D
sulfoxide	NN	O
were	VBD	O
about	IN	O
56	CD	O
%	NN	O
higher	JJR	O
when	WRB	O
8	CD	O
mg	NN	O
dexamethasone	NN	D
was	VBD	O
coadministered	VBN	O
with	IN	O
each	DT	O
dose	NN	O
of	IN	O
albendazole	NN	D
-lrb-	-LRB-	O
15	CD	O
mg/kg/day	NN	O
-rrb-	-RRB-	O
in	IN	O
eight	CD	O
neurocysticercosis	NN	O
patients	NNS	O
.	.	.
		
praziquantel	NNP	D
:	:	O
in	IN	O
the	DT	O
fed	NN	O
state	NN	O
","	","	O
praziquantel	NN	D
-lrb-	-LRB-	O
40	CD	O
mg/kg	NN	O
-rrb-	-RRB-	O
increased	VBD	O
mean	JJ	O
maximum	NN	O
plasma	NN	O
concentration	NN	O
and	CC	O
area	NN	O
under	IN	O
the	DT	O
curve	NN	O
of	IN	O
albendazole	NN	D
sulfoxide	NN	O
by	IN	O
about	IN	O
50	CD	O
%	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
-lrb-	-LRB-	O
n	NN	O
=	JJ	O
10	CD	O
-rrb-	-RRB-	O
compared	VBN	O
with	IN	O
a	DT	O
separate	JJ	O
group	NN	O
of	IN	O
subjects	NNS	O
-lrb-	-LRB-	O
n	NN	O
=	JJ	O
6	CD	O
-rrb-	-RRB-	O
given	VBN	O
albendazole	NN	D
alone	RB	O
.	.	.
		
mean	NN	O
t	NN	O
max	NN	O
and	CC	O
mean	VB	O
plasma	NN	O
elimination	NN	O
half-life	NN	O
of	IN	O
albendazole	NN	D
sulfoxide	NN	O
were	VBD	O
unchanged	JJ	O
.	.	.
		
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
praziquantel	NN	D
were	VBD	O
unchanged	JJ	O
following	VBG	O
coadministration	NN	O
with	IN	O
albendazole	NN	D
-lrb-	-LRB-	O
400	CD	O
mg	NN	O
-rrb-	-RRB-	O
.	.	.
		
cimetidine	NNP	D
:	:	O
albendazole	NNP	O
sulfoxide	NN	O
concentrations	NNS	O
in	IN	O
bile	NN	O
and	CC	O
cystic	JJ	O
fluid	NN	O
were	VBD	O
increased	VBN	O
-lrb-	-LRB-	O
about	IN	O
2-fold	JJ	O
-rrb-	-RRB-	O
in	IN	O
hydatid	NN	O
cyst	NN	O
patients	NNS	O
treated	VBN	O
with	IN	O
cimetidine	NN	D
-lrb-	-LRB-	O
10	CD	O
mg/kg/day	NN	O
-rrb-	-RRB-	O
-lrb-	-LRB-	O
n	NN	O
=	JJ	O
7	CD	O
-rrb-	-RRB-	O
compared	VBN	O
with	IN	O
albendazole	NN	D
-lrb-	-LRB-	O
20	CD	O
mg/kg/day	NN	O
-rrb-	-RRB-	O
alone	RB	O
-lrb-	-LRB-	O
n	NN	O
=	JJ	O
12	CD	O
-rrb-	-RRB-	O
.	.	.
		
albendazole	NNP	O
sulfoxide	NN	O
plasma	NN	O
concentrations	NNS	O
were	VBD	O
unchanged	JJ	O
4	CD	O
hours	NNS	O
after	IN	O
dosing	NN	O
.	.	.
		
theophylline	NNP	D
:	:	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	D
-lrb-	-LRB-	O
aminophylline	NN	D
5.8	CD	O
mg/kg	NN	O
infused	VBD	O
over	IN	O
20	CD	O
minutes	NNS	O
-rrb-	-RRB-	O
were	VBD	O
unchanged	JJ	O
following	VBG	O
a	DT	O
single	JJ	O
oral	JJ	O
dose	NN	O
of	IN	O
albendazole	NN	D
-lrb-	-LRB-	O
400	CD	O
mg	NN	O
-rrb-	-RRB-	O
in	IN	O
6	CD	O
healthy	JJ	O
subjects	NNS	O
.	.	.
		
no	DT	O
information	NN	O
provided	VBN	O
.	.	.
		
proleukin	NNP	B
may	MD	O
affect	VB	O
central	JJ	O
nervous	JJ	O
function	NN	O
.	.	.
		
therefore	RB	O
","	","	O
interactions	NNS	O
could	MD	O
occur	VB	O
following	VBG	O
concomitant	JJ	O
administration	NN	O
of	IN	O
psychotropic	JJ	O
drugs	NNS	D
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
narcotics	NNS	G
","	","	O
analgesics	NNS	G
","	","	O
antiemetics	NNS	G
","	","	O
sedatives	NNS	G
","	","	O
tranquilizers	NNS	G
-rrb-	-RRB-	O
.	.	.
		
concurrent	JJ	O
administration	NN	O
of	IN	O
drugs	NNS	D
possessing	VBG	O
nephrotoxic	JJ	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
aminoglycosides	NNS	G
","	","	O
indomethacin	NN	D
-rrb-	-RRB-	O
","	","	O
myelotoxic	JJ	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
cytotoxic	JJ	G
chemotherapy	NN	O
-rrb-	-RRB-	O
","	","	O
cardiotoxic	JJ	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
doxorubicin	NN	D
-rrb-	-RRB-	O
or	CC	O
hepatotoxic	JJ	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
methotrexate	NN	D
","	","	O
asparaginase	NN	D
-rrb-	-RRB-	O
effects	NNS	O
with	IN	O
proleukin	NN	B
may	MD	O
increase	VB	O
toxicity	NN	O
in	IN	O
these	DT	O
organ	NN	O
systems	NNS	O
.	.	.
		
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
proleukin	NNP	B
in	IN	O
combination	NN	O
with	IN	O
any	DT	O
antineoplastic	JJ	O
agents	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
reduced	VBD	O
kidney	NN	O
and	CC	O
liver	NN	O
function	NN	O
secondary	JJ	O
to	TO	O
proleukin	NN	B
treatment	NN	O
may	MD	O
delay	VB	O
elimination	NN	O
of	IN	O
concomitant	JJ	O
medications	NNS	O
and	CC	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
from	IN	O
those	DT	O
drugs	NNS	D
.	.	.
		
hypersensitivity	NN	O
reactions	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
combination	NN	O
regimens	NNS	O
containing	VBG	O
sequential	JJ	O
high	JJ	O
dose	NN	O
proleukin	NN	B
and	CC	O
antineoplastic	JJ	O
agents	NNS	O
","	","	O
specifically	RB	O
","	","	O
dacarbazine	NN	D
","	","	O
cis-platinum	NN	D
","	","	O
tamoxifen	NN	D
and	CC	O
interferon-alfa	NN	D
.	.	.
		
these	DT	O
reactions	NNS	O
consisted	VBD	O
of	IN	O
erythema	NN	O
","	","	O
pruritus	NN	O
","	","	O
and	CC	O
hypotension	NN	O
and	CC	O
occurred	VBD	O
within	IN	O
hours	NNS	O
of	IN	O
administration	NN	O
of	IN	O
chemotherapy	NN	O
.	.	.
		
these	DT	O
events	NNS	O
required	VBN	O
medical	JJ	O
intervention	NN	O
in	IN	O
some	DT	O
patients	NNS	O
.	.	.
		
myocardial	JJ	O
injury	NN	O
","	","	O
including	VBG	O
myocardial	JJ	O
infarction	NN	O
","	","	O
myocarditis	NN	O
","	","	O
ventricular	JJ	O
hypokinesia	NN	O
","	","	O
and	CC	O
severe	JJ	O
rhabdomyolysis	NN	O
appear	VBP	O
to	TO	O
be	VB	O
increased	VBN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
proleukin	NNP	B
and	CC	O
interferon-alfa	JJ	D
concurrently	RB	O
.	.	.
		
exacerbation	NN	O
or	CC	O
the	DT	O
initial	JJ	O
presentation	NN	O
of	IN	O
a	DT	O
number	NN	O
of	IN	O
autoimmune	JJ	O
and	CC	O
inflammatory	JJ	O
disorders	NNS	O
has	VBZ	O
been	VBN	O
observed	VBN	O
following	VBG	O
concurrent	JJ	O
use	NN	O
of	IN	O
interferon-alfa	NN	D
and	CC	O
proleukin	NN	B
","	","	O
including	VBG	O
crescentic	JJ	O
iga	NN	O
glomerulonephritis	NN	O
","	","	O
oculo-bulbar	JJ	O
myasthenia	NN	O
gravis	NN	O
","	","	O
inflammatory	JJ	O
arthritis	NN	O
","	","	O
thyroiditis	NN	O
","	","	O
bullous	JJ	O
pemphigoid	NN	O
","	","	O
and	CC	O
stevens-johnson	NN	O
syndrome	NN	O
.	.	.
		
although	IN	O
glucocorticoids	NNS	G
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
reduce	VB	O
proleukin-induced	JJ	O
side	JJ	O
effects	NNS	O
including	VBG	O
fever	NN	O
","	","	O
renal	JJ	O
insufficiency	NN	O
","	","	O
hyperbilirubinemia	NN	O
","	","	O
confusion	NN	O
","	","	O
and	CC	O
dyspnea	NN	O
","	","	O
concomitant	JJ	O
administration	NN	O
of	IN	O
these	DT	O
agents	NNS	O
with	IN	O
proleukin	NN	B
may	MD	O
reduce	VB	O
the	DT	O
antitumor	NN	O
effectiveness	NN	O
of	IN	O
proleukin	NNP	B
and	CC	O
thus	RB	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	.
		
12	CD	O
beta-blockers	NNS	G
and	CC	O
other	JJ	O
antihypertensives	NNS	G
may	MD	O
potentiate	VB	O
the	DT	O
hypotension	NN	O
seen	VBN	O
with	IN	O
proleukin	NN	B
.	.	.
		
delayed	VBN	O
adverse	JJ	O
reactions	NNS	O
to	TO	O
iodinated	NNP	O
contrast	NNP	O
media	NNP	O
:	:	O
a	NNP	O
review	NN	O
of	IN	O
the	DT	O
literature	NN	O
revealed	VBD	O
that	IN	O
12.6	CD	O
%	NN	O
-lrb-	-LRB-	O
range	NN	O
28-Nov	CD	O
%	NN	O
-rrb-	-RRB-	O
of	IN	O
501	CD	O
patients	NNS	O
treated	VBN	O
with	IN	O
various	JJ	O
interleukin-2	NN	D
containing	VBG	O
regimens	NNS	O
who	WP	O
were	VBD	O
subsequently	RB	O
administered	VBN	O
radiographic	JJ	O
iodinated	VBN	O
contrast	NN	O
media	NNS	O
experienced	VBD	O
acute	JJ	O
","	","	O
atypical	JJ	O
adverse	JJ	O
reactions	NNS	O
.	.	.
		
the	DT	O
onset	NN	O
of	IN	O
symptoms	NNS	O
usually	RB	O
occurred	VBD	O
within	IN	O
hours	NNS	O
-lrb-	-LRB-	O
most	RBS	O
commonly	RB	O
1	CD	O
to	TO	O
4	CD	O
hours	NNS	O
-rrb-	-RRB-	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
contrast	NN	O
media	NNS	O
.	.	.
		
these	DT	O
reactions	NNS	O
include	VBP	O
fever	NN	O
","	","	O
chills	NNS	O
","	","	O
nausea	NN	O
","	","	O
vomiting	VBG	O
","	","	O
pruritus	NN	O
","	","	O
rash	NN	O
","	","	O
diarrhea	NN	O
","	","	O
hypotension	NN	O
","	","	O
edema	NN	O
","	","	O
and	CC	O
oliguria	NN	O
.	.	.
		
some	DT	O
clinicians	NNS	O
have	VBP	O
noted	VBN	O
that	IN	O
these	DT	O
reactions	NNS	O
resemble	VBP	O
the	DT	O
immediate	JJ	O
side	JJ	O
effects	NNS	O
caused	VBN	O
by	IN	O
interleukin-2	NN	D
administration	NN	O
","	","	O
however	RB	O
the	DT	O
cause	NN	O
of	IN	O
contrast	NN	O
reactions	NNS	O
after	IN	O
interleukin-2	NN	D
therapy	NN	O
is	VBZ	O
unknown	JJ	O
.	.	.
		
most	JJS	O
events	NNS	O
were	VBD	O
reported	VBN	O
to	TO	O
occur	VB	O
when	WRB	O
contrast	NN	O
media	NNS	O
was	VBD	O
given	VBN	O
within	IN	O
4	CD	O
weeks	NNS	O
after	IN	O
the	DT	O
last	JJ	O
dose	NN	O
of	IN	O
interleukin-2	NN	D
.	.	.
		
these	DT	O
events	NNS	O
were	VBD	O
also	RB	O
reported	VBN	O
to	TO	O
occur	VB	O
when	WRB	O
contrast	NN	O
media	NNS	O
was	VBD	O
given	VBN	O
several	JJ	O
months	NNS	O
after	IN	O
interleukin-2	NN	D
treatment	NN	O
.	.	.
		
no	DT	O
formal	JJ	O
interaction	NN	O
studies	NNS	O
have	VBP	O
been	VBN	O
performed	VBN	O
.	.	.
		
the	DT	O
duration	NN	O
of	IN	O
the	DT	O
period	NN	O
following	VBG	O
treatment	NN	O
with	IN	O
amevive	NN	B
before	IN	O
one	CD	O
should	MD	O
consider	VB	O
starting	VBG	O
other	JJ	O
immunosuppressive	JJ	G
therapy	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
.	.	.
		
carcinogenesis	NN	O
","	","	O
mutagenesis	NN	O
","	","	O
and	CC	O
fertility	NN	O
.	.	.
		
in	IN	O
a	DT	O
chronic	JJ	O
toxicity	NN	O
study	NN	O
","	","	O
cynomolgus	NN	O
monkeys	NNS	O
were	VBD	O
dosed	VBN	O
weekly	RB	O
for	IN	O
52	CD	O
weeks	NNS	O
with	IN	O
intravenous	JJ	O
alefacept	NN	D
at	IN	O
1	CD	O
mg/kg/dose	NN	O
or	CC	O
20	CD	O
mg/kg/dose	NN	O
.	.	.
		
one	CD	O
animal	NN	O
in	IN	O
the	DT	O
high	JJ	O
dose	NN	O
group	NN	O
developed	VBD	O
a	DT	O
b-cell	NN	O
lymphoma	NN	O
that	WDT	O
was	VBD	O
detected	VBN	O
after	IN	O
28	CD	O
weeks	NNS	O
of	IN	O
dosing	NN	O
.	.	.
		
additional	JJ	O
animals	NNS	O
in	IN	O
both	DT	O
dose	NN	O
groups	NNS	O
developed	VBD	O
b-cell	NN	O
hyperplasia	NN	O
of	IN	O
the	DT	O
spleen	NN	O
and	CC	O
lymph	NN	O
nodes	NNS	O
.	.	.
		
all	DT	O
animals	NNS	O
in	IN	O
the	DT	O
study	NN	O
were	VBD	O
positive	JJ	O
for	IN	O
an	DT	O
endemic	JJ	O
primate	JJ	O
gammaherpes	NNS	O
virus	NN	O
also	RB	O
known	VBN	O
as	IN	O
lymphocryptovirus	NN	O
-lrb-	-LRB-	O
lcv	NN	O
-rrb-	-RRB-	O
.	.	.
		
latent	JJ	O
lcv	NN	O
infection	NN	O
is	VBZ	O
generally	RB	O
asymptomatic	JJ	O
","	","	O
but	CC	O
can	MD	O
lead	VB	O
to	TO	O
b-cell	NN	O
lymphomas	NNS	O
when	WRB	O
animals	NNS	O
are	VBP	O
immune	JJ	O
suppressed	VBN	O
.	.	.
		
in	IN	O
a	DT	O
separate	JJ	O
study	NN	O
","	","	O
baboons	NNS	O
given	VBN	O
3	CD	O
doses	NNS	O
of	IN	O
alefacept	NN	D
at	IN	O
1	CD	O
mg/kg	NN	O
every	DT	O
8	CD	O
weeks	NNS	O
were	VBD	O
found	VBN	O
to	TO	O
have	VB	O
centroblast	NN	O
proliferation	NN	O
in	IN	O
b-cell	NN	O
dependent	JJ	O
areas	NNS	O
in	IN	O
the	DT	O
germinal	JJ	O
centers	NNS	O
of	IN	O
the	DT	O
spleen	NN	O
following	VBG	O
a	DT	O
116-day	JJ	O
washout	NN	O
period	NN	O
.	.	.
		
the	DT	O
role	NN	O
of	IN	O
amevive	NNP	B
in	IN	O
the	DT	O
development	NN	O
of	IN	O
the	DT	O
lymphoid	JJ	O
malignancy	NN	O
and	CC	O
the	DT	O
hyperplasia	NN	O
observed	VBN	O
in	IN	O
non-human	JJ	O
primates	NNS	O
and	CC	O
the	DT	O
relevance	NN	O
to	TO	O
humans	NNS	O
is	VBZ	O
unknown	JJ	O
.	.	.
		
immunodeficiency-associated	JJ	O
lymphocyte	NN	O
disorders	NNS	O
-lrb-	-LRB-	O
plasmacytic	JJ	O
hyperplasia	NN	O
","	","	O
polymorphic	JJ	O
proliferation	NN	O
","	","	O
and	CC	O
b-cell	NN	O
lymphomas	NNS	O
-rrb-	-RRB-	O
occur	VBP	O
in	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
congenital	JJ	O
or	CC	O
acquired	VBN	O
immunodeficiencies	NNS	O
including	VBG	O
those	DT	O
resulting	VBG	O
from	IN	O
immunosuppressive	JJ	G
therapy	NN	O
.	.	.
		
no	DT	O
carcinogenicity	NN	O
or	CC	O
fertility	NN	O
studies	NNS	O
were	VBD	O
conducted	VBN	O
.	.	.
		
mutagenicity	NN	O
studies	NNS	O
were	VBD	O
conducted	VBN	O
in	FW	O
vitro	FW	O
and	CC	O
in	FW	O
vivo	FW	O
;	:	O
.	.	.
		
no	DT	O
evidence	NN	O
of	IN	O
mutagenicity	NN	O
was	VBD	O
observed	VBN	O
.	.	.
		
pregnancy	NN	O
-lrb-	-LRB-	O
category	NN	O
b	NN	O
-rrb-	-RRB-	O
.	.	.
		
women	NNS	O
of	IN	O
childbearing	JJ	O
potential	JJ	O
make	VB	O
up	RP	O
a	DT	O
considerable	JJ	O
segment	NN	O
of	IN	O
the	DT	O
patient	NN	O
population	NN	O
affected	VBN	O
by	IN	O
psoriasis	NN	O
.	.	.
		
since	IN	O
the	DT	O
effect	NN	O
of	IN	O
amevive	NNP	B
on	IN	O
pregnancy	NN	O
and	CC	O
fetal	JJ	O
development	NN	O
","	","	O
including	VBG	O
immune	JJ	O
system	NN	O
development	NN	O
","	","	O
is	VBZ	O
not	RB	O
known	VBN	O
","	","	O
health	NN	O
care	NN	O
providers	NNS	O
are	VBP	O
encouraged	VBN	O
to	TO	O
enroll	VB	O
patients	NNS	O
currently	RB	O
taking	VBG	O
amevive	NNP	B
who	WP	O
become	VBP	O
pregnant	JJ	O
into	IN	O
the	DT	O
biogen	NNP	O
pregnancy	NNP	O
registry	NNP	O
by	IN	O
calling	VBG	O
1-866-amevive	NN	O
-lrb-	-LRB-	O
1-866-263-8483	CD	O
-rrb-	-RRB-	O
.	.	.
		
reproductive	NNP	O
toxicology	NN	O
studies	NNS	O
have	VBP	O
been	VBN	O
performed	VBN	O
in	IN	O
cynomolgus	NN	O
monkeys	NNS	O
at	IN	O
doses	NNS	O
up	RB	O
to	TO	O
5	CD	O
mg/kg/week	NN	O
-lrb-	-LRB-	O
about	IN	O
62	CD	O
times	NNS	O
the	DT	O
human	JJ	O
dose	NN	O
based	VBN	O
on	IN	O
body	NN	O
weight	NN	O
-rrb-	-RRB-	O
and	CC	O
have	VBP	O
revealed	VBN	O
no	DT	O
evidence	NN	O
of	IN	O
impaired	JJ	O
fertility	NN	O
or	CC	O
harm	NN	O
to	TO	O
the	DT	O
fetus	NN	O
due	JJ	O
to	TO	O
amevive	NNP	B
.	.	.
		
no	DT	O
abortifacient	NN	O
or	CC	O
teratogenic	JJ	O
effects	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
cynomolgus	NN	O
monkeys	NNS	O
following	VBG	O
intravenous	JJ	O
bolus	NN	O
injections	NNS	O
of	IN	O
amevive	NNP	B
administered	VBN	O
weekly	RB	O
during	IN	O
the	DT	O
period	NN	O
of	IN	O
organogenesis	NN	O
to	TO	O
gestation	NN	O
.	.	.
		
amevive	NNP	B
underwent	VBD	O
trans-placental	JJ	O
passage	NN	O
and	CC	O
produced	VBN	O
in	IN	O
utero	NN	O
exposure	NN	O
in	IN	O
the	DT	O
developing	VBG	O
monkeys	NNS	O
.	.	.
		
in	IN	O
utero	NN	O
","	","	O
serum	NN	O
levels	NNS	O
of	IN	O
exposure	NN	O
in	IN	O
these	DT	O
monkeys	NNS	O
were	VBD	O
23	CD	O
%	NN	O
of	IN	O
maternal	JJ	O
serum	NN	O
levels	NNS	O
.	.	.
		
no	DT	O
evidence	NN	O
of	IN	O
fetal	JJ	O
toxicity	NN	O
including	VBG	O
adverse	JJ	O
effects	NNS	O
on	IN	O
immune	JJ	O
system	NN	O
development	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
any	DT	O
of	IN	O
these	DT	O
animals	NNS	O
.	.	.
		
animal	NN	O
reproduction	NN	O
studies	NNS	O
","	","	O
however	RB	O
","	","	O
are	VBP	O
not	RB	O
always	RB	O
predictive	JJ	O
of	IN	O
human	JJ	O
response	NN	O
and	CC	O
there	EX	O
are	VBP	O
no	DT	O
adequate	JJ	O
and	CC	O
well-controlled	JJ	O
studies	NNS	O
in	IN	O
pregnant	JJ	O
women	NNS	O
.	.	.
		
because	IN	O
the	DT	O
risk	NN	O
to	TO	O
the	DT	O
development	NN	O
of	IN	O
the	DT	O
fetal	JJ	O
immune	JJ	O
system	NN	O
and	CC	O
postnatal	JJ	O
immune	JJ	O
function	NN	O
in	IN	O
humans	NNS	O
is	VBZ	O
unknown	JJ	O
","	","	O
amevive	NNP	B
should	MD	O
be	VB	O
used	VBN	O
during	IN	O
pregnancy	NN	O
only	RB	O
if	IN	O
clearly	RB	O
needed	VBN	O
.	.	.
		
if	IN	O
pregnancy	NN	O
occurs	VBZ	O
while	IN	O
taking	VBG	O
amevive	NNP	B
","	","	O
continued	VBD	O
use	NN	O
of	IN	O
the	DT	O
drug	NN	D
should	MD	O
be	VB	O
assessed	VBN	O
.	.	.
		
nursing	NNP	O
mothers	NNP	O
.	.	.
		
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
amevive	NNP	B
is	VBZ	O
excreted	VBN	O
in	IN	O
human	JJ	O
milk	NN	O
.	.	.
		
because	IN	O
many	JJ	O
drugs	NNS	D
are	VBP	O
excreted	VBN	O
in	IN	O
human	JJ	O
milk	NN	O
","	","	O
and	CC	O
because	IN	O
there	EX	O
exists	VBZ	O
the	DT	O
potential	NN	O
for	IN	O
serious	JJ	O
adverse	JJ	O
reactions	NNS	O
in	IN	O
nursing	NN	O
infants	NNS	O
from	IN	O
amevive	NNP	B
","	","	O
a	DT	O
decision	NN	O
should	MD	O
be	VB	O
made	VBN	O
whether	IN	O
to	TO	O
discontinue	VB	O
nursing	NN	O
while	IN	O
taking	VBG	O
the	DT	O
drug	NN	D
or	CC	O
to	TO	O
discontinue	VB	O
the	DT	O
use	NN	O
of	IN	O
the	DT	O
drug	NN	D
","	","	O
taking	VBG	O
into	IN	O
account	NN	O
the	DT	O
importance	NN	O
of	IN	O
the	DT	O
drug	NN	D
to	TO	O
the	DT	O
mother	NN	O
.	.	.
		
geriatric	NNP	O
use	NNP	O
.	.	.
		
of	IN	O
the	DT	O
1357	CD	O
patients	NNS	O
who	WP	O
received	VBD	O
amevive	NNP	B
in	IN	O
clinical	JJ	O
trials	NNS	O
","	","	O
a	DT	O
total	NN	O
of	IN	O
100	CD	O
patients	NNS	O
wer	NN	O
.	.	.
		
65	CD	O
years	NNS	O
of	IN	O
age	NN	O
and	CC	O
13	CD	O
patients	NNS	O
were	VBD	O
.	.	.
		
75	CD	O
years	NNS	O
of	IN	O
age	NN	O
.	.	.
		
no	DT	O
differences	NNS	O
in	IN	O
safety	NN	O
or	CC	O
efficacy	NN	O
were	VBD	O
observed	VBN	O
between	IN	O
older	JJR	O
and	CC	O
younger	JJR	O
patients	NNS	O
","	","	O
but	CC	O
there	EX	O
were	VBD	O
not	RB	O
sufficient	JJ	O
data	NNS	O
to	TO	O
exclude	VB	O
important	JJ	O
differences	NNS	O
.	.	.
		
because	IN	O
the	DT	O
incidence	NN	O
of	IN	O
infections	NNS	O
and	CC	O
certain	JJ	O
malignancies	NNS	O
is	VBZ	O
higher	JJR	O
in	IN	O
the	DT	O
elderly	JJ	O
population	NN	O
","	","	O
in	IN	O
general	JJ	O
","	","	O
caution	NN	O
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
treating	VBG	O
the	DT	O
elderly	JJ	O
.	.	.
		
pediatric	NNP	O
use	NNP	O
.	.	.
		
the	DT	O
safety	NN	O
and	CC	O
efficacy	NN	O
of	IN	O
amevive	NNP	B
in	IN	O
pediatric	JJ	O
patients	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	.
		
amevive	NNP	B
is	VBZ	O
not	RB	O
indicated	VBN	O
for	IN	O
pediatric	JJ	O
patients	NNS	O
.	.	.
		
drug/laboratory	NNP	O
interactions	NNS	O
no	DT	O
formal	JJ	O
drug	NN	D
interaction	NN	O
studies	NNS	O
have	VBP	O
been	VBN	O
performed	VBN	O
with	IN	O
campath	NNP	B
.	.	.
		
an	DT	O
immune	JJ	O
response	NN	O
to	TO	O
campath	NNP	B
may	MD	O
interfere	VB	O
with	IN	O
subsequent	JJ	O
diagnostic	JJ	O
serum	NN	O
tests	NNS	O
that	WDT	O
utilize	VBP	O
antibodie	NN	O
.	.	.
		
intravenous	JJ	O
ranitidine	NN	D
was	VBD	O
shown	VBN	O
to	TO	O
double	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
oral	JJ	O
alendronate	NN	D
.	.	.
		
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
this	DT	O
increased	VBN	O
bioavailability	NN	O
and	CC	O
whether	IN	O
similar	JJ	O
increases	NNS	O
will	MD	O
occur	VB	O
in	IN	O
patients	NNS	O
given	VBN	O
oral	JJ	O
h2-antagonists	NNS	G
is	VBZ	O
unknown	JJ	O
.	.	.
		
no	DT	O
other	JJ	O
specific	JJ	O
drug	NN	D
interaction	NN	O
studies	NNS	O
were	VBD	O
performed	VBN	O
.	.	.
		
products	NNPS	O
containing	VBG	O
calcium	NN	D
and	CC	O
other	JJ	O
multivalent	JJ	O
cations	NNS	O
likely	RB	O
will	MD	O
interfere	VB	O
with	IN	O
absorption	NN	O
of	IN	O
alendronate	NN	D
.	.	.
		
both	CC	O
the	DT	O
magnitude	NN	O
and	CC	O
duration	NN	O
of	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
and	CC	O
cardiovascular	JJ	O
effects	NNS	O
may	MD	O
be	VB	O
enhanced	VBN	O
when	WRB	O
alfenta	NNP	B
is	VBZ	O
administered	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
cns	NN	O
depressants	NNS	O
such	JJ	O
as	IN	O
barbiturates	NNS	G
","	","	O
tranquilizers	NNS	G
","	","	O
opioids	NNS	G
","	","	O
or	CC	O
inhalation	NN	O
general	JJ	O
anesthetics	NNS	G
.	.	.
		
postoperative	JJ	O
respiratory	JJ	O
depression	NN	O
may	MD	O
be	VB	O
enhanced	VBN	O
or	CC	O
prolonged	VBN	O
by	IN	O
these	DT	O
agents	NNS	O
.	.	.
		
in	IN	O
such	JJ	O
cases	NNS	O
of	IN	O
combined	JJ	O
treatment	NN	O
","	","	O
the	DT	O
dose	NN	O
of	IN	O
one	CD	O
or	CC	O
both	DT	O
agents	NNS	O
should	MD	O
be	VB	O
reduced	VBN	O
.	.	.
		
limited	JJ	O
clinical	JJ	O
experience	NN	O
indicates	VBZ	O
that	IN	O
requirements	NNS	O
for	IN	O
volatile	JJ	O
inhalation	NN	O
anesthetics	NNS	G
are	VBP	O
reduced	VBN	O
by	IN	O
30	CD	O
to	TO	O
50	CD	O
%	NN	O
for	IN	O
the	DT	O
first	JJ	O
sixty	NN	O
-lrb-	-LRB-	O
60	CD	O
-rrb-	-RRB-	O
minutes	NNS	O
following	VBG	O
alfenta	NNP	B
induction	NN	O
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
erythromycin	NN	D
with	IN	O
alfenta	NN	B
can	MD	O
significantly	RB	O
inhibit	VB	O
alfenta	NN	B
clearance	NN	O
and	CC	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
prolonged	JJ	O
or	CC	O
delayed	VBN	O
respiratory	JJ	O
depression	NN	O
.	.	.
		
cimetidine	NNP	D
reduces	VBZ	O
the	DT	O
clearance	NN	O
of	IN	O
alfenta	NNP	B
.	.	.
		
therefore	RB	O
smaller	JJR	O
alfenta	NN	B
doses	NNS	O
will	MD	O
be	VB	O
required	VBN	O
with	IN	O
prolonged	JJ	O
administration	NN	O
and	CC	O
the	DT	O
duration	NN	O
of	IN	O
action	NN	O
of	IN	O
alfenta	NNP	B
my	PRP$	O
be	VB	O
extended	VBN	O
.	.	.
		
perioperative	NNP	O
administration	NN	O
of	IN	O
drugs	NNS	D
affecting	VBG	O
hepatic	JJ	O
blood	NN	O
flow	NN	O
or	CC	O
enzyme	NN	O
function	NN	O
may	MD	O
reduce	VB	O
plasma	NN	O
clearance	NN	O
and	CC	O
prolong	VB	O
recovery	NN	O
.	.	.
		
drug-drug	NNP	O
interactions	NNS	O
:	:	O
the	DT	O
pharmacokinetic	JJ	O
and	CC	O
pharmacodynamic	JJ	O
interactions	NNS	O
between	IN	O
uroxatral	NNP	B
and	CC	O
other	JJ	O
alpha-blockers	NNS	G
have	VBP	O
not	RB	O
been	VBN	O
determined	VBN	O
.	.	.
		
however	RB	O
","	","	O
interactions	NNS	O
may	MD	O
be	VB	O
expected	VBN	O
","	","	O
and	CC	O
uroxatral	NNP	B
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
alpha-blockers	NNS	G
.	.	.
		
no	DT	O
drug	NN	D
interaction	NN	O
studies	NNS	O
have	VBP	O
been	VBN	O
performed	VBN	O
.	.	.
		
effects	NNS	O
of	IN	O
other	JJ	O
drugs	NNS	O
on	IN	O
aliskiren	NNP	D
based	VBD	O
on	IN	O
in-vitro	FW	O
studies	NNS	O
","	","	O
aliskiren	NN	D
is	VBZ	O
metabolized	VBN	O
by	IN	O
cyp	NN	O
3a4	NN	O
.	.	.
		
co-administration	NN	O
of	IN	O
lovastatin	NN	D
","	","	O
atenolol	NN	D
","	","	O
warfarin	NN	D
","	","	O
furosemide	NN	D
","	","	O
digoxin	NN	D
","	","	O
celecoxib	NN	D
","	","	O
hydrochlorothiazide	NN	D
","	","	O
ramipril	NN	D
","	","	O
valsartan	NN	D
","	","	O
metformin	NN	D
and	CC	O
amlodipine	NN	D
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
clinically	RB	O
significant	JJ	O
increases	NNS	O
in	IN	O
aliskiren	JJ	D
exposure	NN	O
.	.	.
		
co-administration	NN	O
of	IN	O
irbesartan	NN	D
reduced	VBD	O
aliskiren	JJ	D
cmax	NN	O
up	IN	O
to	TO	O
50	CD	O
%	NN	O
after	IN	O
multiple	JJ	O
dosing	NN	O
.	.	.
		
co-administration	NN	O
of	IN	O
atorvastatin	NN	D
resulted	VBD	O
in	IN	O
about	IN	O
a	DT	O
50	CD	O
%	NN	O
increase	NN	O
in	IN	O
aliskiren	NN	D
cmax	NN	O
and	CC	O
auc	NN	O
after	IN	O
multiple	JJ	O
dosing	NN	O
.	.	.
		
ketoconazole	NN	D
:	:	O
co-administration	NN	O
of	IN	O
200	CD	O
mg	NN	O
twice-daily	JJ	O
ketoconazole	NN	D
with	IN	O
aliskiren	NN	D
resulted	VBD	O
in	IN	O
an	DT	O
approximate	JJ	O
80	CD	O
%	NN	O
increase	NN	O
in	IN	O
plasma	NN	O
levels	NNS	O
of	IN	O
aliskiren	NN	D
.	.	.
		
a	DT	O
400	CD	O
mg	NN	O
once-daily	JJ	O
dose	NN	O
was	VBD	O
not	RB	O
studied	VBN	O
but	CC	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
increase	VB	O
aliskiren	JJ	D
blood	NN	O
levels	NNS	O
further	RB	O
.	.	.
		
effects	NNS	O
of	IN	O
aliskiren	NN	D
on	IN	O
other	JJ	O
drugs	NNS	O
aliskiren	NN	D
does	VBZ	O
not	RB	O
inhibit	VB	O
the	DT	O
cyp450	NN	O
isoenzymes	NNS	O
-lrb-	-LRB-	O
cyp1a2	NN	D
","	","	O
2c8	NN	O
","	","	O
2c9	NN	O
","	","	O
2c19	NN	O
","	","	O
2d6	NN	O
","	","	O
2.00E+01	NN	O
","	","	O
and	CC	O
cyp	NN	O
3a	NN	O
-rrb-	-RRB-	O
or	CC	O
induce	VB	O
cyp	NN	O
3a4	NN	O
.	.	.
		
co-administration	NN	O
of	IN	O
aliskiren	NN	D
did	VBD	O
not	RB	O
significantly	RB	O
affect	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
lovastatin	NN	D
","	","	O
digoxin	NN	D
","	","	O
valsartan	NN	D
","	","	O
amlodipine	NN	D
","	","	O
metformin	NN	D
","	","	O
celecoxib	NN	D
","	","	O
atenolol	NN	D
","	","	O
atorvastatin	NN	D
","	","	O
ramipril	NN	D
or	CC	O
hydrochlorothiazide	NN	D
.	.	.
		
warfarin	NNP	D
:	:	O
the	DT	O
effects	NNS	O
of	IN	O
aliskiren	NN	D
on	IN	O
warfarin	NN	D
pharmacokinetics	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
evaluated	VBN	O
in	IN	O
a	DT	O
well-controlled	JJ	O
clinical	JJ	O
trial	NN	O
.	.	.
		
furosemide	NNP	D
:	:	O
when	WRB	O
aliskiren	NN	D
was	VBD	O
co-administered	VBN	O
with	IN	O
furosemide	NN	D
","	","	O
the	DT	O
auc	NN	O
and	CC	O
cmax	NN	O
of	IN	O
furosemide	NN	D
were	VBD	O
reduced	VBN	O
by	IN	O
about	IN	O
30	CD	O
%	NN	O
and	CC	O
50	CD	O
%	NN	O
","	","	O
respectively	RB	O
.	.	.
		
patients	NNS	O
who	WP	O
are	VBP	O
applying	VBG	O
panretin	NNP	B
gel	NN	O
should	MD	O
not	RB	O
concurrently	RB	O
use	VB	O
products	NNS	O
that	WDT	O
contain	VBP	O
deet	NN	D
-lrb-	-LRB-	O
n	NN	O
","	","	O
n-diethyl-m-toluamide	NN	D
-rrb-	-RRB-	O
","	","	O
a	DT	O
common	JJ	O
component	NN	O
of	IN	O
insect	JJ	O
repellent	NN	O
products	NNS	O
.	.	.
		
animal	NN	O
toxicology	NN	O
studies	NNS	O
showed	VBD	O
increased	VBN	O
deet	NNP	D
toxicity	NN	O
when	WRB	O
deet	NNP	D
was	VBD	O
included	VBN	O
as	IN	O
proof	NN	O
of	IN	O
the	DT	O
formulation	NN	O
.	.	.
		
although	IN	O
there	EX	O
was	VBD	O
no	DT	O
clinical	JJ	O
evidence	NN	O
in	IN	O
the	DT	O
vehicle-controlled	JJ	O
studies	NNS	O
of	IN	O
drug	NN	D
interactions	NNS	O
with	IN	O
systemic	JJ	O
antiretroviral	JJ	O
agents	NNS	O
","	","	O
including	VBG	O
protease	NN	O
inhibitors	NNS	O
","	","	O
macrolide	NN	O
antibiotics	NNS	G
","	","	O
and	CC	O
azole	NN	O
antifungals	NNS	O
","	","	O
the	DT	O
effect	NN	O
of	IN	O
panretin	NNP	B
gel	NN	O
on	IN	O
the	DT	O
steady-state	JJ	O
concentrations	NNS	O
of	IN	O
these	DT	O
drugs	NNS	D
is	VBZ	O
not	RB	O
known	VBN	O
.	.	.
		
no	DT	O
drug	NN	D
interaction	NN	O
data	NNS	O
are	VBP	O
available	JJ	O
on	IN	O
concomitant	JJ	O
administration	NN	O
of	IN	O
panretin	NNP	B
gel	NN	O
and	CC	O
systemic	JJ	O
anti-ks	JJ	O
agents	NNS	O
.	.	.
		
the	DT	O
following	VBG	O
drug	NN	D
interactions	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
some	DT	O
patients	NNS	O
undergoing	VBG	O
treatment	NN	O
with	IN	O
oral	JJ	O
allopurinol	NN	D
.	.	.
		
although	IN	O
the	DT	O
pattern	NN	O
of	IN	O
use	NN	O
for	IN	O
oral	JJ	O
allopurinol	NN	D
includes	VBZ	O
longer	JJR	O
term	NN	O
therapy	NN	O
","	","	O
particularly	RB	O
for	IN	O
gout	NN	O
and	CC	O
renal	JJ	O
calculi	NNS	O
","	","	O
the	DT	O
experience	NN	O
gained	VBD	O
may	MD	O
be	VB	O
relevant	JJ	O
.	.	.
		
mercaptopurine/azathioprine	NNP	O
:	:	O
allopurinol	NN	D
inhibits	VBZ	O
the	DT	O
enzymatic	JJ	O
oxidation	NN	O
of	IN	O
mercaptopurine	NN	D
and	CC	O
azathioprine	NN	D
to	TO	O
6-thiouric	JJ	O
acid	NN	O
.	.	.
		
this	DT	O
oxidation	NN	O
","	","	O
which	WDT	O
is	VBZ	O
catalyzed	VBN	O
by	IN	O
xanthine	NN	O
oxidase	NN	O
","	","	O
inactivates	VBZ	O
mercaptopurine	NN	D
.	.	.
		
in	IN	O
patients	NNS	O
receiving	VBG	O
mercaptopurine	NN	D
-lrb-	-LRB-	O
purinethol	NN	B
-rrb-	-RRB-	O
or	CC	O
azathioprine	NN	D
-lrb-	-LRB-	O
imuran	NN	B
-rrb-	-RRB-	O
","	","	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
300-600	CD	O
mg	NN	O
of	IN	O
allopurinol	NN	D
per	IN	O
day	NN	O
will	MD	O
require	VB	O
a	DT	O
reduction	NN	O
in	IN	O
dose	NN	O
to	TO	O
approximately	RB	O
one-third	JJ	O
to	TO	O
one-fourth	NN	O
of	IN	O
the	DT	O
usual	JJ	O
dose	NN	O
of	IN	O
mercaptopurine	NN	D
or	CC	O
azathioprine	NN	D
.	.	.
		
subsequent	JJ	O
adjustment	NN	O
of	IN	O
doses	NNS	O
of	IN	O
mercaptopurine	NN	D
or	CC	O
azathioprine	NN	D
should	MD	O
be	VB	O
made	VBN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
therapeutic	JJ	O
response	NN	O
and	CC	O
the	DT	O
appearance	NN	O
of	IN	O
toxic	JJ	O
effects	NNS	O
.	.	.
		
dicumarol	NNP	D
:	:	O
it	PRP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
that	IN	O
allopurinol	NN	D
prolongs	VBZ	O
the	DT	O
half-life	NN	O
of	IN	O
the	DT	O
anticoagulant	NN	G
","	","	O
dicumarol	NN	D
.	.	.
		
the	DT	O
clinical	JJ	O
basis	NN	O
of	IN	O
this	DT	O
drug	NN	D
interaction	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
but	CC	O
should	MD	O
be	VB	O
noted	VBN	O
when	WRB	O
allopurinol	NN	D
is	VBZ	O
given	VBN	O
to	TO	O
patients	NNS	O
already	RB	O
on	IN	O
dicumarol	NN	D
therapy	NN	O
.	.	.
		
consequently	RB	O
","	","	O
prothrombin	NN	O
time	NN	O
should	MD	O
be	VB	O
reassessed	VBN	O
periodically	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
both	CC	O
drugs	NNS	D
.	.	.
		
uricosuric	NNP	O
agents	NNPS	O
:	:	O
since	IN	O
the	DT	O
excretion	NN	O
of	IN	O
oxipurinol	NN	D
is	VBZ	O
similar	JJ	O
to	TO	O
that	DT	O
of	IN	O
urate	NN	O
","	","	O
uricosuric	JJ	O
agents	NNS	O
","	","	O
which	WDT	O
increase	VBP	O
the	DT	O
excretion	NN	O
of	IN	O
urate	NN	O
","	","	O
are	VBP	O
also	RB	O
likely	JJ	O
to	TO	O
increase	VB	O
the	DT	O
excretion	NN	O
of	IN	O
oxipurinol	NN	D
and	CC	O
thus	RB	O
lower	JJR	O
the	DT	O
degree	NN	O
of	IN	O
inhibition	NN	O
of	IN	O
xanthine	NN	O
oxidase	NN	O
.	.	.
		
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
uricosuric	JJ	O
agents	NNS	O
and	CC	O
allopurinol	NN	D
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
excretion	NN	O
of	IN	O
oxypurines	NNS	O
-lrb-	-LRB-	O
hypoxanthine	NN	O
and	CC	O
xanthine	NN	O
-rrb-	-RRB-	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
urinary	JJ	O
uric	JJ	O
acid	NN	O
excretion	NN	O
compared	VBN	O
with	IN	O
that	DT	O
observed	VBN	O
with	IN	O
allopurinol	NN	D
alone	RB	O
.	.	.
		
although	IN	O
clinical	JJ	O
evidence	NN	O
to	TO	O
date	NN	O
has	VBZ	O
not	RB	O
demonstrated	VBN	O
renal	JJ	O
precipitation	NN	O
of	IN	O
oxypurines	NNS	O
in	IN	O
patients	NNS	O
either	CC	O
on	IN	O
allopurinol	NN	D
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
uricosuric	JJ	O
agents	NNS	O
","	","	O
the	DT	O
possibility	NN	O
should	MD	O
be	VB	O
kept	VBN	O
in	IN	O
mind	NN	O
.	.	.
		
thiazide	NNP	O
diuretics	NNPS	O
:	:	O
the	DT	O
reports	NNS	O
that	IN	O
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
allopurinol	NN	D
and	CC	O
thiazide	JJ	O
diuretics	NNS	G
may	MD	O
contribute	VB	O
to	TO	O
the	DT	O
enhancement	NN	O
of	IN	O
allopurinol	NN	D
toxicity	NN	O
in	IN	O
some	DT	O
patients	NNS	O
have	VBP	O
been	VBN	O
reviewed	VBN	O
in	IN	O
an	DT	O
attempt	NN	O
to	TO	O
establish	VB	O
a	DT	O
cause-and-effect	JJ	O
relationship	NN	O
and	CC	O
a	DT	O
mechanism	NN	O
of	IN	O
causation	NN	O
.	.	.
		
review	NN	O
of	IN	O
these	DT	O
case	NN	O
reports	VBZ	O
indicates	VBZ	O
that	IN	O
the	DT	O
patients	NNS	O
were	VBD	O
mainly	RB	O
receiving	VBG	O
thiazide	JJ	O
diuretics	NNS	G
for	IN	O
hypertension	NN	O
and	CC	O
that	IN	O
tests	NNS	O
to	TO	O
rule	VB	O
out	RP	O
decreased	VBN	O
renal	JJ	O
function	NN	O
secondary	JJ	O
to	TO	O
hypertensive	JJ	O
nephropathy	NN	O
were	VBD	O
not	RB	O
often	RB	O
performed	VBN	O
.	.	.
		
in	IN	O
those	DT	O
patients	NNS	O
in	IN	O
whom	WP	O
renal	JJ	O
insufficiency	NN	O
was	VBD	O
documented	VBN	O
","	","	O
however	RB	O
","	","	O
the	DT	O
recommendation	NN	O
to	TO	O
lower	VB	O
the	DT	O
dose	NN	O
of	IN	O
allopurinol	NN	D
was	VBD	O
not	RB	O
followed	VBN	O
.	.	.
		
although	IN	O
a	DT	O
causal	JJ	O
mechanism	NN	O
and	CC	O
a	DT	O
cause-and-effect	JJ	O
relationship	NN	O
have	VBP	O
not	RB	O
been	VBN	O
established	VBN	O
","	","	O
current	JJ	O
evidence	NN	O
suggests	VBZ	O
that	IN	O
renal	JJ	O
function	NN	O
should	MD	O
be	VB	O
monitored	VBN	O
in	IN	O
patients	NNS	O
on	IN	O
thiazide	JJ	O
diuretics	NNS	G
and	CC	O
allopurinol	NN	D
even	RB	O
in	IN	O
the	DT	O
absence	NN	O
of	IN	O
renal	JJ	O
failure	NN	O
","	","	O
and	CC	O
dosage	NN	O
levels	NNS	O
should	MD	O
be	VB	O
even	RB	O
more	RBR	O
conservatively	RB	O
adjusted	VBN	O
in	IN	O
those	DT	O
patients	NNS	O
on	IN	O
such	JJ	O
combined	JJ	O
therapy	NN	O
if	IN	O
diminished	VBN	O
renal	JJ	O
function	NN	O
is	VBZ	O
detected	VBN	O
.	.	.
		
ampicillin/amoxicillin	NNP	O
:	:	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
frequency	NN	O
of	IN	O
skin	NN	O
rash	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
among	IN	O
patients	NNS	O
receiving	VBG	O
ampicillin	NN	D
or	CC	O
amoxicillin	NNP	D
concurrently	RB	O
with	IN	O
allopurinol	NN	D
compared	VBN	O
to	TO	O
patients	NNS	O
who	WP	O
are	VBP	O
not	RB	O
receiving	VBG	O
both	CC	O
drugs	NNS	D
.	.	.
		
the	DT	O
cause	NN	O
of	IN	O
the	DT	O
reported	VBN	O
association	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
.	.	.
		
cytotoxic	JJ	O
agents	NNS	O
:	:	O
enhanced	VBN	O
bone	NN	O
marrow	NN	O
suppression	NN	O
by	IN	O
cyclophosphamide	NN	D
and	CC	O
other	JJ	O
cytotoxic	JJ	G
agents	NNS	O
has	VBZ	O
been	VBN	O
reported	VBN	O
among	IN	O
patients	NNS	O
with	IN	O
neoplastic	JJ	O
disease	NN	O
","	","	O
except	IN	O
leukemia	NN	O
","	","	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
allopurinol	NN	D
.	.	.
		
however	RB	O
","	","	O
in	IN	O
a	DT	O
well-controlled	JJ	O
study	NN	O
of	IN	O
patients	NNS	O
with	IN	O
lymphoma	NN	O
on	IN	O
combination	NN	O
therapy	NN	O
","	","	O
allopurinol	NN	D
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
marrow	NN	O
toxicity	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
cyclophosphamide	NN	D
","	","	O
doxorubicin	NN	D
","	","	O
bleomycin	NN	D
","	","	O
procarbazine	NN	D
and/or	CC	O
mechlorethamine	NN	D
.	.	.
		
chlorpropamide	NNP	D
:	:	O
chlorpropamides	NNP	O
plasma	NN	O
half-life	NN	O
may	MD	O
be	VB	O
prolonged	VBN	O
by	IN	O
allopurinol	NN	D
","	","	O
since	IN	O
allopurinol	NN	D
and	CC	O
chlorpropamide	NN	D
may	MD	O
compete	VB	O
for	IN	O
excretion	NN	O
in	IN	O
the	DT	O
renal	JJ	O
tubule	NN	O
.	.	.
		
the	DT	O
risk	NN	O
of	IN	O
hypoglycemia	NN	O
secondary	JJ	O
to	TO	O
this	DT	O
mechanism	NN	O
may	MD	O
be	VB	O
increased	VBN	O
if	IN	O
allopurinol	NN	D
and	CC	O
chlorpropamide	NN	D
are	VBP	O
given	VBN	O
concomitantly	RB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
renal	JJ	O
insufficiency	NN	O
.	.	.
		
cyclosporin	NN	D
:	:	O
reports	NNS	O
indicate	VBP	O
that	IN	O
cyclosporine	NN	D
levels	NNS	O
may	MD	O
be	VB	O
increased	VBN	O
during	IN	O
concomitant	JJ	O
treatment	NN	O
with	IN	O
allopurinol	NN	D
sodium	NN	O
for	IN	O
injection	NN	O
.	.	.
		
monitoring	NN	O
of	IN	O
cyclosporine	NN	D
levels	NNS	O
and	CC	O
possible	JJ	O
adjustment	NN	O
of	IN	O
cyclosporine	NN	D
dosage	NN	O
should	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
these	DT	O
drugs	NNS	D
are	VBP	O
co-administered	JJ	O
.	.	.
		
tolbutamides	NNS	O
conversion	NN	O
to	TO	O
inactive	JJ	O
metabolites	NNS	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
catalyzed	VBN	O
by	IN	O
xanthine	NN	O
oxidase	NN	O
from	IN	O
rat	NN	O
liver	NN	O
.	.	.
		
the	DT	O
clinical	JJ	O
significance	NN	O
","	","	O
if	IN	O
any	DT	O
","	","	O
of	IN	O
these	DT	O
observations	NNS	O
is	VBZ	O
unknown	JJ	O
.	.	.
		
ergot-containing	JJ	O
drugs	NNS	O
:	:	O
these	DT	O
drugs	NNS	D
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
cause	VB	O
prolonged	JJ	O
vasospastic	JJ	O
reactions	NNS	O
.	.	.
		
because	IN	O
there	EX	O
is	VBZ	O
a	DT	O
theoretical	JJ	O
basis	NN	O
that	IN	O
these	DT	O
effects	NNS	O
may	MD	O
be	VB	O
additive	JJ	O
","	","	O
use	NN	O
of	IN	O
ergotamine-containing	JJ	O
or	CC	O
ergot-type	JJ	O
medications	NNS	O
-lrb-	-LRB-	O
like	IN	O
dihydroergotamine	NN	D
or	CC	O
methysergide	NN	D
-rrb-	-RRB-	O
and	CC	O
axert	NN	B
within	IN	O
24	CD	O
hours	NNS	O
of	IN	O
each	DT	O
other	JJ	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	.
		
monoamine	NNP	O
oxidase	NNP	O
inhibitors	NNS	O
:	:	O
coadministration	NN	O
of	IN	O
moclobemide	NN	D
resulted	VBD	O
in	IN	O
a	DT	O
27	CD	O
%	NN	O
decrease	NN	O
in	IN	O
almotriptan	NN	D
clearance	NN	O
and	CC	O
an	DT	O
increase	NN	O
in	IN	O
cmax	NN	O
of	IN	O
approximately	RB	O
6	CD	O
%	NN	O
.	.	.
		
no	DT	O
dose	NN	O
adjustment	NN	O
is	VBZ	O
necessary	JJ	O
.	.	.
		
other	JJ	O
5-ht1b	NN	O
/	:	O
1d	NN	O
agonists	NNS	O
concomitant	JJ	O
use	NN	O
of	IN	O
other	JJ	O
5-ht1b	NN	O
/	:	O
1d	NN	O
agonists	NNS	O
within	IN	O
24	CD	O
hours	NNS	O
of	IN	O
treatment	NN	O
with	IN	O
axert	NN	B
is	VBZ	O
contraindicated	VBN	O
.	.	.
		
propanolol	NNP	D
:	:	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
almotriptan	NN	D
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
coadministration	NN	O
of	IN	O
propranolol	NN	D
.	.	.
		
selective	JJ	O
serotonin	NN	O
reuptake	NNP	O
inhibitors	NNS	O
-lrb-	-LRB-	O
ssris	NNS	G
-rrb-	-RRB-	O
:	:	O
ssris	NNS	G
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
fluoxetine	NN	D
","	","	O
fluvoxamine	NN	D
","	","	O
paroxetine	NN	D
","	","	O
sertraline	NN	D
-rrb-	-RRB-	O
have	VBP	O
been	VBN	O
rarely	RB	O
reported	VBN	O
to	TO	O
cause	VB	O
weakness	NN	O
","	","	O
hyperreflexia	NN	O
","	","	O
and	CC	O
incoordination	NN	O
when	WRB	O
coadministered	VBN	O
with	IN	O
5-ht1	NN	O
agonists	NNS	O
.	.	.
		
if	IN	O
concomitant	JJ	O
treatment	NN	O
with	IN	O
axert	NN	B
and	CC	O
an	DT	O
ssri	NNP	G
is	VBZ	O
clinically	RB	O
warranted	VBN	O
","	","	O
appropriate	JJ	O
observation	NN	O
of	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
advised	VBN	O
.	.	.
		
verapamil	NNP	D
:	:	O
coadministration	NNP	O
of	IN	O
almotriptan	NN	D
and	CC	O
verapamil	NN	D
resulted	VBD	O
in	IN	O
a	DT	O
24	CD	O
%	NN	O
increase	NN	O
in	IN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
almotriptan	NN	D
.	.	.
		
no	DT	O
dose	NN	O
adjustment	NN	O
is	VBZ	O
necessary	JJ	O
.	.	.
		
coadministration	NN	O
of	IN	O
almotriptan	NN	D
and	CC	O
the	DT	O
potent	JJ	O
cyp3a4	NN	D
inhibitor	NN	O
ketoconazole	NN	D
-lrb-	-LRB-	O
400	CD	O
mg	NN	O
q.d.	NN	O
for	IN	O
3	CD	O
days	NNS	O
-rrb-	-RRB-	O
resulted	VBD	O
in	IN	O
an	DT	O
approximately	RB	O
60	CD	O
%	NN	O
increase	NN	O
in	IN	O
the	DT	O
area	NN	O
under	IN	O
the	DT	O
plasma	NN	O
concentration-time	NN	O
curve	NN	O
and	CC	O
maximal	JJ	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
almotriptan	NN	D
.	.	.
		
although	IN	O
the	DT	O
interaction	NN	O
between	IN	O
almotriptan	NN	D
and	CC	O
other	JJ	O
potent	JJ	O
cyp3a4	NN	D
inhibitors	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
itraconazole	NN	D
","	","	O
ritonavir	NN	D
","	","	O
and	CC	O
erythromycin	NN	D
-rrb-	-RRB-	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
","	","	O
increased	VBD	O
exposures	NNS	O
to	TO	O
almotriptan	NN	D
may	MD	O
be	VB	O
expected	VBN	O
when	WRB	O
almotriptan	NN	D
is	VBZ	O
used	VBN	O
concomitantly	RB	O
with	IN	O
these	DT	O
medications	NNS	O
.	.	.
		
axert	NNP	B
is	VBZ	O
not	RB	O
known	VBN	O
to	TO	O
interfere	VB	O
with	IN	O
commonly	RB	O
employed	VBN	O
clinical	JJ	O
laboratory	NN	O
tests	NNS	O
.	.	.
		
because	IN	O
alosetron	NN	D
is	VBZ	O
metabolized	VBN	O
by	IN	O
a	DT	O
variety	NN	O
of	IN	O
hepatic	JJ	O
cyp	NN	O
drug-metabolizing	JJ	O
enzymes	NNS	O
","	","	O
inducers	NNS	O
or	CC	O
inhibitors	NNS	O
of	IN	O
these	DT	O
enzymes	NNS	O
may	MD	O
change	VB	O
the	DT	O
clearance	NN	O
of	IN	O
alosetron	NN	D
.	.	.
		
fluvoxamine	NN	D
is	VBZ	O
a	DT	O
known	JJ	O
strong	JJ	O
inhibitor	NN	O
of	IN	O
cyp1a2	NN	D
and	CC	O
also	RB	O
inhibits	VBZ	O
cyp3a4	NN	D
","	","	O
cyp2c9	NN	D
","	","	O
and	CC	O
cyp2c19	NN	O
.	.	.
		
in	IN	O
a	DT	O
pharmacokinetic	JJ	O
study	NN	O
","	","	O
40	CD	O
healthy	JJ	O
female	JJ	O
subjects	NNS	O
received	VBD	O
fluvoxamine	NN	D
in	IN	O
escalating	VBG	O
doses	NNS	O
from	IN	O
50	CD	O
to	TO	O
200	CD	O
mg	NN	O
per	IN	O
day	NN	O
for	IN	O
16	CD	O
days	NNS	O
","	","	O
with	IN	O
coadministration	NN	O
of	IN	O
alosetron	NN	D
1	CD	O
mg	NN	O
on	IN	O
the	DT	O
last	JJ	O
day	NN	O
.	.	.
		
fluvoxamine	NN	D
increased	VBD	O
mean	JJ	O
alosetron	NN	D
plasma	NN	O
concentrations	NNS	O
-lrb-	-LRB-	O
auc	NN	O
-rrb-	-RRB-	O
approximately	RB	O
6-fold	RB	O
and	CC	O
prolonged	VBD	O
the	DT	O
half-life	NN	O
by	IN	O
approximately	RB	O
3-fold	RB	O
.	.	.
		
concomitant	JJ	O
administration	NN	O
of	IN	O
alosetron	NN	D
and	CC	O
fluvoxamine	NN	D
is	VBZ	O
contraindicated	VBN	O
.	.	.
		
concomitant	JJ	O
administration	NN	O
of	IN	O
alosetron	NN	D
and	CC	O
moderate	JJ	O
cyp1a2	NN	D
inhibitors	NNS	O
","	","	O
including	VBG	O
quinolone	JJ	G
antibiotics	NNS	G
and	CC	O
cimetidine	NN	D
","	","	O
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
","	","	O
but	CC	O
should	MD	O
be	VB	O
avoided	VBN	O
unless	IN	O
clinically	RB	O
necessary	JJ	O
because	IN	O
of	IN	O
similar	JJ	O
potential	JJ	O
drug	NN	D
interactions	NNS	O
.	.	.
		
ketoconazole	NN	D
is	VBZ	O
a	DT	O
known	JJ	O
strong	JJ	O
inhibitor	NN	O
of	IN	O
cyp3a4	NN	D
.	.	.
		
in	IN	O
a	DT	O
pharmacokinetic	JJ	O
study	NN	O
","	","	O
38	CD	O
healthy	JJ	O
female	JJ	O
subjects	NNS	O
received	VBD	O
ketoconazole	NN	D
200	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
for	IN	O
7	CD	O
days	NNS	O
","	","	O
with	IN	O
coadministration	NN	O
of	IN	O
alosetron	NN	D
1	CD	O
mg	NN	O
on	IN	O
the	DT	O
last	JJ	O
day	NN	O
.	.	.
		
ketoconazole	NN	D
increased	VBD	O
mean	JJ	O
alosetron	NN	D
plasma	NN	O
concentrations	NNS	O
-lrb-	-LRB-	O
auc	NN	O
-rrb-	-RRB-	O
by	IN	O
29	CD	O
%	NN	O
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
used	VBN	O
when	WRB	O
alosetron	NN	D
and	CC	O
ketoconazole	NN	D
are	VBP	O
administered	VBN	O
concomitantly	RB	O
.	.	.
		
coadministration	NN	O
of	IN	O
alosetron	NN	D
and	CC	O
strong	JJ	O
cyp3a4	NN	D
inhibitors	NNS	O
","	","	O
such	JJ	O
as	IN	O
clarithromycin	NN	D
","	","	O
telithromycin	NN	D
","	","	O
protease	NN	O
inhibitors	NNS	O
","	","	O
voriconazole	NN	D
","	","	O
and	CC	O
itraconazole	NN	D
has	VBZ	O
not	RB	O
been	VBN	O
evaluated	VBN	O
but	CC	O
should	MD	O
be	VB	O
undertaken	VBN	O
with	IN	O
caution	NN	O
because	IN	O
of	IN	O
similar	JJ	O
potential	JJ	O
drug	NN	D
interactions	NNS	O
.	.	.
		
the	DT	O
effect	NN	O
of	IN	O
induction	NN	O
or	CC	O
inhibition	NN	O
of	IN	O
other	JJ	O
pathways	NNS	O
on	IN	O
exposure	NN	O
to	TO	O
alosetron	NN	D
and	CC	O
its	PRP$	O
metabolites	NNS	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	.
		
in	FW	O
vitro	FW	O
human	JJ	O
liver	NN	O
microsome	NN	O
studies	NNS	O
and	CC	O
an	DT	O
in	FW	O
vivo	FW	O
metabolic	JJ	O
probe	NN	O
study	NN	O
demonstrated	VBD	O
that	IN	O
alosetron	NN	D
did	VBD	O
not	RB	O
inhibit	VB	O
cyp	NN	O
enzymes	NNS	O
2d6	NN	O
","	","	O
3a4	NN	O
","	","	O
2c9	NN	O
","	","	O
or	CC	O
2c19	NN	O
.	.	.
		
in	FW	O
vitro	FW	O
","	","	O
at	IN	O
total	JJ	O
drug	NN	D
concentrations	NNS	O
27-fold	RB	O
higher	JJR	O
than	IN	O
peak	JJ	O
plasma	NN	O
concentrations	NNS	O
observed	VBN	O
with	IN	O
the	DT	O
1-mg	JJ	O
dosage	NN	O
","	","	O
alosetron	NN	D
inhibited	VBD	O
cyp	NN	O
enzymes	NNS	O
1a2	NN	O
-lrb-	-LRB-	O
60	CD	O
%	NN	O
-rrb-	-RRB-	O
and	CC	O
2.00E+01	NN	O
-lrb-	-LRB-	O
50	CD	O
%	NN	O
-rrb-	-RRB-	O
.	.	.
		
in	IN	O
an	DT	O
in	FW	O
vivo	FW	O
metabolic	JJ	O
probe	NN	O
study	NN	O
","	","	O
alosetron	NN	D
did	VBD	O
not	RB	O
inhibit	VB	O
cyp2e1	NN	O
but	CC	O
did	VBD	O
produce	VB	O
30	CD	O
%	NN	O
inhibition	NN	O
of	IN	O
both	CC	O
cyp1a2	NN	D
and	CC	O
n-acetyltransferase	NN	O
.	.	.
		
although	IN	O
not	RB	O
studied	VBN	O
with	IN	O
alosetron	NN	D
","	","	O
inhibition	NN	O
of	IN	O
n-acetyltransferase	NN	O
may	MD	O
have	VB	O
clinically	RB	O
relevant	JJ	O
consequences	NNS	O
for	IN	O
drugs	NNS	D
such	JJ	O
as	IN	O
isoniazid	NN	D
","	","	O
procainamide	NN	D
","	","	O
and	CC	O
hydralazine	NN	D
.	.	.
		
the	DT	O
effect	NN	O
on	IN	O
cyp1a2	NN	D
was	VBD	O
explored	VBN	O
further	RB	O
in	IN	O
a	DT	O
clinical	JJ	O
interaction	NN	O
study	NN	O
with	IN	O
theophylline	NN	D
and	CC	O
no	DT	O
effect	NN	O
on	IN	O
metabolism	NN	O
was	VBD	O
observed	VBN	O
.	.	.
		
another	DT	O
study	NN	O
showed	VBD	O
that	IN	O
alosetron	NN	D
had	VBD	O
no	DT	O
clinically	RB	O
significant	JJ	O
effect	NN	O
on	IN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
the	DT	O
oral	JJ	O
contraceptive	JJ	O
agents	NNS	O
ethinyl	NN	O
estradiol	NN	O
and	CC	O
levonorgestrel	NN	D
-lrb-	-LRB-	O
cyp3a4	NN	D
substrates	NNS	O
-rrb-	-RRB-	O
.	.	.
		
a	DT	O
clinical	JJ	O
interaction	NN	O
study	NN	O
was	VBD	O
also	RB	O
conducted	VBN	O
with	IN	O
alosetron	NN	D
and	CC	O
the	DT	O
cyp3a4	NN	D
substrate	NN	O
cisapride	NN	D
.	.	.
		
no	DT	O
significant	JJ	O
effects	NNS	O
on	IN	O
cisapride	NN	D
metabolism	NN	O
or	CC	O
qt	NN	O
interval	NN	O
were	VBD	O
noted	VBN	O
.	.	.
		
the	DT	O
effect	NN	O
of	IN	O
alosetron	NN	D
on	IN	O
monoamine	NN	O
oxidases	NNS	O
and	CC	O
on	IN	O
intestinal	JJ	O
first	JJ	O
pass	NN	O
secondary	JJ	O
to	TO	O
high	JJ	O
intraluminal	JJ	O
concentrations	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
examined	VBN	O
.	.	.
		
based	VBN	O
on	IN	O
the	DT	O
above	JJ	O
data	NNS	O
from	IN	O
in	FW	O
vitro	FW	O
and	CC	O
in	FW	O
vivo	FW	O
studies	NNS	O
","	","	O
it	PRP	O
is	VBZ	O
unlikely	JJ	O
that	IN	O
alosetron	NN	D
will	MD	O
inhibit	VB	O
the	DT	O
hepatic	JJ	O
metabolic	JJ	O
clearance	NN	O
of	IN	O
drugs	NNS	D
metabolized	VBN	O
by	IN	O
the	DT	O
major	JJ	O
cyp	NN	O
enzyme	NN	O
3a4	NN	O
","	","	O
as	RB	O
well	RB	O
as	IN	O
the	DT	O
cyp	NN	O
enzymes	NNS	O
2d6	NN	O
","	","	O
2c9	NN	O
","	","	O
2c19	NN	O
","	","	O
2.00E+01	NN	O
","	","	O
or	CC	O
1a2	NN	O
.	.	.
		
alosetron	NNP	D
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
induce	VB	O
the	DT	O
major	JJ	O
cytochrome	NN	O
p450	NN	O
-lrb-	-LRB-	O
cyp	NN	O
-rrb-	-RRB-	O
drug	NN	D
metabolizing	VBG	O
enzyme	NN	O
3a	NN	O
.	.	.
		
alosetron	NNP	D
also	RB	O
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
induce	VB	O
cyp	NN	O
enzymes	NNS	O
2.00E+01	NN	O
or	CC	O
2c19	NN	O
.	.	.
		
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
alosetron	NN	D
might	MD	O
induce	VB	O
other	JJ	O
enzymes	NNS	O
.	.	.
		
the	DT	O
benzodiazepines	NNS	G
","	","	O
including	VBG	O
alprazolam	NN	D
","	","	O
produce	VBP	O
additive	JJ	O
cns	NNS	O
depressant	NN	O
effects	NNS	O
when	WRB	O
co-administered	VBN	O
with	IN	O
other	JJ	O
psychotropic	JJ	O
medications	NNS	O
","	","	O
anticonvulsants	NNS	G
","	","	O
antihistaminics	NNS	G
","	","	O
ethanol	NN	D
","	","	O
and	CC	O
other	JJ	O
drugs	NNS	D
which	WDT	O
themselves	PRP	O
produce	VBP	O
cns	NN	O
depression	NN	O
.	.	.
		
the	DT	O
steady	JJ	O
state	NN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
imipramine	NN	D
and	CC	O
desipramine	NN	D
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
increased	VBN	O
an	DT	O
average	NN	O
of	IN	O
31	CD	O
%	NN	O
and	CC	O
20	CD	O
%	NN	O
","	","	O
respectively	RB	O
","	","	O
by	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
alprazolam	NN	D
tablets	NNS	O
in	IN	O
doses	NNS	O
up	RB	O
to	TO	O
4	CD	O
mg/day	NN	O
.	.	.
		
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
these	DT	O
changes	NNS	O
is	VBZ	O
unknown	JJ	O
.	.	.
		
drugs	NNS	O
that	WDT	O
inhibit	VBP	O
alprazolam	NNP	D
metabolism	NNP	O
via	NNP	O
cytochrome	NNP	O
p450	NN	O
3a	NN	O
:	:	O
the	DT	O
initial	JJ	O
step	NN	O
in	IN	O
alprazolam	NN	D
metabolism	NN	O
is	VBZ	O
hydroxylation	NN	O
catalyzed	VBN	O
by	IN	O
cytochrome	NN	O
p450	NN	O
3a	NN	O
-lrb-	-LRB-	O
cyp	NN	O
3a	NN	O
-rrb-	-RRB-	O
.	.	.
		
drugs	NNS	O
which	WDT	O
inhibit	VBP	O
this	DT	O
metabolic	JJ	O
pathway	NN	O
may	MD	O
have	VB	O
a	DT	O
profound	JJ	O
effect	NN	O
on	IN	O
the	DT	O
clearance	NN	O
of	IN	O
alprazolam	NN	D
.	.	.
		
drugs	NNS	O
demonstrated	VBN	O
to	TO	O
be	VB	O
cyp	NN	O
3a	NN	O
inhibitors	NNS	O
of	IN	O
possible	JJ	O
clinical	JJ	O
significance	NN	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
clinical	JJ	O
studies	NNS	O
involving	VBG	O
alprazolam	NN	D
-lrb-	-LRB-	O
caution	NN	O
is	VBZ	O
recommended	VBN	O
during	IN	O
coadministration	NN	O
with	IN	O
alprazolam	NN	D
-rrb-	-RRB-	O
:	:	O
coadministration	NN	O
of	IN	O
fluoxetine	NN	D
with	IN	O
alprazolam	NN	D
increased	VBD	O
the	DT	O
maximum	NN	O
plasma	NN	O
concentration	NN	O
of	IN	O
alprazolam	NN	D
by	IN	O
46	CD	O
%	NN	O
","	","	O
decreased	VBD	O
clearance	NN	O
by	IN	O
21	CD	O
%	NN	O
","	","	O
increased	VBD	O
half-life	NN	O
by	IN	O
17	CD	O
%	NN	O
","	","	O
and	CC	O
decreased	VBD	O
measured	VBN	O
psychomotor	NN	O
performance	NN	O
.	.	.
		
coadministration	NN	O
of	IN	O
propoxyphene	NN	D
decreased	VBD	O
the	DT	O
maximum	NN	O
plasma	NN	O
concentration	NN	O
of	IN	O
alprazolam	NN	D
by	IN	O
6	CD	O
%	NN	O
","	","	O
decreased	VBD	O
clearance	NN	O
by	IN	O
38	CD	O
%	NN	O
","	","	O
and	CC	O
increased	VBD	O
half-life	NN	O
by	IN	O
58	CD	O
%	NN	O
.	.	.
		
coadministration	NN	O
of	IN	O
oral	JJ	O
contraceptives	NNS	G
increased	VBD	O
the	DT	O
maximum	NN	O
plasma	NN	O
concentration	NN	O
of	IN	O
alprazolam	NN	D
by	IN	O
18	CD	O
%	NN	O
","	","	O
decreased	VBD	O
clearance	NN	O
by	IN	O
22	CD	O
%	NN	O
","	","	O
and	CC	O
increased	VBD	O
half-life	NN	O
by	IN	O
29	CD	O
%	NN	O
.	.	.
		
drugs	NNS	O
and	CC	O
other	JJ	O
substances	NNS	O
demonstrated	VBD	O
to	TO	O
be	VB	O
cyp	NN	O
3a	NN	O
inhibitors	NNS	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
clinical	JJ	O
studies	NNS	O
involving	VBG	O
benzodiazepines	NNS	G
metabolized	VBN	O
similarly	RB	O
to	TO	O
alprazolam	NN	D
or	CC	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
in	FW	O
vitro	FW	O
studies	NNS	O
with	IN	O
alprazolam	NN	D
or	CC	O
other	JJ	O
benzodiazepines	NNS	G
-lrb-	-LRB-	O
caution	NN	O
is	VBZ	O
recommended	VBN	O
during	IN	O
coadministration	NN	O
with	IN	O
alprazolam	NN	D
-rrb-	-RRB-	O
:	:	O
available	JJ	O
data	NNS	O
from	IN	O
clinical	JJ	O
studies	NNS	O
of	IN	O
benzodiazepines	NNS	G
other	JJ	O
than	IN	O
alprazolam	NN	D
suggest	VBP	O
a	DT	O
possible	JJ	O
drug	NN	D
interaction	NN	O
with	IN	O
alprazolam	NN	D
for	IN	O
the	DT	O
following	NN	O
:	:	O
diltiazem	NN	D
","	","	O
isoniazid	NN	D
","	","	O
macrolide	NN	O
antibiotics	NNS	G
such	JJ	O
as	IN	O
erythromycin	NN	D
and	CC	O
clarithromycin	NN	D
","	","	O
and	CC	O
grapefruit	NN	O
juice	NN	O
.	.	.
		
data	NNS	O
from	IN	O
in	FW	O
vitro	FW	O
studies	NNS	O
of	IN	O
alprazolam	NN	D
suggest	VBP	O
a	DT	O
possible	JJ	O
drug	NN	D
interaction	NN	O
with	IN	O
alprazolam	NN	D
for	IN	O
the	DT	O
following	NN	O
:	:	O
sertraline	NN	D
and	CC	O
paroxetine	NN	D
.	.	.
		
data	NNS	O
from	IN	O
in	FW	O
vitro	FW	O
studies	NNS	O
of	IN	O
benzodiazepines	NNS	G
other	JJ	O
than	IN	O
alprazolam	NN	D
suggest	VBP	O
a	DT	O
possible	JJ	O
drug	NN	D
interaction	NN	O
for	IN	O
the	DT	O
following	NN	O
:	:	O
ergotamine	NN	D
","	","	O
cyclosporine	NN	D
","	","	O
amiodarone	NN	D
","	","	O
nicardipine	NN	D
","	","	O
and	CC	O
nifedipine	NN	D
.	.	.
		
caution	NN	O
is	VBZ	O
recommended	VBN	O
during	IN	O
the	DT	O
coadministration	NN	O
of	IN	O
any	DT	O
of	IN	O
these	DT	O
with	IN	O
alprazolam	NN	D
.	.	.
		
no	DT	O
drug	NN	D
interactions	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
between	IN	O
prostin	NNP	O
vr	NN	O
pediatric	NNP	O
and	CC	O
the	DT	O
therapy	NN	O
standard	NN	O
in	IN	O
neonates	NNS	O
with	IN	O
restricted	JJ	O
pulmonary	JJ	O
or	CC	O
systemic	JJ	O
blood	NN	O
flow	NN	O
.	.	.
		
standard	JJ	O
therapy	NN	O
includes	VBZ	O
antibiotics	NNS	G
","	","	O
such	JJ	O
as	IN	O
penicillin	NN	D
and	CC	O
gentamicin	NN	D
.	.	.
		
vasopressors	NNS	G
","	","	O
such	JJ	O
as	IN	O
dopamine	NN	D
and	CC	O
isoproterenol	NN	D
.	.	.
		
cardiac	JJ	O
glycosides	NNS	O
.	.	.
		
and	CC	O
diuretics	NNS	G
","	","	O
such	JJ	O
as	IN	O
furosemide	NN	D
.	.	.
		
caverject	NNP	B
:	:	O
the	DT	O
potential	NN	O
for	IN	O
pharmacokinetic	JJ	O
drug-drug	NN	O
interactions	NNS	O
between	IN	O
alprostadil	NN	D
and	CC	O
other	JJ	O
agents	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
formally	RB	O
studied	VBN	O
.	.	.
		
the	DT	O
interaction	NN	O
of	IN	O
activase	NN	B
with	IN	O
other	JJ	O
cardioactive	JJ	O
or	CC	O
cerebroactive	JJ	O
drugs	NNS	D
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	.
		
in	IN	O
addition	NN	O
to	TO	O
bleeding	NN	O
associated	VBN	O
with	IN	O
heparin	NN	D
and	CC	O
vitamin	NN	O
k	NN	O
antagonists	NNS	O
","	","	O
drugs	NNS	D
that	WDT	O
alter	VBP	O
platelet	NN	O
function	NN	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
acetylsalicylic	JJ	O
acid	NN	O
","	","	O
dipyridamole	NN	D
and	CC	O
abciximab	NNP	D
-rrb-	-RRB-	O
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
bleeding	VBG	O
if	IN	O
administered	VBN	O
prior	RB	O
to	TO	O
","	","	O
during	IN	O
","	","	O
or	CC	O
after	IN	O
activase	NN	B
therapy	NN	O
.	.	.
		
use	NN	O
of	IN	O
antithrombotics	NNP	G
aspirin	NNP	B
and	CC	O
heparin	NN	D
have	VBP	O
been	VBN	O
administered	VBN	O
concomitantly	RB	O
with	IN	O
and	CC	O
following	VBG	O
infusions	NNS	O
of	IN	O
activase	NNP	B
in	IN	O
the	DT	O
management	NN	O
of	IN	O
acute	JJ	O
myocardial	JJ	O
infarction	NN	O
or	CC	O
pulmonary	JJ	O
embolism	NN	O
.	.	.
		
because	IN	O
heparin	NN	D
","	","	O
aspirin	NN	B
","	","	O
or	CC	O
activase	NNP	B
may	MD	O
cause	VB	O
bleeding	JJ	O
complications	NNS	O
","	","	O
careful	JJ	O
monitoring	NN	O
for	IN	O
bleeding	NN	O
is	VBZ	O
advised	VBN	O
","	","	O
especially	RB	O
at	IN	O
arterial	JJ	O
puncture	NN	O
sites	NNS	O
.	.	.
		
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
heparin	NN	D
or	CC	O
aspirin	NN	B
during	IN	O
the	DT	O
first	JJ	O
24	CD	O
hours	NNS	O
following	VBG	O
symptom	NN	O
onset	NN	O
were	VBD	O
prohibited	VBN	O
in	IN	O
the	DT	O
ninds	NN	O
t-pa	NN	O
stroke	NNP	O
trial	NNP	O
.	.	.
		
the	DT	O
safety	NN	O
of	IN	O
such	JJ	O
concomitant	JJ	O
use	NN	O
with	IN	O
activase	NN	B
for	IN	O
the	DT	O
management	NN	O
of	IN	O
acute	JJ	O
ischemic	JJ	O
stroke	NN	O
is	VBZ	O
unknown	JJ	O
.	.	.
		
concurrent	JJ	O
administration	NN	O
of	IN	O
hexalen	NN	B
and	CC	O
antidepressants	NNS	G
of	IN	O
the	DT	O
mao	NNP	O
inhibitor	NN	O
class	NN	O
may	MD	O
cause	VB	O
severe	JJ	O
orthostatic	JJ	O
hypotension.cimetidine	NN	O
","	","	O
an	DT	O
inhibitor	NN	O
of	IN	O
microsomal	JJ	O
drug	NN	D
metabolism	NN	O
","	","	O
increased	VBD	O
altretamines	NNS	O
half-life	NN	O
and	CC	O
toxicity	NN	O
in	IN	O
a	DT	O
rat	NN	O
model	NN	O
.	.	.
		
data	NNS	O
from	IN	O
a	DT	O
randomized	JJ	O
trial	NN	O
of	IN	O
hexalen	NN	B
and	CC	O
cisplatin	NN	D
plus	CC	O
or	CC	O
minus	CC	O
pyridoxine	NN	D
in	IN	O
ovarian	JJ	O
cancer	NN	O
indicated	VBD	O
that	IN	O
pyridoxine	NN	D
significantly	RB	O
reduced	VBD	O
neurotoxicity	NN	O
.	.	.
		
however	RB	O
","	","	O
it	PRP	O
adversely	RB	O
affected	VBD	O
response	NN	O
duration	NN	O
suggesting	VBG	O
that	IN	O
pyridoxine	NN	D
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
with	IN	O
hexalen	NN	B
and/or	CC	O
cisplatin	NN	D
.	.	.
		
careful	JJ	O
observation	NN	O
is	VBZ	O
required	VBN	O
when	WRB	O
amantadine	NN	D
is	VBZ	O
administered	VBN	O
concurrently	RB	O
with	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
stimulants	NNS	O
.	.	.
		
coadministration	NN	O
of	IN	O
thioridazine	NN	D
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
worsen	VB	O
the	DT	O
tremor	NN	O
in	IN	O
elderly	JJ	O
patients	NNS	O
with	IN	O
parkinsons	NNPS	O
disease	NN	O
.	.	.
		
however	RB	O
","	","	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
if	IN	O
other	JJ	O
phenothiazines	NNS	G
produce	VBP	O
a	DT	O
similar	JJ	O
response	NN	O
.	.	.
		
special	JJ	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
the	DT	O
administration	NN	O
of	IN	O
ethyol	NNP	B
in	IN	O
patients	NNS	O
receiving	VBG	O
antihypertensive	JJ	O
medications	NNS	O
or	CC	O
other	JJ	O
drugs	NNS	D
that	WDT	O
could	MD	O
cause	VB	O
or	CC	O
potentiate	VB	O
hypotension	NN	O
.	.	.
		
when	WRB	O
amiloride	NN	D
hcl	NN	O
is	VBZ	O
administered	VBN	O
concomitantly	RB	O
with	IN	O
an	DT	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitor	NN	O
","	","	O
the	DT	O
risk	NN	O
of	IN	O
hyperkalemia	NN	O
may	MD	O
be	VB	O
increased	VBN	O
.	.	.
		
therefore	RB	O
","	","	O
if	IN	O
concomitant	JJ	O
use	NN	O
of	IN	O
these	DT	O
agents	NNS	O
is	VBZ	O
indicated	VBN	O
because	IN	O
of	IN	O
demonstrated	VBN	O
hypokalemia	NN	O
","	","	O
they	PRP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
and	CC	O
with	IN	O
frequent	JJ	O
monitoring	NN	O
of	IN	O
serum	NN	O
potassium	NN	D
.	.	.
		
lithium	NN	D
generally	RB	O
should	MD	O
not	RB	O
be	VB	O
given	VBN	O
with	IN	O
diuretics	NNS	G
because	IN	O
they	PRP	O
reduce	VBP	O
its	PRP$	O
renal	JJ	O
clearance	NN	O
and	CC	O
add	VB	O
a	DT	O
high	JJ	O
risk	NN	O
of	IN	O
lithium	NN	D
toxicity	NN	O
.	.	.
		
read	VB	O
circulars	NNS	O
for	IN	O
lithium	NN	D
preparations	NNS	O
before	IN	O
use	NN	O
of	IN	O
such	JJ	O
concomitant	JJ	O
therapy	NN	O
.	.	.
		
in	IN	O
some	DT	O
patients	NNS	O
","	","	O
the	DT	O
administration	NN	O
of	IN	O
a	DT	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
agent	NN	O
can	MD	O
reduce	VB	O
the	DT	O
diuretic	JJ	G
","	","	O
natriuretic	JJ	O
","	","	O
and	CC	O
antihypertensive	JJ	O
effects	NNS	O
of	IN	O
loop	NN	O
","	","	O
potassium-sparing	NN	O
and	CC	O
thiazide	JJ	O
diuretics	NNS	G
.	.	.
		
therefore	RB	O
","	","	O
when	WRB	O
midamor	NN	B
and	CC	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
agents	NNS	O
are	VBP	O
used	VBN	O
concomitantly	RB	O
","	","	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
observed	VBN	O
closely	RB	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
desired	VBN	O
effect	NN	O
of	IN	O
the	DT	O
diuretic	JJ	G
is	VBZ	O
obtained	VBN	O
.	.	.
		
since	IN	O
indomethacin	NN	D
and	CC	O
potassium-sparing	JJ	O
diuretics	NNS	G
","	","	O
including	VBG	O
midamor	NNP	B
","	","	O
may	MD	O
each	DT	O
be	VB	O
associated	VBN	O
with	IN	O
increased	VBN	O
serum	NN	O
potassium	NN	D
levels	NNS	O
","	","	O
the	DT	O
potential	JJ	O
effects	NNS	O
on	IN	O
potassium	NN	D
kinetics	NNS	O
and	CC	O
renal	JJ	O
function	NN	O
should	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
these	DT	O
agents	NNS	O
are	VBP	O
administered	VBN	O
concurrently	RB	O
.	.	.
		
drug	NNP	O
laboratory	NNP	O
test	NNP	O
interactions	NNS	O
:	:	O
prolongation	NN	O
of	IN	O
the	DT	O
template	NN	O
bleeding	NN	O
time	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
during	IN	O
continuous	JJ	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
amicar	NN	B
at	IN	O
dosages	NNS	O
exceeding	VBG	O
24	CD	O
g/day	NN	O
.	.	.
		
platelet	NN	O
function	NN	O
studies	NNS	O
in	IN	O
these	DT	O
patients	NNS	O
have	VBP	O
not	RB	O
demonstrated	VBN	O
any	DT	O
significant	JJ	O
platelet	NN	O
dysfunction	NN	O
.	.	.
		
however	RB	O
","	","	O
in	FW	O
vitro	FW	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
at	IN	O
high	JJ	O
concentrations	NNS	O
-lrb-	-LRB-	O
7.4	CD	O
mmol/l	NN	O
or	CC	O
0.97	CD	O
mg/ml	NN	O
and	CC	O
greater	JJR	O
-rrb-	-RRB-	O
eaca	NN	D
inhibits	VBZ	O
adp	NN	O
and	CC	O
collagen-induced	JJ	O
platelet	NN	O
aggregation	NN	O
","	","	O
the	DT	O
release	NN	O
of	IN	O
atp	NN	O
and	CC	O
serotonin	NN	O
","	","	O
and	CC	O
the	DT	O
binding	NN	O
of	IN	O
fibrinogen	NN	O
to	TO	O
the	DT	O
platelets	NNS	O
in	IN	O
a	DT	O
concentration-response	JJ	O
manner	NN	O
.	.	.
		
following	VBG	O
a	DT	O
10	CD	O
g	NN	O
bolus	NN	O
of	IN	O
amicar	NNP	B
","	","	O
transient	JJ	O
peak	NN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
4.6	CD	O
mmol/l	NN	O
or	CC	O
0.6	CD	O
mg/ml	NN	O
have	VBP	O
been	VBN	O
obtained	VBN	O
.	.	.
		
the	DT	O
concentration	NN	O
of	IN	O
amicar	NNP	B
necessary	JJ	O
to	TO	O
maintain	VB	O
inhibition	NN	O
of	IN	O
fibrinolysis	NN	O
is	VBZ	O
0.99	CD	O
mmol/l	NN	O
or	CC	O
0.13	CD	O
mg/ml	NN	O
.	.	.
		
administration	NN	O
of	IN	O
a	DT	O
5	CD	O
g	NN	O
bolus	NN	O
followed	VBN	O
by	IN	O
1	CD	O
to	TO	O
1.25	CD	O
g/hr	NN	O
should	MD	O
achieve	VB	O
and	CC	O
sustain	VB	O
plasma	NN	O
levels	NNS	O
of	IN	O
0.13	CD	O
mg/ml	NN	O
.	.	.
		
thus	RB	O
","	","	O
concentrations	NNS	O
which	WDT	O
have	VBP	O
been	VBN	O
obtained	VBN	O
in	FW	O
vivo	FW	O
clinically	RB	O
in	IN	O
patients	NNS	O
with	IN	O
normal	JJ	O
renal	JJ	O
function	NN	O
are	VBP	O
considerably	RB	O
lower	JJR	O
than	IN	O
the	DT	O
in	FW	O
vitro	FW	O
concentrations	NNS	O
found	VBN	O
to	TO	O
induce	VB	O
abnormalities	NNS	O
in	IN	O
platelet	NN	O
function	NN	O
tests	NNS	O
.	.	.
		
however	RB	O
","	","	O
higher	JJR	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
amicar	NN	B
may	MD	O
occur	VB	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
renal	JJ	O
failure	NN	O
.	.	.
		
cytadren	NN	B
accelerates	VBZ	O
the	DT	O
metabolism	NN	O
of	IN	O
dexamethasone	NN	D
.	.	.
		
therefore	RB	O
","	","	O
if	IN	O
glucocorticoid	NN	G
replacement	NN	O
is	VBZ	O
needed	VBN	O
","	","	O
hydrocortisone	NN	D
should	MD	O
be	VB	O
prescribed	VBN	O
.	.	.
		
aminoglutethimide	NNP	D
diminishes	VBZ	O
the	DT	O
effect	NN	O
of	IN	O
coumarin	NN	G
and	CC	O
warfarin	NN	D
.	.	.
		
renal	JJ	O
clearance	NN	O
measurements	NNS	O
of	IN	O
pah	NN	D
can	MD	O
not	RB	O
be	VB	O
made	VBN	O
with	IN	O
any	DT	O
significant	JJ	O
accuracy	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
sulfonamides	NNS	G
","	","	O
procaine	NN	D
","	","	O
or	CC	O
thiazolesulfone	NN	D
.	.	.
		
these	DT	O
compounds	NNS	O
interfere	VBP	O
with	IN	O
chemical	NN	O
color	NN	O
development	NN	O
essential	JJ	O
to	TO	O
the	DT	O
analytical	JJ	O
procedures	NNS	O
.	.	.
		
probenecid	NNP	D
depresses	VBZ	O
tubular	JJ	O
secretion	NN	O
of	IN	O
certain	JJ	O
weak	JJ	O
acids	NNS	O
such	JJ	O
as	IN	O
pah	NN	D
.	.	.
		
therefore	RB	O
","	","	O
patients	NNS	O
receiving	VBG	O
probenecid	NN	D
will	MD	O
have	VB	O
erroneously	RB	O
low	JJ	O
erpf	NN	O
and	CC	O
tm	NN	O
pah	NN	D
values	NNS	O
.	.	.
		
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
formal	JJ	O
studies	NNS	O
of	IN	O
the	DT	O
interaction	NN	O
of	IN	O
levulan	NNP	O
kerastick	NNP	O
for	IN	O
topical	NNP	O
solution	NN	O
with	IN	O
any	DT	O
other	JJ	O
drugs	NNS	D
","	","	O
and	CC	O
no	DT	O
drug-specific	JJ	O
interactions	NNS	O
were	VBD	O
noted	VBN	O
during	IN	O
any	DT	O
of	IN	O
the	DT	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
.	.	.
		
it	PRP	O
is	VBZ	O
","	","	O
however	RB	O
","	","	O
possible	JJ	O
that	IN	O
concomitant	JJ	O
use	NN	O
of	IN	O
other	JJ	O
known	JJ	O
photosensitizing	JJ	O
agents	NNS	O
such	JJ	O
as	IN	O
griseofulvin	NN	D
","	","	O
thiazide	JJ	O
diuretics	NNS	G
","	","	O
sulfonylureas	NNS	G
","	","	O
phenothiazines	NNS	G
","	","	O
sulfonamides	NNS	G
and	CC	O
tetracyclines	NNS	G
might	MD	O
increase	VB	O
the	DT	O
photosensitivity	NN	O
reaction	NN	O
of	IN	O
actinic	JJ	O
keratoses	NNS	O
treated	VBN	O
with	IN	O
the	DT	O
levulan	NNP	O
kerastick	NNP	O
for	IN	O
topical	NNP	O
solution	NN	O
.	.	.
		
aminosalicylic	JJ	O
acid	NN	O
may	MD	O
decrease	VB	O
the	DT	O
amount	NN	O
of	IN	O
digoxin	NN	D
-lrb-	-LRB-	O
lanoxin	NN	B
","	","	O
lanoxicaps	NN	D
-rrb-	-RRB-	O
that	WDT	O
gets	VBZ	O
absorbed	VBN	O
into	IN	O
your	PRP$	O
body	NN	O
.	.	.
		
in	IN	O
the	DT	O
case	NN	O
that	IN	O
you	PRP	O
are	VBP	O
taking	VBG	O
digoxin	NN	D
while	IN	O
taking	VBG	O
aminosalicylic	JJ	O
acid	NN	O
","	","	O
higher	JJR	O
doses	NNS	O
of	IN	O
digoxin	NN	D
may	MD	O
be	VB	O
needed	VBN	O
.	.	.
		
aminosalicylic	JJ	O
acid	NN	O
may	MD	O
also	RB	O
decrease	VB	O
the	DT	O
absorption	NN	O
of	IN	O
vitamin	NN	O
b12	NN	O
","	","	O
which	WDT	O
can	MD	O
lead	VB	O
to	TO	O
a	DT	O
deficiency	NN	O
.	.	.
		
therefore	RB	O
you	PRP	O
may	MD	O
need	VB	O
to	TO	O
take	VB	O
a	DT	O
vitamin	NN	O
b12	NN	O
supplement	NN	O
while	IN	O
taking	VBG	O
aminosalicylic	JJ	O
acid	NN	O
.	.	.
		
amiodarone	NNP	D
is	VBZ	O
metabolized	VBN	O
to	TO	O
desethylamiodarone	VBN	D
by	IN	O
the	DT	O
cytochrome	NN	O
p450	NN	O
-lrb-	-LRB-	O
cyp450	NN	O
-rrb-	-RRB-	O
enzyme	NN	O
group	NN	O
","	","	O
specifically	RB	O
cytochromes	VBZ	O
p450	NN	O
3a4	NN	O
-lrb-	-LRB-	O
cyp3a4	NN	D
-rrb-	-RRB-	O
and	CC	O
cyp2c8	NN	O
.	.	.
		
the	DT	O
cyp3a4	NN	D
isoenzyme	NN	O
is	VBZ	O
present	JJ	O
in	IN	O
both	CC	O
the	DT	O
liver	NN	O
and	CC	O
intestines	NNS	O
.	.	.
		
amiodarone	NNP	D
is	VBZ	O
also	RB	O
known	VBN	O
to	TO	O
be	VB	O
an	DT	O
inhibitor	NN	O
of	IN	O
cyp3a4	NN	D
.	.	.
		
therefore	RB	O
","	","	O
amiodarone	NN	D
has	VBZ	O
the	DT	O
potential	NN	O
for	IN	O
interactions	NNS	O
with	IN	O
drugs	NNS	D
or	CC	O
substances	NNS	O
that	WDT	O
may	MD	O
be	VB	O
substrates	NNS	O
","	","	O
inhibitors	NNS	O
or	CC	O
inducers	NNS	O
of	IN	O
cyp3a4	NN	D
.	.	.
		
while	IN	O
only	RB	O
a	DT	O
limited	JJ	O
number	NN	O
of	IN	O
in	FW	O
vivo	FW	O
drug-drug	JJ	O
interactions	NNS	O
with	IN	O
amiodarone	NN	D
have	VBP	O
been	VBN	O
reported	VBN	O
","	","	O
chiefly	RB	O
with	IN	O
the	DT	O
oral	JJ	O
formulation	NN	O
","	","	O
the	DT	O
potential	NN	O
for	IN	O
other	JJ	O
interactions	NNS	O
should	MD	O
be	VB	O
anticipated	VBN	O
.	.	.
		
this	DT	O
is	VBZ	O
especially	RB	O
important	JJ	O
for	IN	O
drugs	NNS	D
associated	VBN	O
with	IN	O
serious	JJ	O
toxicity	NN	O
","	","	O
such	JJ	O
as	IN	O
other	JJ	O
antiarrhythmics	NNS	G
.	.	.
		
if	IN	O
such	JJ	O
drugs	NNS	D
are	VBP	O
needed	VBN	O
","	","	O
their	PRP$	O
dose	NN	O
should	MD	O
be	VB	O
reassessed	VBN	O
and	CC	O
","	","	O
where	WRB	O
appropriate	JJ	O
","	","	O
plasma	NN	O
concentration	NN	O
measured	VBN	O
.	.	.
		
in	IN	O
view	NN	O
of	IN	O
the	DT	O
long	JJ	O
and	CC	O
variable	JJ	O
half-life	NN	O
of	IN	O
amiodarone	NN	D
","	","	O
potential	NN	O
for	IN	O
drug	NN	D
interactions	NNS	O
exists	VBZ	O
not	RB	O
only	RB	O
with	IN	O
concomitant	JJ	O
medication	NN	O
but	CC	O
also	RB	O
with	IN	O
drugs	NNS	D
administered	VBN	O
after	IN	O
discontinuation	NN	O
of	IN	O
amiodarone	NN	D
.	.	.
		
since	IN	O
amiodarone	NN	D
is	VBZ	O
a	DT	O
substrate	NN	O
for	IN	O
cyp3a4	NN	D
and	CC	O
cyp2c8	NN	O
","	","	O
drugs/substances	NNS	O
that	WDT	O
inhibit	VBP	O
these	DT	O
isoenzymes	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
metabolism	NN	O
and	CC	O
increase	NN	O
serum	NN	O
concentration	NN	O
of	IN	O
amiodarone	NN	D
.	.	.
		
reported	VBN	O
examples	NNS	O
include	VBP	O
the	DT	O
following	NN	O
:	:	O
protease	NN	O
inhibitors	NNS	O
:	:	O
protease	NN	O
inhibitors	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
inhibit	VB	O
cyp3a4	NN	D
to	TO	O
varying	VBG	O
degrees	NNS	O
.	.	.
		
a	DT	O
case	NN	O
report	NN	O
of	IN	O
one	CD	O
patient	NN	O
taking	VBG	O
amiodarone	NN	D
200	CD	O
mg	NN	O
and	CC	O
indinavir	NN	D
800	CD	O
mg	NN	O
three	CD	O
times	NNS	O
a	DT	O
day	NN	O
resulted	VBD	O
in	IN	O
increases	NNS	O
in	IN	O
amiodarone	NN	D
concentrations	NNS	O
from	IN	O
0.9	CD	O
mg/l	NN	O
to	TO	O
1.3	CD	O
mg/l	NN	O
.	.	.
		
dea	NNP	O
concentrations	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
.	.	.
		
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
toxicity	NN	O
.	.	.
		
monitoring	VBG	O
for	IN	O
amiodarone	NN	D
toxicity	NN	O
and	CC	O
serial	NN	O
measurement	NN	O
of	IN	O
amiodarone	NN	D
serum	NN	O
concentration	NN	O
during	IN	O
concomitant	JJ	O
protease	NN	O
inhibitor	NN	O
therapy	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	.
		
histamine	NN	O
h2	NN	O
antagonists	NNS	O
:	:	O
cimetidine	NN	D
inhibits	VBZ	O
cyp3a4	NN	D
and	CC	O
can	MD	O
increase	VB	O
serum	NN	O
amiodarone	NN	D
levels	NNS	O
.	.	.
		
other	JJ	O
substances	NNS	O
:	:	O
grapefruit	NN	O
juice	NN	O
given	VBN	O
to	TO	O
healthy	JJ	O
volunteers	NNS	O
increased	VBD	O
amiodarone	NN	D
auc	NN	O
by	IN	O
50	CD	O
%	NN	O
and	CC	O
cmax	NN	O
by	IN	O
84	CD	O
%	NN	O
","	","	O
resulting	VBG	O
in	IN	O
increased	VBN	O
plasma	NN	O
levels	NNS	O
of	IN	O
amiodarone	NN	D
.	.	.
		
grapefruit	NN	O
juice	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
oral	JJ	O
amiodarone	NN	D
.	.	.
		
this	DT	O
information	NN	O
should	MD	O
be	VB	O
considered	VBN	O
when	WRB	O
changing	VBG	O
from	IN	O
intravenous	JJ	O
amiodarone	NN	D
to	TO	O
oral	JJ	O
amiodarone	NN	D
.	.	.
		
amiodarone	NNP	D
may	MD	O
suppress	VB	O
certain	JJ	O
cyp450	NN	O
enzymes	NNS	O
","	","	O
including	VBG	O
cyp1a2	NN	D
","	","	O
cyp2c9	NN	D
","	","	O
cyp2d6	NN	D
","	","	O
and	CC	O
cyp3a4	NN	D
.	.	.
		
this	DT	O
inhibition	NN	O
can	MD	O
result	VB	O
in	IN	O
unexpectedly	RB	O
high	JJ	O
plasma	NN	O
levels	NNS	O
of	IN	O
other	JJ	O
drugs	NNS	D
which	WDT	O
are	VBP	O
metabolized	VBN	O
by	IN	O
those	DT	O
cyp450	NN	O
enzymes	NNS	O
.	.	.
		
reported	VBN	O
examples	NNS	O
of	IN	O
this	DT	O
interaction	NN	O
include	VBP	O
the	DT	O
following	NN	O
:	:	O
immunosuppressives	NNS	O
:	:	O
cyclosporine	NN	D
-lrb-	-LRB-	O
cyp3a4	NN	D
substrate	NN	O
-rrb-	-RRB-	O
administered	VBN	O
in	IN	O
combination	NN	O
with	IN	O
oral	JJ	O
amiodarone	NN	D
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
produce	VB	O
persistently	RB	O
elevated	JJ	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
cyclosporine	NN	D
resulting	VBG	O
in	IN	O
elevated	JJ	O
creatinine	NN	O
","	","	O
despite	IN	O
reduction	NN	O
in	IN	O
dose	NN	O
of	IN	O
cyclosporine	NN	D
.	.	.
		
hmg-coa	NN	O
reductase	NN	O
inhibitors	NNS	O
:	:	O
simvastatin	NN	D
-lrb-	-LRB-	O
cyp3a4	NN	D
substrate	NN	O
-rrb-	-RRB-	O
in	IN	O
combination	NN	O
with	IN	O
amiodarone	NN	D
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
reports	NNS	O
of	IN	O
myopathy/rhabdomyolysis	NN	O
.	.	.
		
cardiovasculars	NNP	O
:	:	O
cardiac	JJ	O
glycosides	NNS	O
:	:	O
in	IN	O
patients	NNS	O
receiving	VBG	O
digoxin	NN	D
therapy	NN	O
","	","	O
administration	NN	O
of	IN	O
oral	JJ	O
amiodarone	NN	D
regularly	RB	O
results	VBZ	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
serum	NN	O
digoxin	NN	D
concentration	NN	O
that	WDT	O
may	MD	O
reach	VB	O
toxic	JJ	O
levels	NNS	O
with	IN	O
resultant	JJ	O
clinical	JJ	O
toxicity	NN	O
.	.	.
		
amiodarone	NNP	D
taken	VBN	O
concomitantly	RB	O
with	IN	O
digoxin	NN	D
increases	VBZ	O
the	DT	O
serum	NN	O
digoxin	NN	D
concentration	NN	O
by	IN	O
70	CD	O
%	NN	O
after	IN	O
one	CD	O
day	NN	O
.	.	.
		
on	IN	O
administration	NN	O
of	IN	O
oral	JJ	O
amiodarone	NN	D
","	","	O
the	DT	O
need	NN	O
for	IN	O
digitalis	NN	G
therapy	NN	O
should	MD	O
be	VB	O
reviewed	VBN	O
and	CC	O
the	DT	O
dose	NN	O
reduced	VBN	O
by	IN	O
approximately	RB	O
50	CD	O
%	NN	O
or	CC	O
discontinued	VBN	O
.	.	.
		
if	IN	O
digitalis	NN	G
treatment	NN	O
is	VBZ	O
continued	VBN	O
","	","	O
serum	NN	O
levels	NNS	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
and	CC	O
patients	NNS	O
observed	VBN	O
for	IN	O
clinical	JJ	O
evidence	NN	O
of	IN	O
toxicity	NN	O
.	.	.
		
these	DT	O
precautions	NNS	O
probably	RB	O
should	MD	O
apply	VB	O
to	TO	O
digitoxin	NN	D
administration	NN	O
as	RB	O
well	RB	O
.	.	.
		
antiarrhythmics	NNS	D
:	:	O
other	JJ	O
antiarrhythmic	JJ	D
drugs	NNS	D
","	","	O
such	JJ	O
as	IN	O
quinidine	NN	D
","	","	O
procainamide	NN	D
","	","	O
disopyramide	NN	D
","	","	O
and	CC	O
phenytoin	NN	D
","	","	O
have	VBP	O
been	VBN	O
used	VBN	O
concurrently	RB	O
with	IN	O
amiodarone	NN	D
.	.	.
		
there	EX	O
have	VBP	O
been	VBN	O
case	NN	O
reports	NNS	O
of	IN	O
increased	VBN	O
steady-state	JJ	O
levels	NNS	O
of	IN	O
quinidine	NN	D
","	","	O
procainamide	NN	D
","	","	O
and	CC	O
phenytoin	NN	D
during	IN	O
concomitant	JJ	O
therapy	NN	O
with	IN	O
amiodarone	NN	D
.	.	.
		
phenytoin	NN	D
decreases	VBZ	O
serum	NN	O
amiodarone	NN	D
levels	NNS	O
.	.	.
		
amiodarone	NNP	D
taken	VBN	O
concomitantly	RB	O
with	IN	O
quinidine	NN	D
increases	VBZ	O
quinidine	NN	D
serum	NN	O
concentration	NN	O
by	IN	O
33	CD	O
%	NN	O
after	IN	O
two	CD	O
days	NNS	O
.	.	.
		
amiodarone	NNP	D
taken	VBN	O
concomitantly	RB	O
with	IN	O
procainamide	NN	D
for	IN	O
less	JJR	O
than	IN	O
seven	CD	O
days	NNS	O
increases	VBZ	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
procainamide	NN	D
and	CC	O
n-acetyl	NN	O
procainamide	NN	D
by	IN	O
55	CD	O
%	NN	O
and	CC	O
33	CD	O
%	NN	O
","	","	O
respectively	RB	O
.	.	.
		
quinidine	NN	D
and	CC	O
procainamide	NN	D
doses	NNS	O
should	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
one-third	NN	O
when	WRB	O
either	CC	O
is	VBZ	O
administered	VBN	O
with	IN	O
amiodarone	NN	D
.	.	.
		
plasma	NN	O
levels	NNS	O
of	IN	O
flecainide	NN	D
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
increase	VB	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
oral	JJ	O
amiodarone	NN	D
.	.	.
		
because	IN	O
of	IN	O
this	DT	O
","	","	O
the	DT	O
dosage	NN	O
of	IN	O
flecainide	NN	D
should	MD	O
be	VB	O
adjusted	VBN	O
when	WRB	O
these	DT	O
drugs	NNS	D
are	VBP	O
administered	VBN	O
concomitantly	RB	O
.	.	.
		
in	IN	O
general	JJ	O
","	","	O
any	DT	O
added	VBD	O
antiarrhythmic	JJ	D
drug	NN	D
should	MD	O
be	VB	O
initiated	VBN	O
at	IN	O
a	DT	O
lower	JJR	O
than	IN	O
usual	JJ	O
dose	NN	O
with	IN	O
careful	JJ	O
monitoring	NN	O
.	.	.
		
combination	NN	O
of	IN	O
amiodarone	NN	D
with	IN	O
other	JJ	O
antiarrhythmic	JJ	D
therapy	NN	O
should	MD	O
be	VB	O
reserved	VBN	O
for	IN	O
patients	NNS	O
with	IN	O
life-threatening	JJ	O
ventricular	JJ	O
arrhythmias	NNS	O
who	WP	O
are	VBP	O
incompletely	RB	O
responsive	JJ	O
to	TO	O
a	DT	O
single	JJ	O
agent	NN	O
or	CC	O
incompletely	RB	O
responsive	JJ	O
to	TO	O
amiodarone	NN	D
.	.	.
		
during	IN	O
transfer	NN	O
to	TO	O
oral	JJ	O
amiodarone	NN	D
","	","	O
the	DT	O
dose	NN	O
levels	NNS	O
of	IN	O
previously	RB	O
administered	VBN	O
agents	NNS	O
should	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
30	CD	O
to	TO	O
50	CD	O
%	NN	O
several	JJ	O
days	NNS	O
after	IN	O
the	DT	O
addition	NN	O
of	IN	O
oral	JJ	O
amiodarone	NN	D
.	.	.
		
the	DT	O
continued	JJ	O
need	NN	O
for	IN	O
the	DT	O
other	JJ	O
antiarrhythmic	JJ	D
agent	NN	O
should	MD	O
be	VB	O
reviewed	VBN	O
after	IN	O
the	DT	O
effects	NNS	O
of	IN	O
amiodarone	NN	D
have	VBP	O
been	VBN	O
established	VBN	O
","	","	O
and	CC	O
discontinuation	NN	O
ordinarily	RB	O
should	MD	O
be	VB	O
attempted	VBN	O
.	.	.
		
if	IN	O
the	DT	O
treatment	NN	O
is	VBZ	O
continued	VBN	O
","	","	O
these	DT	O
patients	NNS	O
should	MD	O
be	VB	O
particularly	RB	O
carefully	RB	O
monitored	VBN	O
for	IN	O
adverse	JJ	O
effects	NNS	O
","	","	O
especially	RB	O
conduction	NN	O
disturbances	NNS	O
and	CC	O
exacerbation	NN	O
of	IN	O
tachyarrhythmias	NNS	O
","	","	O
as	IN	O
amiodarone	NN	D
is	VBZ	O
continued	VBN	O
.	.	.
		
in	IN	O
amiodarone-treated	JJ	O
patients	NNS	O
who	WP	O
require	VBP	O
additional	JJ	O
antiarrhythmic	JJ	D
therapy	NN	O
","	","	O
the	DT	O
initial	JJ	O
dose	NN	O
of	IN	O
such	JJ	O
agents	NNS	O
should	MD	O
be	VB	O
approximately	RB	O
half	NN	O
of	IN	O
the	DT	O
usual	JJ	O
recommended	VBN	O
dose	NN	O
.	.	.
		
antihypertensives	NNS	D
:	:	O
amiodarone	NN	D
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
-	:	O
receptor	NN	D
blocking	VBG	O
agents	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
propranolol	NN	D
","	","	O
a	DT	O
cyp3a4	NN	D
inhibitor	NN	O
-rrb-	-RRB-	O
or	CC	O
calcium	NN	D
channel	NN	O
antagonists	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
verapamil	NN	D
","	","	O
a	DT	O
cyp3a4	NN	D
substrate	NN	O
","	","	O
and	CC	O
diltiazem	NN	D
","	","	O
a	DT	O
cyp3a4	NN	D
inhibitor	NN	O
-rrb-	-RRB-	O
because	IN	O
of	IN	O
the	DT	O
possible	JJ	O
potentiation	NN	O
of	IN	O
bradycardia	NN	O
","	","	O
sinus	NN	O
arrest	NN	O
","	","	O
and	CC	O
av	NN	O
block	NN	O
.	.	.
		
if	IN	O
necessary	JJ	O
","	","	O
amiodarone	NN	D
can	MD	O
continue	VB	O
to	TO	O
be	VB	O
used	VBN	O
after	IN	O
insertion	NN	O
of	IN	O
a	DT	O
pacemaker	NN	O
in	IN	O
patients	NNS	O
with	IN	O
severe	JJ	O
bradycardia	NN	O
or	CC	O
sinus	NN	O
arrest	NN	O
.	.	.
		
anticoagulants	NNPS	G
:	:	O
potentiation	NN	O
of	IN	O
warfarin-type	JJ	O
-lrb-	-LRB-	O
cyp2c9	NN	D
and	CC	O
cyp3a4	NN	D
substrate	NN	O
-rrb-	-RRB-	O
anticoagulant	JJ	G
response	NN	O
is	VBZ	O
almost	RB	O
always	RB	O
seen	VBN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
amiodarone	NN	D
and	CC	O
can	MD	O
result	VB	O
in	IN	O
serious	JJ	O
or	CC	O
fatal	JJ	O
bleeding	NN	O
.	.	.
		
since	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
warfarin	NN	D
with	IN	O
amiodarone	NN	D
increases	VBZ	O
the	DT	O
prothrombin	NN	O
time	NN	O
by	IN	O
100	CD	O
%	NN	O
after	IN	O
3	CD	O
to	TO	O
4	CD	O
days	NNS	O
","	","	O
the	DT	O
dose	NN	O
of	IN	O
the	DT	O
anticoagulant	NN	G
should	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
one-third	NN	O
to	TO	O
one-half	NN	O
","	","	O
and	CC	O
prothrombin	NN	O
times	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
.	.	.
		
some	DT	O
drugs/substances	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
accelerate	VB	O
the	DT	O
metabolism	NN	O
of	IN	O
amiodarone	NN	D
by	IN	O
stimulating	VBG	O
the	DT	O
synthesis	NN	O
of	IN	O
cyp3a4	NN	D
-lrb-	-LRB-	O
enzyme	NN	O
induction	NN	O
-rrb-	-RRB-	O
.	.	.
		
this	DT	O
may	MD	O
lead	VB	O
to	TO	O
low	JJ	O
amiodarone	NN	D
serum	NN	O
levels	NNS	O
and	CC	O
potential	JJ	O
decrease	NN	O
in	IN	O
efficacy	NN	O
.	.	.
		
reported	VBN	O
examples	NNS	O
of	IN	O
this	DT	O
interaction	NN	O
include	VBP	O
the	DT	O
following	NN	O
:	:	O
antibiotics	NNS	G
:	:	O
rifampin	NNP	D
is	VBZ	O
a	DT	O
potent	JJ	O
inducer	NN	O
of	IN	O
cyp3a4	NN	D
.	.	.
		
administration	NN	O
of	IN	O
rifampin	NN	D
concomitantly	RB	O
with	IN	O
oral	JJ	O
amiodarone	NN	D
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
result	VB	O
in	IN	O
decreases	NNS	O
in	IN	O
serum	NN	O
concentrations	NNS	O
of	IN	O
amiodarone	NN	D
and	CC	O
desethylamiodarone	NN	D
.	.	.
		
other	JJ	O
substances	NNS	O
","	","	O
including	VBG	O
herbal	JJ	O
preparations	NNS	O
:	:	O
st.	NNP	O
john	NNP	O
s	VBZ	O
wort	NNP	O
-lrb-	-LRB-	O
hypericum	NNP	O
perforatum	NN	O
-rrb-	-RRB-	O
induces	VBZ	O
cyp3a4	NN	D
.	.	.
		
since	IN	O
amiodarone	NN	D
is	VBZ	O
a	DT	O
substrate	NN	O
for	IN	O
cyp3a4	NN	D
","	","	O
there	EX	O
is	VBZ	O
the	DT	O
potential	NN	O
that	IN	O
the	DT	O
use	NN	O
of	IN	O
st.	NNP	O
john	NNP	O
s	VBZ	O
wort	NNP	O
in	IN	O
patients	NNS	O
receiving	VBG	O
amiodarone	NN	D
could	MD	O
result	VB	O
in	IN	O
reduced	VBN	O
amiodarone	NN	D
levels	NNS	O
.	.	.
		
other	JJ	O
reported	VBN	O
interactions	NNS	O
with	IN	O
amiodarone	NN	D
:	:	O
fentanyl	NN	D
-lrb-	-LRB-	O
cyp3a4	NN	D
substrate	NN	O
-rrb-	-RRB-	O
in	IN	O
combination	NN	O
with	IN	O
amiodarone	NN	D
may	MD	O
cause	VB	O
hypotension	NN	O
","	","	O
bradycardia	NN	O
","	","	O
and	CC	O
decreased	VBD	O
cardiac	JJ	O
output	NN	O
.	.	.
		
sinus	NN	O
bradycardia	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
with	IN	O
oral	JJ	O
amiodarone	NN	D
in	IN	O
combination	NN	O
with	IN	O
lidocaine	NN	D
-lrb-	-LRB-	O
cyp3a4	NN	D
substrate	NN	O
-rrb-	-RRB-	O
given	VBN	O
for	IN	O
local	JJ	O
anesthesia	NN	D
.	.	.
		
seizure	NN	O
","	","	O
associated	VBN	O
with	IN	O
increased	VBN	O
lidocaine	NN	D
concentrations	NNS	O
","	","	O
has	VBZ	O
been	VBN	O
reported	VBN	O
with	IN	O
concomitant	JJ	O
administration	NN	O
of	IN	O
intravenous	JJ	O
amiodarone	NN	D
.	.	.
		
dextromethorphan	NNP	D
is	VBZ	O
a	DT	O
substrate	NN	O
for	IN	O
both	DT	O
cyp2d6	NN	D
and	CC	O
cyp3a4	NN	D
.	.	.
		
amiodarone	NN	D
inhibits	VBZ	O
cyp2d6	NN	D
.	.	.
		
cholestyramine	NNP	D
increases	VBZ	O
enterohepatic	JJ	O
elimination	NN	O
of	IN	O
amiodarone	NN	D
and	CC	O
may	MD	O
reduce	VB	O
its	PRP$	O
serum	NN	O
levels	NNS	O
and	CC	O
t1/2	NN	O
.	.	.
		
disopyramide	NNP	D
increases	VBZ	O
qt	NNP	O
prolongation	NN	O
which	WDT	O
could	MD	O
cause	VB	O
arrhythmia	NN	O
.	.	.
		
fluoroquinolones	NNP	D
","	","	O
macrolide	NN	O
antibiotics	NNS	G
","	","	O
and	CC	O
azoles	NNS	O
are	VBP	O
known	VBN	O
to	TO	O
cause	VB	O
qtc	NN	O
prolongation	NN	O
.	.	.
		
there	EX	O
have	VBP	O
been	VBN	O
reports	NNS	O
of	IN	O
qtc	NN	O
prolongation	NN	O
","	","	O
with	IN	O
or	CC	O
without	IN	O
tdp	NN	O
","	","	O
in	IN	O
patients	NNS	O
taking	VBG	O
amiodarone	NN	D
when	WRB	O
fluoroquinolones	NNS	D
","	","	O
macrolide	NN	O
antibiotics	NNS	G
","	","	O
or	CC	O
azoles	NNS	O
were	VBD	O
administered	VBN	O
concomitantly	RB	O
.	.	.
		
hemodynamic	JJ	O
and	CC	O
electrophysiologic	JJ	O
interactions	NNS	O
have	VBP	O
also	RB	O
been	VBN	O
observed	VBN	O
after	IN	O
concomitant	JJ	O
administration	NN	O
with	IN	O
propranolol	NN	D
","	","	O
diltiazem	NN	D
","	","	O
and	CC	O
verapamil	NN	D
.	.	.
		
volatile	JJ	O
anesthetic	NNP	D
agents	NNPS	O
:	:	O
.	.	.
		
in	IN	O
addition	NN	O
to	TO	O
the	DT	O
interactions	NNS	O
noted	VBD	O
above	RB	O
","	","	O
chronic	JJ	O
-lrb-	-LRB-	O
2	CD	O
weeks	NNS	O
-rrb-	-RRB-	O
oral	JJ	O
cordarone	NNP	D
administration	NN	O
impairs	VBZ	O
metabolism	NN	O
of	IN	O
phenytoin	NN	D
","	","	O
dextromethorphan	NN	D
","	","	O
and	CC	O
methotrexate	NN	D
.	.	.
		
electrolyte	NNP	O
disturbances	NNPS	O
patients	NNPS	O
with	IN	O
hypokalemia	NN	O
or	CC	O
hypomagnesemia	NN	O
should	MD	O
have	VB	O
the	DT	O
condition	NN	O
corrected	VBN	O
whenever	WRB	O
possible	JJ	O
before	IN	O
being	VBG	O
treated	VBN	O
with	IN	O
cordarone	JJ	D
i.v.	NNP	O
","	","	O
as	IN	O
these	DT	O
disorders	NNS	O
can	MD	O
exaggerate	VB	O
the	DT	O
degree	NN	O
of	IN	O
qtc	NN	O
prolongation	NN	O
and	CC	O
increase	VB	O
the	DT	O
potential	NN	O
for	IN	O
tdp	NN	O
.	.	.
		
special	JJ	O
attention	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
electrolyte	NN	O
and	CC	O
acid-base	NN	O
balance	NN	O
in	IN	O
patients	NNS	O
experiencing	VBG	O
severe	JJ	O
or	CC	O
prolonged	JJ	O
diarrhea	NN	O
or	CC	O
in	IN	O
patients	NNS	O
receiving	VBG	O
concomitant	JJ	O
diuretics	NNS	G
.	.	.
		
drugs	NNS	O
metabolized	VBN	O
by	IN	O
p450	NN	O
2d6	NN	O
-	:	O
the	DT	O
biochemical	JJ	O
activity	NN	O
of	IN	O
the	DT	O
drug	NN	D
metabolizing	VBG	O
isozyme	NN	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
-lrb-	-LRB-	O
debrisoquin	NN	D
hydroxylase	NN	O
-rrb-	-RRB-	O
is	VBZ	O
reduced	VBN	O
in	IN	O
a	DT	O
subset	NN	O
of	IN	O
the	DT	O
caucasian	JJ	O
population	NN	O
-lrb-	-LRB-	O
about	IN	O
10-Jul	CD	O
%	NN	O
of	IN	O
caucasians	NNS	O
are	VBP	O
so	RB	O
called	VBN	O
poor	JJ	O
metabolizers	NNS	O
-rrb-	-RRB-	O
;	:	O
.	.	.
		
reliable	JJ	O
estimates	NNS	O
of	IN	O
the	DT	O
prevalence	NN	O
of	IN	O
reduced	VBN	O
p450	NN	O
2d6	NN	O
isozyme	NN	O
activity	NN	O
among	IN	O
asian	JJ	O
","	","	O
african	JJ	O
and	CC	O
other	JJ	O
populations	NNS	O
are	VBP	O
not	RB	O
yet	RB	O
available	JJ	O
.	.	.
		
poor	NNP	O
metabolizers	NNS	O
have	VBP	O
higher	JJR	O
than	IN	O
expected	VBN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
tricyclic	JJ	O
antidepressants	NNS	G
-lrb-	-LRB-	O
tcas	NNS	G
-rrb-	-RRB-	O
when	WRB	O
given	VBN	O
usual	JJ	O
doses	NNS	O
depending	VBG	O
on	IN	O
the	DT	O
fraction	NN	O
of	IN	O
drug	NN	D
metabolized	VBN	O
by	IN	O
p450	NN	O
2d6	NN	O
","	","	O
the	DT	O
increase	NN	O
in	IN	O
plasma	NN	O
concentration	NN	O
may	MD	O
be	VB	O
small	JJ	O
","	","	O
or	CC	O
quite	RB	O
large	JJ	O
-lrb-	-LRB-	O
8-fold	JJ	O
increase	NN	O
in	IN	O
plasma	NN	O
auc	NN	O
of	IN	O
the	DT	O
tca	NNP	G
-rrb-	-RRB-	O
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
certain	JJ	O
drugs	NNS	D
inhibit	VBP	O
the	DT	O
activity	NN	O
of	IN	O
this	DT	O
isozyme	NN	O
and	CC	O
make	VB	O
normal	JJ	O
metabolizers	NNS	O
resemble	VBP	O
poor	JJ	O
metabolizers	NNS	O
.	.	.
		
an	DT	O
individual	NN	O
who	WP	O
is	VBZ	O
stable	JJ	O
on	IN	O
a	DT	O
given	VBN	O
dose	NN	O
of	IN	O
tca	NNP	G
may	MD	O
become	VB	O
abruptly	RB	O
toxic	JJ	O
when	WRB	O
given	VBN	O
one	CD	O
of	IN	O
these	DT	O
inhibiting	VBG	O
drugs	NNS	D
as	IN	O
concomitant	JJ	O
therapy	NN	O
.	.	.
		
the	DT	O
drugs	NNS	D
that	WDT	O
inhibit	VBP	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
include	VBP	O
some	DT	O
that	WDT	O
are	VBP	O
not	RB	O
metabolized	VBN	O
by	IN	O
the	DT	O
enzyme	NN	O
-lrb-	-LRB-	O
quinidine	NN	D
.	.	.
		
cimetidine	NN	D
-rrb-	-RRB-	O
and	CC	O
many	JJ	O
that	WDT	O
are	VBP	O
substrates	NNS	O
for	IN	O
p450	NN	O
2d6	NN	O
-lrb-	-LRB-	O
many	JJ	O
other	JJ	O
antidepressants	NNS	G
","	","	O
phenothiazines	NNS	G
","	","	O
and	CC	O
the	DT	O
type	NN	O
1c	NN	O
antiarrhythmics	NNS	G
propafenone	NN	D
and	CC	O
flecainide	NN	D
-rrb-	-RRB-	O
.	.	.
		
while	IN	O
all	PDT	O
the	DT	O
selective	JJ	O
serotonin	NN	O
reuptake	NN	O
inhibitors	NNS	O
-lrb-	-LRB-	O
ssris	NNS	G
-rrb-	-RRB-	O
","	","	O
e.g.	FW	O
","	","	O
fluoxetine	NN	D
","	","	O
sertraline	NN	D
","	","	O
and	CC	O
paroxetine	NN	D
","	","	O
inhibit	VBP	O
p450	NN	O
2d6	NN	O
","	","	O
they	PRP	O
may	MD	O
vary	VB	O
in	IN	O
the	DT	O
extent	NN	O
of	IN	O
inhibition	NN	O
.	.	.
		
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
ssri-tca	NNP	O
interactions	NNS	O
may	MD	O
pose	VB	O
clinical	JJ	O
problems	NNS	O
will	MD	O
depend	VB	O
on	IN	O
the	DT	O
degree	NN	O
of	IN	O
inhibition	NN	O
and	CC	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
the	DT	O
ssri	NNP	G
involved	VBN	O
.	.	.
		
nevertheless	RB	O
","	","	O
caution	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
the	DT	O
coadministration	NN	O
of	IN	O
tcas	NNS	G
with	IN	O
any	DT	O
of	IN	O
the	DT	O
ssris	NNS	G
and	CC	O
also	RB	O
in	IN	O
switching	NN	O
from	IN	O
one	CD	O
class	NN	O
to	TO	O
the	DT	O
other	JJ	O
.	.	.
		
of	IN	O
particular	JJ	O
importance	NN	O
","	","	O
sufficient	JJ	O
time	NN	O
must	MD	O
elapse	VB	O
before	IN	O
initiating	VBG	O
tca	NNP	G
treatment	NN	O
in	IN	O
a	DT	O
patient	NN	O
being	VBG	O
withdrawn	VBN	O
from	IN	O
fluoxetine	NN	D
","	","	O
given	VBN	O
the	DT	O
long	JJ	O
half-life	NN	O
of	IN	O
the	DT	O
parent	NN	O
and	CC	O
active	JJ	O
metabolite	NN	O
-lrb-	-LRB-	O
at	IN	O
least	JJS	O
5	CD	O
weeks	NNS	O
may	MD	O
be	VB	O
necessary	JJ	O
-rrb-	-RRB-	O
.	.	.
		
concomitant	JJ	O
use	NN	O
of	IN	O
tricyclic	JJ	O
antidepressants	NNS	G
with	IN	O
drugs	NNS	D
that	WDT	O
can	MD	O
inhibit	VB	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
may	MD	O
require	VB	O
lower	JJR	O
doses	NNS	O
than	IN	O
usually	RB	O
prescribed	VBN	O
for	IN	O
either	CC	O
the	DT	O
tricyclic	JJ	O
antidepressant	JJ	O
or	CC	O
the	DT	O
other	JJ	O
drug	NN	D
.	.	.
		
furthermore	RB	O
","	","	O
whenever	WRB	O
one	CD	O
of	IN	O
these	DT	O
other	JJ	O
drugs	NNS	D
is	VBZ	O
withdrawn	VBN	O
from	IN	O
co-therapy	JJ	O
","	","	O
an	DT	O
increased	VBN	O
dose	NN	O
of	IN	O
tricyclic	JJ	O
antidepressant	JJ	O
may	MD	O
be	VB	O
required	VBN	O
.	.	.
		
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
monitor	VB	O
tca	NNP	G
plasma	NN	O
levels	NNS	O
whenever	WRB	O
a	DT	O
tca	NNP	G
is	VBZ	O
going	VBG	O
to	TO	O
be	VB	O
coadministered	VBN	O
with	IN	O
another	DT	O
drug	NN	D
known	VBN	O
to	TO	O
be	VB	O
an	DT	O
inhibitor	NN	O
of	IN	O
p450	NN	O
2d6	NN	O
.	.	.
		
monoamine	NNP	O
oxidase	NNP	O
inhibitors	NNS	O
:	:	O
guanethidine	NN	D
or	CC	O
similarly	RB	O
acting	VBG	O
compounds	NNS	O
.	.	.
		
thyroid	NN	D
medication	NN	O
.	.	.
		
alcohol	NN	D
","	","	O
barbiturates	NNS	G
and	CC	O
other	JJ	O
cns	NN	O
depressants	NNS	O
.	.	.
		
and	CC	O
disulfiram	NN	D
when	WRB	O
amitriptyline	NNP	D
hcl	NN	O
is	VBZ	O
given	VBN	O
with	IN	O
anticholinergic	JJ	G
agents	NNS	O
or	CC	O
sympathomimetic	JJ	D
drugs	NNS	D
","	","	O
including	VBG	O
epinephrine	NN	D
combined	VBN	O
with	IN	O
local	JJ	O
anesthetics	NNS	G
","	","	O
close	JJ	O
supervision	NN	O
and	CC	O
careful	JJ	O
adjustment	NN	O
of	IN	O
dosages	NNS	O
are	VBP	O
required	VBN	O
.	.	.
		
hyperpyrexia	NNP	O
has	VBZ	O
been	VBN	O
reported	VBN	O
when	WRB	O
amitriptyline	NNP	D
hcl	NN	O
is	VBZ	O
administered	VBN	O
with	IN	O
anticholinergic	JJ	G
agents	NNS	O
or	CC	O
with	IN	O
neuroleptic	JJ	D
drugs	NNS	D
","	","	O
particularly	RB	O
during	IN	O
hot	JJ	O
weather	NN	O
.	.	.
		
paralytic	JJ	O
ileus	NN	O
may	MD	O
occur	VB	O
in	IN	O
patients	NNS	O
taking	VBG	O
tricyclic	JJ	O
antidepressants	NNS	G
in	IN	O
combination	NN	O
with	IN	O
anticholinergic-type	JJ	O
drugs	NNS	D
.	.	.
		
cimetidine	NNP	D
is	VBZ	O
reported	VBN	O
to	TO	O
reduce	VB	O
hepatic	JJ	O
metabolism	NN	O
of	IN	O
certain	JJ	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
thereby	RB	O
delaying	VBG	O
elimination	NN	O
and	CC	O
increasing	VBG	O
steady-state	JJ	O
concentrations	NNS	O
of	IN	O
these	DT	O
drugs	NNS	D
.	.	.
		
clinically	RB	O
significant	JJ	O
effects	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
with	IN	O
the	DT	O
tricyclic	JJ	O
antidepressants	NNS	G
when	WRB	O
used	VBN	O
concomitantly	RB	O
with	IN	O
cimetidine	NN	D
.	.	.
		
increases	NNS	O
in	IN	O
plasma	NN	O
levels	NNS	O
of	IN	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
and	CC	O
in	IN	O
the	DT	O
frequency	NN	O
and	CC	O
severity	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
","	","	O
particularly	RB	O
anticholinergic	JJ	G
","	","	O
have	VBP	O
been	VBN	O
reported	VBN	O
when	WRB	O
cimetidine	NN	D
was	VBD	O
added	VBN	O
to	TO	O
the	DT	O
drug	NN	D
regimen	NN	O
.	.	.
		
discontinuation	NN	O
of	IN	O
cimetidine	NN	D
in	IN	O
well-controlled	JJ	O
patients	NNS	O
receiving	VBG	O
tricyclic	JJ	O
antidepressants	NNS	G
and	CC	O
cimetidine	NN	D
may	MD	O
decrease	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
and	CC	O
efficacy	NN	O
of	IN	O
the	DT	O
antidepressants	NNS	G
.	.	.
		
caution	NN	O
is	VBZ	O
advised	VBN	O
if	IN	O
patients	NNS	O
receive	VBP	O
large	JJ	O
doses	NNS	O
of	IN	O
ethchlorvynol	NN	D
concurrently	RB	O
.	.	.
		
transient	JJ	O
delirium	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
treated	VBN	O
with	IN	O
one	CD	O
gram	NN	O
of	IN	O
ethchlorvynol	NN	D
and	CC	O
75	CD	O
-	:	O
150	CD	O
mg	NN	O
of	IN	O
amitriptyline	NNP	D
hcl	NN	O
.	.	.
		
when	WRB	O
administered	VBN	O
concurrently	RB	O
","	","	O
the	DT	O
following	VBG	O
drugs	NNS	D
may	MD	O
interact	VB	O
with	IN	O
amphotericin	NN	O
b	NN	O
:	:	O
antineoplastic	JJ	O
agents	NNS	O
:	:	O
may	MD	O
enhance	VB	O
the	DT	O
potential	NN	O
for	IN	O
renal	JJ	O
toxicity	NN	O
","	","	O
bronchospasm	NN	O
and	CC	O
hypotension	NN	O
.	.	.
		
antineoplastic	JJ	O
agents	NNS	O
-lrb-	-LRB-	O
e.	FW	O
g.	FW	O
","	","	O
nitrogen	NN	O
mustard	NN	O
","	","	O
etc.	FW	O
-rrb-	-RRB-	O
should	MD	O
be	VB	O
given	VBN	O
concomitantly	RB	O
only	RB	O
with	IN	O
great	JJ	O
caution	NN	O
.	.	.
		
corticosteroids	NNS	G
and	CC	O
corticotropin	NN	D
-lrb-	-LRB-	O
acth	NN	D
-rrb-	-RRB-	O
:	:	O
may	MD	O
potentiate	VB	O
amphotericin	NN	O
b	NN	O
-	:	O
induced	VBN	O
hypokalemia	NN	O
which	WDT	O
may	MD	O
predispose	VB	O
the	DT	O
patient	NN	O
to	TO	O
cardiac	JJ	O
dysfunction	NN	O
.	.	.
		
avoid	VB	O
concomitant	JJ	O
use	NN	O
unless	IN	O
necessary	JJ	O
to	TO	O
control	VB	O
side	JJ	O
effects	NNS	O
of	IN	O
amphotericin	NN	O
b	NN	O
.	.	.
		
if	IN	O
used	VBN	O
concomitantly	RB	O
","	","	O
closely	RB	O
monitor	VB	O
serum	NN	O
electrolytes	NNS	O
and	CC	O
cardiac	JJ	O
function	NN	O
.	.	.
		
digitalis	NN	G
glycosides	NNS	O
:	:	O
amphotericin	NN	O
b-induced	JJ	O
hypokalemia	NN	O
may	MD	O
potentiate	VB	O
digitalis	NN	G
toxicity	NN	O
.	.	.
		
serum	NN	O
potassium	NN	D
levels	NNS	O
and	CC	O
cardiac	JJ	O
function	NN	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
and	CC	O
any	DT	O
deficit	NN	O
promptly	RB	O
corrected	VBN	O
.	.	.
		
flucytosine	NNP	D
:	:	O
while	IN	O
a	DT	O
synergistic	JJ	O
relationship	NN	O
with	IN	O
amphotericin	NN	O
b	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
","	","	O
concomitant	JJ	O
use	NN	O
may	MD	O
increase	VB	O
the	DT	O
toxicity	NN	O
of	IN	O
flucytosine	NN	D
by	IN	O
possibly	RB	O
increasing	VBG	O
its	PRP$	O
cellular	JJ	O
uptake	NN	O
and/or	CC	O
impairing	VBG	O
its	PRP$	O
renal	JJ	O
excretion	NN	O
.	.	.
		
imidazoles	NNS	G
-lrb-	-LRB-	O
e.	FW	O
g.	FW	O
","	","	O
ketoconazole	NN	D
","	","	O
miconazole	NN	D
","	","	O
clotrimazole	NN	D
","	","	O
fluconazole	NN	D
","	","	O
etc.	FW	O
-rrb-	-RRB-	O
:	:	O
in	FW	O
vitro	FW	O
and	CC	O
animal	JJ	O
studies	NNS	O
with	IN	O
the	DT	O
combination	NN	O
of	IN	O
amphotericin	NN	O
b	NN	O
and	CC	O
imidazoles	NNS	G
suggest	VBP	O
that	IN	O
imidazoles	NNS	G
may	MD	O
induce	VB	O
fungal	JJ	O
resistance	NN	O
to	TO	O
amphotericin	NN	O
b.	NNP	O
combination	NNP	O
therapy	NN	O
should	MD	O
be	VB	O
administered	VBN	O
with	IN	O
caution	NN	O
","	","	O
especially	RB	O
in	IN	O
immunocompromised	JJ	O
patients	NNS	O
.	.	.
		
other	JJ	O
nephrotoxic	JJ	O
medications	NNS	O
:	:	O
agents	NNS	O
such	JJ	O
as	IN	O
aminoglycosides	NNS	G
","	","	O
cyclosporine	NN	D
","	","	O
and	CC	O
pentamidine	NN	D
may	MD	O
enhance	VB	O
the	DT	O
potential	NN	O
for	IN	O
drug-induced	JJ	O
renal	JJ	O
toxicity	NN	O
","	","	O
and	CC	O
should	MD	O
be	VB	O
used	VBN	O
concomitantly	RB	O
only	RB	O
with	IN	O
great	JJ	O
caution	NN	O
.	.	.
		
intensive	JJ	O
monitoring	NN	O
of	IN	O
renal	JJ	O
function	NN	O
is	VBZ	O
recommended	VBN	O
in	IN	O
patients	NNS	O
requiring	VBG	O
any	DT	O
combination	NN	O
of	IN	O
nephrotoxic	JJ	O
medications	NNS	O
.	.	.
		
skeletal	JJ	O
muscle	NN	O
relaxants	NNS	O
:	:	O
amphotericin	NN	O
b-induced	JJ	O
hypokalemia	NN	O
may	MD	O
enhance	VB	O
the	DT	O
curariform	NN	O
effect	NN	O
of	IN	O
skeletal	JJ	O
muscle	NN	O
relaxants	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
tubocurarine	NN	D
-rrb-	-RRB-	O
.	.	.
		
serum	NN	O
potassium	NN	D
levels	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
and	CC	O
deficiencies	NNS	O
corrected	VBN	O
.	.	.
		
leukocyte	NN	O
transfusions	NNS	O
:	:	O
acute	JJ	O
pulmonary	JJ	O
toxicity	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
intravenous	JJ	O
amphotericin	NN	O
b	NN	O
and	CC	O
leukocyte	NN	O
transfusions	NNS	O
.	.	.
		
when	WRB	O
administered	VBN	O
concurrently	RB	O
","	","	O
the	DT	O
following	VBG	O
drugs	NNS	D
may	MD	O
interact	VB	O
with	IN	O
ampicillin	NN	D
.	.	.
		
allopurinol	NNP	D
:	:	O
increased	VBN	O
possibility	NN	O
of	IN	O
skin	NN	O
rash	NN	O
","	","	O
particularly	RB	O
in	IN	O
hyperuricemic	JJ	O
patients	NNS	O
may	MD	O
occur	VB	O
.	.	.
		
bacteriostatic	JJ	O
antibiotics	NNS	G
:	:	O
chloramphenicol	NN	D
","	","	O
erythromycins	NNS	D
","	","	O
sulfonamides	NNS	G
","	","	O
or	CC	O
tetracyclines	NNS	G
may	MD	O
interfere	VB	O
with	IN	O
the	DT	O
bactericidal	JJ	O
effect	NN	O
of	IN	O
penicillins	NNS	G
.	.	.
		
this	DT	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
in	IN	O
view	NN	O
","	","	O
however	RB	O
","	","	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
this	DT	O
interaction	NN	O
is	VBZ	O
not	RB	O
well	RB	O
documented	VBN	O
.	.	.
		
oral	JJ	O
contraceptives	NNS	G
:	:	O
may	MD	O
be	VB	O
less	RBR	O
effective	JJ	O
and	CC	O
increased	VBD	O
breakthrough	NN	O
bleeding	NN	O
may	MD	O
occur	VB	O
.	.	.
		
probenecid	NNP	D
:	:	O
may	NNP	O
decrease	VB	O
renal	JJ	O
tubular	JJ	O
secretion	NN	O
of	IN	O
ampicillin	NN	D
resulting	VBG	O
in	IN	O
increased	VBN	O
blood	NN	O
levels	NNS	O
and/or	CC	O
ampicillin	NN	D
toxicity	NN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interaction	NN	O
after	IN	O
treatment	NN	O
with	IN	O
ampicillin	NN	D
","	","	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
occur	VB	O
with	IN	O
copper	NN	O
sulfate	NN	O
tests	NNS	O
-lrb-	-LRB-	O
benedicts	NNS	O
solution	NN	O
","	","	O
fehlings	NNP	O
solution	NN	O
","	","	O
or	CC	O
clinitest	NNP	O
tablets	NNS	O
-rrb-	-RRB-	O
but	CC	O
not	RB	O
with	IN	O
enzyme	NN	O
based	VBN	O
tests	NNS	O
such	JJ	O
as	IN	O
clinistix	NNP	O
and	CC	O
glucose	NNP	O
enzymatic	JJ	O
test	NN	O
strip	NNP	O
usp	NNP	O
.	.	.
		
amprenavir	NNP	D
is	VBZ	O
metabolized	VBN	O
in	IN	O
the	DT	O
liver	NN	O
by	IN	O
the	DT	O
cytochrome	NN	O
p450	NN	O
enzyme	NN	O
system	NN	O
.	.	.
		
amprenavir	NN	D
inhibits	VBZ	O
cyp3a4	NN	D
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
used	VBN	O
when	WRB	O
coadministering	VBG	O
medications	NNS	O
that	WDT	O
are	VBP	O
substrates	NNS	O
","	","	O
inhibitors	NNS	O
","	","	O
or	CC	O
inducers	NNS	O
of	IN	O
cyp3a4	NN	D
","	","	O
or	CC	O
potentially	RB	O
toxic	JJ	O
medications	NNS	O
that	WDT	O
are	VBP	O
metabolized	VBN	O
by	IN	O
cyp3a4	NN	D
.	.	.
		
amprenavir	NNP	D
does	VBZ	O
not	RB	O
inhibit	VB	O
cyp2d6	NN	D
","	","	O
cyp1a2	NN	D
","	","	O
cyp2c9	NN	D
","	","	O
cyp2c19	NN	O
","	","	O
cyp2e1	NN	O
","	","	O
or	CC	O
uridine	NN	O
glucuronosyltransferase	NN	O
-lrb-	-LRB-	O
udpgt	NN	O
-rrb-	-RRB-	O
.	.	.
		
hiv	NN	O
protease	NN	O
inhibitors	NNS	O
:	:	O
the	DT	O
effect	NN	O
of	IN	O
amprenavir	NN	D
on	IN	O
total	JJ	O
drug	NN	D
concentrations	NNS	O
of	IN	O
other	JJ	O
hiv	NN	O
protease	NN	O
inhibitors	NNS	O
in	IN	O
subjects	NNS	O
receiving	VBG	O
both	CC	O
agents	NNS	O
was	VBD	O
evaluated	VBN	O
using	VBG	O
comparisons	NNS	O
to	TO	O
historical	JJ	O
data	NNS	O
.	.	.
		
indinavir	NNP	D
steady-state	JJ	O
cmax	NNP	O
","	","	O
a.c.	NNP	O
and	CC	O
cmin	NNP	O
were	VBD	O
decreased	VBN	O
by	IN	O
22	CD	O
%	NN	O
","	","	O
38	CD	O
%	NN	O
","	","	O
and	CC	O
27	CD	O
%	NN	O
","	","	O
respectively	RB	O
","	","	O
by	IN	O
concomitant	JJ	O
amprenavir	NN	D
.	.	.
		
similar	JJ	O
decreases	NNS	O
in	IN	O
cmax	NN	O
and	CC	O
auc	NN	O
were	VBD	O
seen	VBN	O
after	IN	O
the	DT	O
first	JJ	O
dose	NN	O
.	.	.
		
saquinavir	NNP	D
steady-state	JJ	O
cmax	NNP	O
","	","	O
a.c.	NNP	O
and	CC	O
cmin	NNP	O
were	VBD	O
increased	VBN	O
21	CD	O
%	NN	O
","	","	O
decreased	VBD	O
19	CD	O
%	NN	O
","	","	O
and	CC	O
decreased	VBD	O
48	CD	O
%	NN	O
","	","	O
respectively	RB	O
","	","	O
by	IN	O
concomitant	JJ	O
amprenavir	NN	D
.	.	.
		
nelfinavir	NNP	D
steady-state	JJ	O
cmax	NNP	O
","	","	O
a.c.	NNP	O
and	CC	O
cmin	NNP	O
were	VBD	O
increased	VBN	O
by	IN	O
12	CD	O
%	NN	O
","	","	O
15	CD	O
%	NN	O
","	","	O
and	CC	O
14	CD	O
%	NN	O
","	","	O
respectively	RB	O
","	","	O
by	IN	O
concomitant	JJ	O
amprenavir	NN	D
.	.	.
		
methadone	NNP	D
:	:	O
coadministration	NNP	O
of	IN	O
amprenavir	NN	D
and	CC	O
methadone	NN	D
can	MD	O
decrease	VB	O
plasma	NN	O
levels	NNS	O
of	IN	O
methadone	NN	D
.	.	.
		
coadministration	NN	O
of	IN	O
amprenavir	NN	D
and	CC	O
methadone	NN	D
as	IN	O
compared	VBN	O
to	TO	O
a	DT	O
non-matched	JJ	O
historicalcontrol	NN	O
group	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
30	CD	O
%	NN	O
","	","	O
27	CD	O
%	NN	O
","	","	O
and	CC	O
25	CD	O
%	NN	O
decrease	NN	O
in	IN	O
serum	NN	O
amprenavir	NN	D
auc	NN	O
","	","	O
cmax	NN	O
","	","	O
andcmin	NN	O
","	","	O
respectively	RB	O
.	.	.
		
amprenavir	NNP	D
is	VBZ	O
an	DT	O
inhibitor	NN	O
of	IN	O
cytochrome	NN	O
p450	NN	O
c.p.a.	NN	O
metabolism	NN	O
and	CC	O
therefore	RB	O
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
concurrently	RB	O
with	IN	O
medications	NNS	O
with	IN	O
narrow	JJ	O
therapeutic	JJ	O
windows	NNS	O
that	WDT	O
are	VBP	O
substrates	NNS	O
of	IN	O
cyp3a4	NN	D
.	.	.
		
there	EX	O
are	VBP	O
other	JJ	O
agents	NNS	O
that	WDT	O
may	MD	O
result	VB	O
in	IN	O
serious	JJ	O
and/or	CC	O
life-threatening	JJ	O
drug	NN	D
interactions	NNS	O
.	.	.
		
laboratory	NN	O
tests	NNS	O
:	:	O
the	DT	O
combination	NN	O
of	IN	O
amprenavir	NNP	D
and	CC	O
low-dose	JJ	O
ritonavir	NN	D
has	VBZ	O
been	VBN	O
associated	VBN	O
with	IN	O
elevations	NNS	O
of	IN	O
cholesterol	NN	O
and	CC	O
triglycerides	NNS	O
","	","	O
sgot	NN	O
-lrb-	-LRB-	O
ast	NNP	O
-rrb-	-RRB-	O
","	","	O
and	CC	O
sgpt	NN	O
-lrb-	-LRB-	O
alt	NN	O
-rrb-	-RRB-	O
in	IN	O
some	DT	O
patients	NNS	O
.	.	.
		
appropriate	JJ	O
laboratory	NN	O
testing	NN	O
should	MD	O
be	VB	O
considered	VBN	O
prior	RB	O
to	TO	O
initiating	VBG	O
combination	NN	O
therapy	NN	O
with	IN	O
amprenavir	NN	D
and	CC	O
ritonavir	NN	D
and	CC	O
at	IN	O
periodic	JJ	O
intervals	NNS	O
or	CC	O
if	IN	O
any	DT	O
clinical	JJ	O
signs	NNS	O
or	CC	O
symptoms	NNS	O
of	IN	O
hyperlipidemia	NN	O
or	CC	O
elevated	JJ	O
liver	NN	O
function	NN	O
tests	NNS	O
occur	VBP	O
during	IN	O
therapy	NN	O
.	.	.
		
for	IN	O
comprehensive	JJ	O
information	NN	O
concerning	VBG	O
laboratory	NN	O
test	NN	O
alterations	NNS	O
associated	VBN	O
with	IN	O
ritonavir	NN	D
","	","	O
physicians	NNS	O
should	MD	O
refer	VB	O
to	TO	O
the	DT	O
complete	JJ	O
prescribing	VBG	O
information	NN	O
for	IN	O
norvir	NN	B
-lrb-	-LRB-	O
ritonavir	NN	D
-rrb-	-RRB-	O
.	.	.
		
taking	VBG	O
amyl	NN	O
nitrite	NN	D
after	IN	O
drinking	VBG	O
alcohol	NN	D
may	MD	O
worsen	VB	O
side	JJ	O
effects	NNS	O
and	CC	O
may	MD	O
cause	VB	O
severe	JJ	O
hypotension	NN	O
and	CC	O
cardiovascular	JJ	O
collapse	NN	O
.	.	.
		
limited	JJ	O
pk	NN	O
and/or	CC	O
pd	NN	O
studies	NNS	O
investigating	VBG	O
possible	JJ	O
interactions	NNS	O
between	IN	O
anagrelide	NN	D
and	CC	O
other	JJ	O
medicinal	JJ	O
products	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
.	.	.
		
in	FW	O
vivo	FW	O
interaction	NN	O
studies	NNS	O
in	IN	O
humans	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
digoxin	NN	D
and	CC	O
warfarin	NN	D
do	VBP	O
not	RB	O
affect	VB	O
the	DT	O
pk	NN	O
properties	NNS	O
of	IN	O
anagrelide	NN	D
","	","	O
nor	CC	O
does	VBZ	O
anagrelide	NN	D
affect	VB	O
the	DT	O
pk	NN	O
properties	NNS	O
of	IN	O
digoxin	NN	D
or	CC	O
warfarin	NN	D
.	.	.
		
although	IN	O
additional	JJ	O
drug	NN	D
interaction	NN	O
studies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
conducted	VBN	O
","	","	O
the	DT	O
most	RBS	O
common	JJ	O
medications	NNS	O
used	VBN	O
concomitantly	RB	O
with	IN	O
anagrelide	NN	D
in	IN	O
clinical	JJ	O
trials	NNS	O
were	VBD	O
aspirin	NN	B
","	","	O
acetaminophen	NN	D
","	","	O
furosemide	NN	D
","	","	O
iron	NN	D
","	","	O
ranitidine	NN	D
","	","	O
hydroxyurea	NN	D
","	","	O
and	CC	O
allopurinol	NN	D
.	.	.
		
there	EX	O
is	VBZ	O
no	DT	O
clinical	JJ	O
evidence	NN	O
to	TO	O
suggest	VB	O
that	IN	O
anagrelide	NN	D
interacts	VBZ	O
with	IN	O
any	DT	O
of	IN	O
these	DT	O
compounds	NNS	O
.	.	.
		
an	DT	O
in	FW	O
vivo	FW	O
interaction	NN	O
study	NN	O
in	IN	O
humans	NNS	O
demonstrated	VBD	O
that	IN	O
a	DT	O
single	JJ	O
1mg	JJ	O
dose	NN	O
of	IN	O
anagrelide	NN	D
administered	VBN	O
concomitantly	RB	O
with	IN	O
a	DT	O
single	JJ	O
900	CD	O
mg	NN	O
dose	NN	O
of	IN	O
aspirin	NN	B
was	VBD	O
generally	RB	O
well	RB	O
tolerated	VBN	O
.	.	.
		
there	EX	O
was	VBD	O
no	DT	O
effect	NN	O
on	IN	O
bleeding	JJ	O
time	NN	O
","	","	O
pt	NN	O
or	CC	O
aptt	NN	O
.	.	.
		
no	DT	O
clinically	RB	O
relevant	JJ	O
pharmacokinetic	JJ	O
interactions	NNS	O
between	IN	O
anagrelide	NN	D
and	CC	O
acetylsalicylic	JJ	O
acid	NN	O
were	VBD	O
observed	VBN	O
.	.	.
		
in	IN	O
that	DT	O
same	JJ	O
study	NN	O
","	","	O
aspirin	NN	B
alone	RB	O
produced	VBD	O
a	DT	O
marked	JJ	O
inhibition	NN	O
in	IN	O
platelet	NN	O
aggregation	NN	O
ex	FW	O
vivo	FW	O
.	.	.
		
anagrelide	NN	D
alone	RB	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
platelet	NN	O
aggregation	NN	O
","	","	O
but	CC	O
did	VBD	O
slightly	RB	O
enhance	VB	O
the	DT	O
inhibition	NN	O
of	IN	O
platelet	NN	O
aggregation	NN	O
by	IN	O
aspirin	NN	B
.	.	.
		
anagrelide	NNP	D
is	VBZ	O
metabolized	VBN	O
at	IN	O
least	JJS	O
in	IN	O
part	NN	O
by	IN	O
cyp1a2	NN	D
.	.	.
		
it	PRP	O
is	VBZ	O
known	VBN	O
that	IN	O
cyp1a2	NN	D
is	VBZ	O
inhibited	VBN	O
by	IN	O
several	JJ	O
medicinal	JJ	O
products	NNS	O
","	","	O
including	VBG	O
fluvoxamine	NN	D
","	","	O
and	CC	O
such	JJ	O
medicinal	JJ	O
products	NNS	O
could	MD	O
theoretically	RB	O
adversely	RB	O
influence	VB	O
the	DT	O
clearance	NN	O
of	IN	O
anagrelide	NN	D
.	.	.
		
anagrelide	NNP	D
demonstrates	VBZ	O
some	DT	O
limited	JJ	O
inhibitory	JJ	O
activity	NN	O
towards	IN	O
cyp1a2	NN	D
which	WDT	O
may	MD	O
present	VB	O
a	DT	O
theoretical	JJ	O
potential	NN	O
for	IN	O
interaction	NN	O
with	IN	O
other	JJ	O
coadministered	JJ	O
medicinal	JJ	O
products	NNS	O
sharing	VBG	O
that	IN	O
clearance	NN	O
mechanism	NN	O
e.g.	FW	O
anagrelide	FW	D
demonstrates	VBZ	O
some	DT	O
limited	JJ	O
inhibitory	JJ	O
activity	NN	O
towards	IN	O
cyp1a2	NN	D
which	WDT	O
may	MD	O
present	VB	O
a	DT	O
theoretical	JJ	O
potential	NN	O
for	IN	O
interaction	NN	O
with	IN	O
other	JJ	O
coadministered	JJ	O
medicinal	JJ	O
products	NNS	O
sharing	VBG	O
that	IN	O
clearance	NN	O
mechanism	NN	O
e.g.	FW	O
theophylline	FW	D
.	.	.
		
anagrelide	NNP	D
is	VBZ	O
an	DT	O
inhibitor	NN	O
of	IN	O
cyclic	JJ	O
amp	NN	O
pde	NN	O
iii	CD	O
.	.	.
		
the	DT	O
effects	NNS	O
of	IN	O
medicinal	JJ	O
products	NNS	O
with	IN	O
similar	JJ	O
properties	NNS	O
such	JJ	O
as	IN	O
inotropes	NNS	O
milrinone	NN	D
","	","	O
enoximone	NN	D
","	","	O
amrinone	NN	D
","	","	O
olprinone	NN	D_n
and	CC	O
cilostazol	NN	D
may	MD	O
be	VB	O
exacerbated	VBN	O
by	IN	O
anagrelide	NN	D
.	.	.
		
there	EX	O
is	VBZ	O
a	DT	O
single	JJ	O
case	NN	O
report	NN	O
","	","	O
which	WDT	O
suggests	VBZ	O
that	IN	O
sucralfate	NN	D
may	MD	O
interfere	VB	O
with	IN	O
anagrelide	NN	D
absorption	NN	O
.	.	.
		
food	NNP	O
has	VBZ	O
no	DT	O
clinically	RB	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
bioavailability	NN	O
of	IN	O
anagrelide	NN	D
.	.	.
		
no	DT	O
drug-drug	NN	O
interaction	NN	O
studies	NNS	O
in	IN	O
human	JJ	O
subjects	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
.	.	.
		
toxicologic	JJ	O
and	CC	O
toxicokinetic	JJ	O
studies	NNS	O
in	IN	O
rats	NNS	O
did	VBD	O
not	RB	O
demonstrate	VB	O
any	DT	O
alterations	NNS	O
in	IN	O
the	DT	O
clearance	NN	O
or	CC	O
toxicologic	JJ	O
profile	NN	O
of	IN	O
either	CC	O
methotrexate	NN	D
or	CC	O
kineret	NN	B
when	WRB	O
the	DT	O
two	CD	O
agents	NNS	O
were	VBD	O
administered	VBN	O
together	RB	O
.	.	.
		
in	IN	O
a	DT	O
study	NN	O
in	IN	O
which	WDT	O
patients	NNS	O
with	IN	O
active	JJ	O
ra	NN	O
were	VBD	O
treated	VBN	O
for	IN	O
up	RB	O
to	TO	O
24	CD	O
weeks	NNS	O
with	IN	O
concurrent	JJ	O
kineret	NN	B
and	CC	O
etanercept	NN	D
therapy	NN	O
","	","	O
a	DT	O
7	CD	O
%	NN	O
rate	NN	O
of	IN	O
serious	JJ	O
infections	NNS	O
was	VBD	O
observed	VBN	O
","	","	O
which	WDT	O
was	VBD	O
higher	JJR	O
than	IN	O
that	DT	O
observed	VBN	O
with	IN	O
etanercept	NN	D
alone	RB	O
-lrb-	-LRB-	O
0	CD	O
%	NN	O
-rrb-	-RRB-	O
.	.	.
		
two	CD	O
percent	NN	O
of	IN	O
patients	NNS	O
treated	VBN	O
concurrently	RB	O
with	IN	O
kineret	NN	B
and	CC	O
etanercept	NN	D
developed	VBD	O
neutropenia	NN	O
-lrb-	-LRB-	O
anc	NNP	O
1	CD	O
x	CC	O
109/l	CD	O
-rrb-	-RRB-	O
.	.	.
		
anastrozole	NNP	D
inhibited	VBD	O
in	FW	O
vitro	FW	O
metabolic	JJ	O
reactions	NNS	O
catalyzed	VBN	O
by	IN	O
cytochromes	NNS	O
p450	NN	O
1a2	NN	O
","	","	O
2c8/9	NN	O
","	","	O
and	CC	O
3a4	NN	O
but	CC	O
only	RB	O
at	IN	O
relatively	RB	O
high	JJ	O
concentrations	NNS	O
.	.	.
		
anastrozole	NNP	D
did	VBD	O
not	RB	O
inhibit	VB	O
p450	NN	O
2a6	NN	O
or	CC	O
the	DT	O
polymorphic	JJ	O
p450	NN	O
2d6	NN	O
in	IN	O
human	JJ	O
liver	NN	O
microsomes	NNS	O
.	.	.
		
anastrozole	NNP	D
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
antipyrine	NN	D
.	.	.
		
although	IN	O
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
formal	JJ	O
interaction	NN	O
studies	NNS	O
other	JJ	O
than	IN	O
with	IN	O
antipyrine	NN	D
","	","	O
based	VBN	O
on	IN	O
these	DT	O
in	FW	O
vivo	FW	O
and	CC	O
in	FW	O
vitro	FW	O
studies	NNS	O
","	","	O
it	PRP	O
is	VBZ	O
unlikely	JJ	O
that	IN	O
co-administration	NN	O
of	IN	O
a	DT	O
1	CD	O
mg	NN	O
dose	NN	O
of	IN	O
arimidex	NN	B
with	IN	O
other	JJ	O
drugs	NNS	D
will	MD	O
result	VB	O
in	IN	O
clinically	RB	O
significant	JJ	O
drug	NN	D
inhibition	NN	O
of	IN	O
cytochrome	NN	O
p450-mediated	JJ	O
metabolism	NN	O
of	IN	O
the	DT	O
other	JJ	O
drugs	NNS	D
.	.	.
		
an	DT	O
interaction	NN	O
study	NN	O
with	IN	O
warfarin	NN	D
showed	VBD	O
no	DT	O
clinically	RB	O
significant	JJ	O
effect	NN	O
of	IN	O
anastrozole	NN	D
on	IN	O
warfarin	NN	D
pharmacokinetics	NNS	O
or	CC	O
anticoagulant	JJ	G
activity	NN	O
.	.	.
		
at	IN	O
a	DT	O
median	JJ	O
follow-up	NN	O
of	IN	O
33	CD	O
months	NNS	O
","	","	O
the	DT	O
combination	NN	O
of	IN	O
arimidex	NNP	B
and	CC	O
tamoxifen	NN	D
did	VBD	O
not	RB	O
demonstrate	VB	O
any	DT	O
efficacy	NN	O
benefit	NN	O
when	WRB	O
compared	VBN	O
with	IN	O
tamoxifen	NN	D
in	IN	O
all	DT	O
patients	NNS	O
as	RB	O
well	RB	O
as	IN	O
in	IN	O
the	DT	O
hormone	NN	O
receptor-positive	JJ	O
subpopulation	NN	O
.	.	.
		
this	DT	O
treatment	NN	O
arm	NN	O
was	VBD	O
discontinued	VBN	O
from	IN	O
the	DT	O
trial	NN	O
.	.	.
		
based	VBN	O
on	IN	O
clinical	JJ	O
and	CC	O
pharmacokinetic	JJ	O
results	NNS	O
from	IN	O
the	DT	O
atac	NN	O
trial	NN	O
","	","	O
tamoxifen	NN	D
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
with	IN	O
anastrozole	NN	D
-lrb-	-LRB-	O
see	VB	O
clinical	NNP	O
pharmacology	NNP	O
drug	NNP	O
interactions	NNS	O
and	CC	O
clinical	JJ	O
pharmacology	NN	O
-	:	O
clinical	JJ	O
studies	NNS	O
-	:	O
adjuvant	JJ	O
treatment	NN	O
of	IN	O
breast	NN	O
cancer	NN	O
in	IN	O
postmenopausal	NNP	O
women	NNP	O
subsections	NNS	O
-rrb-	-RRB-	O
.	.	.
		
co-administration	NN	O
of	IN	O
anastrozole	NN	D
and	CC	O
tamoxifen	NN	D
resulted	VBD	O
in	IN	O
a	DT	O
reduction	NN	O
of	IN	O
anastrozole	NN	D
plasma	NN	O
levels	NNS	O
by	IN	O
27	CD	O
%	NN	O
compared	VBN	O
with	IN	O
those	DT	O
achieved	VBN	O
with	IN	O
anastrozole	NN	D
alone	RB	O
.	.	.
		
estrogen-containing	JJ	O
therapies	NNS	O
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
with	IN	O
arimidex	NN	B
as	IN	O
they	PRP	O
may	MD	O
diminish	VB	O
its	PRP$	O
pharmacologic	JJ	O
action	NN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
no	DT	O
clinically	RB	O
significant	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
results	NNS	O
of	IN	O
clinical	JJ	O
laboratory	NN	O
tests	NNS	O
have	VBP	O
been	VBN	O
observed	VBN	O
.	.	.
		
no	DT	O
clinically	RB	O
relevant	JJ	O
drug-drug	JJ	O
interactions	NNS	O
have	VBP	O
been	VBN	O
observed	VBN	O
with	IN	O
drugs	NNS	D
likely	JJ	O
to	TO	O
be	VB	O
co-administered	VBN	O
with	IN	O
anidulafungin	NN	D
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
observed	VBN	O
when	WRB	O
anileridine	NN	D
is	VBZ	O
coadministered	VBN	O
with	IN	O
other	JJ	O
opioids	NNS	G
","	","	O
sedatives	NNS	G
","	","	O
phenothiazines	NNS	G
","	","	O
or	CC	O
anesthetics	NNS	G
","	","	O
as	IN	O
these	DT	O
agents	NNS	O
may	MD	O
increase	VB	O
respiratory	JJ	O
and	CC	O
circulatory	JJ	O
depression	NN	O
.	.	.
		
addition	NN	O
or	CC	O
deletion	NN	O
of	IN	O
any	DT	O
drug	NN	D
from	IN	O
the	DT	O
therapeutic	JJ	O
regimen	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
oral	JJ	O
anticoagulants	NNS	G
may	MD	O
affect	VB	O
patient	NN	O
response	NN	O
to	TO	O
the	DT	O
anticoagulant	NN	G
.	.	.
		
frequent	JJ	O
determination	NN	O
of	IN	O
prothrombin	NN	O
time	NN	O
and	CC	O
close	JJ	O
monitoring	NN	O
of	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
essential	JJ	O
to	TO	O
ascertain	VB	O
when	WRB	O
adjustment	NN	O
of	IN	O
dosage	NN	O
of	IN	O
anticoagulant	NN	G
may	MD	O
be	VB	O
needed	VBN	O
.	.	.
		
because	IN	O
of	IN	O
the	DT	O
variability	NN	O
of	IN	O
individual	JJ	O
patient	NN	O
response	NN	O
","	","	O
multiple	JJ	O
interacting	VBG	O
mechanisms	NNS	O
with	IN	O
some	DT	O
drugs	NNS	D
","	","	O
the	DT	O
dependency	NN	O
of	IN	O
the	DT	O
extent	NN	O
of	IN	O
the	DT	O
interaction	NN	O
on	IN	O
the	DT	O
dosage	NN	O
and	CC	O
duration	NN	O
of	IN	O
therapy	NN	O
","	","	O
and	CC	O
the	DT	O
possible	JJ	O
administration	NN	O
of	IN	O
several	JJ	O
interacting	VBG	O
drugs	NNS	D
simultaneously	RB	O
","	","	O
it	PRP	O
is	VBZ	O
difficult	JJ	O
to	TO	O
predict	VB	O
the	DT	O
direction	NN	O
and	CC	O
degree	NN	O
of	IN	O
the	DT	O
ultimate	JJ	O
effect	NN	O
of	IN	O
concomitant	JJ	O
medications	NNS	O
on	IN	O
anticoagulant	JJ	G
response	NN	O
.	.	.
		
for	IN	O
example	NN	O
","	","	O
since	IN	O
cholestyramine	NN	D
may	MD	O
reduce	VB	O
the	DT	O
gastrointestinal	JJ	O
absorption	NN	O
of	IN	O
both	CC	O
the	DT	O
oral	JJ	O
anticoagulants	NNS	G
and	CC	O
vitamin	NN	O
k	NN	O
","	","	O
the	DT	O
net	JJ	O
effects	NNS	O
are	VBP	O
unpredictable	JJ	O
.	.	.
		
therefore	RB	O
","	","	O
the	DT	O
potential	JJ	O
exists	VBZ	O
for	IN	O
interaction	NN	O
between	IN	O
carbamazepine	NN	D
and	CC	O
any	DT	O
agent	NN	O
metabolized	VBN	O
by	IN	O
one	CD	O
-lrb-	-LRB-	O
or	CC	O
more	JJR	O
-rrb-	-RRB-	O
of	IN	O
these	DT	O
enzymes	NNS	O
.	.	.
		
agents	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
found	VBN	O
","	","	O
or	CC	O
are	VBP	O
expected	VBN	O
to	TO	O
have	VB	O
decreased	VBN	O
plasma	NN	O
levels	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
equetrotm	NNP	B
due	JJ	O
to	TO	O
induction	NN	O
of	IN	O
cyp	NN	O
enzymes	NNS	O
are	VBP	O
the	DT	O
following	NN	O
:	:	O
acetaminophen	NNP	D
","	","	O
alprazolam	NN	D
","	","	O
amitriptyline	NNP	D
","	","	O
bupropion	NN	D
","	","	O
buspirone	NN	D
","	","	O
citalopram	NN	D
","	","	O
clobazam	NN	D
","	","	O
clonazepam	NN	D
","	","	O
clozapine	NN	D
","	","	O
cyclosporin	NN	D
","	","	O
delavirdine	NN	D
","	","	O
desipramine	NN	D
","	","	O
diazepam	NN	D
","	","	O
dicumarol	NN	D
","	","	O
doxycycline	NN	D
","	","	O
ethosuximide	NN	D
","	","	O
felbamate	NN	D
","	","	O
felodipine	NN	D
","	","	O
glucocorticoids	NNS	G
","	","	O
haloperidol	NN	D
","	","	O
itraconazole	NN	D
","	","	O
lamotrigine	NN	D
","	","	O
levothyroxine	NN	D
","	","	O
lorazepam	NN	D
","	","	O
methadone	NN	D
","	","	O
midazolam	NN	D
","	","	O
mirtazapine	NN	D
","	","	O
nortriptyline	NN	D_n
","	","	O
olanzapine	NN	D
","	","	O
oral	JJ	O
contraceptives	NNS	G
-lrb-	-LRB-	O
3	CD	O
-rrb-	-RRB-	O
","	","	O
oxcarbazepine	NN	D
","	","	O
phenytoin	NN	D
-lrb-	-LRB-	O
4	CD	O
-rrb-	-RRB-	O
","	","	O
praziquantel	NN	D
","	","	O
protease	NN	O
inhibitors	NNS	O
","	","	O
quetiapine	NN	D
","	","	O
risperidone	NN	D
","	","	O
theophylline	NN	D
","	","	O
topiramate	NN	D
","	","	O
tiagabine	NN	D
","	","	O
tramadol	NN	D
","	","	O
triazolam	NN	D
","	","	O
valproate	NN	D
","	","	O
warfarin	NN	D
-lrb-	-LRB-	O
5	CD	O
-rrb-	-RRB-	O
","	","	O
ziprasidone	NN	D
","	","	O
and	CC	O
zonisamide	NN	D
.	.	.
		
thus	RB	O
","	","	O
if	IN	O
a	DT	O
patient	NN	O
has	VBZ	O
been	VBN	O
titrated	VBN	O
to	TO	O
a	DT	O
stable	JJ	O
dosage	NN	O
on	IN	O
one	CD	O
of	IN	O
the	DT	O
agents	NNS	O
in	IN	O
this	DT	O
category	NN	O
","	","	O
and	CC	O
then	RB	O
begins	VBZ	O
a	DT	O
course	NN	O
of	IN	O
treatment	NN	O
with	IN	O
equetrotm	NN	B
","	","	O
it	PRP	O
is	VBZ	O
reasonable	JJ	O
to	TO	O
expect	VB	O
that	IN	O
a	DT	O
dose	NN	O
increase	NN	O
for	IN	O
the	DT	O
concomitant	JJ	O
agent	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
.	.	.
		
agents	NNS	O
with	IN	O
increased	VBN	O
levels	NNS	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
carbamazepine	NNP	D
:	:	O
equetrotm	NNP	B
increases	VBZ	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
the	DT	O
following	VBG	O
agents	NNS	O
:	:	O
clomipramine	NNP	O
hcl	NN	O
","	","	O
phenytoin	NNP	D
-lrb-	-LRB-	O
6	CD	O
-rrb-	-RRB-	O
","	","	O
and	CC	O
primidone	NN	D
thus	RB	O
","	","	O
if	IN	O
a	DT	O
patient	NN	O
has	VBZ	O
been	VBN	O
titrated	VBN	O
to	TO	O
a	DT	O
stable	JJ	O
dosage	NN	O
on	IN	O
one	CD	O
of	IN	O
the	DT	O
agents	NNS	O
in	IN	O
this	DT	O
category	NN	O
","	","	O
and	CC	O
then	RB	O
begins	VBZ	O
a	DT	O
course	NN	O
of	IN	O
the	DT	O
treatment	NN	O
with	IN	O
equetrotm	NN	B
","	","	O
it	PRP	O
is	VBZ	O
reasonable	JJ	O
to	TO	O
expect	VB	O
that	IN	O
a	DT	O
dose	NN	O
decrease	NN	O
for	IN	O
the	DT	O
concomitant	JJ	O
agent	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
.	.	.
		
pharmacological/pharmacodynamic	JJ	O
interactions	NNS	O
with	IN	O
carbamazepine	NNP	D
concomitant	JJ	O
administration	NN	O
of	IN	O
carbamazepine	NN	D
and	CC	O
lithium	NN	D
may	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
neurotoxic	JJ	O
side	JJ	O
effects	NNS	O
.	.	.
		
given	VBN	O
the	DT	O
anticonvulsant	JJ	O
properties	NNS	O
of	IN	O
carbamazepine	NN	D
","	","	O
equetrotm	NN	B
may	MD	O
reduce	VB	O
the	DT	O
thyroid	NN	D
function	NN	O
as	IN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
with	IN	O
other	JJ	O
anticonvulsants	NNS	G
.	.	.
		
additionally	RB	O
","	","	O
anti-malarial	JJ	O
drugs	NNS	D
","	","	O
such	JJ	O
as	IN	O
chloroquine	NN	D
and	CC	O
mefloquine	NN	D
","	","	O
may	MD	O
antagonize	VB	O
the	DT	O
activity	NN	O
of	IN	O
carbamazepine	NN	D
.	.	.
		
thus	RB	O
if	IN	O
a	DT	O
patient	NN	O
has	VBZ	O
been	VBN	O
titrated	VBN	O
to	TO	O
a	DT	O
stable	JJ	O
dosage	NN	O
on	IN	O
one	CD	O
of	IN	O
the	DT	O
agents	NNS	O
in	IN	O
this	DT	O
category	NN	O
","	","	O
and	CC	O
then	RB	O
begins	VBZ	O
a	DT	O
course	NN	O
of	IN	O
treatment	NN	O
with	IN	O
equetrotm	NN	B
","	","	O
it	PRP	O
is	VBZ	O
reasonable	JJ	O
to	TO	O
expect	VB	O
that	IN	O
a	DT	O
dose	NN	O
adjustment	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
.	.	.
		
because	IN	O
of	IN	O
its	PRP$	O
primary	JJ	O
cns	NN	O
effect	NN	O
","	","	O
caution	NN	O
should	MD	O
be	VB	O
used	VBN	O
when	WRB	O
equetrotm	NNP	B
is	VBZ	O
taken	VBN	O
with	IN	O
other	JJ	O
centrally	RB	O
acting	VBG	O
drugs	NNS	D
and	CC	O
alcohol	NN	D
.	.	.
		
geocillin	NN	B
-lrb-	-LRB-	O
carbenicillin	NN	O
indanyl	NN	O
sodium	NN	O
-rrb-	-RRB-	O
blood	NN	O
levels	NNS	O
may	MD	O
be	VB	O
increased	VBN	O
and	CC	O
prolonged	VBN	O
by	IN	O
concurrent	JJ	O
administration	NN	O
of	IN	O
probenecid	NN	D
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
the	DT	O
following	VBG	O
drugs	NNS	D
are	VBP	O
administered	VBN	O
concomitantly	RB	O
with	IN	O
lodosyn	NN	B
-lrb-	-LRB-	O
carbidopa	NN	D
-rrb-	-RRB-	O
given	VBN	O
with	IN	O
levodopa	NN	D
or	CC	O
carbidopa-levodopa	NN	O
combination	NN	O
products	NNS	O
.	.	.
		
for	IN	O
patients	NNS	O
receiving	VBG	O
monoamine	NN	O
oxidase	NN	O
inhibitors	NNS	O
","	","	O
see	VBP	O
contraindications	NNS	O
.	.	.
		
dopamine	NN	O
d2	NN	O
receptor	NN	D
antagonists	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
phenothiazines	NNS	G
","	","	O
butyrophenones	NNS	G
","	","	O
risperidone	NN	D
-rrb-	-RRB-	O
and	CC	O
isoniazid	NN	D
may	MD	O
reduce	VB	O
the	DT	O
therapeutic	JJ	O
effects	NNS	O
of	IN	O
levodopa	NN	D
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
levodopa	NN	D
in	IN	O
parkinsons	NNPS	O
disease	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
reversed	VBN	O
by	IN	O
phenytoin	NN	D
and	CC	O
papaverine	NN	D
.	.	.
		
patients	NNS	O
taking	VBG	O
these	DT	O
drugs	NNS	D
with	IN	O
lodosyn	NN	B
and	CC	O
levodopa	NN	D
or	CC	O
carbidopa-levodopa	NN	O
combination	NN	O
products	NNS	O
should	MD	O
be	VB	O
carefully	RB	O
observed	VBN	O
for	IN	O
loss	NN	O
of	IN	O
therapeutic	JJ	O
response	NN	O
.	.	.
		
iron	NNP	D
salts	NNS	O
may	MD	O
reduce	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
carbidopa	NN	D
and	CC	O
levodopa	NN	D
.	.	.
		
the	DT	O
clinical	JJ	O
relevance	NN	O
is	VBZ	O
unclear	JJ	O
.	.	.
		
although	IN	O
metoclopramide	NN	D
may	MD	O
increase	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
levodopa	NN	D
by	IN	O
increasing	VBG	O
gastric	JJ	O
emptying	NN	O
","	","	O
metoclopramide	NN	D
may	MD	O
also	RB	O
adversely	RB	O
affect	VB	O
disease	NN	O
control	NN	O
by	IN	O
its	PRP$	O
dopamine	NN	D
receptor	NN	D
antagonistic	JJ	O
properties	NNS	O
.	.	.
		
iodine	NN	D
or	CC	O
iodine	NN	D
excess	NN	O
may	MD	O
decrease	VB	O
the	DT	O
effect	NN	O
of	IN	O
carbimazole	NNP	D
","	","	O
and	CC	O
an	DT	O
iodine	NN	D
deficiency	NN	O
can	MD	O
increase	VB	O
the	DT	O
effect	NN	O
of	IN	O
carbimazole	NN	D
.	.	.
		
serum	NN	O
concentration	NN	O
of	IN	O
digoxin	NN	D
and	CC	O
digitoxin	NN	D
may	MD	O
increase	VB	O
when	WRB	O
patients	NNS	O
take	VBP	O
antithyroid	JJ	O
agents	NNS	O
.	.	.
		
a	DT	O
decrease	NN	O
of	IN	O
the	DT	O
dosage	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
when	WRB	O
patient	NN	O
becomes	VBZ	O
euthyroid	JJ	O
.	.	.
		
antithyroid	JJ	O
agents	NNS	O
may	MD	O
decrease	VB	O
thyroidal	JJ	O
uptake	NN	O
of	IN	O
sodium	NN	O
iodide	NN	O
i131	NN	O
","	","	O
a	DT	O
rebound	NN	O
in	IN	O
uptake	NN	O
may	MD	O
occur	VB	O
up	RP	O
to	TO	O
5	CD	O
days	NNS	O
after	IN	O
sudden	JJ	O
withdrawal	NN	O
of	IN	O
carbimazole	NN	D
.	.	.
		
patients	NNS	O
response	NN	O
to	TO	O
oral	JJ	O
anticoagulants	NNS	G
may	MD	O
be	VB	O
affected	VBN	O
by	IN	O
his/her	NN	O
thyroid	NN	D
and	CC	O
metabolic	JJ	O
status	NN	O
.	.	.
		
an	DT	O
evaluation	NN	O
of	IN	O
prothrombin	NN	O
time	NN	O
and	CC	O
an	DT	O
adjustment	NN	O
of	IN	O
anticoagulant	JJ	G
dosage	NN	O
are	VBP	O
recommende	NN	O
.	.	.
		
antihistamines	NNS	G
may	MD	O
enhance	VB	O
the	DT	O
effects	NNS	O
of	IN	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
barbiturates	NNS	G
","	","	O
alcohol	NN	D
","	","	O
and	CC	O
other	JJ	O
cns	NN	O
depressants	NNS	O
.	.	.
		
mao	NN	O
inhibitors	NNS	O
prolong	VB	O
and	CC	O
intensify	VB	O
the	DT	O
anticholinergic	JJ	G
effects	NNS	O
of	IN	O
antihistamines	NNS	G
.	.	.
		
sympathomimetic	JJ	O
amines	NNS	O
may	MD	O
reduce	VB	O
the	DT	O
antihypertensive	JJ	O
effects	NNS	O
of	IN	O
reserpine	NN	D
","	","	O
veratrum	NN	O
alkaloids	NNS	O
","	","	O
methyldopa	NN	D
and	CC	O
mecamylamine	NN	D
.	.	.
		
effects	NNS	O
of	IN	O
sympathomimetics	NNS	G
are	VBP	O
increased	VBN	O
with	IN	O
mao	NN	O
inhibitors	NNS	O
and	CC	O
beta	NN	O
adrenergic	JJ	O
blockers	NNS	O
.	.	.
		
the	DT	O
renal	JJ	O
effects	NNS	O
of	IN	O
nephrotoxic	JJ	O
compounds	NNS	O
may	MD	O
be	VB	O
potentiated	VBN	O
by	IN	O
carboplatin	NNP	D
.	.	.
		
hemabate	NN	B
may	MD	O
augment	VB	O
the	DT	O
activity	NN	O
of	IN	O
other	JJ	O
oxytocic	JJ	O
agents	NNS	O
.	.	.
		
concomitant	JJ	O
use	NN	O
with	IN	O
other	JJ	O
oxytocic	JJ	O
agents	NNS	O
is	VBZ	O
not	RB	O
recommende	NN	O
.	.	.
		
ocupress	NN	B
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	O
who	WP	O
are	VBP	O
receiving	VBG	O
a	DT	O
beta-adrenergic	JJ	O
blocking	VBG	O
agent	NN	O
orally	RB	O
because	IN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
additive	JJ	O
effects	NNS	O
on	IN	O
systemic	JJ	O
beta-blockade	NN	O
.	.	.
		
close	JJ	O
observation	NN	O
of	IN	O
the	DT	O
patient	NN	O
is	VBZ	O
recommended	VBN	O
when	WRB	O
a	DT	O
beta-blocker	NN	G
is	VBZ	O
administered	VBN	O
to	TO	O
patients	NNS	O
receiving	VBG	O
catecholamine-depleting	JJ	O
drugs	NNS	D
such	JJ	O
as	IN	O
reserpine	NN	D
","	","	O
because	IN	O
of	IN	O
possible	JJ	O
additive	JJ	O
effects	NNS	O
and	CC	O
the	DT	O
production	NN	O
of	IN	O
hypotension	NN	O
and/or	CC	O
marked	JJ	O
bradycardia	NN	O
","	","	O
which	WDT	O
may	MD	O
produce	VB	O
vertigo	NN	O
","	","	O
syncope	NN	O
","	","	O
or	CC	O
postural	JJ	O
hypotension	NN	O
.	.	.
		
inhibitors	NNS	O
of	IN	O
cyp2d6	NN	D
;	:	O
.	.	.
		
poor	JJ	O
metabolizers	NNS	O
of	IN	O
debrisoquin	NN	D
:	:	O
interactions	NNS	O
of	IN	O
carvedilol	NN	D
with	IN	O
strong	JJ	O
inhibitors	NNS	O
of	IN	O
cyp2d6	NN	D
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
quinidine	NN	D
","	","	O
fluoxetine	NN	D
","	","	O
paroxetine	NN	D
","	","	O
and	CC	O
propafenone	NN	D
-rrb-	-RRB-	O
have	VBP	O
not	RB	O
been	VBN	O
studied	VBN	O
","	","	O
but	CC	O
these	DT	O
drugs	NNS	D
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
increase	VB	O
blood	NN	O
levels	NNS	O
of	IN	O
the	DT	O
r	NN	O
-lrb-	-LRB-	O
+	CC	O
-rrb-	-RRB-	O
enantiomer	NN	O
of	IN	O
carvedilol	NN	D
.	.	.
		
retrospective	JJ	O
analysis	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
in	IN	O
clinical	JJ	O
trials	NNS	O
showed	VBD	O
that	IN	O
poor	JJ	O
2d6	NN	O
metabolizers	NNS	O
had	VBD	O
a	DT	O
higher	JJR	O
rate	NN	O
of	IN	O
dizziness	NN	O
during	IN	O
up-titration	NN	O
","	","	O
presumably	RB	O
resulting	VBG	O
from	IN	O
vasodilating	VBG	O
effects	NNS	O
of	IN	O
the	DT	O
higher	JJR	O
concentrations	NNS	O
of	IN	O
the	DT	O
a-blocking	NN	O
r	NN	O
-lrb-	-LRB-	O
+	CC	O
-rrb-	-RRB-	O
enantiomer	NN	O
.	.	.
		
catecholamine-depleting	JJ	O
agents	NNS	O
:	:	O
patients	NNS	O
taking	VBG	O
both	CC	O
agents	NNS	O
with	IN	O
b-blocking	NN	O
properties	NNS	O
and	CC	O
a	DT	O
drug	NN	D
that	WDT	O
can	MD	O
deplete	VB	O
catecholamines	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
reserpine	NN	D
and	CC	O
monoamine	NN	O
oxidase	NN	O
inhibitors	NNS	O
-rrb-	-RRB-	O
should	MD	O
be	VB	O
observed	VBN	O
closely	RB	O
for	IN	O
signs	NNS	O
of	IN	O
hypotension	NN	O
and/or	CC	O
severe	JJ	O
bradycardia	NN	O
.	.	.
		
clonidine	NNP	D
:	:	O
concomitant	JJ	O
administration	NN	O
of	IN	O
clonidine	NN	D
with	IN	O
agents	NNS	O
with	IN	O
b-blocking	NN	O
properties	NNS	O
may	MD	O
potentiate	VB	O
blood-pressure	NN	O
-	:	O
and	CC	O
heart-rate-lowering	JJ	O
effects	NNS	O
.	.	.
		
when	WRB	O
concomitant	JJ	O
treatment	NN	O
with	IN	O
agents	NNS	O
with	IN	O
b-blocking	NN	O
properties	NNS	O
and	CC	O
clonidine	NN	D
is	VBZ	O
to	TO	O
be	VB	O
terminated	VBN	O
","	","	O
the	DT	O
b-blocking	JJ	O
agent	NN	O
should	MD	O
be	VB	O
discontinued	VBN	O
first	RB	O
.	.	.
		
clonidine	NN	D
therapy	NN	O
can	MD	O
then	RB	O
be	VB	O
discontinued	VBN	O
several	JJ	O
days	NNS	O
later	RB	O
by	IN	O
gradually	RB	O
decreasing	VBG	O
the	DT	O
dosage	NN	O
.	.	.
		
cyclosporine	NN	D
:	:	O
modest	JJ	O
increases	NNS	O
in	IN	O
mean	JJ	O
trough	NN	O
cyclosporine	NN	D
concentrations	NNS	O
were	VBD	O
observed	VBN	O
following	VBG	O
initiation	NN	O
of	IN	O
carvedilol	NN	D
treatment	NN	O
in	IN	O
21	CD	O
renal	JJ	O
transplant	NN	O
patients	NNS	O
suffering	VBG	O
from	IN	O
chronic	JJ	O
vascular	JJ	O
rejection	NN	O
.	.	.
		
in	IN	O
about	RB	O
30	CD	O
%	NN	O
of	IN	O
patients	NNS	O
","	","	O
the	DT	O
dose	NN	O
of	IN	O
cyclosporine	NN	D
had	VBD	O
to	TO	O
be	VB	O
reduced	VBN	O
in	IN	O
order	NN	O
to	TO	O
maintain	VB	O
cyclosporine	NN	D
concentrations	NNS	O
within	IN	O
the	DT	O
therapeutic	JJ	O
range	NN	O
","	","	O
while	IN	O
in	IN	O
the	DT	O
remainder	NN	O
no	DT	O
adjustment	NN	O
was	VBD	O
needed	VBN	O
.	.	.
		
on	IN	O
the	DT	O
average	NN	O
for	IN	O
the	DT	O
group	NN	O
","	","	O
the	DT	O
dose	NN	O
of	IN	O
cyclosporine	NN	D
was	VBD	O
reduced	VBN	O
about	IN	O
20	CD	O
%	NN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	.
		
due	JJ	O
to	TO	O
wide	JJ	O
interindividual	JJ	O
variability	NN	O
in	IN	O
the	DT	O
dose	NN	O
adjustment	NN	O
required	VBN	O
","	","	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
cyclosporine	NN	D
concentrations	NNS	O
be	VB	O
monitored	VBN	O
closely	RB	O
after	IN	O
initiation	NN	O
of	IN	O
carvedilol	NN	D
therapy	NN	O
and	CC	O
that	IN	O
the	DT	O
dose	NN	O
of	IN	O
cyclosporine	NN	D
be	VB	O
adjusted	VBN	O
as	IN	O
appropriate	JJ	O
.	.	.
		
digoxin	NNP	D
:	:	O
digoxin	NN	D
concentrations	NNS	O
are	VBP	O
increased	VBN	O
by	IN	O
about	RB	O
15	CD	O
%	NN	O
when	WRB	O
digoxin	NN	D
and	CC	O
carvedilol	NN	D
are	VBP	O
administered	VBN	O
concomitantly	RB	O
.	.	.
		
both	DT	O
digoxin	NN	D
and	CC	O
coreg	NNP	B
slow	JJ	O
av	NN	O
conduction	NN	O
.	.	.
		
therefore	RB	O
","	","	O
increased	VBD	O
monitoring	NN	O
of	IN	O
digoxin	NN	D
is	VBZ	O
recommended	VBN	O
when	WRB	O
initiating	VBG	O
","	","	O
adjusting	VBG	O
","	","	O
or	CC	O
discontinuing	VBG	O
coreg	NNP	B
.	.	.
		
inducers	NNS	O
and	CC	O
inhibitors	NNS	O
of	IN	O
hepatic	JJ	O
metabolism	NN	O
:	:	O
rifampin	NNP	D
reduced	VBD	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
carvedilol	NN	D
by	IN	O
about	RB	O
70	CD	O
%	NN	O
.	.	.
		
cimetidine	NN	D
increased	VBD	O
auc	NN	O
by	IN	O
about	IN	O
30	CD	O
%	NN	O
but	CC	O
caused	VBD	O
no	DT	O
change	NN	O
in	IN	O
cmax	NNP	O
.	.	.
		
calcium	NN	D
channel	NNP	O
blockers	NNPS	O
:	:	O
isolated	VBN	O
cases	NNS	O
of	IN	O
conduction	NN	O
disturbance	NN	O
-lrb-	-LRB-	O
rarely	RB	O
with	IN	O
hemodynamic	JJ	O
compromise	NN	O
-rrb-	-RRB-	O
have	VBP	O
been	VBN	O
observed	VBN	O
when	WRB	O
coreg	NNP	B
is	VBZ	O
co-administered	VBN	O
with	IN	O
diltiazem	NN	D
.	.	.
		
as	IN	O
with	IN	O
other	JJ	O
agents	NNS	O
with	IN	O
b-blocking	NN	O
properties	NNS	O
","	","	O
if	IN	O
coreg	NNP	B
is	VBZ	O
to	TO	O
be	VB	O
administered	VBN	O
orally	RB	O
with	IN	O
calcium	NN	D
channel	NN	O
blockers	NNS	O
of	IN	O
the	DT	O
verapamil	NN	D
or	CC	O
diltiazem	NN	D
type	NN	O
","	","	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
ecg	NN	O
and	CC	O
blood	NN	O
pressure	NN	O
be	VB	O
monitored	VBN	O
.	.	.
		
insulin	NN	D
or	CC	O
oral	JJ	O
hypoglycemics	NNS	G
:	:	O
agents	NNS	O
with	IN	O
b-blocking	NN	O
properties	NNS	O
may	MD	O
enhance	VB	O
the	DT	O
blood-sugar-reducing	JJ	O
effect	NN	O
of	IN	O
insulin	NN	D
and	CC	O
oral	JJ	O
hypoglycemics	NNS	G
.	.	.
		
therefore	RB	O
","	","	O
in	IN	O
patients	NNS	O
taking	VBG	O
insulin	NN	D
or	CC	O
oral	JJ	O
hypoglycemics	NNS	G
","	","	O
regular	JJ	O
monitoring	NN	O
of	IN	O
blood	NN	O
glucose	NN	O
is	VBZ	O
recommended	VBN	O
.	.	.
		
studies	NNS	O
in	FW	O
vitro	FW	O
show	VBP	O
that	IN	O
caspofungin	NN	D
acetate	NN	O
is	VBZ	O
not	RB	O
an	DT	O
inhibitor	NN	O
of	IN	O
any	DT	O
enzyme	NN	O
in	IN	O
the	DT	O
cytochrome	NN	O
p450	NN	O
-lrb-	-LRB-	O
cyp	NN	O
-rrb-	-RRB-	O
system	NN	O
.	.	.
		
in	IN	O
clinical	JJ	O
studies	NNS	O
","	","	O
caspofungin	NN	D
did	VBD	O
not	RB	O
induce	VB	O
the	DT	O
cyp3a4	NN	D
metabolism	NN	O
of	IN	O
other	JJ	O
drugs	NNS	D
.	.	.
		
caspofungin	NNP	D
is	VBZ	O
not	RB	O
a	DT	O
substrate	NN	O
for	IN	O
p-glycoprotein	NN	O
and	CC	O
is	VBZ	O
a	DT	O
poor	JJ	O
substrate	NN	O
for	IN	O
cytochrome	NN	O
p450	NN	O
enzymes	NNS	O
.	.	.
		
clinical	JJ	O
studies	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
show	VBP	O
that	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
cancidas	NNP	B
are	VBP	O
not	RB	O
altered	VBN	O
by	IN	O
itraconazole	NN	D
","	","	O
amphotericin	NN	O
b	NN	O
","	","	O
mycophenolate	NN	D
","	","	O
nelfinavir	NN	D
","	","	O
or	CC	O
tacrolimus	NN	D
.	.	.
		
cancidas	NNP	B
has	VBZ	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
itraconazole	NN	D
","	","	O
amphotericin	NN	O
b	NN	O
","	","	O
or	CC	O
the	DT	O
active	JJ	O
metabolite	NN	O
of	IN	O
mycophenolate	NN	D
.	.	.
		
cancidas	NNP	B
reduced	VBD	O
the	DT	O
blood	NN	O
auc0-12	NN	O
of	IN	O
tacrolimus	NN	D
by	IN	O
approximately	RB	O
20	CD	O
%	NN	O
","	","	O
peak	JJ	O
blood	NN	O
concentration	NN	O
-lrb-	-LRB-	O
cmax	NN	O
-rrb-	-RRB-	O
by	IN	O
16	CD	O
%	NN	O
","	","	O
and	CC	O
12-hour	JJ	O
blood	NN	O
concentration	NN	O
-lrb-	-LRB-	O
c12hr	NN	O
-rrb-	-RRB-	O
by	IN	O
26	CD	O
%	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
when	WRB	O
tacrolimus	NN	D
-lrb-	-LRB-	O
2	CD	O
doses	NNS	O
of	IN	O
0.1	CD	O
mg/kg	NN	O
12	CD	O
hours	NNS	O
apart	RB	O
-rrb-	-RRB-	O
was	VBD	O
administered	VBN	O
on	IN	O
the	DT	O
10th	JJ	O
day	NN	O
of	IN	O
cancidas	NNP	B
70	CD	O
mg	NN	O
daily	RB	O
","	","	O
as	IN	O
compared	VBN	O
to	TO	O
results	NNS	O
from	IN	O
a	DT	O
control	NN	O
period	NN	O
in	IN	O
which	WDT	O
tacrolimus	NN	D
was	VBD	O
administered	VBN	O
alone	RB	O
.	.	.
		
for	IN	O
patients	NNS	O
receiving	VBG	O
both	CC	O
therapies	NNS	O
","	","	O
standard	JJ	O
monitoring	NN	O
of	IN	O
tacrolimus	NN	D
blood	NN	O
concentrations	NNS	O
and	CC	O
appropriate	JJ	O
tacrolimus	NN	D
dosage	NN	O
adjustments	NNS	O
are	VBP	O
recommended	VBN	O
.	.	.
		
in	IN	O
two	CD	O
clinical	JJ	O
studies	NNS	O
","	","	O
cyclosporine	NN	D
-lrb-	-LRB-	O
one	CD	O
4	CD	O
mg/kg	NN	O
dose	NN	O
or	CC	O
two	CD	O
3	CD	O
mg/kg	NN	O
doses	NNS	O
-rrb-	-RRB-	O
increased	VBD	O
the	DT	O
auc	NN	O
of	IN	O
caspofungin	NN	D
by	IN	O
approximately	RB	O
35	CD	O
%	NN	O
.	.	.
		
cancidas	NNP	B
did	VBD	O
not	RB	O
increase	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
cyclosporine	NN	D
.	.	.
		
there	EX	O
were	VBD	O
transient	JJ	O
increases	NNS	O
in	IN	O
liver	NN	O
alt	NN	O
and	CC	O
ast	NNP	O
when	WRB	O
cancidas	NNP	B
and	CC	O
cyclosporine	NN	D
were	VBD	O
co-administered	VBN	O
.	.	.
		
a	DT	O
drug-drug	JJ	O
interaction	NN	O
study	NN	O
with	IN	O
rifampin	NN	D
in	IN	O
healthy	JJ	O
volunteers	NNS	O
has	VBZ	O
shown	VBN	O
a	DT	O
30	CD	O
%	NN	O
decrease	NN	O
in	IN	O
caspofungin	NN	D
trough	NN	O
concentrations	NNS	O
.	.	.
		
patients	NNS	O
on	IN	O
rifampin	NN	D
should	MD	O
receive	VB	O
70	CD	O
mg	NN	O
of	IN	O
cancidas	NNP	B
daily	RB	O
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
results	VBZ	O
from	IN	O
regression	NN	O
analyses	NNS	O
of	IN	O
patient	NN	O
pharmacokinetic	JJ	O
data	NNS	O
suggest	VBP	O
that	IN	O
co-administration	NN	O
of	IN	O
other	JJ	O
inducers	NNS	O
of	IN	O
drug	NN	D
clearance	NN	O
-lrb-	-LRB-	O
efavirenz	NN	D
","	","	O
nevirapine	NN	D
","	","	O
phenytoin	NN	D
","	","	O
dexamethasone	NN	D
","	","	O
or	CC	O
carbamazepine	NN	D
-rrb-	-RRB-	O
with	IN	O
cancidas	NNS	B
may	MD	O
result	VB	O
in	IN	O
clinically	RB	O
meaningful	JJ	O
reductions	NNS	O
in	IN	O
caspofungin	NN	D
concentrations	NNS	O
.	.	.
		
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
which	WDT	O
drug	NN	D
clearance	NN	O
mechanism	NN	O
involved	VBN	O
in	IN	O
caspofungin	NN	D
disposition	NN	O
may	MD	O
be	VB	O
inducible	JJ	O
.	.	.
		
when	WRB	O
cancidas	NNP	B
is	VBZ	O
co-administered	VBN	O
with	IN	O
inducers	NNS	O
of	IN	O
drug	NN	D
clearance	NN	O
","	","	O
such	JJ	O
as	IN	O
efavirenz	NN	D
","	","	O
nevirapine	NN	D
","	","	O
phenytoin	NN	D
","	","	O
dexamethasone	NN	D
","	","	O
or	CC	O
carbamazepine	NN	D
","	","	O
use	NN	O
of	IN	O
a	DT	O
daily	JJ	O
dose	NN	O
of	IN	O
70	CD	O
mg	NN	O
of	IN	O
cancidas	NNP	B
should	MD	O
be	VB	O
considere	NN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
positive	JJ	O
direct	JJ	O
coombs	NNP	O
tests	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
the	DT	O
cephalosporin	NN	G
antibiotics	NNS	G
.	.	.
		
in	IN	O
hematologic	JJ	O
studies	NNS	O
or	CC	O
in	IN	O
transfusion	NN	O
cross-matching	NN	O
procedures	NNS	O
when	WRB	O
anti-globulin	JJ	O
tests	NNS	O
are	VBP	O
performed	VBN	O
on	IN	O
the	DT	O
minor	JJ	O
side	NN	O
or	CC	O
in	IN	O
coombs	NNP	O
testing	NN	O
of	IN	O
newborns	NNS	O
whose	WP$	O
mothers	NNS	O
have	VBP	O
received	VBN	O
cephalosporin	NN	G
antibiotics	NNS	G
before	IN	O
parturition	NN	O
","	","	O
it	PRP	O
should	MD	O
be	VB	O
recognized	VBN	O
that	IN	O
a	DT	O
positive	JJ	O
coombs	NNP	O
test	NN	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
the	DT	O
drug	NN	D
.	.	.
		
probenecid	NNP	D
may	MD	O
decrease	VB	O
renal	JJ	O
tubular	JJ	O
secretion	NN	O
of	IN	O
cephalosporins	NNS	G
when	WRB	O
used	VBN	O
concurrently	RB	O
","	","	O
resulting	VBG	O
in	IN	O
increased	VBN	O
and	CC	O
more	RBR	O
prolonged	JJ	O
cephalosporin	NN	G
blood	NN	O
levels	NNS	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
a	DT	O
FALSE	JJ	O
positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
occur	VB	O
with	IN	O
benedicts	NNS	O
solution	NN	O
","	","	O
fehlings	NNP	O
solution	NN	O
or	CC	O
with	IN	O
clinitest	NN	O
tablets	NNS	O
","	","	O
but	CC	O
not	RB	O
with	IN	O
enzyme-based	JJ	O
tests	NNS	O
such	JJ	O
as	IN	O
clinistix	NN	O
.	.	.
		
positive	JJ	O
direct	JJ	O
and	CC	O
indirect	JJ	O
antiglobulin	NN	O
-lrb-	-LRB-	O
coombs	NNS	O
-rrb-	-RRB-	O
tests	NNS	O
have	VBP	O
occurred	VBN	O
;	:	O
.	.	.
		
these	DT	O
may	MD	O
also	RB	O
occur	VB	O
in	IN	O
neonates	NNS	O
whose	WP$	O
mothers	NNS	O
received	VBD	O
cephalosporins	NNS	G
before	IN	O
delivery	NN	O
.	.	.
		
antacids	NNS	G
-lrb-	-LRB-	O
aluminum	NN	D
-	:	O
or	CC	O
magnesium-containing	JJ	O
-rrb-	-RRB-	O
:	:	O
concomitant	JJ	O
administration	NN	O
of	IN	O
300-mg	JJ	O
cefdinir	NN	D
capsules	NNS	O
with	IN	O
30	CD	O
ml	NN	O
maalox	NNP	B
tc	NNP	O
suspension	NN	O
reduces	VBZ	O
the	DT	O
rate	NN	O
-lrb-	-LRB-	O
cmax	NN	O
-rrb-	-RRB-	O
and	CC	O
extent	NN	O
-lrb-	-LRB-	O
auc	NN	O
-rrb-	-RRB-	O
of	IN	O
absorption	NN	O
by	IN	O
approximately	RB	O
40	CD	O
%	NN	O
.	.	.
		
time	NNP	O
to	TO	O
reach	VB	O
cmax	NNP	O
is	VBZ	O
also	RB	O
prolonged	VBN	O
by	IN	O
1	CD	O
hour	NN	O
.	.	.
		
there	EX	O
are	VBP	O
no	DT	O
significant	JJ	O
effects	NNS	O
on	IN	O
cefdinir	NN	D
pharmacokinetics	NNS	O
if	IN	O
the	DT	O
antacid	NN	G
is	VBZ	O
administered	VBN	O
2	CD	O
hours	NNS	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
cefdinir	NN	D
.	.	.
		
if	IN	O
antacids	NNS	G
are	VBP	O
required	VBN	O
during	IN	O
omnicef	NN	B
therapy	NN	O
","	","	O
omnicef	NN	B
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
before	IN	O
or	CC	O
after	IN	O
the	DT	O
antacid	NN	G
.	.	.
		
probenecid	NNP	D
:	:	O
as	IN	O
with	IN	O
other	JJ	O
b-lactam	NN	O
antibiotics	NNS	G
","	","	O
probenecid	NN	D
inhibits	VBZ	O
the	DT	O
renal	JJ	O
excretion	NN	O
of	IN	O
cefdinir	NN	D
","	","	O
resulting	VBG	O
in	IN	O
an	DT	O
approximate	JJ	O
doubling	NN	O
in	IN	O
a.c.	NNP	O
a	DT	O
54	CD	O
%	NN	O
increase	NN	O
in	IN	O
peak	JJ	O
cefdinir	NN	D
plasma	NN	O
levels	NNS	O
","	","	O
and	CC	O
a	DT	O
50	CD	O
%	NN	O
prolongation	NN	O
in	IN	O
the	DT	O
apparent	JJ	O
elimination	NN	O
half-life	NN	O
.	.	.
		
iron	NNP	D
supplements	NNP	O
and	CC	O
foods	NNP	O
fortified	VBD	O
with	IN	O
iron	NNP	D
concomitant	JJ	O
administration	NN	O
of	IN	O
cefdinir	NN	D
with	IN	O
a	DT	O
therapeutic	JJ	O
iron	NN	D
supplement	NN	O
containing	VBG	O
60	CD	O
mg	NN	O
of	IN	O
elemental	JJ	O
iron	NN	D
-lrb-	-LRB-	O
as	IN	O
feso4	NN	O
-rrb-	-RRB-	O
or	CC	O
vitamins	NNS	G
supplemented	VBN	O
with	IN	O
10	CD	O
mg	NN	O
of	IN	O
elemental	JJ	O
iron	NN	D
reduced	VBD	O
extent	NN	O
of	IN	O
absorption	NN	O
by	IN	O
80	CD	O
%	NN	O
and	CC	O
31	CD	O
%	NN	O
","	","	O
respectively	RB	O
.	.	.
		
if	IN	O
iron	NN	D
supplements	NNS	O
are	VBP	O
required	VBN	O
during	IN	O
omnicef	NN	B
therapy	NN	O
","	","	O
omnicef	NN	B
should	MD	O
be	VB	O
taken	VBN	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
before	IN	O
or	CC	O
after	IN	O
the	DT	O
supplement	NN	O
.	.	.
		
the	DT	O
effect	NN	O
of	IN	O
foods	NNS	O
highly	RB	O
fortified	VBD	O
with	IN	O
elemental	JJ	O
iron	NN	D
-lrb-	-LRB-	O
primarily	RB	O
iron-fortified	JJ	O
breakfast	NN	O
cereals	NNS	O
-rrb-	-RRB-	O
on	IN	O
cefdinir	NN	D
absorption	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	.
		
concomitantly	RB	O
administered	VBN	O
iron-fortified	JJ	O
infant	NN	O
formula	NN	O
-lrb-	-LRB-	O
2.2	CD	O
mg	NN	O
elemental	JJ	O
iron/6	NN	O
oz	NN	O
-rrb-	-RRB-	O
has	VBZ	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
cefdinir	NN	D
pharmacokinetics	NNS	O
.	.	.
		
therefore	RB	O
","	","	O
omnicef	NN	B
for	IN	O
oral	NNP	O
suspension	NNP	O
can	MD	O
be	VB	O
administered	VBN	O
with	IN	O
iron-fortified	JJ	O
infant	NN	O
formula	NN	O
.	.	.
		
there	EX	O
have	VBP	O
been	VBN	O
rare	JJ	O
reports	NNS	O
of	IN	O
reddish	JJ	O
stools	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
received	VBN	O
cefdinir	NN	D
in	IN	O
japan	NNP	O
.	.	.
		
the	DT	O
reddish	JJ	O
color	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
the	DT	O
formation	NN	O
of	IN	O
a	DT	O
nonabsorbable	JJ	O
complex	NN	O
between	IN	O
cefdinir	NN	D
or	CC	O
its	PRP$	O
breakdown	NN	O
products	NNS	O
and	CC	O
iron	NN	D
in	IN	O
the	DT	O
gastrointestinal	JJ	O
tract	NN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
ketones	NNS	O
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
occur	VB	O
with	IN	O
tests	NNS	O
using	VBG	O
nitroprusside	NN	D
","	","	O
but	CC	O
not	RB	O
with	IN	O
those	DT	O
using	VBG	O
nitroferricyanide	NN	D
.	.	.
		
the	DT	O
administration	NN	O
of	IN	O
cefdinir	NN	D
may	MD	O
result	VB	O
in	IN	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
urine	NN	O
using	VBG	O
clinitest	NNP	O
","	","	O
benedict	NNP	O
s	VBZ	O
solution	NN	O
","	","	O
or	CC	O
fehlings	NNP	O
solution	NN	O
.	.	.
		
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
glucose	NN	O
tests	NNS	O
based	VBN	O
on	IN	O
enzymatic	JJ	O
glucose	NN	O
oxidase	NN	O
reactions	NNS	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
clinistix	NNP	O
or	CC	O
tes-tape	NNP	O
-rrb-	-RRB-	O
be	VB	O
used	VBN	O
.	.	.
		
cephalosporins	NNS	G
are	VBP	O
known	VBN	O
to	TO	O
occasionally	RB	O
induce	VB	O
a	DT	O
positive	JJ	O
direct	JJ	O
coombs	NNS	O
test	NN	O
.	.	.
		
oral	JJ	O
contraceptives	NNS	G
multiple	JJ	O
doses	NNS	O
of	IN	O
cefditoren	NN	D
pivoxil	NN	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
ethinyl	NN	O
estradiol	NN	O
","	","	O
the	DT	O
estrogenic	JJ	O
component	NN	O
in	IN	O
most	JJS	O
oral	JJ	O
contraceptives	NNS	G
.	.	.
		
although	IN	O
the	DT	O
clinical	JJ	O
significance	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
","	","	O
it	PRP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
that	IN	O
cefditoren	NN	D
pivoxil	NN	O
be	VB	O
taken	VBN	O
concomitantly	RB	O
with	IN	O
antacids	NNS	G
.	.	.
		
h2-receptor	NN	O
antagonists	NNS	O
:	:	O
co-administration	NN	O
of	IN	O
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
intravenously	RB	O
administered	VBN	O
famotidine	NN	D
-lrb-	-LRB-	O
20	CD	O
mg	NN	O
-rrb-	-RRB-	O
reduced	VBD	O
the	DT	O
oral	JJ	O
absorption	NN	O
of	IN	O
a	DT	O
single	JJ	O
400	CD	O
mg	NN	O
dose	NN	O
of	IN	O
cefditoren	NN	D
pivoxil	NN	O
administered	VBN	O
following	VBG	O
a	DT	O
meal	NN	O
","	","	O
as	IN	O
evidenced	VBN	O
by	IN	O
a	DT	O
27	CD	O
%	NN	O
decrease	NN	O
in	IN	O
mean	JJ	O
cmax	NN	O
and	CC	O
a	DT	O
22	CD	O
%	NN	O
decrease	NN	O
in	IN	O
mean	JJ	O
auc	NN	O
.	.	.
		
although	IN	O
the	DT	O
clinical	JJ	O
significance	NN	O
is	VBZ	O
not	RB	O
known	VBN	O
","	","	O
it	PRP	O
is	VBZ	O
not	RB	O
recommended	VBN	O
that	IN	O
cefditoren	NN	D
pivoxil	NN	O
be	VB	O
taken	VBN	O
concomitantly	RB	O
with	IN	O
h2	NN	O
receptor	NN	D
antagonists	NNS	O
.	.	.
		
probenecid	NNP	D
:	:	O
as	IN	O
with	IN	O
other	JJ	O
b-lactam	NN	O
antibiotics	NNS	G
","	","	O
co-administration	NN	O
of	IN	O
probenecid	NN	D
with	IN	O
cefditoren	NN	D
pivoxil	NN	O
resulted	VBD	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
plasma	NN	O
exposure	NN	O
of	IN	O
cefditoren	NNS	D
","	","	O
with	IN	O
a	DT	O
49	CD	O
%	NN	O
increase	NN	O
in	IN	O
mean	NN	O
cmax	NN	O
","	","	O
a	DT	O
122	CD	O
%	NN	O
increase	NN	O
in	IN	O
mean	JJ	O
auc	NN	O
","	","	O
and	CC	O
a	DT	O
53	CD	O
%	NN	O
increase	NN	O
in	IN	O
half-life	NN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
cephalosporins	NNS	G
are	VBP	O
known	VBN	O
to	TO	O
occasionally	RB	O
induce	VB	O
a	DT	O
positive	JJ	O
direct	JJ	O
coombs	NNS	O
test	NN	O
.	.	.
		
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
occur	VB	O
with	IN	O
copper	NN	O
reduction	NN	O
tests	NNS	O
-lrb-	-LRB-	O
benedicts	NNS	O
or	CC	O
fehlings	NNS	O
solution	NN	O
or	CC	O
with	IN	O
clinitest	NN	O
tablets	NNS	O
-rrb-	-RRB-	O
","	","	O
but	CC	O
not	RB	O
with	IN	O
enzyme-based	JJ	O
tests	NNS	O
for	IN	O
glycosuria	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
clinistix	NN	O
","	","	O
tes-tape	NN	O
-rrb-	-RRB-	O
.	.	.
		
as	IN	O
a	DT	O
false-negative	JJ	O
result	NN	O
may	MD	O
occur	VB	O
in	IN	O
the	DT	O
ferricyanide	JJ	O
test	NN	O
","	","	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
either	CC	O
the	DT	O
glucose	NN	O
oxidase	NN	O
or	CC	O
hexokinase	NN	O
method	NN	O
be	VB	O
used	VBN	O
to	TO	O
determine	VB	O
blood/plasma	NN	O
glucose	NN	O
levels	NNS	O
in	IN	O
patients	NNS	O
receiving	VBG	O
cefditoren	NN	D
pivoxil	NN	O
.	.	.
		
renal	JJ	O
function	NN	O
should	MD	O
be	VB	O
monitored	VBN	O
carefully	RB	O
if	IN	O
high	JJ	O
doses	NNS	O
of	IN	O
aminoglycosides	NNS	G
are	VBP	O
to	TO	O
be	VB	O
administered	VBN	O
with	IN	O
maxipime	NN	B
because	IN	O
of	IN	O
the	DT	O
increased	VBN	O
potential	NN	O
of	IN	O
nephrotoxicity	NN	O
and	CC	O
ototoxicity	NN	O
of	IN	O
aminoglycoside	NN	G
antibiotics	NNS	G
.	.	.
		
nephrotoxicity	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
following	VBG	O
concomitant	JJ	O
administration	NN	O
of	IN	O
other	JJ	O
cephalosporins	NNS	G
with	IN	O
potent	JJ	O
diuretics	NNS	G
such	JJ	O
as	IN	O
furosemide	NN	D
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
the	DT	O
administration	NN	O
of	IN	O
cefepime	NN	D
may	MD	O
result	VB	O
in	IN	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
when	WRB	O
using	VBG	O
clinitest	NNP	O
tablets	NNS	O
.	.	.
		
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
glucose	NN	O
tests	NNS	O
based	VBN	O
on	IN	O
enzymatic	JJ	O
glucose	NN	O
oxidase	NN	O
reactions	NNS	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
clinistix	NNP	O
or	CC	O
tes-tape	NNP	O
-rrb-	-RRB-	O
be	VB	O
used	VBN	O
.	.	.
		
carbamazepine	NNP	D
:	:	O
elevated	JJ	O
carbamazepine	NN	D
levels	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
postmarketing	VBG	O
experience	NN	O
when	WRB	O
suprax	NNP	B
is	VBZ	O
administered	VBN	O
concomitantly	RB	O
.	.	.
		
drug	NN	O
monitoring	NN	O
may	MD	O
be	VB	O
of	IN	O
assistance	NN	O
in	IN	O
detecting	VBG	O
alterations	NNS	O
in	IN	O
carbamazepine	NN	D
plasma	NN	O
concentrations	NNS	O
.	.	.
		
warfarin	NNP	D
and	CC	O
anticoagulants	NNPS	G
:	:	O
increased	VBN	O
prothrombin	NN	O
time	NN	O
","	","	O
with	IN	O
or	CC	O
without	IN	O
clinical	JJ	O
bleeding	NN	O
","	","	O
has	VBZ	O
been	VBN	O
reported	VBN	O
when	WRB	O
cefixime	NN	D
is	VBZ	O
administered	VBN	O
concomitantly	RB	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
ketones	NNS	O
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
occur	VB	O
with	IN	O
tests	NNS	O
using	VBG	O
nitroprusside	NN	D
but	CC	O
not	RB	O
with	IN	O
those	DT	O
using	VBG	O
nitroferricyanide	NN	D
.	.	.
		
the	DT	O
administration	NN	O
of	IN	O
suprax	NNP	B
may	MD	O
result	VB	O
in	IN	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
using	VBG	O
clinitest	NNP	O
**	SYM	O
","	","	O
benedict	NNP	O
s	VBZ	O
solution	NN	O
","	","	O
or	CC	O
fehling	NN	O
s	NNS	O
solution	NN	O
.	.	.
		
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
glucose	NN	O
tests	NNS	O
based	VBN	O
on	IN	O
enzymatic	JJ	O
glucose	NN	O
oxidase	NN	O
reactions	NNS	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
clinistix	NNP	O
**	SYM	O
or	CC	O
tes-tape	JJ	O
**	SYM	O
-rrb-	-RRB-	O
be	VB	O
used	VBN	O
.	.	.
		
a	DT	O
false-positive	JJ	O
direct	JJ	O
coombs	NNS	O
test	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
other	JJ	O
cephalosporin	NN	G
antibiotics	NNS	G
.	.	.
		
therefore	RB	O
","	","	O
it	PRP	O
should	MD	O
be	VB	O
recognized	VBN	O
that	IN	O
a	DT	O
positive	JJ	O
coombs	NNP	O
test	NN	O
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
the	DT	O
drug	NN	D
.	.	.
		
increased	VBN	O
nephrotoxicity	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
following	VBG	O
concomitant	JJ	O
administration	NN	O
of	IN	O
cephalosporins	NNS	G
and	CC	O
aminoglycoside	NN	G
antibiotics	NNS	G
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
cephalosporins	NNS	G
","	","	O
including	VBG	O
cefotaxime	NN	O
sodium	NN	O
","	","	O
are	VBP	O
known	VBN	O
to	TO	O
occasionally	RB	O
induce	VB	O
a	DT	O
positive	JJ	O
direct	JJ	O
coombs	NNS	O
test	NN	O
.	.	.
		
increases	NNS	O
in	IN	O
serum	NN	O
creatinine	NN	O
have	VBP	O
occurred	VBN	O
when	WRB	O
cefotan	NNP	B
was	VBD	O
given	VBN	O
alone	RB	O
.	.	.
		
if	IN	O
cefotan	NNP	B
and	CC	O
an	DT	O
aminoglycoside	NN	G
are	VBP	O
used	VBN	O
concomitantly	RB	O
","	","	O
renal	JJ	O
function	NN	O
should	MD	O
be	VB	O
carefully	RB	O
monitored	VBN	O
","	","	O
because	IN	O
nephrotoxicity	NN	O
may	MD	O
be	VB	O
potentiated	VBN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
:	:	O
the	DT	O
administration	NN	O
of	IN	O
cefotan	NNP	B
may	MD	O
result	VB	O
in	IN	O
a	DT	O
FALSE	JJ	O
positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
using	VBG	O
clinitest	NNP	O
","	","	O
benedicts	NNP	O
solution	NN	O
","	","	O
or	CC	O
fehlings	NNP	O
solution	NN	O
.	.	.
		
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
glucose	NN	O
tests	NNS	O
based	VBN	O
on	IN	O
enzymatic	JJ	O
glucose	NN	O
oxidase	NN	O
be	VB	O
used	VBN	O
.	.	.
		
as	IN	O
with	IN	O
other	JJ	O
cephalosporins	NNS	G
","	","	O
high	JJ	O
concentrations	NNS	O
of	IN	O
cefotetan	NN	D
may	MD	O
interfere	VB	O
with	IN	O
measurement	NN	O
of	IN	O
serum	NN	O
and	CC	O
urine	NN	O
creatinine	NN	O
levels	NNS	O
by	IN	O
jaffe	NNP	O
reaction	NN	O
and	CC	O
produce	VBP	O
FALSE	JJ	O
increases	NNS	O
in	IN	O
the	DT	O
levels	NNS	O
of	IN	O
creatinine	NN	O
reported	VBD	O
.	.	.
		
increased	VBN	O
nephrotoxicity	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
following	VBG	O
concomitant	JJ	O
administration	NN	O
of	IN	O
cephalosporins	NNS	G
and	CC	O
aminoglycoside	NN	G
antibiotics	NNS	G
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
as	IN	O
with	IN	O
cephalothin	NN	D
","	","	O
high	JJ	O
concentrations	NNS	O
of	IN	O
cefoxitin	NN	D
-lrb-	-LRB-	O
100	CD	O
micrograms/ml	NNS	O
-rrb-	-RRB-	O
may	MD	O
interfere	VB	O
with	IN	O
measurement	NN	O
of	IN	O
serum	NN	O
and	CC	O
urine	NN	O
creatinine	NN	O
levels	NNS	O
by	IN	O
the	DT	O
jaff	NNP	O
reaction	NN	O
","	","	O
and	CC	O
produce	VBP	O
FALSE	JJ	O
increases	NNS	O
of	IN	O
modest	JJ	O
degree	NN	O
in	IN	O
the	DT	O
levels	NNS	O
of	IN	O
creatinine	NN	O
reported	VBD	O
.	.	.
		
serum	NN	O
samples	NNS	O
from	IN	O
patients	NNS	O
treated	VBN	O
with	IN	O
cefoxitin	NN	D
should	MD	O
not	RB	O
be	VB	O
analyzed	VBN	O
for	IN	O
creatinine	NN	O
if	IN	O
withdrawn	VBN	O
within	IN	O
2	CD	O
hours	NNS	O
of	IN	O
drug	NN	D
administration	NN	O
.	.	.
		
high	JJ	O
concentrations	NNS	O
of	IN	O
cefoxitin	NN	D
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
interfere	VB	O
with	IN	O
measurement	NN	O
of	IN	O
urinary	JJ	O
17-hydroxy-corticosteroids	NNS	O
by	IN	O
the	DT	O
porter-silber	NNP	O
reaction	NN	O
","	","	O
and	CC	O
produce	VBP	O
FALSE	JJ	O
increases	NNS	O
of	IN	O
modest	JJ	O
degree	NN	O
in	IN	O
the	DT	O
levels	NNS	O
reported	VBD	O
.	.	.
		
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
occur	VB	O
.	.	.
		
this	DT	O
has	VBZ	O
been	VBN	O
observed	VBN	O
with	IN	O
clinitest	NN	O
reagent	NN	O
tablets	NNS	O
.	.	.
		
registered	NNP	O
trademark	NN	O
of	IN	O
ames	NNP	O
company	NNP	O
","	","	O
division	NNP	O
of	IN	O
miles	NNP	O
laboratories	NNPS	O
","	","	O
inc.	NNP	O
.	.	.
		
nephrotoxicity	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
following	VBG	O
concomitant	JJ	O
administration	NN	O
of	IN	O
aminoglycoside	NN	G
antibiotics	NNS	G
and	CC	O
cephalosporin	NN	G
antibiotics	NNS	G
.	.	.
		
concomitant	JJ	O
administration	NN	O
of	IN	O
probenecid	NN	D
doubled	VBD	O
the	DT	O
auc	NN	O
for	IN	O
cefprozil	NN	D
.	.	.
		
the	DT	O
bioavailability	NN	O
of	IN	O
the	DT	O
capsule	NN	O
formulation	NN	O
of	IN	O
cefprozil	NN	D
was	VBD	O
not	RB	O
affected	VBN	O
when	WRB	O
administered	VBN	O
5	CD	O
minutes	NNS	O
following	VBG	O
an	DT	O
antacid	NN	G
.	.	.
		
nephrotoxicity	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
following	VBG	O
concomitant	JJ	O
administration	NN	O
of	IN	O
cephalosporins	NNS	G
with	IN	O
aminoglycoside	NN	G
antibiotics	NNS	G
or	CC	O
potent	JJ	O
diuretics	NNS	G
such	JJ	O
as	IN	O
furosemide	NN	D
.	.	.
		
renal	JJ	O
function	NN	O
should	MD	O
be	VB	O
carefully	RB	O
monitored	VBN	O
","	","	O
especially	RB	O
if	IN	O
higher	JJR	O
dosages	NNS	O
of	IN	O
the	DT	O
aminoglycosides	NNS	G
are	VBP	O
to	TO	O
be	VB	O
administered	VBN	O
or	CC	O
if	IN	O
therapy	NN	O
is	VBZ	O
prolonged	VBN	O
","	","	O
because	IN	O
of	IN	O
the	DT	O
potential	JJ	O
nephrotoxicity	NN	O
and	CC	O
ototoxicity	NN	O
of	IN	O
aminoglycosidic	JJ	O
antibiotics	NNS	G
.	.	.
		
nephrotoxicity	NN	O
and	CC	O
ototoxicity	NN	O
were	VBD	O
not	RB	O
noted	VBN	O
when	WRB	O
ceftazidime	NN	D
was	VBD	O
given	VBN	O
alone	RB	O
in	IN	O
clinical	JJ	O
trials	NNS	O
.	.	.
		
chloramphenicol	NN	D
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
be	VB	O
antagonistic	JJ	O
to	TO	O
beta-lactam	JJ	O
antibiotics	NNS	G
","	","	O
including	VBG	O
ceftazidime	NN	D
","	","	O
based	VBN	O
on	IN	O
in	FW	O
vitro	FW	O
studies	NNS	O
and	CC	O
time	NN	O
kill	VBP	O
curves	NNS	O
with	IN	O
enteric	JJ	O
gram-negative	JJ	O
bacilli	NNS	O
.	.	.
		
due	JJ	O
to	TO	O
the	DT	O
possibility	NN	O
of	IN	O
antagonism	NN	O
in	FW	O
vivo	FW	O
","	","	O
particularly	RB	O
when	WRB	O
bactericidal	JJ	O
activity	NN	O
is	VBZ	O
desired	VBN	O
","	","	O
this	DT	O
drug	NN	D
combination	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
the	DT	O
administration	NN	O
of	IN	O
ceftazidime	NN	D
may	MD	O
result	VB	O
in	IN	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
when	WRB	O
using	VBG	O
clinitest	NN	O
tablets	NNS	O
","	","	O
benedicts	NNP	O
solution	NN	O
","	","	O
or	CC	O
fehlings	NNP	O
solution	NN	O
.	.	.
		
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
glucose	NN	O
tests	NNS	O
based	VBN	O
on	IN	O
enzymatic	JJ	O
glucose	NN	O
oxidase	NN	O
reactions	NNS	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
clinistix	NN	O
or	CC	O
tes-tape	NN	O
-rrb-	-RRB-	O
be	VB	O
used	VBN	O
.	.	.
		
theophylline	NNP	D
:	:	O
twelve	CD	O
healthy	JJ	O
male	JJ	O
volunteers	NNS	O
were	VBD	O
administered	VBN	O
one	CD	O
200-mg	JJ	O
ceftibuten	NN	D
capsule	NN	O
twice	RB	O
daily	RB	O
for	IN	O
6	CD	O
days	NNS	O
.	.	.
		
with	IN	O
the	DT	O
morning	NN	O
dose	NN	O
of	IN	O
ceftibuten	NN	D
on	IN	O
day	NN	O
6	CD	O
","	","	O
each	DT	O
volunteer	NN	O
received	VBD	O
a	DT	O
single	JJ	O
intravenous	JJ	O
infusion	NN	O
of	IN	O
theophylline	NN	D
-lrb-	-LRB-	O
4	CD	O
mg/kg	NN	O
-rrb-	-RRB-	O
.	.	.
		
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	D
were	VBD	O
not	RB	O
altered	VBN	O
.	.	.
		
the	DT	O
effect	NN	O
of	IN	O
ceftibuten	NN	D
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
theophylline	NN	D
administered	VBN	O
orally	RB	O
has	VBZ	O
not	RB	O
been	VBN	O
investigated	VBN	O
.	.	.
		
antacids	NNS	G
or	CC	O
h	NN	O
2	CD	O
-	:	O
receptor	NN	D
antagonists	NNS	O
:	:	O
the	DT	O
effect	NN	O
of	IN	O
increased	VBN	O
gastric	JJ	O
ph	NN	O
on	IN	O
the	DT	O
bioavailability	NN	O
of	IN	O
ceftibuten	NN	D
was	VBD	O
evaluated	VBN	O
in	IN	O
18	CD	O
healthy	JJ	O
adult	JJ	O
volunteers	NNS	O
.	.	.
		
each	DT	O
volunteer	NN	O
was	VBD	O
administered	VBN	O
one	CD	O
400-mg	JJ	O
ceftibuten	NN	D
capsule	NN	O
.	.	.
		
a	DT	O
single	JJ	O
dose	NN	O
of	IN	O
liquid	JJ	O
antacid	NN	G
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
c	NN	O
max	NN	O
or	CC	O
auc	NN	O
of	IN	O
ceftibuten	NN	D
.	.	.
		
however	RB	O
","	","	O
150	CD	O
mg	NN	O
of	IN	O
ranitidine	NN	D
q12h	NN	O
for	IN	O
3	CD	O
days	NNS	O
increased	VBD	O
the	DT	O
ceftibuten	NN	D
c	NN	O
max	NN	O
by	IN	O
23	CD	O
%	NN	O
and	CC	O
ceftibuten	NN	D
auc	NN	O
by	IN	O
16	CD	O
%	NN	O
.	.	.
		
the	DT	O
clinical	JJ	O
relevance	NN	O
of	IN	O
these	DT	O
increases	NNS	O
is	VBZ	O
not	RB	O
known	VBN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
:	:	O
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
chemical	NN	O
or	CC	O
laboratory	NN	O
test	NN	O
interactions	NNS	O
with	IN	O
ceftibuten	NN	D
noted	VBD	O
to	TO	O
date	NN	O
.	.	.
		
false-positive	JJ	O
direct	JJ	O
coombs	NNP	O
tests	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
during	IN	O
treatment	NN	O
with	IN	O
other	JJ	O
cephalosporins	NNS	G
.	.	.
		
therefore	RB	O
","	","	O
it	PRP	O
should	MD	O
be	VB	O
recognized	VBN	O
that	IN	O
a	DT	O
positive	JJ	O
coombs	NNP	O
test	NN	O
could	MD	O
be	VB	O
due	JJ	O
to	TO	O
the	DT	O
drug	NN	D
.	.	.
		
the	DT	O
results	NNS	O
of	IN	O
assays	NNS	O
using	VBG	O
red	JJ	O
cells	NNS	O
from	IN	O
healthy	JJ	O
subjects	NNS	O
to	TO	O
determine	VB	O
whether	IN	O
ceftibuten	NN	D
would	MD	O
cause	VB	O
direct	JJ	O
coombs	NNP	O
reactions	NNS	O
in	FW	O
vitro	FW	O
showed	VBD	O
no	DT	O
positive	JJ	O
reaction	NN	O
at	IN	O
ceftibuten	NN	D
concentrations	NNS	O
as	IN	O
high	JJ	O
as	IN	O
40	CD	O
g/ml	NN	O
.	.	.
		
although	IN	O
the	DT	O
occurrence	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
reported	VBN	O
with	IN	O
cefizox	NN	B
","	","	O
nephrotoxicity	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
following	VBG	O
concomitant	JJ	O
administration	NN	O
of	IN	O
other	JJ	O
cephalosporins	NNS	G
and	CC	O
aminoglycosides	NNS	G
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
:	:	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
occur	VB	O
with	IN	O
copper	NN	O
reduction	NN	O
tests	NNS	O
-lrb-	-LRB-	O
benedict	NNP	O
s	NNS	O
or	CC	O
fehling	NN	O
s	NNS	O
solution	NN	O
or	CC	O
with	IN	O
clinitest	NNP	O
tablets	NNS	O
-rrb-	-RRB-	O
but	CC	O
not	RB	O
with	IN	O
enzyme-based	JJ	O
tests	NNS	O
for	IN	O
glycosuria	NN	O
.	.	.
		
as	IN	O
a	DT	O
false-negative	JJ	O
result	NN	O
may	MD	O
occur	VB	O
in	IN	O
the	DT	O
ferricyanide	JJ	O
test	NN	O
","	","	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
either	CC	O
the	DT	O
glucose	NN	O
oxidase	NN	O
or	CC	O
hexokinase	NN	O
method	NN	O
be	VB	O
used	VBN	O
to	TO	O
determine	VB	O
blood	NN	O
plasma	NN	O
glucose	NN	O
levels	NNS	O
in	IN	O
patients	NNS	O
receiving	VBG	O
cefuroxime	NN	D
.	.	.
		
cefuroxime	RB	D
does	VBZ	O
not	RB	O
interfere	VB	O
with	IN	O
the	DT	O
assay	NN	O
of	IN	O
serum	NN	O
and	CC	O
urine	NN	O
creatinine	NN	O
by	IN	O
the	DT	O
alkaline	NN	O
picrate	NN	O
method	NN	O
.	.	.
		
general	NNP	O
:	:	O
significant	JJ	O
interactions	NNS	O
may	MD	O
occur	VB	O
when	WRB	O
celecoxib	NN	D
is	VBZ	O
administered	VBN	O
together	RB	O
with	IN	O
drugs	NNS	D
that	WDT	O
inhibit	VBP	O
p450	NN	O
2c9	NN	O
.	.	.
		
celecoxib	NNP	D
metabolism	NN	O
is	VBZ	O
predominantly	RB	O
mediated	VBN	O
via	IN	O
cytochrome	NN	O
p450	NN	O
2c9	NN	O
in	IN	O
the	DT	O
liver	NN	O
.	.	.
		
co-administration	NN	O
of	IN	O
celecoxib	NN	D
with	IN	O
drugs	NNS	D
that	WDT	O
are	VBP	O
known	VBN	O
to	TO	O
inhibit	VB	O
2c9	NN	O
should	MD	O
be	VB	O
done	VBN	O
with	IN	O
caution	NN	O
.	.	.
		
in	FW	O
vitro	FW	O
studies	NNS	O
indicate	VBP	O
that	IN	O
celecoxib	NN	D
is	VBZ	O
not	RB	O
an	DT	O
inhibitor	NN	O
of	IN	O
cytochrome	NN	O
p450	NN	O
2c9	NN	O
","	","	O
2c19	NN	O
or	CC	O
3a4	NN	O
.	.	.
		
in	FW	O
vitro	FW	O
studies	NNS	O
also	RB	O
indicate	VBP	O
that	IN	O
celecoxib	NN	D
","	","	O
although	IN	O
not	RB	O
a	DT	O
substrate	NN	O
","	","	O
is	VBZ	O
an	DT	O
inhibitor	NN	O
of	IN	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
.	.	.
		
therefore	RB	O
","	","	O
there	EX	O
is	VBZ	O
a	DT	O
potential	NN	O
for	IN	O
an	DT	O
in	FW	O
vivo	FW	O
drug	NN	D
interaction	NN	O
with	IN	O
drugs	NNS	D
that	WDT	O
are	VBP	O
metabolized	VBN	O
by	IN	O
p450	NN	O
2d6	NN	O
.	.	.
		
clinical	JJ	O
studies	NNS	O
with	IN	O
celecoxib	NNS	D
have	VBP	O
identified	VBN	O
potentially	RB	O
significant	JJ	O
interactions	NNS	O
with	IN	O
fluconazole	NN	D
and	CC	O
lithium	NN	D
.	.	.
		
experience	NN	O
with	IN	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	D
-lrb-	-LRB-	O
nsaids	NNS	G
-rrb-	-RRB-	O
suggests	VBZ	O
the	DT	O
potential	NN	O
for	IN	O
interactions	NNS	O
with	IN	O
furosemide	NN	D
and	CC	O
ace	NN	O
inhibitors	NNS	O
.	.	.
		
the	DT	O
effects	NNS	O
celecoxib	VBP	D
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
and/or	CC	O
pharmacodynamics	NNS	O
of	IN	O
glyburide	NN	D
","	","	O
ketoconazole	NN	D
","	","	O
methotrexate	NN	D
","	","	O
phenytoin	NN	D
","	","	O
tolbutamide	NN	D
","	","	O
and	CC	O
warfarin	NN	D
have	VBP	O
been	VBN	O
studied	VBN	O
in	FW	O
vivo	FW	O
and	CC	O
clinically	RB	O
important	JJ	O
interactions	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
found	VBN	O
.	.	.
		
ace	NN	O
inhibitors	NNS	O
:	:	O
reports	NNS	O
suggest	VBP	O
that	IN	O
nsaids	NNS	G
may	MD	O
diminish	VB	O
the	DT	O
antihypertensive	JJ	O
effect	NN	O
of	IN	O
angiotensin	NN	O
converting	VBG	O
enzyme	NN	O
-lrb-	-LRB-	O
ace	NN	O
-rrb-	-RRB-	O
inhibitors	NNS	O
.	.	.
		
this	DT	O
interaction	NN	O
should	MD	O
be	VB	O
given	VBN	O
consideration	NN	O
in	IN	O
patients	NNS	O
taking	VBG	O
celebrex	NNP	B
concomitantly	RB	O
with	IN	O
ace-inhibitors	NNS	G
.	.	.
		
furosemide	NNP	D
:	:	O
clinical	JJ	O
studies	NNS	O
","	","	O
as	RB	O
well	RB	O
as	IN	O
post	NN	O
marketing	NN	O
observations	NNS	O
","	","	O
have	VBP	O
shown	VBN	O
that	IN	O
nsaids	NNS	G
can	MD	O
reduce	VB	O
the	DT	O
natriuretic	JJ	O
effect	NN	O
of	IN	O
furosemide	NN	D
and	CC	O
thiazides	NNS	G
in	IN	O
some	DT	O
patients	NNS	O
.	.	.
		
this	DT	O
response	NN	O
has	VBZ	O
been	VBN	O
attributed	VBN	O
to	TO	O
inhibition	NN	O
of	IN	O
renal	JJ	O
prostaglandin	NN	O
synthesis	NN	O
.	.	.
		
aspirin	NN	B
:	:	O
celebrex	NNP	B
can	MD	O
be	VB	O
used	VBN	O
with	IN	O
low	JJ	O
dose	NN	O
aspirin	NN	B
.	.	.
		
however	RB	O
","	","	O
concomitant	JJ	O
administration	NN	O
of	IN	O
aspirin	NN	B
with	IN	O
celebrex	NNP	B
may	MD	O
result	VB	O
in	IN	O
an	DT	O
increased	VBN	O
rate	NN	O
of	IN	O
gi	NN	O
ulceration	NN	O
or	CC	O
other	JJ	O
complications	NNS	O
","	","	O
compared	VBN	O
to	TO	O
use	VB	O
of	IN	O
celebrex	NNP	B
alone	RB	O
.	.	.
		
because	IN	O
of	IN	O
its	PRP$	O
lack	NN	O
of	IN	O
platelet	NN	O
effects	NNS	O
","	","	O
celebrex	NNP	B
is	VBZ	O
not	RB	O
a	DT	O
substitute	NN	O
for	IN	O
aspirin	NN	B
for	IN	O
cardiovascular	JJ	O
prophylaxis	NN	O
.	.	.
		
fluconazole	NNP	D
:	:	O
concomitant	JJ	O
administration	NN	O
of	IN	O
fluconazole	NN	D
at	IN	O
200	CD	O
mg	NN	O
qd	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
two-fold	JJ	O
increase	NN	O
in	IN	O
celecoxib	NN	D
plasma	NN	O
concentration	NN	O
.	.	.
		
this	DT	O
increase	NN	O
is	VBZ	O
due	JJ	O
to	TO	O
the	DT	O
inhibition	NN	O
of	IN	O
celecoxib	NN	D
metabolism	NN	O
via	IN	O
p450	NN	O
2c9	NN	O
by	IN	O
fluconazole	NN	D
-lrb-	-LRB-	O
see	VB	O
clinical	NNP	O
pharmacology	NNP	O
-	:	O
pharmacokinetics	NNS	O
:	:	O
metabolism	NN	O
-rrb-	-RRB-	O
.	.	.
		
celebrex	NNP	B
should	MD	O
be	VB	O
introduced	VBN	O
at	IN	O
the	DT	O
lowest	JJS	O
recommended	VBN	O
dose	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
fluconazole	NN	D
.	.	.
		
lithium	NN	D
:	:	O
in	IN	O
a	DT	O
study	NN	O
conducted	VBN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
","	","	O
mean	VB	O
steady-state	JJ	O
lithium	NN	D
plasma	NN	O
levels	NNS	O
increased	VBD	O
approximately	RB	O
17	CD	O
%	NN	O
in	IN	O
subjects	NNS	O
receiving	VBG	O
lithium	NN	D
450	CD	O
mg	NN	O
bid	NNP	O
with	IN	O
celebrex	NNP	B
200	CD	O
mg	NN	O
bid	NNP	O
as	IN	O
compared	VBN	O
to	TO	O
subjects	NNS	O
receiving	VBG	O
lithium	NN	D
alone	RB	O
.	.	.
		
patients	NNS	O
on	IN	O
lithium	NN	D
treatment	NN	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
when	WRB	O
celebrex	NNP	B
is	VBZ	O
introduced	VBN	O
or	CC	O
withdrawn	VBN	O
.	.	.
		
methotrexate	NNP	D
:	:	O
in	IN	O
an	DT	O
interaction	NN	O
study	NN	O
of	IN	O
rheumatoid	JJ	O
arthritis	NN	O
patients	NNS	O
taking	VBG	O
methotrexate	NN	D
","	","	O
celebrex	NNP	B
did	VBD	O
not	RB	O
have	VB	O
a	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
methotrexate	NN	D
.	.	.
		
warfarin	NNP	D
:	:	O
the	DT	O
effect	NN	O
of	IN	O
celecoxib	NN	D
on	IN	O
the	DT	O
anti-coagulant	JJ	O
effect	NN	O
of	IN	O
warfarin	NN	D
was	VBD	O
studied	VBN	O
in	IN	O
a	DT	O
group	NN	O
of	IN	O
healthy	JJ	O
subjects	NNS	O
receiving	VBG	O
daily	JJ	O
doses	NNS	O
of	IN	O
5-Feb	CD	O
mg	NN	O
of	IN	O
warfarin	NN	D
.	.	.
		
in	IN	O
these	DT	O
subjects	NNS	O
","	","	O
celecoxib	NN	D
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
anticoagulant	JJ	G
effect	NN	O
of	IN	O
warfarin	NN	D
as	IN	O
determined	VBN	O
by	IN	O
prothrombin	NN	O
time	NN	O
.	.	.
		
however	RB	O
","	","	O
caution	NN	O
should	MD	O
be	VB	O
used	VBN	O
when	WRB	O
administering	VBG	O
celebrex	NN	B
with	IN	O
warfarin	NN	D
since	IN	O
these	DT	O
patients	NNS	O
are	VBP	O
at	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
bleeding	VBG	O
complications	NNS	O
.	.	.
		
metformin	NNP	D
:	:	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
given	VBN	O
single	JJ	O
500	CD	O
mg	NN	O
doses	NNS	O
of	IN	O
cephalexin	NN	D
and	CC	O
metformin	NN	D
","	","	O
plasma	NN	O
metformin	NN	D
mean	VB	O
cmax	NN	O
and	CC	O
auc	NN	O
increased	VBN	O
by	IN	O
an	DT	O
average	NN	O
of	IN	O
34	CD	O
%	NN	O
and	CC	O
24	CD	O
%	NN	O
","	","	O
respectively	RB	O
","	","	O
and	CC	O
metformin	NN	D
mean	VBP	O
renal	JJ	O
clearance	NN	O
decreased	VBN	O
by	IN	O
14	CD	O
%	NN	O
.	.	.
		
no	DT	O
information	NN	O
is	VBZ	O
available	JJ	O
about	IN	O
the	DT	O
interaction	NN	O
of	IN	O
cephalexin	NN	D
and	CC	O
metformin	NN	D
following	VBG	O
multiple	JJ	O
doses	NNS	O
of	IN	O
either	CC	O
drug	NN	D
.	.	.
		
although	IN	O
not	RB	O
observed	VBN	O
in	IN	O
this	DT	O
study	NN	O
","	","	O
adverse	JJ	O
effects	NNS	O
could	MD	O
potentially	RB	O
arise	VB	O
from	IN	O
co-administration	NN	O
of	IN	O
cephalexin	NN	D
and	CC	O
metformin	NN	D
by	IN	O
inhibition	NN	O
of	IN	O
tubular	JJ	O
secretion	NN	O
via	IN	O
organic	JJ	O
cationic	JJ	O
transporter	NN	O
systems	NNS	O
.	.	.
		
accordingly	RB	O
","	","	O
careful	JJ	O
patient	NN	O
monitoring	NN	O
and	CC	O
dose	NN	O
adjustment	NN	O
of	IN	O
metformin	NN	D
is	VBZ	O
recommended	VBN	O
in	IN	O
patients	NNS	O
concomitantly	RB	O
taking	VBG	O
cephalexin	NN	D
and	CC	O
metformin	NN	D
.	.	.
		
probenecid	NNP	D
:	:	O
as	IN	O
with	IN	O
other	JJ	O
b-lactams	NNS	G
","	","	O
the	DT	O
renal	JJ	O
excretion	NN	O
of	IN	O
cephalexin	NN	D
is	VBZ	O
inhibited	VBN	O
by	IN	O
probenecid	NN	D
.	.	.
		
drug	NN	O
/	:	O
laboratory	NNP	O
test	NNP	O
interactions	NNS	O
as	IN	O
a	DT	O
result	NN	O
of	IN	O
administration	NN	O
of	IN	O
keflex	NNP	B
","	","	O
a	DT	O
false-positive	JJ	O
reaction	NN	O
for	IN	O
glucose	NN	O
in	IN	O
the	DT	O
urine	NN	O
may	MD	O
occur	VB	O
.	.	.
		
this	DT	O
has	VBZ	O
been	VBN	O
observed	VBN	O
with	IN	O
benedict	NNP	O
s	NNS	O
and	CC	O
fehling	NN	O
s	NNS	O
solutions	NNS	O
and	CC	O
also	RB	O
with	IN	O
clinitest	NNP	O
tablets	NNS	O
.	.	.
		
immunosuppressive	JJ	D
drugs	NNS	O
","	","	O
fibric	JJ	O
acid	NN	O
derivatives	NNS	O
","	","	O
niacin	NN	D
-lrb-	-LRB-	O
nicotinic	JJ	O
acid	NN	O
","	","	O
erythromycin	NNP	D
","	","	O
azole	NNP	O
antifungals	NNPS	G
:	:	O
skeletal	JJ	O
muscle	NN	O
.	.	.
		
antacid	NN	G
-lrb-	-LRB-	O
magnesium-aluminum	NNP	O
hydroxide	NNP	O
-rrb-	-RRB-	O
:	:	O
cerivastatin	NNP	D
plasma	NN	O
concentrations	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
co-administration	NN	O
of	IN	O
antacid	NN	G
.	.	.
		
cimetldine	NNP	D
:	:	O
cerivastatin	NNP	D
plasma	NN	O
concentrations	NNS	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
co-administration	NN	O
of	IN	O
cimetidine	NN	D
.	.	.
		
cholestyramine	NNP	D
:	:	O
the	DT	O
influence	NN	O
of	IN	O
the	DT	O
bile-acidsequestering	JJ	O
agent	NN	O
cholestyramine	NN	D
on	IN	O
the	DT	O
pharmacokinetits	NNS	O
of	IN	O
cerivastatin	NN	D
sodium	NN	O
was	VBD	O
evaluated	VBN	O
in	IN	O
12	CD	O
healthy	JJ	O
males	NNS	O
in	IN	O
2	CD	O
separate	JJ	O
randomized	JJ	O
crossover	NN	O
studies	NNS	O
.	.	.
		
in	IN	O
the	DT	O
first	JJ	O
study	NN	O
","	","	O
concomitant	JJ	O
administration	NN	O
of	IN	O
0.2	CD	O
mg	NN	O
cerivastatin	NN	D
sodium	NN	O
and	CC	O
12	CD	O
g	NN	O
cholestyramine	NN	D
resulted	VBD	O
in	IN	O
decreases	NNS	O
of	IN	O
more	JJR	O
than	IN	O
22	CD	O
%	NN	O
for	IN	O
auc	NN	O
and	CC	O
40	CD	O
%	NN	O
for	IN	O
cmax	NNP	O
when	WRB	O
compared	VBN	O
to	TO	O
dosing	NN	O
cerivastatin	NN	D
sodium	NN	O
alone	RB	O
.	.	.
		
however	RB	O
","	","	O
in	IN	O
the	DT	O
second	JJ	O
study	NN	O
","	","	O
administration	NN	O
of	IN	O
12	CD	O
g	NN	O
cholestyramine	NN	D
1	CD	O
hour	NN	O
before	IN	O
the	DT	O
evening	NN	O
meal	NN	O
and	CC	O
0.3	CD	O
mg	NN	O
cerivastatin	NN	D
sodium	NN	O
approximately	RB	O
4	CD	O
hours	NNS	O
after	IN	O
the	DT	O
same	JJ	O
evening	NN	O
meal	NN	O
resulted	VBD	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
the	DT	O
cerivastatin	NN	D
auc	NN	O
of	IN	O
less	JJR	O
than	IN	O
8	CD	O
%	NN	O
","	","	O
and	CC	O
a	DT	O
decrease	NN	O
in	IN	O
cmax	NN	O
of	IN	O
about	IN	O
30	CD	O
%	NN	O
when	WRB	O
compared	VBN	O
to	TO	O
dosing	NN	O
cerivastatin	NN	D
sodium	NN	O
alone	RB	O
.	.	.
		
therefore	RB	O
","	","	O
it	PRP	O
would	MD	O
be	VB	O
expected	VBN	O
that	IN	O
a	DT	O
dosing	NN	O
schedule	NN	O
of	IN	O
cerivastatin	NN	D
sodium	NN	O
given	VBN	O
at	IN	O
bedtime	NN	O
and	CC	O
cholestyramine	NN	D
given	VBN	O
before	IN	O
the	DT	O
evening	NN	O
meal	NN	O
would	MD	O
not	RB	O
result	VB	O
in	IN	O
a	DT	O
significant	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
clinical	JJ	O
effect	NN	O
of	IN	O
cerivastatin	NN	D
sodium	NN	O
.	.	.
		
digoxin	NNP	D
:	:	O
plasma	NN	O
digoxin	NN	D
levels	NNS	O
and	CC	O
digoxin	NN	D
clearance	NN	O
at	IN	O
steady-state	JJ	O
were	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
co-administration	NN	O
of	IN	O
0.2	CD	O
mg	NN	O
cerivastatin	NN	D
sodium	NN	O
.	.	.
		
cerivastatin	NNP	D
plasma	NN	O
concentrations	NNS	O
were	VBD	O
also	RB	O
not	RB	O
affected	VBN	O
by	IN	O
co-administration	NN	O
of	IN	O
digoxin	NN	D
.	.	.
		
warfarin	NNP	D
:	:	O
co	NNP	O
-	:	O
administration	NN	O
of	IN	O
warfarin	NN	D
and	CC	O
cerivastatin	NN	D
to	TO	O
healthy	JJ	O
volunteers	NNS	O
did	VBD	O
not	RB	O
result	VB	O
in	IN	O
any	DT	O
changes	NNS	O
in	IN	O
prothrombin	NN	O
time	NN	O
or	CC	O
clotting	NN	O
factor	NN	O
vii	NN	O
when	WRB	O
compared	VBN	O
to	TO	O
co-administration	NN	O
of	IN	O
warfarin	NN	D
and	CC	O
placebo	NN	O
.	.	.
		
the	DT	O
auc	NN	O
and	CC	O
cmax	NN	O
of	IN	O
both	CC	O
the	DT	O
-lrb-	-LRB-	O
r	NN	O
-rrb-	-RRB-	O
and	CC	O
-lrb-	-LRB-	O
s	NN	O
-rrb-	-RRB-	O
isomers	NNS	O
of	IN	O
warfarin	NN	D
were	VBD	O
unaffected	JJ	O
by	IN	O
concurrent	JJ	O
dosing	NN	O
of	IN	O
0.3	CD	O
mg	NN	O
cerivastatin	NN	D
sodium	NN	O
.	.	.
		
co-administration	NN	O
of	IN	O
warfarin	NN	D
and	CC	O
cerivastatin	NN	D
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
cerivastatin	NN	D
sodium	NN	O
.	.	.
		
erythromycin	NNP	D
:	:	O
in	IN	O
hypercholesterolemic	JJ	O
patients	NNS	O
","	","	O
steady-state	JJ	O
cerivastatin	NN	D
auc	NN	O
and	CC	O
cmax	NN	O
increased	VBD	O
approximately	RB	O
50	CD	O
%	NN	O
and	CC	O
24	CD	O
%	NN	O
respectively	RB	O
after	IN	O
10	CD	O
days	NNS	O
with	IN	O
co-administration	NN	O
of	IN	O
erythromycin	NN	D
","	","	O
a	DT	O
known	JJ	O
inhibitor	NN	O
of	IN	O
cytochrome	NN	O
p450	NN	O
3a4	NN	O
.	.	.
		
other	JJ	O
concomitant	JJ	O
therapy	NN	O
:	:	O
although	IN	O
specific	JJ	O
interaction	NN	O
studies	NNS	O
were	VBD	O
not	RB	O
performed	VBN	O
","	","	O
in	IN	O
clinical	JJ	O
studies	NNS	O
","	","	O
cerivastatin	NN	D
sodium	NN	O
was	VBD	O
used	VBN	O
concomitantly	RB	O
with	IN	O
angiotensin	NN	O
-	:	O
converting	VBG	O
enzyme	NN	O
-lrb-	-LRB-	O
ace	NN	O
-rrb-	-RRB-	O
inhibitors	NNS	O
","	","	O
betablockers	NNS	G
","	","	O
calcium-channel	JJ	O
blockers	NNS	O
","	","	O
diuretics	NNS	G
","	","	O
and	CC	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	D
-lrb-	-LRB-	O
nsaids	NNS	G
-rrb-	-RRB-	O
without	IN	O
evidence	NN	O
of	IN	O
clinically	RB	O
significant	JJ	O
adverse	JJ	O
interactions	NNS	O
.	.	.
		
pharmacokinetic	JJ	O
interaction	NN	O
studies	NNS	O
with	IN	O
cetirizine	NN	D
in	IN	O
adults	NNS	O
were	VBD	O
conducted	VBN	O
with	IN	O
pseudoephedrine	NN	D
","	","	O
antipyrine	NN	D
","	","	O
ketoconazole	NN	D
","	","	O
erythromycin	NN	D
and	CC	O
azithromycin	NN	D
.	.	.
		
no	DT	O
interactions	NNS	O
were	VBD	O
observed	VBN	O
in	IN	O
a	DT	O
multiple	JJ	O
dose	NN	O
study	NN	O
of	IN	O
theophylline	NN	D
-lrb-	-LRB-	O
400	CD	O
mg	NN	O
once	RB	O
daily	RB	O
for	IN	O
3	CD	O
days	NNS	O
-rrb-	-RRB-	O
and	CC	O
cetirizine	NN	D
-lrb-	-LRB-	O
20	CD	O
mg	NN	O
once	RB	O
daily	RB	O
for	IN	O
3	CD	O
days	NNS	O
-rrb-	-RRB-	O
","	","	O
a	DT	O
16	CD	O
%	NN	O
decrease	NN	O
in	IN	O
the	DT	O
clearance	NN	O
of	IN	O
cetirizine	NN	D
was	VBD	O
observed	VBN	O
.	.	.
		
the	DT	O
disposition	NN	O
of	IN	O
theophylline	NN	D
was	VBD	O
not	RB	O
altered	VBN	O
by	IN	O
concomitant	JJ	O
cetirizine	NN	D
administration	NN	O
.	.	.
		
drug-drug	NNP	O
interactions	NNS	O
:	:	O
no	DT	O
clinically	RB	O
significant	JJ	O
drug	NN	D
interactions	NNS	O
have	VBP	O
been	VBN	O
found	VBN	O
with	IN	O
theophylline	NN	D
at	IN	O
a	DT	O
low	JJ	O
dose	NN	O
","	","	O
azithromycin	NN	D
","	","	O
pseudoephedrine	NN	D
","	","	O
ketoconazole	NN	D
","	","	O
or	CC	O
erythromycin	NN	D
.	.	.
		
there	EX	O
was	VBD	O
a	DT	O
small	JJ	O
decrease	NN	O
in	IN	O
the	DT	O
clearance	NN	O
of	IN	O
cetirizine	NN	D
caused	VBN	O
by	IN	O
a	DT	O
400-mg	JJ	O
dose	NN	O
of	IN	O
theophylline	NN	D
.	.	.
		
it	PRP	O
is	VBZ	O
possible	JJ	O
that	IN	O
larger	JJR	O
theophylline	NN	D
doses	NNS	O
could	MD	O
have	VB	O
a	DT	O
greater	JJR	O
effect	NN	O
.	.	.
		
no	DT	O
formal	JJ	O
drug	NN	D
interaction	NN	O
studies	NNS	O
have	VBP	O
been	VBN	O
performed	VBN	O
with	IN	O
cetrotide	NN	B
.	.	.
		
a	DT	O
drug	NN	D
interaction	NN	O
study	NN	O
was	VBD	O
performed	VBN	O
in	IN	O
which	WDT	O
erbitux	NNP	B
was	VBD	O
administered	VBN	O
in	IN	O
combination	NN	O
with	IN	O
irinotecan	NN	D
.	.	.
		
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
any	DT	O
pharmacokinetic	JJ	O
interactions	NNS	O
between	IN	O
erbitux	NNP	B
and	CC	O
irinotecan	NN	D
.	.	.
		
cevimeline	NNP	D
should	MD	O
be	VB	O
administered	VBN	O
with	IN	O
caution	NN	O
to	TO	O
patients	NNS	O
taking	VBG	O
beta	NN	O
adrenergic	JJ	O
antagonists	NNS	O
","	","	O
because	IN	O
of	IN	O
the	DT	O
possibility	NN	O
of	IN	O
conduction	NN	O
disturbances	NNS	O
.	.	.
		
drugs	NNS	O
with	IN	O
parasympathomimetic	JJ	O
effects	NNS	O
administered	VBN	O
concurrently	RB	O
with	IN	O
cevimeline	NN	D
can	MD	O
be	VB	O
expected	VBN	O
to	TO	O
have	VB	O
additive	JJ	O
effects	NNS	O
.	.	.
		
cevimeline	NNP	D
might	MD	O
interfere	VB	O
with	IN	O
desirable	JJ	O
antimuscarinic	JJ	O
effects	NNS	O
of	IN	O
drugs	NNS	D
used	VBN	O
concomitantly	RB	O
.	.	.
		
drugs	NNS	O
which	WDT	O
inhibit	VBP	O
cyp2d6	NN	D
and	CC	O
cyp3a3/4	NN	O
also	RB	O
inhibit	VBP	O
the	DT	O
metabolism	NN	O
of	IN	O
cevimeline	NN	D
.	.	.
		
cevimeline	NNP	D
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
individuals	NNS	O
known	VBN	O
or	CC	O
suspected	VBN	O
to	TO	O
be	VB	O
deficient	JJ	O
in	IN	O
cyp2d6	NN	D
activity	NN	O
","	","	O
based	VBN	O
on	IN	O
previous	JJ	O
experience	NN	O
","	","	O
as	IN	O
they	PRP	O
may	MD	O
be	VB	O
at	IN	O
a	DT	O
higher	JJR	O
risk	NN	O
of	IN	O
adverse	JJ	O
events	NNS	O
.	.	.
		
in	IN	O
an	DT	O
in	FW	O
vitro	FW	O
study	NN	O
","	","	O
cytochrome	NN	O
p450	NN	O
isozymes	NNS	O
1a2	NN	O
","	","	O
2a6	NN	O
","	","	O
2c9	NN	O
","	","	O
2c19	NN	O
","	","	O
2d6	NN	O
","	","	O
2.00E+01	NN	O
","	","	O
and	CC	O
3a4	NN	O
were	VBD	O
not	RB	O
inhibited	VBN	O
by	IN	O
exposure	NN	O
to	TO	O
cevimeline	NN	D
.	.	.
		
there	EX	O
are	VBP	O
no	DT	O
known	JJ	O
drug/drug	NN	O
interactions	NNS	O
with	IN	O
chlorambucil	NN	D
.	.	.
		
although	IN	O
clinical	JJ	O
studies	NNS	O
have	VBP	O
not	RB	O
established	VBN	O
a	DT	O
cause	NN	O
and	CC	O
effect	NN	O
relationship	NN	O
","	","	O
physicians	NNS	O
should	MD	O
be	VB	O
aware	JJ	O
that	IN	O
variable	JJ	O
effects	NNS	O
an	DT	O
blood	NN	O
coagulation	NN	O
have	VBP	O
been	VBN	O
reported	VBN	O
very	RB	O
rarely	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
oral	JJ	O
anticoagulants	NNS	G
and	CC	O
chlordiazepoxide	NN	D
.	.	.
		
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
alcohol	NN	D
or	CC	O
other	JJ	O
central	JJ	O
nervous	JJ	O
system	NN	O
depressants	NNS	O
may	MD	O
have	VB	O
an	DT	O
additive	JJ	O
effect	NN	O
.	.	.
		
the	DT	O
administration	NN	O
of	IN	O
local	JJ	O
anesthetic	JJ	O
solutions	NNS	O
containing	VBG	O
epinephrine	NN	D
or	CC	O
norepinephrine	NN	D
to	TO	O
patients	NNS	O
receiving	VBG	O
monoamine	NN	O
oxidase	NN	O
inhibitors	NNS	O
","	","	O
tricyclic	JJ	O
antidepressants	NNS	G
or	CC	O
phenothiazines	NNS	G
may	MD	O
produce	VB	O
severe	JJ	O
","	","	O
prolonged	JJ	O
hypotension	NN	O
or	CC	O
hypertension	NN	O
.	.	.
		
concurrent	JJ	O
use	NN	O
of	IN	O
these	DT	O
agents	NNS	O
should	MD	O
generally	RB	O
be	VB	O
avoided	VBN	O
.	.	.
		
in	IN	O
situations	NNS	O
when	WRB	O
concurrent	JJ	O
therapy	NN	O
is	VBZ	O
necessary	JJ	O
","	","	O
careful	JJ	O
patient	NN	O
monitoring	NN	O
is	VBZ	O
essential	JJ	O
.	.	.
		
concurrent	JJ	O
administration	NN	O
of	IN	O
vasopressor	NN	O
drugs	NNS	D
-lrb-	-LRB-	O
for	IN	O
the	DT	O
treatment	NN	O
of	IN	O
hypotension	NN	O
related	JJ	O
to	TO	O
obstetric	JJ	O
blocks	NNS	O
-rrb-	-RRB-	O
and	CC	O
ergot-type	JJ	O
oxytocic	JJ	O
drugs	NNS	D
may	MD	O
cause	VB	O
severe	JJ	O
","	","	O
persistent	JJ	O
hypertension	NN	O
or	CC	O
cerebrovascular	JJ	O
accidents	NNS	O
.	.	.
		
the	DT	O
para-aminobenzoic	JJ	O
acid	NN	O
metabolite	NN	O
of	IN	O
chloroprocaine	NN	D
inhibits	VBZ	O
the	DT	O
action	NN	O
of	IN	O
sulfonamides	NNS	G
.	.	.
		
therefore	RB	O
","	","	O
chloroprocaine	NN	D
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
in	IN	O
any	DT	O
condition	NN	O
in	IN	O
which	WDT	O
a	DT	O
sulfonamide	NN	O
drug	NN	D
is	VBZ	O
being	VBG	O
employed	VBN	O
.	.	.
		
antacids	NNS	G
and	CC	O
kaolin	NN	D
:	:	O
antacids	NNS	G
and	CC	O
kaolin	NN	D
can	MD	O
reduce	VB	O
absorption	NN	O
of	IN	O
chloroquine	NN	D
.	.	.
		
an	DT	O
interval	NN	O
of	IN	O
at	IN	O
least	JJS	O
4	CD	O
hours	NNS	O
between	IN	O
intake	NN	O
of	IN	O
these	DT	O
agents	NNS	O
and	CC	O
chloroquine	NN	D
should	MD	O
be	VB	O
observed	VBN	O
.	.	.
		
cimetidine	NNP	D
:	:	O
cimetidine	NNP	D
can	MD	O
inhibit	VB	O
the	DT	O
metabolism	NN	O
of	IN	O
chloroquine	NN	D
","	","	O
increasing	VBG	O
its	PRP$	O
plasma	NN	O
level	NN	O
.	.	.
		
concomitant	JJ	O
use	NN	O
of	IN	O
cimetidine	NN	D
should	MD	O
be	VB	O
avoided	VBN	O
.	.	.
		
ampicillin	NNP	D
:	:	O
in	IN	O
a	DT	O
study	NN	O
of	IN	O
healthy	JJ	O
volunteers	NNS	O
","	","	O
chloroquine	NN	D
significantly	RB	O
reduced	VBD	O
the	DT	O
bioavailability	NN	O
of	IN	O
ampicillin	NN	D
.	.	.
		
an	DT	O
interval	NN	O
of	IN	O
at	IN	O
least	JJS	O
two	CD	O
hours	NNS	O
between	IN	O
intake	NN	O
of	IN	O
this	DT	O
agent	NN	O
and	CC	O
chloroquine	NN	D
should	MD	O
be	VB	O
observed	VBN	O
.	.	.
		
cyclosporin	NN	D
:	:	O
after	IN	O
introduction	NN	O
of	IN	O
chloroquine	NN	D
-lrb-	-LRB-	O
oral	JJ	O
form	NN	O
-rrb-	-RRB-	O
","	","	O
a	DT	O
sudden	JJ	O
increase	NN	O
in	IN	O
serum	NN	O
cyclosporin	NN	D
level	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
.	.	.
		
therefore	RB	O
","	","	O
close	JJ	O
monitoring	NN	O
of	IN	O
serum	NN	O
cyclosporin	NN	D
level	NN	O
is	VBZ	O
recommended	VBN	O
and	CC	O
","	","	O
if	IN	O
necessary	JJ	O
","	","	O
chloroquine	NN	D
should	MD	O
be	VB	O
discontinued	VBN	O
.	.	.
		
when	WRB	O
given	VBN	O
concurrently	RB	O
the	DT	O
following	VBG	O
drugs	NNS	D
may	MD	O
interact	VB	O
with	IN	O
thiazide	JJ	O
diuretics	NNS	G
.	.	.
		
-	:	O
alcohol	NN	D
","	","	O
barbiturates	NNS	G
","	","	O
or	CC	O
narcotics	NNS	G
:	:	O
potentiation	NN	O
of	IN	O
otthostatic	JJ	O
hypotension	NN	O
may	MD	O
occu	VB	O
.	.	.
		
-	:	O
antidiabetic	JJ	O
drugs	NNS	D
:	:	O
-lrb-	-LRB-	O
oral	JJ	O
agents	NNS	O
and	CC	O
insulin	NN	D
-rrb-	-RRB-	O
dosage	NN	O
adjustment	NN	O
of	IN	O
the	DT	O
antidiabetic	JJ	O
drug	NN	D
may	MD	O
be	VB	O
require	VB	O
.	.	.
		
-	:	O
other	JJ	O
antihypertensive	JJ	O
drugs	NNS	D
:	:	O
additive	JJ	O
effect	NN	O
or	CC	O
potentiatio	NN	O
.	.	.
		
-	:	O
cholestyramine	NN	D
and	CC	O
colestipol	NN	D
resins	NNS	G
:	:	O
cholestytamine	NN	D
and	CC	O
colestipol	NN	D
resins	NNS	G
have	VBP	O
the	DT	O
potential	NN	O
of	IN	O
binding	VBG	O
thiazide	JJ	O
diuretics	NNS	G
and	CC	O
reducing	VBG	O
diuretic	JJ	G
absorption	NN	O
from	IN	O
the	DT	O
gastrointestinal	JJ	O
trac	NN	O
.	.	.
		
-	:	O
corticosteroids	NNS	G
","	","	O
acth	NN	D
:	:	O
intensified	VBN	O
electrolyte	NN	O
depletion	NN	O
","	","	O
particularly	RB	O
hypokalemi	NN	O
.	.	.
		
-	:	O
pressor	NN	O
amines	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
norepinephrine	NN	D
-rrb-	-RRB-	O
:	:	O
possible	JJ	O
decreased	VBN	O
response	NN	O
to	TO	O
pressor	NN	O
amines	NNS	O
but	CC	O
not	RB	O
sufficient	JJ	O
to	TO	O
preclude	VB	O
their	PRP$	O
us	PRP	O
.	.	.
		
-	:	O
skeletal	JJ	O
muscle	NN	O
relaxants	NNS	O
","	","	O
nondepolarizing	JJ	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
tubocurarine	NN	D
-rrb-	-RRB-	O
:	:	O
possible	JJ	O
increased	VBN	O
responsiveness	NN	O
to	TO	O
the	DT	O
muscle	NN	O
relaxan	NN	O
.	.	.
		
-	:	O
lithium	NN	D
:	:	O
generally	RB	O
should	MD	O
not	RB	O
be	VB	O
given	VBN	O
with	IN	O
diuretics	NNS	G
.	.	.
		
diuretic	JJ	O
agents	NNS	O
reduce	VB	O
the	DT	O
renal	JJ	O
clearance	NN	O
of	IN	O
lithium	NN	D
and	CC	O
add	VB	O
a	DT	O
high	JJ	O
risk	NN	O
of	IN	O
lithium	NN	D
toxicity	NN	O
.	.	.
		
refer	VB	O
to	TO	O
the	DT	O
package	NN	O
insert	NN	O
for	IN	O
lithium	NN	D
preparations	NNS	O
before	IN	O
use	NN	O
of	IN	O
such	JJ	O
preparations	NNS	O
with	IN	O
chlorothiazid	NN	O
.	.	.
		
-	:	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	O
:	:	O
in	IN	O
some	DT	O
patients	NNS	O
","	","	O
the	DT	O
administration	NN	O
of	IN	O
a	DT	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
agent	NN	O
can	MD	O
reduce	VB	O
the	DT	O
diuretic	JJ	G
","	","	O
natriuretic	JJ	O
","	","	O
and	CC	O
antihypertensive	JJ	O
effects	NNS	O
of	IN	O
loop	NN	O
","	","	O
potassium-sparing	NN	O
and	CC	O
thiazide	JJ	O
diuretics	NNS	G
.	.	.
		
therefore	RB	O
","	","	O
when	WRB	O
chlorothiazide	NN	D
and	CC	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
agents	NNS	O
are	VBP	O
used	VBN	O
concomitantly	RB	O
","	","	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
observed	VBN	O
closely	RB	O
to	TO	O
determine	VB	O
if	IN	O
the	DT	O
desired	VBN	O
effect	NN	O
of	IN	O
the	DT	O
diuretic	JJ	G
is	VBZ	O
obtaine	NN	O
.	.	.
		
-	:	O
drug/laboratory	NN	O
test	NN	O
interactions	NNS	O
:	:	O
thiazides	NNS	G
should	MD	O
be	VB	O
discontinued	VBN	O
before	IN	O
carrying	VBG	O
out	RP	O
tests	NNS	O
for	IN	O
parathyroid	JJ	O
function	NN	O
.	.	.
		
chlorotrianisene	NN	D
may	MD	O
interact	VB	O
with	IN	O
antidepressants	NNS	G
","	","	O
aspirin	NN	B
","	","	O
barbiturates	NNS	G
","	","	O
bromocriptine	NN	D
","	","	O
calcium	NN	D
supplements	NNS	O
","	","	O
corticosteroids	NNS	G
","	","	O
corticotropin	NN	D
","	","	O
cyclosporine	NN	D
","	","	O
dantrolene	NN	D
","	","	O
nicotine	NN	D
","	","	O
somatropin	NN	D
","	","	O
tamoxifen	NN	D
","	","	O
and	CC	O
warfarin	NN	D
.	.	.
		
may	NNP	O
interact	VBP	O
with	IN	O
skin	NN	O
products	NNS	O
or	CC	O
shampoos	NNS	O
for	IN	O
dandruff	NN	O
or	CC	O
psoriasis	NN	O
.	.	.
		
substrate	NN	O
of	IN	O
cyp2d6	NN	D
-lrb-	-LRB-	O
minor	JJ	O
-rrb-	-RRB-	O
","	","	O
3a4	NN	O
-lrb-	-LRB-	O
major	JJ	O
-rrb-	-RRB-	O
;	:	O
.	.	.
		
inhibits	VBZ	O
cyp2d6	NN	D
-lrb-	-LRB-	O
weak	JJ	O
-rrb-	-RRB-	O
.	.	.
		
increased	VBN	O
toxicity	NN	O
-lrb-	-LRB-	O
cns	NN	O
depression	NN	O
-rrb-	-RRB-	O
:	:	O
cns	NN	O
depressants	NNS	O
","	","	O
mao	NN	O
inhibitors	NNS	O
","	","	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
phenothiazines	NNS	G
.	.	.
		
cyp3a4	NN	D
inhibitors	NNS	O
:	:	O
may	NNP	O
increase	VB	O
the	DT	O
levels/effects	NNS	O
of	IN	O
chlorpheniramine	NN	D
.	.	.
		
example	NN	O
inhibitors	NNS	O
include	VBP	O
azole	NN	O
antifungals	NNS	O
","	","	O
ciprofloxacin	NN	D
","	","	O
clarithromycin	NN	D
","	","	O
diclofenac	NN	D
","	","	O
doxycycline	NN	D
","	","	O
erythromycin	NN	D
","	","	O
imatinib	NN	D
","	","	O
isoniazid	NN	D
","	","	O
nefazodone	NN	D
","	","	O
nicardipine	NN	D
","	","	O
propofol	NN	D
","	","	O
protease	NN	O
inhibitors	NNS	O
","	","	O
quinidine	NN	D
","	","	O
and	CC	O
verapamil	NN	D
.	.	.
		
the	DT	O
concurrent	JJ	O
use	NN	O
of	IN	O
two	CD	O
or	CC	O
more	JJR	O
drugs	NNS	D
with	IN	O
anticholinergic	JJ	G
activity	NN	O
--	:	O
such	JJ	O
as	IN	O
an	DT	O
antipsychotic	JJ	O
drug	NN	D
-lrb-	-LRB-	O
eg	FW	O
","	","	O
chlorpromazine	NN	D
-rrb-	-RRB-	O
","	","	O
an	DT	O
antiparkinsonian	JJ	O
drug	NN	D
-lrb-	-LRB-	O
eg	FW	O
","	","	O
trihexyphenidyl	NN	D
-rrb-	-RRB-	O
","	","	O
and/or	CC	O
a	DT	O
tricyclic	JJ	O
antidepressant	JJ	O
-lrb-	-LRB-	O
eg	FW	O
","	","	O
amitriptyline	NNP	D
-rrb-	-RRB-	O
--	:	O
commonly	RB	O
results	VBZ	O
in	IN	O
excessive	JJ	O
anticholinergic	JJ	G
effects	NNS	O
","	","	O
including	VBG	O
dry	JJ	O
mouth	NN	O
and	CC	O
associated	VBN	O
dental	JJ	O
complications	NNS	O
","	","	O
blurred	VBD	O
vision	NN	O
","	","	O
and	CC	O
","	","	O
in	IN	O
patients	NNS	O
exposed	VBN	O
to	TO	O
high	JJ	O
temperature	NN	O
and	CC	O
humidity	NN	O
","	","	O
hyperpyrexia	NN	O
.	.	.
		
interactions	NNS	O
may	MD	O
also	RB	O
occur	VB	O
with	IN	O
the	DT	O
following	NN	O
:	:	O
anti-depressants/anti-anxiety	JJ	O
drugs	NNS	D
","	","	O
drugs	NNS	D
used	VBN	O
to	TO	O
treat	VB	O
an	DT	O
overactive	JJ	O
thyroid	NN	D
","	","	O
beta-blockers	NNS	G
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
propranolol	NN	D
-rrb-	-RRB-	O
","	","	O
sparfloxacin	NN	D
","	","	O
grepafloxacin	NN	D
","	","	O
guanethidine	NN	D
","	","	O
guanadrel	NN	D
","	","	O
metrizamide	NN	D
","	","	O
cabergoline	NN	D
","	","	O
lithium	NN	D
","	","	O
narcotic	JJ	G
pain	NN	O
medication	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
codeine	NN	D
-rrb-	-RRB-	O
","	","	O
drugs	NNS	D
used	VBN	O
to	TO	O
aid	VB	O
sleep	NN	O
","	","	O
drowsiness-causing	JJ	O
antihistamines	NNS	G
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
diphenhydramine	NN	D
-rrb-	-RRB-	O
","	","	O
any	DT	O
other	JJ	O
drugs	NNS	D
that	WDT	O
may	MD	O
make	VB	O
you	PRP	O
drowsy	JJ	O
.	.	.
		
the	DT	O
hypoglycemic	JJ	O
action	NN	O
of	IN	O
sulfonylurea	NN	G
may	MD	O
be	VB	O
potentiated	VBN	O
by	IN	O
certain	JJ	O
drugs	NNS	D
including	VBG	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
agents	NNS	O
and	CC	O
other	JJ	O
drugs	NNS	D
that	WDT	O
are	VBP	O
highly	RB	O
protein	NN	O
bound	VBD	O
","	","	O
salicylates	NNS	G
","	","	O
sulfonamides	NNS	G
","	","	O
chloramphenicol	NN	D
","	","	O
probenecid	NN	D
","	","	O
coumarins	NNS	G
","	","	O
monoamine	NN	O
oxidase	NN	O
inhibitors	NNS	O
","	","	O
and	CC	O
beta	NN	O
adrenergic	JJ	O
blocking	VBG	O
agents	NNS	O
.	.	.
		
when	WRB	O
such	JJ	O
drugs	NNS	D
are	VBP	O
administered	VBN	O
to	TO	O
a	DT	O
patient	NN	O
receiving	VBG	O
diabinese	NNP	B
","	","	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
observed	VBN	O
closely	RB	O
for	IN	O
hypoglycemia	NN	O
.	.	.
		
when	WRB	O
such	JJ	O
drugs	NNS	D
are	VBP	O
withdrawn	VBN	O
from	IN	O
a	DT	O
patient	NN	O
receiving	VBG	O
diabinese	NNP	B
","	","	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
observed	VBN	O
closely	RB	O
for	IN	O
loss	NN	O
of	IN	O
control	NN	O
.	.	.
		
certain	JJ	O
drugs	NNS	D
tend	VBP	O
to	TO	O
produce	VB	O
hyperglycemia	NN	O
and	CC	O
may	MD	O
lead	VB	O
to	TO	O
loss	NN	O
of	IN	O
control	NN	O
.	.	.
		
these	DT	O
drugs	NNS	D
include	VBP	O
the	DT	O
thiazides	NNS	G
and	CC	O
other	JJ	O
diuretics	NNS	G
","	","	O
corticosteroids	NNS	G
","	","	O
phenothiazines	NNS	G
","	","	O
thyroid	NN	D
products	NNS	O
","	","	O
estrogens	NNS	G
","	","	O
oral	JJ	O
contraceptives	NNS	G
","	","	O
phenytoin	NN	D
","	","	O
nicotinic	JJ	O
acid	NN	O
","	","	O
sympathomimetics	NNS	G
","	","	O
calcium	NN	D
channel	NN	O
blocking	VBG	O
drugs	NNS	D
","	","	O
and	CC	O
isoniazid	NN	D
.	.	.
		
when	WRB	O
such	JJ	O
drugs	NNS	D
are	VBP	O
administered	VBN	O
to	TO	O
a	DT	O
patient	NN	O
receiving	VBG	O
diabinese	NNP	B
","	","	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
closely	RB	O
observed	VBN	O
for	IN	O
loss	NN	O
of	IN	O
control	NN	O
.	.	.
		
when	WRB	O
such	JJ	O
drugs	NNS	D
are	VBP	O
withdrawn	VBN	O
from	IN	O
a	DT	O
patient	NN	O
receiving	VBG	O
diabinese	NNP	B
","	","	O
the	DT	O
patient	NN	O
should	MD	O
be	VB	O
observed	VBN	O
closely	RB	O
for	IN	O
hypoglycemia	NN	O
.	.	.
		
since	IN	O
animal	NN	O
studies	NNS	O
suggest	VBP	O
that	IN	O
the	DT	O
action	NN	O
of	IN	O
barbiturates	NNS	G
may	MD	O
be	VB	O
prolonged	VBN	O
by	IN	O
therapy	NN	O
with	IN	O
chlorpropamide	NN	D
","	","	O
barbiturates	NNS	G
should	MD	O
be	VB	O
employed	VBN	O
with	IN	O
caution	NN	O
.	.	.
		
in	IN	O
some	DT	O
patients	NNS	O
","	","	O
a	DT	O
disulfiram-like	JJ	O
reaction	NN	O
may	MD	O
be	VB	O
produced	VBN	O
by	IN	O
the	DT	O
ingestion	NN	O
of	IN	O
alcohol	NN	D
.	.	.
		
a	DT	O
potential	JJ	O
interaction	NN	O
between	IN	O
oral	JJ	O
miconazole	NN	D
and	CC	O
oral	JJ	O
hypoglycemic	JJ	O
agents	NNS	O
leading	VBG	O
to	TO	O
severe	JJ	O
hypoglycemia	NN	O
has	VBZ	O
been	VBN	O
reported	VBN	O
.	.	.
		
whether	IN	O
this	DT	O
interaction	NN	O
also	RB	O
occurs	VBZ	O
with	IN	O
the	DT	O
intravenous	JJ	O
","	","	O
topical	JJ	O
","	","	O
or	CC	O
vaginal	JJ	O
preparations	NNS	O
of	IN	O
miconazole	NN	D
is	VBZ	O
not	RB	O
known	VBN	O
.	.	.
		
chlorprothixene	NN	D
may	MD	O
increase	VB	O
the	DT	O
plasma-level	NN	O
of	IN	O
concomitantly	RB	O
given	VBN	O
lithium	NN	D
.	.	.
		
in	IN	O
order	NN	O
to	TO	O
avoid	VB	O
lithium	NN	D
intoxication	NN	O
","	","	O
lithium	NN	D
plasma	NN	O
levels	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
.	.	.
		
if	IN	O
chlorprothixene	NN	D
is	VBZ	O
given	VBN	O
concomitantly	RB	O
with	IN	O
opioids	NNS	G
","	","	O
the	DT	O
opioid	JJ	G
dose	NN	O
should	MD	O
be	VB	O
reduced	VBN	O
-lrb-	-LRB-	O
by	IN	O
approx	RB	O
.	.	.
		
50	CD	O
%	NN	O
-rrb-	-RRB-	O
","	","	O
because	IN	O
chlorprothixene	NN	D
amplifies	VBZ	O
the	DT	O
therapeutic	JJ	O
actions	NNS	O
and	CC	O
side-effects	NNS	O
of	IN	O
opioids	NNS	G
massively	RB	O
.	.	.
		
avoid	VB	O
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
chlorprothixene	NN	D
and	CC	O
tramadol	NN	D
-lrb-	-LRB-	O
ultram	NN	B
-rrb-	-RRB-	O
.	.	.
		
massive	JJ	O
seizures	NNS	O
may	MD	O
be	VB	O
encountered	VBN	O
with	IN	O
this	DT	O
combination	NN	O
.	.	.
		
consider	VB	O
additive	JJ	O
sedative	JJ	G
effects	NNS	O
and	CC	O
confusional	JJ	O
states	NNS	O
to	TO	O
emerge	VB	O
","	","	O
if	IN	O
chlorprothixene	NN	D
is	VBZ	O
given	VBN	O
with	IN	O
benzodiazepines	NNS	G
or	CC	O
barbituates	NNS	G
.	.	.
		
choose	VB	O
particular	JJ	O
low	JJ	O
doses	NNS	O
of	IN	O
these	DT	O
drugs	NNS	D
.	.	.
		
exert	VB	O
particular	JJ	O
caution	NN	O
in	IN	O
combining	VBG	O
chlorprothixene	NN	D
with	IN	O
other	JJ	O
anticholinergic	JJ	G
drugs	NNS	D
-lrb-	-LRB-	O
tricyclic	JJ	O
antidepressants	NNS	G
and	CC	O
antiparkinsonian	JJ	O
agents	NNS	O
-rrb-	-RRB-	O
:	:	O
particularly	RB	O
the	DT	O
elderly	JJ	O
may	MD	O
develop	VB	O
delirium	NN	O
","	","	O
high	JJ	O
fever	NN	O
","	","	O
severe	JJ	O
obstipation	NN	O
","	","	O
even	RB	O
ileus	NN	O
and	CC	O
glaucoma	NN	O
.	.	.
		
chlorthalidone	NNP	D
may	MD	O
add	VB	O
to	TO	O
or	CC	O
potentiate	VB	O
the	DT	O
action	NN	O
of	IN	O
other	JJ	O
antihypertensive	JJ	O
drugs	NNS	D
.	.	.
		
potentiation	NN	O
occurs	VBZ	O
with	IN	O
ganglionic	JJ	O
peripheral	JJ	O
adrenergic	JJ	O
blocking	NN	O
drugs	NNS	D
.	.	.
		
medication	NN	O
such	JJ	O
as	IN	O
digitalis	NN	G
may	MD	O
also	RB	O
influence	VB	O
serum	NN	O
electrolytes	NNS	O
.	.	.
		
warning	NN	O
signs	NNS	O
","	","	O
irrespective	RB	O
of	IN	O
cause	NN	O
","	","	O
are	VBP	O
:	:	O
dryness	NN	O
of	IN	O
mouth	NN	O
","	","	O
thirst	NN	O
","	","	O
weakness	NN	O
","	","	O
lethargy	NN	O
","	","	O
drowsiness	NN	O
","	","	O
restlessness	NN	O
","	","	O
muscle	NN	O
pains	NNS	O
or	CC	O
cramps	NNS	O
","	","	O
muscular	JJ	O
fatigue	NN	O
","	","	O
hypotension	NN	O
","	","	O
oliguria	NN	O
","	","	O
tachycardia	NN	O
","	","	O
and	CC	O
gastrointestinal	JJ	O
disturbances	NNS	O
such	JJ	O
as	IN	O
nausea	NN	O
and	CC	O
vomiting	NN	O
.	.	.
		
insulin	NN	D
requirements	NNS	O
in	IN	O
diabetic	JJ	O
patients	NNS	O
may	MD	O
be	VB	O
increased	VBN	O
","	","	O
decreased	VBN	O
","	","	O
or	CC	O
unchanged	JJ	O
.	.	.
		
higher	JJR	O
dosage	NN	O
of	IN	O
oral	JJ	O
hypoglycemic	JJ	O
agents	NNS	O
may	MD	O
be	VB	O
required	VBN	O
.	.	.
		
latent	JJ	O
diabetes	NN	O
mellitus	NN	O
may	MD	O
become	VB	O
manifest	JJ	O
during	IN	O
chlorthalidone	NN	D
administration	NN	O
.	.	.
		
chlorthalidone	NNP	D
and	CC	O
related	JJ	O
drugs	NNS	D
may	MD	O
increase	VB	O
the	DT	O
responsiveness	NN	O
to	TO	O
tubocurarine	NN	D
.	.	.
		
chlorthalidone	NNP	D
and	CC	O
related	JJ	O
drugs	NNS	D
may	MD	O
decrease	VB	O
arterial	JJ	O
responsiveness	NN	O
to	TO	O
norepinephrine	NN	D
.	.	.
		
this	DT	O
diminution	NN	O
is	VBZ	O
not	RB	O
sufficient	JJ	O
to	TO	O
preclude	VB	O
effectiveness	NN	O
of	IN	O
the	DT	O
pressor	NN	O
agent	NN	O
for	IN	O
therapeutic	JJ	O
use	NN	O
.	.	.
		
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
alcohol	NN	D
or	CC	O
other	JJ	O
central	JJ	O
nervous	JJ	O
system	NN	O
depressants	NNS	O
may	MD	O
have	VB	O
an	DT	O
additive	JJ	O
effect	NN	O
.	.	.
		
interactions	NNS	O
for	IN	O
vitamin	NN	O
d	NN	O
analogues	NNS	O
-lrb-	-LRB-	O
vitamin	NN	O
d2	NN	O
","	","	O
vitamin	NN	O
d3	NN	O
","	","	O
calcitriol	NN	D
","	","	O
and	CC	O
calcidiol	NN	D
-rrb-	-RRB-	O
:	:	O
cholestyramine	NNP	D
:	:	O
cholestyramine	NNP	D
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
reduce	VB	O
intestinal	JJ	O
absorption	NN	O
of	IN	O
fat	JJ	O
soluble	JJ	O
vitamins	NNS	G
.	.	.
		
as	IN	O
such	JJ	O
it	PRP	O
may	MD	O
impair	VB	O
intestinal	JJ	O
absorption	NN	O
of	IN	O
any	DT	O
of	IN	O
vitamin	NN	O
d.	NNP	O
phenytoin/phenobarbital	NNP	O
:	:	O
the	DT	O
coadministration	NN	O
of	IN	O
phenytoin	NN	D
or	CC	O
phenobarbital	NN	D
will	MD	O
not	RB	O
affect	VB	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
vitamin	NN	O
d	NN	O
","	","	O
but	CC	O
may	MD	O
reduce	VB	O
endogenous	JJ	O
plasma	NN	O
levels	NNS	O
of	IN	O
calcitriol/ergocalcitriol	NN	O
by	IN	O
accelerating	VBG	O
metabolism	NN	O
.	.	.
		
since	IN	O
blood	NN	O
level	NN	O
of	IN	O
calcitriol/ergocalcitriol	NN	O
will	MD	O
be	VB	O
reduced	VBN	O
","	","	O
higher	JJR	O
doses	NNS	O
of	IN	O
rocaltrol	NNP	B
may	MD	O
be	VB	O
necessary	JJ	O
if	IN	O
these	DT	O
drugs	NNS	D
are	VBP	O
administered	VBN	O
simultaneously	RB	O
.	.	.
		
thiazides	NNP	G
:	:	O
thiazides	NNS	G
are	VBP	O
known	VBN	O
to	TO	O
induce	VB	O
hypercalcemia	NN	O
by	IN	O
the	DT	O
reduction	NN	O
of	IN	O
calcium	NN	D
excretion	NN	O
in	IN	O
urine	NN	O
.	.	.
		
some	DT	O
reports	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
thiazides	NNS	G
with	IN	O
vitamin	NN	O
d	NN	O
causes	VBZ	O
hypercalcemia	NN	O
.	.	.
		
therefore	RB	O
","	","	O
precaution	NN	O
should	MD	O
be	VB	O
taken	VBN	O
when	WRB	O
coadministration	NN	O
is	VBZ	O
necessary	JJ	O
.	.	.
		
digitalis	NNP	G
:	:	O
vitamin	NN	O
d	NN	O
dosage	NN	O
must	MD	O
be	VB	O
determined	VBN	O
with	IN	O
care	NN	O
in	IN	O
patients	NNS	O
undergoing	VBG	O
treatment	NN	O
with	IN	O
digitalis	NN	G
","	","	O
as	IN	O
hypercalcemia	NN	O
in	IN	O
such	JJ	O
patients	NNS	O
may	MD	O
precipitate	VB	O
cardiac	JJ	O
arrhythmias	NNS	O
.	.	.
		
ketoconazole	NN	D
:	:	O
ketoconazole	NN	D
may	MD	O
inhibit	VB	O
both	DT	O
synthetic	JJ	O
and	CC	O
catabolic	JJ	O
enzymes	NNS	O
of	IN	O
vitamin	NN	O
d.	NNP	O
reductions	NNPS	O
in	IN	O
serum	NN	O
endogenous	JJ	O
vitamin	NN	O
d	NN	O
concentrations	NNS	O
have	VBP	O
been	VBN	O
observed	VBN	O
following	VBG	O
the	DT	O
administration	NN	O
of	IN	O
300	CD	O
mg/day	NN	O
to	TO	O
1200	CD	O
mg/day	NN	O
ketoconazole	NN	D
for	IN	O
a	DT	O
week	NN	O
to	TO	O
healthy	JJ	O
men	NNS	O
.	.	.
		
however	RB	O
","	","	O
in	FW	O
vivo	FW	O
drug	NN	D
interaction	NN	O
studies	NNS	O
of	IN	O
ketoconazole	NN	D
with	IN	O
vitamin	NN	O
d	NN	O
have	VBP	O
not	RB	O
been	VBN	O
investigated	VBN	O
.	.	.
		
corticosteroids	NNS	G
:	:	O
a	DT	O
relationship	NN	O
of	IN	O
functional	JJ	O
antagonism	NN	O
exists	VBZ	O
between	IN	O
vitamin	NN	O
d	NN	O
analogues	NNS	O
","	","	O
which	WDT	O
promote	VBP	O
calcium	NN	D
absorption	NN	O
","	","	O
and	CC	O
corticosteroids	NNS	G
","	","	O
which	WDT	O
inhibit	VBP	O
calcium	NN	D
absorption	NN	O
.	.	.
		
phosphate-binding	JJ	O
agents	NNS	O
:	:	O
since	IN	O
vitamin	NN	O
d	NN	O
also	RB	O
has	VBZ	O
an	DT	O
effect	NN	O
on	IN	O
phosphate	NN	D_n
transport	NN	O
in	IN	O
the	DT	O
intestine	NN	O
","	","	O
kidneys	NNS	O
and	CC	O
bones	NNS	O
","	","	O
the	DT	O
dosage	NN	O
of	IN	O
phosphate-binding	JJ	O
agents	NNS	O
must	MD	O
be	VB	O
adjusted	VBN	O
in	IN	O
accordance	NN	O
with	IN	O
the	DT	O
serum	NN	O
phosphate	NN	D_n
concentration	NN	O
.	.	.
		
vitamin	NN	O
d	NN	O
:	:	O
the	DT	O
coadministration	NN	O
of	IN	O
any	DT	O
of	IN	O
the	DT	O
vitamin	NN	O
d	NN	O
analogues	NNS	O
should	MD	O
be	VB	O
avoided	VBN	O
as	IN	O
this	DT	O
could	MD	O
create	VB	O
possible	JJ	O
additive	JJ	O
effects	NNS	O
and	CC	O
hypercalcemia	NN	O
.	.	.
		
calcium	NN	D
supplements	NNS	O
:	:	O
uncontrolled	JJ	O
intake	NN	O
of	IN	O
additional	JJ	O
calcium-containing	JJ	O
preparations	NNS	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	.
		
magnesium	NN	D
:	:	O
magnesium-containing	JJ	O
preparations	NNS	O
-lrb-	-LRB-	O
eg	FW	O
","	","	O
antacids	NNS	G
-rrb-	-RRB-	O
may	MD	O
cause	VB	O
hypermagnesemia	NN	O
and	CC	O
should	MD	O
therefore	RB	O
not	RB	O
be	VB	O
taken	VBN	O
during	IN	O
therapy	NN	O
with	IN	O
vitamin	NN	O
d	NN	O
by	IN	O
patients	NNS	O
on	IN	O
chronic	JJ	O
renal	JJ	O
dialysis	NN	O
.	.	.
		
cholestyramine	NNP	D
resin	NN	G
may	MD	O
delay	VB	O
or	CC	O
reduce	VB	O
the	DT	O
absorption	NN	O
of	IN	O
concomitant	JJ	O
oral	JJ	O
medication	NN	O
such	JJ	O
as	IN	O
phenylbutazone	NN	G
","	","	O
warfarin	NN	D
","	","	O
thiazide	JJ	O
diuretics	NNS	G
-lrb-	-LRB-	O
acidic	JJ	O
-rrb-	-RRB-	O
or	CC	O
propranolol	NN	D
-lrb-	-LRB-	O
basic	JJ	O
-rrb-	-RRB-	O
","	","	O
as	RB	O
well	RB	O
as	IN	O
tetracycline	NN	D
penicillin	NN	D
g	NN	O
","	","	O
phenobarbital	NN	D
","	","	O
thyroid	NN	D
and	CC	O
thyroxine	NN	D
preparations	NNS	O
","	","	O
estrogens	NNS	G
and	CC	O
progestins	NNS	G
","	","	O
and	CC	O
digitalis	NN	G
.	.	.
		
interference	NN	O
with	IN	O
the	DT	O
absorption	NN	O
of	IN	O
oral	JJ	O
phosphate	NN	D_n
supplements	NNS	O
has	VBZ	O
been	VBN	O
observed	VBN	O
with	IN	O
another	DT	O
positively-charged	JJ	O
bile	NN	O
acid	NN	O
sequestrant	NN	O
.	.	.
		
cholestyramine	NNP	D
resin	NN	G
may	MD	O
interfere	VB	O
with	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
drugs	NNS	D
that	WDT	O
undergo	VBP	O
enterohepatic	JJ	O
circulation	NN	O
","	","	O
the	DT	O
discontinuance	NN	O
of	IN	O
cholestyramine	NN	D
resin	NN	G
could	MD	O
pose	VB	O
a	DT	O
hazard	NN	O
to	TO	O
health	NN	O
if	IN	O
a	DT	O
potentially	RB	O
toxic	JJ	O
drug	NN	D
such	JJ	O
as	IN	O
digitalis	NN	G
has	VBZ	O
been	VBN	O
filtrated	VBN	O
to	TO	O
a	DT	O
maintenance	NN	O
level	NN	O
while	IN	O
the	DT	O
patient	NN	O
was	VBD	O
taking	VBG	O
cholestyramine	NN	D
resin	NN	G
.	.	.
		
because	IN	O
cholestyramine	NN	D
binds	VBZ	O
bile	NN	O
acids	NNS	O
","	","	O
cholestyramine	NN	D
resin	NN	G
may	MD	O
interfere	VB	O
with	IN	O
normal	JJ	O
fat	JJ	O
digestion	NN	O
and	CC	O
absorption	NN	O
and	CC	O
thus	RB	O
may	MD	O
prevent	VB	O
absorption	NN	O
of	IN	O
fat	JJ	O
soluble	JJ	O
vitamins	NNS	G
such	JJ	O
as	IN	O
a	DT	O
","	","	O
d	NN	O
","	","	O
e	NN	O
","	","	O
and	CC	O
k	NN	O
.	.	.
		
when	WRB	O
cholestyramine	NN	D
resin	NN	G
is	VBZ	O
given	VBN	O
for	IN	O
long	JJ	O
periods	NNS	O
of	IN	O
time	NN	O
","	","	O
concomitant	JJ	O
supplementation	NN	O
with	IN	O
water-miscible	JJ	O
-lrb-	-LRB-	O
or	CC	O
parenteral	JJ	O
-rrb-	-RRB-	O
forms	NNS	O
of	IN	O
fat-soluble	JJ	O
vitamins	NNS	G
should	MD	O
be	VB	O
considered	VBN	O
.	.	.
		
since	IN	O
cholestyramine	NNP	D
resin	NNP	G
may	NNP	O
bind	VBP	O
other	JJ	O
drugs	NNS	O
given	VBP	O
concurrently	RB	O
","	","	O
it	PRP	O
is	VBZ	O
recommended	NNP	O
that	WDT	O
patients	NNS	O
take	VBP	O
other	JJ	O
drugs	NNS	O
at	IN	O
least	NN	O
1	CD	O
hour	NN	O
before	IN	O
or	NN	O
4	CD	O
to	TO	O
6	CD	O
hours	NNS	O
after	IN	O
cholestyramine	NNP	D
resin	NNP	G
-lrb-	-LRB-	O
or	NN	O
at	IN	O
as	JJ	O
great	JJ	O
an	DT	O
interval	NNP	O
as	NNP	O
possible	NN	O
-rrb-	-RRB-	O
to	TO	O
avoid	VB	O
impeding	NNP	O
their	NNP	O
absorption	NNP	O
.	.	.
		
based	VBN	O
on	IN	O
in	FW	O
vitro	FW	O
studies	NNS	O
in	IN	O
human	JJ	O
liver	NN	O
microsomes	NNS	O
","	","	O
des-ciclesonide	NN	D
appears	VBZ	O
to	TO	O
have	VB	O
no	DT	O
inhibitory	JJ	O
or	CC	O
induction	NN	O
potential	NN	O
on	IN	O
the	DT	O
metabolism	NN	O
of	IN	O
other	JJ	O
drugs	NNS	D
metabolized	VBN	O
by	IN	O
cyp	NN	O
450	CD	O
enzymes	NNS	O
.	.	.
		
the	DT	O
inhibitory	JJ	O
potential	NN	O
of	IN	O
ciclesonide	NN	D
on	IN	O
cyp450	NN	O
isoenzymes	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	.
		
in	FW	O
vitro	FW	O
studies	NNS	O
demonstrated	VBD	O
that	IN	O
the	DT	O
plasma	NN	O
protein	NN	O
binding	NN	O
of	IN	O
des-ciclesonide	NN	D
was	VBD	O
not	RB	O
affected	VBN	O
by	IN	O
warfarin	NN	D
or	CC	O
salicylic	JJ	O
acid	NN	O
","	","	O
indicating	VBG	O
no	DT	O
potential	NN	O
for	IN	O
protein	NN	O
binding-based	JJ	O
drug	NN	D
interactions	NNS	O
.	.	.
		
in	IN	O
a	DT	O
drug	NN	D
interaction	NN	O
study	NN	O
","	","	O
co-administration	NN	O
of	IN	O
orally	RB	O
inhaled	VBN	O
ciclesonide	NN	D
and	CC	O
oral	JJ	O
erythromycin	NN	D
","	","	O
an	DT	O
inhibitor	NN	O
of	IN	O
cytochrome	NN	O
p450	NN	O
3a4	NN	O
","	","	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
either	CC	O
des-ciclesonide	NN	D
or	CC	O
erythromycin	NN	D
.	.	.
		
in	IN	O
another	DT	O
drug	NN	D
interaction	NN	O
study	NN	O
","	","	O
co-administration	NN	O
of	IN	O
orally	RB	O
inhaled	VBN	O
ciclesonide	NN	D
and	CC	O
oral	JJ	O
ketoconazole	NN	D
","	","	O
a	DT	O
potent	JJ	O
inhibitor	NN	O
of	IN	O
cytochrome	NN	O
p450	NN	O
3a4	NN	O
","	","	O
increased	VBD	O
the	DT	O
exposure	NN	O
-lrb-	-LRB-	O
auc	NN	O
-rrb-	-RRB-	O
of	IN	O
des-ciclesonide	NN	D
by	IN	O
approximately	RB	O
3.6-fold	RB	O
at	IN	O
steady	JJ	O
state	NN	O
","	","	O
while	IN	O
levels	NNS	O
of	IN	O
ciclesonide	NN	D
remained	VBD	O
unchanged	JJ	O
.	.	.
		
therefore	RB	O
","	","	O
ketoconazole	NN	D
should	MD	O
be	VB	O
administered	VBN	O
with	IN	O
caution	NN	O
with	IN	O
intranasal	JJ	O
ciclesonide	NN	D
.	.	.
		
probenecid	NNP	D
:	:	O
probenecid	NNP	D
is	VBZ	O
known	VBN	O
to	TO	O
interact	VB	O
with	IN	O
the	DT	O
metabolism	NN	O
or	CC	O
renal	JJ	O
tubular	JJ	O
excretion	NN	O
of	IN	O
many	JJ	O
drugs	NNS	D
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
acetaminophen	NN	D
","	","	O
acyclovir	NN	D
","	","	O
angiotensin-converting	JJ	O
enzyme	NN	O
inhibitors	NNS	O
","	","	O
aminosalicylic	JJ	O
acid	NN	O
","	","	O
barbiturates	NNS	G
","	","	O
benzodiazepines	NNS	G
","	","	O
bumetanide	NN	D
","	","	O
clofibrate	NN	D
","	","	O
methotrexate	NN	D
","	","	O
famotidine	NN	D
","	","	O
furosemide	NN	D
","	","	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
agents	NNS	O
","	","	O
theophylline	NN	D
","	","	O
and	CC	O
zidovudine	NN	D
-rrb-	-RRB-	O
.	.	.
		
concomitant	JJ	O
medications	NNS	O
should	MD	O
be	VB	O
carefully	RB	O
assessed	VBN	O
.	.	.
		
zidovudine	NN	D
should	MD	O
either	RB	O
be	VB	O
temporarily	RB	O
discontinued	VBN	O
or	CC	O
decreased	VBN	O
by	IN	O
50	CD	O
%	NN	O
when	WRB	O
coadministered	VBN	O
with	IN	O
probenecid	NN	D
on	IN	O
the	DT	O
day	NN	O
of	IN	O
vistide	NNP	B
infusion	NN	O
.	.	.
		
nephrotoxic	JJ	O
agents	NNS	O
:	:	O
concomitant	JJ	O
administration	NN	O
of	IN	O
vistide	NNP	B
and	CC	O
agents	NNS	O
with	IN	O
nephrotoxic	JJ	O
potential	JJ	O
-lsb-	-LRB-	O
e.g.	FW	O
","	","	O
intravenous	JJ	O
aminoglycosides	NNS	G
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
tobramycin	NN	D
","	","	O
gentamicin	NN	D
","	","	O
and	CC	O
amikacin	NN	D
-rrb-	-RRB-	O
","	","	O
amphotericin	NN	O
b	NN	O
","	","	O
foscarnet	NN	D
","	","	O
intravenous	JJ	O
pentamidine	NN	D
","	","	O
vancomycin	NN	D
","	","	O
and	CC	O
non-steroidal	JJ	O
anti-inflammatory	JJ	O
agents	NNS	O
-rsb-	-RRB-	O
is	VBZ	O
contraindicated	VBN	O
.	.	.
		
such	JJ	O
agents	NNS	O
must	MD	O
be	VB	O
discontinued	VBN	O
at	IN	O
least	JJS	O
seven	CD	O
days	NNS	O
prior	RB	O
to	TO	O
starting	VBG	O
therapy	NN	O
with	IN	O
vistide	NN	B
.	.	.
		
since	IN	O
pletal	NN	B
is	VBZ	O
extensively	RB	O
metabolized	VBN	O
by	IN	O
cytochrome	NN	O
p-450	NN	O
isoenzymes	NNS	O
","	","	O
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
pletal	NNP	B
is	VBZ	O
coadministered	VBN	O
with	IN	O
inhibitors	NNS	O
of	IN	O
c.p.a.	NNP	O
such	JJ	O
as	IN	O
ketoconazole	NN	D
and	CC	O
erythromycin	NN	D
or	CC	O
inhibitors	NNS	O
of	IN	O
cyp2c19	NN	O
such	JJ	O
as	IN	O
omeprazole	NN	D
.	.	.
		
pharmacokinetic	JJ	O
studies	NNS	O
have	VBP	O
demonstrated	VBN	O
that	IN	O
omeprazole	NN	D
and	CC	O
erythromycin	NN	D
significantly	RB	O
increased	VBD	O
the	DT	O
systemic	JJ	O
exposure	NN	O
of	IN	O
cilostazol	NN	D
and/or	CC	O
its	PRP$	O
major	JJ	O
metabolites	NNS	O
.	.	.
		
population	NNP	O
pharmacokinetic	JJ	O
studies	NNS	O
showed	VBD	O
higher	JJR	O
concentrations	NNS	O
of	IN	O
cilostazol	NN	D
among	IN	O
patients	NNS	O
concurrently	RB	O
treated	VBN	O
with	IN	O
diltiazem	NN	D
","	","	O
an	DT	O
inhibitor	NN	O
of	IN	O
c.p.a.	NNP	O
pletal	NNP	B
does	VBZ	O
not	RB	O
","	","	O
however	RB	O
","	","	O
appear	VBP	O
to	TO	O
cause	VB	O
increased	VBN	O
blood	NN	O
levels	NNS	O
of	IN	O
drugs	NNS	D
metabolized	VBN	O
by	IN	O
cyp3a4	NN	D
","	","	O
as	IN	O
it	PRP	O
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
lovastatin	NN	D
","	","	O
a	DT	O
drug	NN	D
with	IN	O
metabolism	NN	O
very	RB	O
sensitive	JJ	O
to	TO	O
c.p.a.	NNP	O
inhibition	NN	O
.	.	.
		
tagamet	NNP	B
","	","	O
apparently	RB	O
through	IN	O
an	DT	O
effect	NN	O
on	IN	O
certain	JJ	O
microsomal	JJ	O
enzyme	NN	O
systems	NNS	O
","	","	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
reduce	VB	O
the	DT	O
hepatic	JJ	O
metabolism	NN	O
of	IN	O
warfarin-type	JJ	O
anticoagulants	NNS	G
","	","	O
phenytoin	NN	D
","	","	O
propranolol	NN	D
","	","	O
nifedipine	NN	D
","	","	O
chlordiazepoxide	NN	D
","	","	O
diazepam	NN	D
","	","	O
certain	JJ	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
lidocaine	NN	D
","	","	O
theophylline	NN	D
and	CC	O
metronidazole	NN	D
","	","	O
thereby	RB	O
delaying	VBG	O
elimination	NN	O
and	CC	O
increasing	VBG	O
blood	NN	O
levels	NNS	O
of	IN	O
these	DT	O
drugs	NNS	D
.	.	.
		
clinically	RB	O
significant	JJ	O
effects	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
with	IN	O
the	DT	O
warfarin	NN	D
anticoagulants	NNS	G
.	.	.
		
therefore	RB	O
","	","	O
close	JJ	O
monitoring	NN	O
of	IN	O
prothrombin	NN	O
time	NN	O
is	VBZ	O
recommended	VBN	O
","	","	O
and	CC	O
adjustment	NN	O
of	IN	O
the	DT	O
anticoagulant	JJ	G
dose	NN	O
may	MD	O
be	VB	O
necessary	JJ	O
when	WRB	O
tagamet	NNP	B
is	VBZ	O
administered	VBN	O
concomitantly	RB	O
.	.	.
		
interaction	NN	O
with	IN	O
phenytoin	NN	D
","	","	O
lidocaine	NN	D
and	CC	O
theophylline	NN	D
has	VBZ	O
also	RB	O
been	VBN	O
reported	VBN	O
to	TO	O
produce	VB	O
adverse	JJ	O
clinical	JJ	O
effects	NNS	O
.	.	.
		
however	RB	O
","	","	O
a	DT	O
crossover	NN	O
study	NN	O
in	IN	O
healthy	JJ	O
subjects	NNS	O
receiving	VBG	O
either	CC	O
tagamet	NNP	B
300	CD	O
mg	NN	O
q.i.d.	NN	O
or	CC	O
800	CD	O
mg	NN	O
h.s.	NN	O
concomitantly	RB	O
with	IN	O
a	DT	O
300	CD	O
mg	NN	O
b.i.d.	NN	O
dosage	NN	O
of	IN	O
theophylline	NN	D
-lrb-	-LRB-	O
theo-dur	NNP	B
","	","	O
key	NNP	O
pharmaceuticals	NNP	O
","	","	O
inc.	NNP	O
-rrb-	-RRB-	O
demonstrated	VBD	O
less	JJR	O
alteration	NN	O
in	IN	O
steady-state	JJ	O
theophylline	NN	D
peak	NN	O
serum	NN	O
levels	NNS	O
with	IN	O
the	DT	O
800	CD	O
mg	NN	O
h.s.	NN	O
regimen	NN	O
","	","	O
particularly	RB	O
in	IN	O
subjects	NNS	O
aged	JJ	O
54	CD	O
years	NNS	O
and	CC	O
older	JJR	O
.	.	.
		
data	NNS	O
beyond	IN	O
10	CD	O
days	NNS	O
are	VBP	O
not	RB	O
available	JJ	O
.	.	.
		
-lrb-	-LRB-	O
note	NN	O
:	:	O
all	DT	O
patients	NNS	O
receiving	VBG	O
theophylline	NN	D
should	MD	O
be	VB	O
monitored	VBN	O
appropriately	RB	O
","	","	O
regardless	RB	O
of	IN	O
concomitant	JJ	O
drug	NN	D
therapy	NN	O
.	.	.
		
dosage	NN	O
of	IN	O
the	DT	O
drugs	NNS	D
mentioned	VBN	O
above	IN	O
and	CC	O
other	JJ	O
similarly	RB	O
metabolized	VBN	O
drugs	NNS	D
","	","	O
particularly	RB	O
those	DT	O
of	IN	O
low	JJ	O
therapeutic	JJ	O
ratio	NN	O
or	CC	O
in	IN	O
patients	NNS	O
with	IN	O
renal	JJ	O
and/or	CC	O
hepatic	JJ	O
impairment	NN	O
","	","	O
may	MD	O
require	VB	O
adjustment	NN	O
when	WRB	O
starting	VBG	O
or	CC	O
stopping	VBG	O
concomitantly	RB	O
administered	VBN	O
tagamet	NNP	B
to	TO	O
maintain	VB	O
optimum	JJ	O
therapeutic	JJ	O
blood	NN	O
levels	NNS	O
.	.	.
		
alteration	NN	O
of	IN	O
ph	NN	O
may	MD	O
affect	VB	O
absorption	NN	O
of	IN	O
certain	JJ	O
drugs	NNS	D
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
ketoconazole	NN	D
-rrb-	-RRB-	O
.	.	.
		
if	IN	O
these	DT	O
products	NNS	O
are	VBP	O
needed	VBN	O
","	","	O
they	PRP	O
should	MD	O
be	VB	O
given	VBN	O
at	IN	O
least	JJS	O
2	CD	O
hours	NNS	O
before	IN	O
cimetidine	NN	D
administration	NN	O
.	.	.
		
additional	JJ	O
clinical	JJ	O
experience	NN	O
may	MD	O
reveal	VB	O
other	JJ	O
drugs	NNS	D
affected	VBN	O
by	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
tagamet	NNP	B
.	.	.
		
and/or	CC	O
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
see	VB	O
clinical	NNP	O
pharmacology	NNP	O
","	","	O
pharmacokinetics	NNP	O
and	CC	O
drug	NNP	O
interactions	NNS	O
.	.	.
		
effect	NN	O
of	IN	O
sensipar	NN	B
on	IN	O
other	JJ	O
drugs	NNS	D
:	:	O
drugs	NNS	O
metabolized	VBN	O
by	IN	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
-lrb-	-LRB-	O
cyp2d6	NN	D
-rrb-	-RRB-	O
:	:	O
sensipar	NN	B
is	VBZ	O
a	DT	O
strong	JJ	O
in	FW	O
vitro	FW	O
inhibitor	NN	O
of	IN	O
cyp2d6	NN	D
.	.	.
		
therefore	RB	O
","	","	O
dose	NN	O
adjustments	NNS	O
of	IN	O
concomitant	JJ	O
medications	NNS	O
that	WDT	O
are	VBP	O
predominantly	RB	O
metabolized	VBN	O
by	IN	O
cyp2d6	NN	D
and	CC	O
have	VBP	O
a	DT	O
narrow	JJ	O
therapeutic	JJ	O
index	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
flecainide	NN	D
","	","	O
vinblastine	NN	D
","	","	O
thioridazine	NN	D
and	CC	O
most	RBS	O
tricyclic	JJ	O
antidepressants	NNS	G
-rrb-	-RRB-	O
may	MD	O
be	VB	O
required	VBN	O
.	.	.
		
amitriptyline	NNP	D
:	:	O
concurrent	JJ	O
administration	NN	O
of	IN	O
25	CD	O
mg	NN	O
or	CC	O
100	CD	O
mg	NN	O
cinacalcet	NN	D
with	IN	O
50	CD	O
mg	NN	O
amitriptyline	NNP	D
increased	VBD	O
amitriptyline	NNP	D
exposure	NN	O
and	CC	O
nortriptyline	NN	D_n
-lrb-	-LRB-	O
active	JJ	O
metabolite	NN	O
-rrb-	-RRB-	O
exposure	NN	O
by	IN	O
approximately	RB	O
20	CD	O
%	NN	O
in	IN	O
cyp2d6	NN	D
extensive	JJ	O
metabolizers	NNS	O
.	.	.
		
effect	NN	O
of	IN	O
other	JJ	O
drugs	NNS	D
on	IN	O
sensipar	NNP	B
:	:	O
sensipar	NNP	B
is	VBZ	O
metabolized	VBN	O
by	IN	O
multiple	JJ	O
cytochrome	NN	O
p450	NN	O
enzymes	NNS	O
","	","	O
primarily	RB	O
cyp3a4	NN	D
","	","	O
cyp2d6	NN	D
","	","	O
and	CC	O
cyp1a2	NN	D
.	.	.
		
ketoconazole	NN	D
:	:	O
sensipar	NN	B
is	VBZ	O
metabolized	VBN	O
in	IN	O
part	NN	O
by	IN	O
cyp3a4	NN	D
.	.	.
		
co-administration	NN	O
of	IN	O
ketoconazole	NN	D
","	","	O
a	DT	O
strong	JJ	O
inhibitor	NN	O
of	IN	O
cyp3a4	NN	D
","	","	O
increased	VBD	O
cinacalcet	NN	D
exposure	NN	O
following	VBG	O
a	DT	O
single	JJ	O
90	CD	O
mg	NN	O
dose	NN	O
of	IN	O
sensipar	NN	B
by	IN	O
2.3	CD	O
fold	NN	O
.	.	.
		
dose	NN	O
adjustment	NN	O
of	IN	O
sensipar	NN	B
may	MD	O
be	VB	O
required	VBN	O
and	CC	O
pth	NN	O
and	CC	O
serum	NN	O
calcium	NN	D
concentrations	NNS	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
if	IN	O
a	DT	O
patient	NN	O
initiates	VBZ	O
or	CC	O
discontinues	VBZ	O
therapy	NN	O
with	IN	O
a	DT	O
strong	JJ	O
cyp3a4	NN	D
inhibitor	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
ketoconazole	NN	D
","	","	O
erythromycin	NN	D
","	","	O
itraconazole	NN	D
.	.	.
		
see	VB	O
dosage	NNP	O
and	CC	O
administration	NNP	O
-rrb-	-RRB-	O
.	.	.
		
elevated	JJ	O
plasma	NN	O
levels	NNS	O
of	IN	O
theophylline	NN	D
have	VBP	O
been	VBN	O
reported	VBN	O
with	IN	O
concomitant	JJ	O
use	NN	O
of	IN	O
some	DT	O
quinolones	NNS	G
.	.	.
		
there	EX	O
have	VBP	O
been	VBN	O
reports	NNS	O
of	IN	O
theophylline-related	JJ	O
side-effects	NNS	O
in	IN	O
patients	NNS	O
on	IN	O
concomitant	JJ	O
theophylline-quinolone	JJ	O
therapy	NN	O
.	.	.
		
therefore	RB	O
","	","	O
monitoring	NN	O
of	IN	O
theophylline	NN	D
plasma	NN	O
levels	NNS	O
should	MD	O
be	VB	O
considered	VBN	O
and	CC	O
dosage	NN	O
of	IN	O
theophylline	NN	D
adjusted	VBN	O
as	IN	O
required	VBN	O
.	.	.
		
quinolones	NNS	G
have	VBP	O
also	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
interfere	VB	O
with	IN	O
the	DT	O
metabolism	NN	O
of	IN	O
caffeine	NN	D
.	.	.
		
this	DT	O
may	MD	O
lead	VB	O
to	TO	O
reduced	VBN	O
clearance	NN	O
of	IN	O
caffeine	NN	D
and	CC	O
a	DT	O
prolongation	NN	O
of	IN	O
its	PRP$	O
plasma	NN	O
half-life	NN	O
.	.	.
		
although	IN	O
this	DT	O
interaction	NN	O
has	VBZ	O
not	RB	O
been	VBN	O
reported	VBN	O
with	IN	O
cinoxacin	NN	D
","	","	O
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
cinoxacin	NN	D
is	VBZ	O
given	VBN	O
concomitantly	RB	O
with	IN	O
caffeine-containing	JJ	O
products	NNS	O
.	.	.
		
antacids	NNS	G
or	CC	O
sucralfate	NN	D
substantially	RB	O
interfere	VBP	O
with	IN	O
the	DT	O
absorption	NN	O
of	IN	O
some	DT	O
quinolones	NNS	G
","	","	O
resulting	VBG	O
in	IN	O
low	JJ	O
urine	NN	O
levels	NNS	O
.	.	.
		
also	RB	O
","	","	O
concomitant	JJ	O
administration	NN	O
of	IN	O
quinolones	NNS	G
with	IN	O
products	NNS	O
containing	VBG	O
iron	NN	D
","	","	O
multivitamins	NNS	G
containing	VBG	O
zinc	NN	D
","	","	O
or	CC	O
videx	NNP	B
-lrb-	-LRB-	O
didanosine	NN	D
-rrb-	-RRB-	O
chewable/buffered	VBD	O
tablets	NNS	O
or	CC	O
the	DT	O
pediatric	JJ	O
powder	NN	O
for	IN	O
oral	JJ	O
solution	NN	O
may	MD	O
result	VB	O
in	IN	O
low	JJ	O
urine	NN	O
levels	NNS	O
.	.	.
		
quinolones	NNP	G
","	","	O
including	VBG	O
cinoxacin	NN	D
","	","	O
may	MD	O
enhance	VB	O
the	DT	O
effects	NNS	O
of	IN	O
oral	JJ	O
anticoagulants	NNS	G
","	","	O
such	JJ	O
as	IN	O
warfarin	NN	D
or	CC	O
its	PRP$	O
derivatives	NNS	O
.	.	.
		
when	WRB	O
these	DT	O
products	NNS	O
are	VBP	O
administered	VBN	O
concomitantly	RB	O
","	","	O
prothrombin	NN	O
time	NN	O
or	CC	O
other	JJ	O
suitable	JJ	O
coagulation	NN	O
tests	NNS	O
should	MD	O
be	VB	O
closely	RB	O
monitored	VBN	O
.	.	.
		
seizures	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
patients	NNS	O
taking	VBG	O
another	DT	O
quinolone	NN	G
class	NN	O
antimicrobial	JJ	O
and	CC	O
the	DT	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
drug	NN	D
fenbufen	NN	D
concurrently	RB	O
.	.	.
		
animal	NN	O
studies	NNS	O
also	RB	O
suggest	VBP	O
an	DT	O
increased	VBN	O
potential	NN	O
for	IN	O
seizures	NNS	O
when	WRB	O
these	DT	O
2	CD	O
drugs	NNS	D
are	VBP	O
given	VBN	O
concomitantly	RB	O
.	.	.
		
fenbufen	NNP	D
is	VBZ	O
not	RB	O
approved	VBN	O
in	IN	O
the	DT	O
united	NNP	O
states	NNPS	O
at	IN	O
this	DT	O
time	NN	O
.	.	.
		
physicians	NNP	O
are	VBP	O
provided	VBN	O
this	DT	O
information	NN	O
to	TO	O
increase	VB	O
awareness	NN	O
of	IN	O
the	DT	O
potential	NN	O
for	IN	O
serious	JJ	O
interactions	NNS	O
when	WRB	O
cinoxacin	NN	D
and	CC	O
certain	JJ	O
nonsteroidal	JJ	O
anti-inflammatory	JJ	O
agents	NNS	O
are	VBP	O
administered	VBN	O
concomitantly	RB	O
.	.	.
		
elevated	JJ	O
cyclosporine	NN	D
serum	NN	O
levels	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
with	IN	O
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
quinolones	NNS	G
and	CC	O
cyclosporine	NN	D
.	.	.
		
some	DT	O
quinolones	NNS	G
","	","	O
including	VBG	O
ciprofloxacin	NN	D
","	","	O
have	VBP	O
also	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
interfere	VB	O
with	IN	O
the	DT	O
metabolism	NN	O
of	IN	O
caffeine	NN	D
.	.	.
		
this	DT	O
may	MD	O
lead	VB	O
to	TO	O
reduced	VBN	O
clearance	NN	O
of	IN	O
caffeine	NN	D
and	CC	O
a	DT	O
prolongation	NN	O
of	IN	O
its	PRP$	O
serum	NN	O
half-life	NN	O
.	.	.
		
some	DT	O
quinolones	NNS	G
","	","	O
including	VBG	O
ciprofloxacin	NN	D
","	","	O
have	VBP	O
been	VBN	O
associated	VBN	O
with	IN	O
transient	JJ	O
elevations	NNS	O
in	IN	O
serum	NN	O
creatinine	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
cyclosporine	NN	D
concomitantly	RB	O
.	.	.
		
glyburide	NNP	D
:	:	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
ciprofloxacin	NN	D
with	IN	O
the	DT	O
sulfonylurea	NN	G
glyburide	NN	D
has	VBZ	O
","	","	O
on	IN	O
rare	JJ	O
occasions	NNS	O
","	","	O
resulted	VBD	O
in	IN	O
severe	JJ	O
hypoglycemia	NN	O
.	.	.
		
histamine	NN	O
h2-receptor	NN	O
antagonists	NNS	O
:	:	O
histamine	NN	O
h2-receptor	NN	O
antagonists	NNS	O
appear	VBP	O
to	TO	O
have	VB	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
bioavailability	NN	O
of	IN	O
ciprofloxacin	NN	D
.	.	.
		
methotrexate	NNP	D
renal	JJ	O
tubular	JJ	O
transport	NN	O
of	IN	O
methotrexate	NN	D
may	MD	O
be	VB	O
inhibited	VBN	O
by	IN	O
concomitant	JJ	O
administration	NN	O
of	IN	O
ciprofloxacin	NN	D
","	","	O
potentially	RB	O
leading	VBG	O
to	TO	O
increased	VBN	O
plasma	NN	O
levels	NNS	O
of	IN	O
methotrexate	NN	D
.	.	.
		
this	DT	O
might	MD	O
increase	VB	O
the	DT	O
risk	NN	O
of	IN	O
methotrexate	NN	D
toxic	JJ	O
reactions	NNS	O
.	.	.
		
therefore	RB	O
","	","	O
patients	NNS	O
under	IN	O
methotrexate	NN	D
therapy	NN	O
should	MD	O
be	VB	O
carefully	RB	O
monitored	VBN	O
when	WRB	O
concomitant	JJ	O
ciprofloxacin	NN	D
therapy	NN	O
is	VBZ	O
indicated	VBN	O
.	.	.
		
multivalent	JJ	O
cation-containing	NNP	O
products	NNPS	O
:	:	O
concurrent	JJ	O
administration	NN	O
of	IN	O
a	DT	O
quinolone	NN	G
","	","	O
including	VBG	O
ciprofloxacin	NN	D
","	","	O
with	IN	O
multivalent	JJ	O
cation-containing	JJ	O
products	NNS	O
such	JJ	O
as	IN	O
magnesium	NN	D
or	CC	O
aluminum	NN	D
antacids	NNS	G
","	","	O
sucralfate	NN	D
","	","	O
videx	NNP	B
chewable/buffered	VBD	O
tablets	NNS	O
or	CC	O
pediatric	JJ	O
powder	NN	O
","	","	O
or	CC	O
products	NNS	O
containing	VBG	O
calcium	NN	D
","	","	O
iron	NN	D
","	","	O
or	CC	O
zinc	NN	D
may	MD	O
substantially	RB	O
decrease	VB	O
the	DT	O
absorption	NN	O
of	IN	O
ciprofloxacin	NN	D
","	","	O
resulting	VBG	O
in	IN	O
serum	NN	O
and	CC	O
urine	NN	O
levels	NNS	O
considerably	RB	O
lower	JJR	O
than	IN	O
desired	VBN	O
.	.	.
		
proquin	NNP	O
xr	NNP	O
should	MD	O
be	VB	O
administered	VBN	O
at	IN	O
least	JJS	O
4	CD	O
hours	NNS	O
before	IN	O
or	CC	O
2	CD	O
hours	NNS	O
after	IN	O
these	DT	O
products	NNS	O
.	.	.
		
this	DT	O
time	NN	O
window	NN	O
is	VBZ	O
different	JJ	O
than	IN	O
for	IN	O
other	JJ	O
oral	JJ	O
formulations	NNS	O
of	IN	O
ciprofloxacin	NN	D
","	","	O
which	WDT	O
are	VBP	O
usually	RB	O
administered	VBN	O
2	CD	O
hours	NNS	O
before	IN	O
or	CC	O
6	CD	O
hours	NNS	O
after	IN	O
antacids	NNS	G
.	.	.
		
non-steroidal	JJ	O
anti-inflammatory	JJ	O
drugs	NNS	D
-lrb-	-LRB-	O
but	CC	O
not	RB	O
aspirin	NN	B
-rrb-	-RRB-	O
:	:	O
these	DT	O
drugs	NNS	D
in	IN	O
combination	NN	O
with	IN	O
very	RB	O
high	JJ	O
doses	NNS	O
of	IN	O
quinolones	NNS	G
have	VBP	O
been	VBN	O
shown	VBN	O
to	TO	O
provoke	VB	O
convulsions	NNS	O
in	IN	O
pre-clinical	JJ	O
studies	NNS	O
.	.	.
		
omeprazole	NNP	D
:	:	O
the	DT	O
rate	NN	O
and	CC	O
extent	NN	O
of	IN	O
absorption	NN	O
of	IN	O
ciprofloxacin	NN	D
was	VBD	O
bioequivalent	JJ	O
when	WRB	O
proquin	NNP	O
xr	NNP	O
was	VBD	O
given	VBN	O
alone	RB	O
or	CC	O
when	WRB	O
proquin	NNP	O
xr	NNP	O
was	VBD	O
given	VBN	O
2	CD	O
hours	NNS	O
after	IN	O
omeprazole	NN	D
at	IN	O
the	DT	O
dose	NN	O
that	WDT	O
maximally	RB	O
suppresses	VBZ	O
gastric	JJ	O
acid	NN	O
secretion	NN	O
.	.	.
		
omeprazole	NNP	D
should	MD	O
be	VB	O
taken	VBN	O
as	IN	O
directed	VBN	O
and	CC	O
proquin	NNP	O
xr	NN	O
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
a	DT	O
main	JJ	O
meal	NN	O
of	IN	O
the	DT	O
day	NN	O
","	","	O
preferably	RB	O
the	DT	O
evening	NN	O
meal	NN	O
.	.	.
		
phenytoin	NNP	D
:	:	O
altered	JJ	O
serum	NN	O
levels	NNS	O
of	IN	O
phenytoin	NN	D
-lrb-	-LRB-	O
increased	VBN	O
and	CC	O
decreased	VBN	O
-rrb-	-RRB-	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
concomitant	JJ	O
ciprofloxacin	NN	D
.	.	.
		
probenecid	NNP	D
:	:	O
probenecid	NNP	D
interferes	VBZ	O
with	IN	O
renal	JJ	O
tubular	JJ	O
secretion	NN	O
of	IN	O
ciprofloxacin	NN	D
and	CC	O
produces	VBZ	O
an	DT	O
increase	NN	O
in	IN	O
the	DT	O
level	NN	O
of	IN	O
ciprofloxacin	NN	D
in	IN	O
serum	NN	O
.	.	.
		
theophylline	NNP	D
:	:	O
as	IN	O
with	IN	O
some	DT	O
other	JJ	O
quinolones	NNS	G
","	","	O
concurrent	JJ	O
administration	NN	O
of	IN	O
ciprofloxacin	NN	D
with	IN	O
theophylline	NN	D
may	MD	O
lead	VB	O
to	TO	O
elevated	JJ	O
serum	NN	O
concentrations	NNS	O
of	IN	O
theophylline	NN	D
and	CC	O
prolongation	NN	O
of	IN	O
its	PRP$	O
elimination	NN	O
half-life	NN	O
.	.	.
		
this	DT	O
may	MD	O
result	VB	O
in	IN	O
increased	VBN	O
risk	NN	O
of	IN	O
theophylline-related	JJ	O
adverse	JJ	O
reactions	NNS	O
.	.	.
		
if	IN	O
concomitant	JJ	O
use	NN	O
can	MD	O
not	RB	O
be	VB	O
avoided	VBN	O
","	","	O
serum	NN	O
levels	NNS	O
of	IN	O
theophylline	NN	D
should	MD	O
be	VB	O
monitored	VBN	O
and	CC	O
dosage	NN	O
adjustments	NNS	O
made	VBN	O
as	IN	O
appropriate	JJ	O
.	.	.
		
warfarin	NNP	D
:	:	O
quinolones	NNS	G
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
enhance	VB	O
the	DT	O
effects	NNS	O
of	IN	O
the	DT	O
oral	JJ	O
anticoagulant	JJ	G
warfarin	NN	D
or	CC	O
its	PRP$	O
derivatives	NNS	O
.	.	.
		
when	WRB	O
these	DT	O
products	NNS	O
are	VBP	O
administered	VBN	O
concomitantly	RB	O
","	","	O
prothrombin	NN	O
time	NN	O
or	CC	O
other	JJ	O
suitable	JJ	O
coagulation	NN	O
tests	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
.	.	.
		
cisapride	NNP	D
is	VBZ	O
metabolized	VBN	O
mainly	RB	O
via	IN	O
the	DT	O
cytochrome	NN	O
p450	NN	O
3a4	NN	O
enzyme	NN	O
.	.	.
		
in	IN	O
some	DT	O
cases	NNS	O
where	WRB	O
serious	JJ	O
ventricular	JJ	O
arrhythmias	NNS	O
","	","	O
qt	NN	O
prolongation	NN	O
","	","	O
and	CC	O
torsades	NNS	O
de	IN	O
pointes	NNS	O
have	VBP	O
occurred	VBN	O
when	WRB	O
cisapride	NN	D
was	VBD	O
taken	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
one	CD	O
of	IN	O
the	DT	O
cytochrome	NN	O
p450	NN	O
3a4	NN	O
inhibitors	NNS	O
","	","	O
elevated	JJ	O
blood	NN	O
cisapride	NN	D
levels	NNS	O
were	VBD	O
noted	VBN	O
at	IN	O
the	DT	O
time	NN	O
of	IN	O
the	DT	O
qt	NNP	O
prolongation	NN	O
.	.	.
		
antibiotics	NNS	G
:	:	O
in	FW	O
vitro	FW	O
and/or	CC	O
in	FW	O
vivo	FW	O
data	NNS	O
show	VBP	O
that	IN	O
clarithromycin	NN	D
","	","	O
erythromycin	NN	D
","	","	O
and	CC	O
troleandomycin	NN	D
markedly	RB	O
inhibit	VBP	O
the	DT	O
metabolism	NN	O
of	IN	O
cisapride	NN	D
","	","	O
which	WDT	O
can	MD	O
result	VB	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
plasma	NN	O
cisapride	NN	D
levels	NNS	O
and	CC	O
prolongation	NN	O
of	IN	O
the	DT	O
qt	NNP	O
interval	NN	O
on	IN	O
the	DT	O
ecg	NN	O
.	.	.
		
anticholinergics	NNP	G
:	:	O
concurrent	JJ	O
administration	NN	O
of	IN	O
certain	JJ	O
anticholinergic	JJ	G
compounds	NNS	O
","	","	O
such	JJ	O
as	IN	O
belladonna	NN	O
alkaloids	NNS	O
and	CC	O
dicyclomine	NN	D
","	","	O
would	MD	O
be	VB	O
expected	VBN	O
to	TO	O
compromise	VB	O
the	DT	O
beneficial	JJ	O
effects	NNS	O
of	IN	O
cisapride	NN	D
.	.	.
		
anticoagulants	NNS	G
-lrb-	-LRB-	O
oral	JJ	O
-rrb-	-RRB-	O
:	:	O
in	IN	O
patients	NNS	O
receiving	VBG	O
oral	JJ	O
anticoagulants	NNS	G
","	","	O
the	DT	O
coagulation	NN	O
times	NNS	O
were	VBD	O
increased	VBN	O
in	IN	O
some	DT	O
cases	NNS	O
.	.	.
		
it	PRP	O
is	VBZ	O
advisable	JJ	O
to	TO	O
check	VB	O
coagulation	NN	O
time	NN	O
within	IN	O
the	DT	O
first	JJ	O
few	JJ	O
days	NNS	O
after	IN	O
the	DT	O
start	NN	O
and	CC	O
discontinuation	NN	O
of	IN	O
cisapride	NN	D
therapy	NN	O
","	","	O
with	IN	O
an	DT	O
appropriate	JJ	O
adjustment	NN	O
of	IN	O
the	DT	O
anticoagulant	JJ	G
dose	NN	O
","	","	O
if	IN	O
necessary	JJ	O
.	.	.
		
antidepressants	NNS	G
:	:	O
in	FW	O
vitro	FW	O
data	NNS	O
indicate	VBP	O
that	IN	O
nefazodone	NN	D
inhibits	VBZ	O
the	DT	O
metabolism	NN	O
of	IN	O
cisapride	NN	D
","	","	O
which	WDT	O
can	MD	O
result	VB	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
plasma	NN	O
cisapride	NN	D
levels	NNS	O
and	CC	O
prolongation	NN	O
of	IN	O
the	DT	O
qt	NNP	O
interval	NN	O
on	IN	O
the	DT	O
ecg	NN	O
.	.	.
		
antifungals	NNS	G
:	:	O
in	FW	O
vitro	FW	O
and/or	CC	O
in	FW	O
vivo	FW	O
data	NNS	O
indicate	VBP	O
that	IN	O
fluconazole	NN	D
","	","	O
itraconazole	NN	D
","	","	O
and	CC	O
oral	JJ	O
ketoconazole	NN	D
markedly	RB	O
inhibit	VBP	O
the	DT	O
metabolism	NN	O
of	IN	O
cisapride	NN	D
","	","	O
which	WDT	O
can	MD	O
result	VB	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
plasma	NN	O
cisapride	NN	D
levels	NNS	O
and	CC	O
prolongation	NN	O
of	IN	O
the	DT	O
qt	NNP	O
interval	NN	O
on	IN	O
the	DT	O
ecg	NN	O
.	.	.
		
human	JJ	O
pharmacokinetic	JJ	O
data	NNS	O
indicate	VBP	O
that	IN	O
oral	JJ	O
ketoconazole	NN	D
markedly	RB	O
inhibits	VBZ	O
the	DT	O
metabolism	NN	O
of	IN	O
cisapride	NN	D
","	","	O
resulting	VBG	O
in	IN	O
a	DT	O
mean	NN	O
eight-fold	JJ	O
increase	NN	O
in	IN	O
auc	NN	O
of	IN	O
cisapride	NN	D
.	.	.
		
a	DT	O
study	NN	O
in	IN	O
14	CD	O
normal	JJ	O
male	NN	O
and	CC	O
female	JJ	O
volunteers	NNS	O
suggests	VBZ	O
that	IN	O
coadministration	NN	O
of	IN	O
cisapride	NN	D
and	CC	O
ketoconazole	NN	D
can	MD	O
result	VB	O
in	IN	O
prolongation	NN	O
of	IN	O
the	DT	O
qt	NNP	O
interval	NN	O
on	IN	O
the	DT	O
ecg	NN	O
.	.	.
		
h2	NN	O
receptor	NN	O
antagonists	NNS	O
:	:	O
cimetidine	NN	D
coadministration	NN	O
leads	VBZ	O
to	TO	O
an	DT	O
increased	VBN	O
peak	NN	O
plasma	NN	O
concentration	NN	O
and	CC	O
auc	NN	O
of	IN	O
cisapride	NN	D
","	","	O
there	EX	O
is	VBZ	O
no	DT	O
effect	NN	O
on	IN	O
cisapride	NN	D
absorption	NN	O
when	WRB	O
it	PRP	O
is	VBZ	O
coadministered	VBN	O
with	IN	O
ranitidine	NN	D
.	.	.
		
the	DT	O
gastrointestinal	JJ	O
absorption	NN	O
of	IN	O
cimetidine	NN	D
and	CC	O
ranitidine	NN	D
is	VBZ	O
accelerated	VBN	O
when	WRB	O
they	PRP	O
are	VBP	O
coadministered	VBN	O
with	IN	O
cisapride	NN	D
.	.	.
		
protease	NN	O
inhibitors	NNS	O
:	:	O
in	FW	O
vitro	FW	O
data	NNS	O
indicate	VBP	O
that	IN	O
indinavir	NN	D
and	CC	O
ritonavir	NN	D
markedly	RB	O
inhibit	VBP	O
the	DT	O
metabolism	NN	O
of	IN	O
cisapride	NN	D
which	WDT	O
can	MD	O
result	VB	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
plasma	NN	O
cisapride	NN	D
levels	NNS	O
and	CC	O
prolongation	NN	O
of	IN	O
the	DT	O
qt	NNP	O
interval	NN	O
on	IN	O
the	DT	O
ecg	NN	O
.	.	.
		
other	JJ	O
:	:	O
coadministration	NN	O
of	IN	O
grapefruit	NN	O
juice	NN	O
with	IN	O
cisapride	NN	D
increases	VBZ	O
the	DT	O
bioavailability	NN	O
of	IN	O
cisapride	NN	D
and	CC	O
concomitant	JJ	O
use	NN	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	.
		
cisapride	NNP	D
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
concomitantly	RB	O
with	IN	O
other	JJ	O
drugs	NNS	D
known	VBN	O
to	TO	O
prolong	VB	O
the	DT	O
qt	NNP	O
interval	NN	O
:	:	O
certain	JJ	O
antiarrhythmics	NNS	G
","	","	O
including	VBG	O
those	DT	O
of	IN	O
class	NNP	O
ia	NNP	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
quinidine	NN	D
and	CC	O
procainamide	NN	D
-rrb-	-RRB-	O
and	CC	O
class	NN	O
iii	CD	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
sotalol	NN	D
-rrb-	-RRB-	O
.	.	.
		
tricyclic	JJ	O
antidepressants	NNS	G
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
amitriptyline	NNP	D
-rrb-	-RRB-	O
.	.	.
		
certain	JJ	O
tetracyclic	JJ	O
antidepressants	NNS	G
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
maprotiline	NN	D
-rrb-	-RRB-	O
.	.	.
		
certain	JJ	O
antipsychotic	JJ	O
medications	NNS	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
sertindole	NN	D
-rrb-	-RRB-	O
.	.	.
		
astemizole	NN	D
","	","	O
bepridil	NN	D
","	","	O
sparfloxacin	NN	D
","	","	O
and	CC	O
terodiline	NN	D
.	.	.
		
the	DT	O
preceding	VBG	O
lists	NNS	O
of	IN	O
drugs	NNS	D
are	VBP	O
not	RB	O
comprehensive	JJ	O
.	.	.
		
the	DT	O
acceleration	NN	O
of	IN	O
gastric	JJ	O
emptying	NN	O
by	IN	O
cisapride	NN	D
could	MD	O
affect	VB	O
the	DT	O
rate	NN	O
of	IN	O
absorption	NN	O
of	IN	O
other	JJ	O
drugs	NNS	D
.	.	.
		
patients	NNS	O
receiving	VBG	O
narrow	JJ	O
therapeutic	JJ	O
ratio	NN	O
drugs	NNS	D
or	CC	O
other	JJ	O
drugs	NNS	D
that	WDT	O
require	VBP	O
careful	JJ	O
titration	NN	O
should	MD	O
be	VB	O
followed	VBN	O
closely	RB	O
;	:	O
.	.	.
		
if	IN	O
plasma	NN	O
levels	NNS	O
are	VBP	O
being	VBG	O
monitored	VBN	O
","	","	O
they	PRP	O
should	MD	O
be	VB	O
reassessed	VBN	O
.	.	.
		
administration	NN	O
of	IN	O
0.1-mg	JJ	O
/	:	O
kg	NN	O
-lrb-	-LRB-	O
2	CD	O
x	CC	O
ed95	NN	O
-rrb-	-RRB-	O
nimbex	NN	B
at	IN	O
10	CD	O
%	NN	O
or	CC	O
95	CD	O
%	NN	O
recovery	NN	O
following	VBG	O
an	DT	O
intubating	VBG	O
dose	NN	O
of	IN	O
succinylcholine	NN	D
-lrb-	-LRB-	O
1	CD	O
mg/kg	NN	O
-rrb-	-RRB-	O
produced	VBD	O
95	CD	O
%	NN	O
neuromuscular	JJ	O
block	NN	O
.	.	.
		
the	DT	O
time	NN	O
to	TO	O
onset	NN	O
of	IN	O
maximum	NN	O
block	NN	O
following	VBG	O
nimbex	NNP	B
is	VBZ	O
approximately	RB	O
2	CD	O
minutes	NNS	O
faster	RBR	O
with	IN	O
prior	JJ	O
administration	NN	O
of	IN	O
succinylcholine	NN	D
.	.	.
		
prior	RB	O
administration	NN	O
of	IN	O
succinylcholine	NN	D
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
neuromuscular	JJ	O
block	NN	O
following	VBG	O
initial	JJ	O
or	CC	O
maintenance	NN	O
bolus	NN	O
doses	NNS	O
of	IN	O
nimbex	NNP	B
.	.	.
		
infusion	NN	O
requirements	NNS	O
of	IN	O
nimbex	NNP	B
in	IN	O
patients	NNS	O
administered	VBN	O
succinylcholine	NN	D
prior	RB	O
to	TO	O
infusions	NNS	O
of	IN	O
nimbex	NNP	B
were	VBD	O
comparable	JJ	O
to	TO	O
or	CC	O
slightly	RB	O
greater	JJR	O
than	IN	O
when	WRB	O
succinylcholine	NN	D
was	VBD	O
not	RB	O
administered	VBN	O
.	.	.
		
the	DT	O
use	NN	O
of	IN	O
nimbex	NN	B
before	IN	O
succinylcholine	NN	D
to	TO	O
attenuate	VB	O
some	DT	O
of	IN	O
the	DT	O
side	JJ	O
effects	NNS	O
of	IN	O
succinylcholine	NN	D
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	.
		
although	IN	O
not	RB	O
studied	VBN	O
systematically	RB	O
in	IN	O
clinical	JJ	O
trials	NNS	O
","	","	O
no	DT	O
drug	NN	D
interactions	NNS	O
were	VBD	O
observed	VBN	O
when	WRB	O
vecuronium	NN	D
","	","	O
pancuronium	NN	D
","	","	O
or	CC	O
atracurium	NN	D
were	VBD	O
administered	VBN	O
following	VBG	O
varying	VBG	O
degrees	NNS	O
of	IN	O
recovery	NN	O
from	IN	O
single	JJ	O
doses	NNS	O
or	CC	O
infusions	NNS	O
of	IN	O
nimbex	NNP	B
.	.	.
		
isoflurane	NN	D
or	CC	O
enflurane	NN	D
administered	VBN	O
with	IN	O
nitrous	JJ	O
oxide/oxygen	NN	O
to	TO	O
achieve	VB	O
1.25	CD	O
mac	NNP	O
-lsb-	-LRB-	O
minimum	NNP	O
alveolar	JJ	O
concentration	NN	O
-rsb-	-RRB-	O
may	MD	O
prolong	VB	O
the	DT	O
clinically	RB	O
effective	JJ	O
duration	NN	O
of	IN	O
action	NN	O
of	IN	O
initial	JJ	O
and	CC	O
maintenance	NN	O
doses	NNS	O
of	IN	O
nimbex	NNP	B
and	CC	O
decrease	VB	O
the	DT	O
required	VBN	O
infusion	NN	O
rate	NN	O
of	IN	O
nimbex	NNP	B
.	.	.
		
the	DT	O
magnitude	NN	O
of	IN	O
these	DT	O
effects	NNS	O
may	MD	O
depend	VB	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
administration	NN	O
of	IN	O
the	DT	O
volatile	JJ	O
agents	NNS	O
.	.	.
		
fifteen	CD	O
to	TO	O
30	CD	O
minutes	NNS	O
of	IN	O
exposure	NN	O
to	TO	O
1.25	CD	O
mac	NNP	O
isoflurane	NN	D
or	CC	O
enflurane	NN	D
had	VBD	O
minimal	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
action	NN	O
of	IN	O
initial	JJ	O
doses	NNS	O
of	IN	O
nimbex	NNP	B
and	CC	O
therefore	RB	O
","	","	O
no	DT	O
adjustment	NN	O
to	TO	O
the	DT	O
initial	JJ	O
dose	NN	O
should	MD	O
be	VB	O
necessary	JJ	O
when	WRB	O
nimbex	NNP	B
is	VBZ	O
administered	VBN	O
shortly	RB	O
after	IN	O
initiation	NN	O
of	IN	O
volatile	JJ	O
agents	NNS	O
.	.	.
		
in	IN	O
long	JJ	O
surgical	JJ	O
procedures	NNS	O
during	IN	O
enflurane	NN	D
or	CC	O
isoflurane	NN	D
anesthesia	NN	D
","	","	O
less	JJR	O
frequent	JJ	O
maintenance	NN	O
dosing	NN	O
","	","	O
lower	JJR	O
maintenance	NN	O
doses	NNS	O
","	","	O
or	CC	O
reduced	VBN	O
infusion	NN	O
rates	NNS	O
of	IN	O
nimbex	NNP	B
may	MD	O
be	VB	O
necessary	JJ	O
.	.	.
		
the	DT	O
average	JJ	O
infusion	NN	O
rate	NN	O
requirement	NN	O
may	MD	O
be	VB	O
decreased	VBN	O
by	IN	O
as	RB	O
much	JJ	O
as	IN	O
30	CD	O
%	NN	O
to	TO	O
40	CD	O
%	NN	O
.	.	.
		
in	IN	O
clinical	JJ	O
studies	NNS	O
propofol	NN	D
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
duration	NN	O
of	IN	O
action	NN	O
or	CC	O
dosing	NN	O
requirements	NNS	O
for	IN	O
nimbex	NNP	B
.	.	.
		
other	JJ	O
drugs	NNS	D
which	WDT	O
may	MD	O
enhance	VB	O
the	DT	O
neuromuscular	JJ	O
blocking	VBG	O
action	NN	O
of	IN	O
nondepolarizing	JJ	O
agents	NNS	O
such	JJ	O
as	IN	O
nimbex	NNP	B
include	VBP	O
certain	JJ	O
antibiotics	NNS	G
-lrb-	-LRB-	O
e.	FW	O
g.	FW	O
","	","	O
aminoglycosides	NNS	G
","	","	O
tetracyclines	NNS	G
","	","	O
bacitracin	NN	D
","	","	O
polymyxins	NNS	G
","	","	O
lincomycin	NN	D
","	","	O
clindamycin	NN	D
","	","	O
colistin	NN	D
","	","	O
and	CC	O
sodium	NN	O
colistemethate	NN	O
-rrb-	-RRB-	O
","	","	O
magnesium	NN	D
salts	NNS	O
","	","	O
lithium	NN	D
","	","	O
local	JJ	O
anesthetics	NNS	G
","	","	O
procainamide	NN	D
","	","	O
and	CC	O
quinidine	NN	D
.	.	.
		
resistance	NN	O
to	TO	O
the	DT	O
neuromuscular	JJ	O
blocking	VBG	O
action	NN	O
of	IN	O
nondepolarizing	JJ	O
neuromuscular	JJ	O
blocking	VBG	O
agents	NNS	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
in	IN	O
patients	NNS	O
chronically	RB	O
administered	VBN	O
phenytoin	NN	D
or	CC	O
carbamazepine	NN	D
.	.	.
		
while	IN	O
the	DT	O
effects	NNS	O
of	IN	O
chronic	JJ	O
phenytoin	NN	D
or	CC	O
carbamazepine	NN	D
therapy	NN	O
on	IN	O
the	DT	O
action	NN	O
of	IN	O
nimbex	NNP	B
are	VBP	O
unknown	JJ	O
","	","	O
slightly	RB	O
shorter	JJR	O
durations	NNS	O
of	IN	O
neuromuscular	JJ	O
block	NN	O
may	MD	O
be	VB	O
anticipated	VBN	O
and	CC	O
infusion	NN	O
rate	NN	O
requirements	NNS	O
may	MD	O
be	VB	O
higher	JJR	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
none	NN	O
known	VBN	O
.	.	.
		
plasma	NN	O
levels	NNS	O
of	IN	O
anticonvulsant	JJ	O
agents	NNS	O
may	MD	O
become	VB	O
subtherapeutic	JJ	O
during	IN	O
cisplatin	NN	D
therapy	NN	O
.	.	.
		
central	NNP	O
nervous	JJ	O
system	NN	O
depressant	NN	O
-lrb-	-LRB-	O
cns	NN	O
-rrb-	-RRB-	O
drugs	NNS	D
including	VBG	O
alcohol	NN	D
","	","	O
antidepressants	NNS	G
","	","	O
antihistamines	NNS	G
","	","	O
antipsychotics	NNS	G
","	","	O
blood	NN	O
pressure	NN	O
medications	NNS	O
-lrb-	-LRB-	O
reserpine	NN	D
","	","	O
methyldopa	NN	D
","	","	O
beta-blockers	NNS	G
-rrb-	-RRB-	O
","	","	O
motion	NN	O
sickness	NN	O
medications	NNS	O
","	","	O
muscle	NN	O
relaxants	NNS	O
","	","	O
narcotics	NNS	G
","	","	O
sedatives	NNS	G
","	","	O
sleeping	VBG	O
pills	NNS	O
and	CC	O
tranquilizer	NN	O
.	.	.
		
there	EX	O
are	VBP	O
no	RB	O
known	VBN	O
drug	NN	D
interactions	NNS	O
with	IN	O
leustatin	NNP	B
injection	NN	O
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
if	IN	O
leustatin	NNP	B
injection	NN	O
is	VBZ	O
administered	VBN	O
before	RB	O
","	","	O
after	IN	O
","	","	O
or	CC	O
in	IN	O
conjunction	NN	O
with	IN	O
other	JJ	O
drugs	NNS	D
known	VBN	O
to	TO	O
cause	VB	O
immunosuppression	NN	O
or	CC	O
myelosuppression	NN	O
.	.	.
		
the	DT	O
concurrent	JJ	O
administration	NN	O
of	IN	O
allopurinol	NN	D
and	CC	O
ampicillin	NN	D
increases	NNS	O
substantially	RB	O
the	DT	O
incidence	NN	O
of	IN	O
rashes	NNS	O
in	IN	O
patients	NNS	O
receiving	VBG	O
both	CC	O
drugs	NNS	D
as	IN	O
compared	VBN	O
to	TO	O
patients	NNS	O
receiving	VBG	O
ampicillin	NN	D
alone	RB	O
.	.	.
		
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
this	DT	O
potentiation	NN	O
of	IN	O
ampicillin	NN	D
rashes	NNS	O
is	VBZ	O
due	JJ	O
to	TO	O
allopurinol	NN	D
or	CC	O
the	DT	O
hyperuricemia	NN	O
present	JJ	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	.
		
in	IN	O
controlled	JJ	O
clinical	JJ	O
trials	NNS	O
of	IN	O
augmentin	NNP	O
xr	NNP	O
","	","	O
22	CD	O
patients	NNS	O
received	VBD	O
concomitant	JJ	O
allopurinol	NN	D
and	CC	O
augmentin	NNP	O
xr	NNP	O
.	.	.
		
no	DT	O
rashes	NNS	O
were	VBD	O
reported	VBN	O
in	IN	O
these	DT	O
patients	NNS	O
.	.	.
		
however	RB	O
","	","	O
this	DT	O
sample	NN	O
size	NN	O
is	VBZ	O
too	RB	O
small	JJ	O
to	TO	O
allow	VB	O
for	IN	O
any	DT	O
conclusions	NNS	O
to	TO	O
be	VB	O
drawn	VBN	O
regarding	VBG	O
the	DT	O
risk	NN	O
of	IN	O
rashes	NNS	O
with	IN	O
concomitant	JJ	O
augmentin	NNP	O
xr	NN	O
and	CC	O
allopurinol	NN	D
use	NN	O
.	.	.
		
in	IN	O
common	JJ	O
with	IN	O
other	JJ	O
broad-spectrum	JJ	O
antibiotics	NNS	G
","	","	O
augmentin	NNP	O
xr	NNP	O
may	MD	O
reduce	VB	O
the	DT	O
efficacy	NN	O
of	IN	O
oral	JJ	O
contraceptive	NN	O
.	.	.
		
additive	JJ	O
cns	NN	O
depression	NN	O
may	MD	O
occur	VB	O
when	WRB	O
antihistamines	NNS	G
are	VBP	O
administered	VBN	O
concomitantly	RB	O
with	IN	O
other	JJ	O
cns	NN	O
depressants	NNS	O
including	VBG	O
barbiturates	NNS	G
","	","	O
tranquilizers	NNS	G
","	","	O
and	CC	O
alcohol	NN	D
.	.	.
		
patients	NNS	O
receiving	VBG	O
antihistamines	NNS	G
should	MD	O
be	VB	O
advised	VBN	O
against	IN	O
the	DT	O
concurrent	JJ	O
use	NN	O
of	IN	O
other	JJ	O
cns	NNS	O
depressant	NN	O
drugs	NNS	D
.	.	.
		
monoamine	NN	O
oxidase	NN	O
-lrb-	-LRB-	O
mao	NN	O
-rrb-	-RRB-	O
inhibitors	NNS	O
prolong	VB	O
and	CC	O
intensify	VB	O
the	DT	O
anticholinergic	JJ	G
effects	NNS	O
of	IN	O
antihistamines	NNS	G
.	.	.
		
amantadine	NNP	D
","	","	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
and	CC	O
maois	NNS	G
may	MD	O
increase	VB	O
anticholinergic	JJ	G
effect	NN	O
of	IN	O
clidinium	NN	D
.	.	.
		
clidinium	NNP	D
may	MD	O
decrease	VB	O
the	DT	O
effect	NN	O
of	IN	O
phenothiazines	NNS	G
","	","	O
levodopa	NN	D
","	","	O
and	CC	O
ketoconazole	NN	D
.	.	.
		
clindamycin	NNP	D
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
have	VB	O
neuromuscular	JJ	O
blocking	VBG	O
properties	NNS	O
that	WDT	O
may	MD	O
enhance	VB	O
the	DT	O
action	NN	O
of	IN	O
other	JJ	O
neuromuscular	JJ	O
blocking	VBG	O
agents	NNS	O
.	.	.
		
therefore	RB	O
","	","	O
it	PRP	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
such	JJ	O
agents	NNS	O
.	.	.
		
antagonism	NN	O
has	VBZ	O
been	VBN	O
demonstrated	VBN	O
between	IN	O
clindamycin	NN	D
and	CC	O
erythromycin	NN	D
in	FW	O
vitro	FW	O
.	.	.
		
because	IN	O
of	IN	O
possible	JJ	O
clinical	JJ	O
significance	NN	O
","	","	O
these	DT	O
two	CD	O
drugs	NNS	D
should	MD	O
not	RB	O
be	VB	O
administered	VBN	O
concurrently	RB	O
.	.	.
		
alcohol	NN	D
-lrb-	-LRB-	O
increases	NNS	O
bioavailability	NN	O
by	IN	O
50	CD	O
%	NN	O
-rrb-	-RRB-	O
","	","	O
cimetidine	NN	D
","	","	O
and	CC	O
valproates	NNS	O
.	.	.
		
no	DT	O
separate	JJ	O
information	NN	O
available	JJ	O
.	.	.
		
although	IN	O
no	DT	O
clinical	JJ	O
drug-drug	JJ	O
interaction	NN	O
studies	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
to	TO	O
date	NN	O
","	","	O
on	IN	O
the	DT	O
basis	NN	O
of	IN	O
the	DT	O
in	FW	O
vitro	FW	O
studies	NNS	O
","	","	O
cytochrome	NN	O
p450	NN	O
inhibitors	NNS	O
and	CC	O
inducers	NNS	O
are	VBP	O
unlikely	JJ	O
to	TO	O
affect	VB	O
the	DT	O
metabolism	NN	O
of	IN	O
clofarabine	NN	D
.	.	.
		
the	DT	O
effect	NN	O
of	IN	O
clofarabine	NN	D
on	IN	O
the	DT	O
metabolism	NN	O
of	IN	O
cytochrome	NN	O
p450	NN	O
substrates	NNS	O
has	VBZ	O
not	RB	O
been	VBN	O
studied	VBN	O
.	.	.
		
drug/laboratory	NNP	O
tests	NNP	O
interactions	NNS	O
there	EX	O
are	VBP	O
no	DT	O
known	JJ	O
clinically	RB	O
significant	JJ	O
interactions	NNS	O
of	IN	O
clolar	NN	B
with	IN	O
other	JJ	O
medications	NNS	O
or	CC	O
laboratory	NN	O
tests	NNS	O
.	.	.
		
no	DT	O
formal	JJ	O
drug/laboratory	JJ	O
test	NN	O
interaction	NN	O
studies	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
with	IN	O
clolar	NN	B
.	.	.
		
preliminary	JJ	O
data	NNS	O
which	WDT	O
suggest	VBP	O
that	IN	O
dapsone	NN	D
may	MD	O
inhibit	VB	O
the	DT	O
anti-inflammatory	JJ	O
activity	NN	O
of	IN	O
lamprene	NNP	B
have	VBP	O
not	RB	O
been	VBN	O
confirmed	VBN	O
.	.	.
		
if	IN	O
leprosy-associated	JJ	O
inflammatory	JJ	O
reactions	NNS	O
develop	VBP	O
in	IN	O
patients	NNS	O
being	VBG	O
treated	VBN	O
with	IN	O
dapsone	NN	D
and	CC	O
clofazimine	NN	D
","	","	O
it	PRP	O
is	VBZ	O
still	RB	O
advisable	JJ	O
to	TO	O
continue	VB	O
treatment	NN	O
with	IN	O
both	CC	O
drugs	NNS	D
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
anticoagulants	NNS	G
are	VBP	O
given	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
atromid-s	NN	B
.	.	.
		
usually	RB	O
","	","	O
the	DT	O
dosage	NN	O
of	IN	O
the	DT	O
anticoagulant	NN	G
should	MD	O
be	VB	O
reduced	VBN	O
by	IN	O
one-half	NN	O
-lrb-	-LRB-	O
depending	VBG	O
on	IN	O
the	DT	O
individual	JJ	O
case	NN	O
-rrb-	-RRB-	O
to	TO	O
maintain	VB	O
the	DT	O
prothrombin	NN	O
time	NN	O
at	IN	O
the	DT	O
desired	VBN	O
level	NN	O
to	TO	O
prevent	VB	O
bleeding	JJ	O
complications	NNS	O
.	.	.
		
frequent	JJ	O
prothrombin	NN	O
determinations	NNS	O
are	VBP	O
advisable	JJ	O
until	IN	O
it	PRP	O
has	VBZ	O
been	VBN	O
determined	VBN	O
definitely	RB	O
that	IN	O
the	DT	O
prothrombin	NN	O
level	NN	O
has	VBZ	O
been	VBN	O
stabilized	VBN	O
.	.	.
		
atromid-s	NN	B
may	MD	O
displace	VB	O
acidic	JJ	O
drugs	NNS	D
such	JJ	O
as	IN	O
phenytoin	NN	D
or	CC	O
tolbutamide	NN	D
from	IN	O
their	PRP$	O
binding	NN	O
sites	NNS	O
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
treating	VBG	O
patients	NNS	O
with	IN	O
either	DT	O
of	IN	O
these	DT	O
drugs	NNS	D
or	CC	O
other	JJ	O
highly	RB	O
protein-bound	JJ	O
drugs	NNS	D
and	CC	O
atromid-s	NN	B
.	.	.
		
the	DT	O
hypoglycemic	JJ	O
effect	NN	O
of	IN	O
tolbutamide	NN	D
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
increase	VB	O
when	WRB	O
atromid-s	NN	B
is	VBZ	O
given	VBN	O
concurrently	RB	O
.	.	.
		
fulminant	JJ	O
rhabdomyolysis	NN	O
has	VBZ	O
been	VBN	O
seen	VBN	O
as	IN	O
early	JJ	O
as	IN	O
three	CD	O
weeks	NNS	O
after	IN	O
initiation	NN	O
of	IN	O
combined	JJ	O
therapy	NN	O
with	IN	O
another	DT	O
fibrate	NN	G
and	CC	O
lovastatin	NN	D
but	CC	O
may	MD	O
be	VB	O
seen	VBN	O
after	IN	O
several	JJ	O
months	NNS	O
.	.	.
		
for	IN	O
these	DT	O
reasons	NNS	O
","	","	O
it	PRP	O
is	VBZ	O
felt	VBN	O
that	IN	O
","	","	O
in	IN	O
most	JJS	O
subjects	NNS	O
who	WP	O
have	VBP	O
had	VBD	O
an	DT	O
unsatisfactory	JJ	O
lipid	NN	O
response	NN	O
to	TO	O
either	CC	O
drug	NN	D
alone	RB	O
","	","	O
the	DT	O
possible	JJ	O
benefits	NNS	O
of	IN	O
combined	JJ	O
therapy	NN	O
with	IN	O
lovastatin	NN	D
and	CC	O
a	DT	O
fibrate	NN	G
do	VBP	O
not	RB	O
outweigh	VB	O
the	DT	O
risks	NNS	O
of	IN	O
severe	JJ	O
myopathy	NN	O
","	","	O
rhabdomyolysis	NN	O
","	","	O
and	CC	O
acute	JJ	O
renal	JJ	O
failure	NN	O
.	.	.
		
while	IN	O
it	PRP	O
is	VBZ	O
not	RB	O
known	VBN	O
whether	IN	O
this	DT	O
interaction	NN	O
occurs	VBZ	O
with	IN	O
fibrates	NNS	G
other	JJ	O
than	IN	O
gemfibrozil	NN	D
","	","	O
myopathy	NN	O
and	CC	O
rhabdomyolysis	NN	O
have	VBP	O
occasionally	RB	O
been	VBN	O
associated	VBN	O
with	IN	O
the	DT	O
use	NN	O
of	IN	O
fibrates	NNS	G
alone	RB	O
","	","	O
including	VBG	O
clofibrate	NN	D
.	.	.
		
therefore	RB	O
","	","	O
the	DT	O
combined	VBN	O
use	NN	O
of	IN	O
lovastatin	NN	D
with	IN	O
fibrates	NNS	G
should	MD	O
generally	RB	O
be	VB	O
avoided	VBN	O
.	.	.
		
drug	NN	O
interactions	NNS	O
with	IN	O
clomiphene	NN	O
citrate	NN	O
tablets	NNS	O
usp	NNP	O
have	VBP	O
not	RB	O
been	VBN	O
documented	VBN	O
.	.	.
		
the	DT	O
risks	NNS	O
of	IN	O
using	VBG	O
anafranil	NNP	B
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
drugs	NNS	D
have	VBP	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
.	.	.
		
given	VBN	O
the	DT	O
primary	JJ	O
cns	NN	O
effects	NNS	O
of	IN	O
anafranil	NNP	B
","	","	O
caution	NN	O
is	VBZ	O
advised	VBN	O
in	IN	O
using	VBG	O
it	PRP	O
concomitantly	RB	O
with	IN	O
other	JJ	O
cns-active	JJ	O
drugs	NNS	D
.	.	.
		
anafranil	NNP	B
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
with	IN	O
mao	NN	O
inhibitors	NNS	O
.	.	.
		
close	JJ	O
supervision	NN	O
and	CC	O
careful	JJ	O
adjustment	NN	O
of	IN	O
dosage	NN	O
are	VBP	O
required	VBN	O
when	WRB	O
anafranil	NNP	B
is	VBZ	O
administered	VBN	O
with	IN	O
anticholinergic	JJ	G
or	CC	O
sympathomimetic	JJ	D
drugs	NNS	D
.	.	.
		
several	JJ	O
tricyclic	JJ	O
antidepressants	NNS	G
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
block	VB	O
the	DT	O
pharmacologic	JJ	O
effects	NNS	O
of	IN	O
guanethidine	NN	D
","	","	O
clonidine	NN	D
","	","	O
or	CC	O
similar	JJ	O
agents	NNS	O
","	","	O
and	CC	O
such	PDT	O
an	DT	O
effect	NN	O
may	MD	O
be	VB	O
anticipated	VBN	O
with	IN	O
cmi	NN	D
because	IN	O
of	IN	O
its	PRP$	O
structural	JJ	O
similarity	NN	O
to	TO	O
other	JJ	O
tricyclic	JJ	O
antidepressants	NNS	G
.	.	.
		
the	DT	O
plasma	NN	O
concentration	NN	O
of	IN	O
cmi	NNP	D
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
increased	VBN	O
by	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
haloperidol	NN	D
.	.	.
		
plasma	NN	O
levels	NNS	O
of	IN	O
several	JJ	O
closely	RB	O
related	JJ	O
tricyclic	JJ	O
antidepressants	NNS	G
have	VBP	O
been	VBN	O
reported	VBN	O
to	TO	O
be	VB	O
increased	VBN	O
by	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
methylphenidate	NN	D
or	CC	O
hepatic	JJ	O
enzyme	NN	O
inhibitors	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
cimetidine	NN	D
","	","	O
fluoxetine	NN	D
-rrb-	-RRB-	O
and	CC	O
decreased	VBN	O
by	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
hepatic	JJ	O
enzyme	NN	O
inducers	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
barbiturates	NNS	G
","	","	O
phenytoin	NN	D
-rrb-	-RRB-	O
","	","	O
and	CC	O
such	PDT	O
an	DT	O
effect	NN	O
may	MD	O
be	VB	O
anticipated	VBN	O
with	IN	O
cmi	NNP	D
as	RB	O
well	RB	O
.	.	.
		
administration	NN	O
of	IN	O
cmi	NNP	D
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
increase	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
phenobarbital	NN	D
","	","	O
if	IN	O
given	VBN	O
concomitantly	RB	O
.	.	.
		
drugs	NNS	O
metabolized	VBN	O
by	IN	O
p450	NN	O
2d6	NN	O
:	:	O
the	DT	O
biochemical	JJ	O
activity	NN	O
of	IN	O
the	DT	O
drug	NN	D
metabolizing	VBG	O
isozyme	NN	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
-lrb-	-LRB-	O
debrisoquin	NN	D
hydroxylase	NN	O
-rrb-	-RRB-	O
is	VBZ	O
reduced	VBN	O
in	IN	O
a	DT	O
subset	NN	O
of	IN	O
the	DT	O
aucasian	JJ	O
population	NN	O
-lrb-	-LRB-	O
about	IN	O
7	CD	O
%	NN	O
-10	CD	O
%	NN	O
of	IN	O
caucasians	NNPS	O
are	VBP	O
so-called	JJ	O
poor	JJ	O
metabolizers	NNS	O
-rrb-	-RRB-	O
;	:	O
.	.	.
		
reliable	JJ	O
estimates	NNS	O
of	IN	O
the	DT	O
prevalence	NN	O
of	IN	O
reduced	VBN	O
p450	NN	O
2d6	NN	O
isozyme	NN	O
activity	NN	O
among	IN	O
asian	JJ	O
","	","	O
african	JJ	O
and	CC	O
other	JJ	O
populations	NNS	O
are	VBP	O
not	RB	O
yet	RB	O
available	JJ	O
.	.	.
		
poor	NNP	O
metabolizers	NNS	O
have	VBP	O
higher	JJR	O
than	IN	O
expected	VBN	O
lasma	NN	O
concentrations	NNS	O
of	IN	O
tricyclic	JJ	O
antidepressants	NNS	G
-lrb-	-LRB-	O
tcas	NNS	G
-rrb-	-RRB-	O
when	WRB	O
given	VBN	O
usual	JJ	O
doses	NNS	O
.	.	.
		
depending	VBG	O
on	IN	O
the	DT	O
fraction	NN	O
of	IN	O
drug	NN	D
metabolized	VBN	O
by	IN	O
p450	NN	O
2d6	NN	O
","	","	O
the	DT	O
increase	NN	O
in	IN	O
plasma	NN	O
concentration	NN	O
may	MD	O
be	VB	O
small	JJ	O
","	","	O
or	CC	O
quite	RB	O
large	JJ	O
-lrb-	-LRB-	O
8	CD	O
fold	JJ	O
increase	NN	O
in	IN	O
plasma	NN	O
auc	NN	O
of	IN	O
the	DT	O
tca	NNP	G
-rrb-	-RRB-	O
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
certain	JJ	O
drugs	NNS	D
inhibit	VBP	O
the	DT	O
activity	NN	O
of	IN	O
this	DT	O
isozyme	NN	O
and	CC	O
make	VB	O
normal	JJ	O
metabolizers	NNS	O
resemble	VBP	O
poor	JJ	O
metabolizers	NNS	O
.	.	.
		
an	DT	O
individual	NN	O
who	WP	O
is	VBZ	O
stable	JJ	O
on	IN	O
a	DT	O
given	VBN	O
dose	NN	O
of	IN	O
tcamay	NN	O
become	VBP	O
abruptly	RB	O
toxic	JJ	O
when	WRB	O
given	VBN	O
one	CD	O
of	IN	O
these	DT	O
inhibiting	VBG	O
drugs	NNS	D
as	IN	O
concomitant	JJ	O
therapy	NN	O
.	.	.
		
the	DT	O
drugs	NNS	D
that	WDT	O
inhibit	VBP	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
include	VBP	O
some	DT	O
that	WDT	O
are	VBP	O
not	RB	O
metabolized	VBN	O
by	IN	O
the	DT	O
enzyme	NN	O
-lrb-	-LRB-	O
quinidine	NN	D
.	.	.
		
cimetidine	NN	D
-rrb-	-RRB-	O
and	CC	O
many	JJ	O
that	WDT	O
are	VBP	O
substrates	NNS	O
for	IN	O
p450	NN	O
2d6	NN	O
-lrb-	-LRB-	O
many	JJ	O
other	JJ	O
antidepressants	NNS	G
","	","	O
phenothiazines	NNS	G
","	","	O
and	CC	O
the	DT	O
type	NN	O
1c	NN	O
antiarrhythmics	NNS	G
propafenone	NN	D
and	CC	O
flecainide	NN	D
-rrb-	-RRB-	O
.	.	.
		
while	IN	O
all	PDT	O
the	DT	O
selective	JJ	O
serotonin	NN	O
reuptake	NN	O
inhibitors	NNS	O
-lrb-	-LRB-	O
ssris	NNS	G
-rrb-	-RRB-	O
","	","	O
e.g.	FW	O
","	","	O
fluoxetine	NN	D
","	","	O
sertraline	NN	D
","	","	O
paroxetine	NN	D
","	","	O
and	CC	O
fluvoxamine	NN	D
","	","	O
inhibit	VBP	O
p450	NN	O
2d6	NN	O
","	","	O
they	PRP	O
may	MD	O
vary	VB	O
in	IN	O
the	DT	O
extent	NN	O
of	IN	O
inhibition	NN	O
.	.	.
		
fluvoxamine	NNP	D
has	VBZ	O
also	RB	O
been	VBN	O
shown	VBN	O
to	TO	O
inhibit	VB	O
p450	NN	O
1a2	NN	O
","	","	O
an	DT	O
isoform	NN	O
also	RB	O
involved	VBN	O
in	IN	O
tcametabolism	NN	O
.	.	.
		
the	DT	O
extent	NN	O
to	TO	O
which	WDT	O
ssri-tcainteractions	NNS	O
may	MD	O
pose	VB	O
clinical	JJ	O
problems	NNS	O
will	MD	O
depend	VB	O
on	IN	O
the	DT	O
degree	NN	O
of	IN	O
inhibition	NN	O
and	CC	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
the	DT	O
ssri	NNP	G
involved	VBN	O
.	.	.
		
nevertheless	RB	O
","	","	O
caution	NN	O
is	VBZ	O
indicated	VBN	O
in	IN	O
the	DT	O
co-administration	NN	O
of	IN	O
tcas	NNS	G
with	IN	O
any	DT	O
of	IN	O
the	DT	O
ssris	NNS	G
and	CC	O
also	RB	O
in	IN	O
switching	NN	O
from	IN	O
one	CD	O
class	NN	O
to	TO	O
the	DT	O
other	JJ	O
.	.	.
		
of	IN	O
particular	JJ	O
importance	NN	O
","	","	O
sufficient	JJ	O
time	NN	O
must	MD	O
elapse	VB	O
before	IN	O
initiating	VBG	O
tcatreatment	NN	O
in	IN	O
a	DT	O
patient	NN	O
being	VBG	O
withdrawn	VBN	O
from	IN	O
fluoxetine	NN	D
","	","	O
given	VBN	O
the	DT	O
long	JJ	O
half-life	NN	O
of	IN	O
the	DT	O
parent	NN	O
and	CC	O
active	JJ	O
metabolite	NN	O
-lrb-	-LRB-	O
at	IN	O
least	JJS	O
5	CD	O
weeks	NNS	O
may	MD	O
be	VB	O
necessary	JJ	O
-rrb-	-RRB-	O
.	.	.
		
concomitant	JJ	O
use	NN	O
of	IN	O
agents	NNS	O
in	IN	O
the	DT	O
tricyclic	JJ	O
antidepressant	JJ	O
class	NN	O
-lrb-	-LRB-	O
which	WDT	O
includes	VBZ	O
anafranil	NNP	B
-rrb-	-RRB-	O
with	IN	O
drugs	NNS	D
that	WDT	O
can	MD	O
inhibit	VB	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
may	MD	O
require	VB	O
lower	JJR	O
doses	NNS	O
than	IN	O
usually	RB	O
prescribed	VBN	O
for	IN	O
either	CC	O
the	DT	O
tricyclic	JJ	O
antidepressant	JJ	O
agent	NN	O
or	CC	O
the	DT	O
other	JJ	O
drug	NN	D
.	.	.
		
furthermore	RB	O
","	","	O
whenever	WRB	O
one	CD	O
of	IN	O
these	DT	O
drugs	NNS	D
is	VBZ	O
withdrawn	VBN	O
from	IN	O
co-therapy	JJ	O
","	","	O
an	DT	O
increased	VBN	O
dose	NN	O
of	IN	O
tricyclic	JJ	O
antidepressant	JJ	O
agent	NN	O
may	MD	O
be	VB	O
required	VBN	O
.	.	.
		
it	PRP	O
is	VBZ	O
desirable	JJ	O
to	TO	O
monitor	VB	O
tcaplasma	NN	O
levels	NNS	O
whenever	WRB	O
an	DT	O
agent	NN	O
of	IN	O
the	DT	O
tricyclic	JJ	O
antidepressant	JJ	O
class	NN	O
including	VBG	O
anafranil	NNP	B
is	VBZ	O
going	VBG	O
to	TO	O
be	VB	O
co-administered	VBN	O
with	IN	O
another	DT	O
drug	NN	D
known	VBN	O
to	TO	O
be	VB	O
an	DT	O
inhibitor	NN	O
of	IN	O
p450	NN	O
2d6	NN	O
-lrb-	-LRB-	O
and/or	CC	O
p450	NN	O
1a2	NN	O
-rrb-	-RRB-	O
.	.	.
		
because	IN	O
anafranil	NNP	B
is	VBZ	O
highly	RB	O
bound	VBN	O
to	TO	O
serum	NN	O
protein	NN	O
","	","	O
the	DT	O
administration	NN	O
of	IN	O
anafranil	NNP	B
to	TO	O
patients	NNS	O
taking	VBG	O
other	JJ	O
drugs	NNS	D
that	WDT	O
are	VBP	O
highly	RB	O
bound	VBN	O
to	TO	O
protein	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
warfarin	NN	D
","	","	O
digoxin	NN	D
-rrb-	-RRB-	O
may	MD	O
cause	VB	O
an	DT	O
increase	NN	O
in	IN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
these	DT	O
drugs	NNS	D
","	","	O
potentially	RB	O
resulting	VBG	O
in	IN	O
adverse	JJ	O
effects	NNS	O
.	.	.
		
conversely	RB	O
","	","	O
adverse	JJ	O
effects	NNS	O
may	MD	O
result	VB	O
from	IN	O
displacement	NN	O
of	IN	O
protein-bound	JJ	O
anafranil	NNP	B
by	IN	O
other	JJ	O
highly	RB	O
bound	VBN	O
drugs	NNS	D
.	.	.
		
effect	NN	O
of	IN	O
clonazepam	NNP	D
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
other	JJ	O
drugs	NNS	O
:	:	O
clonazepam	NN	D
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
alter	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
phenytoin	NN	D
","	","	O
carbamazepine	NN	D
","	","	O
or	CC	O
phenobarbital	NN	D
.	.	.
		
the	DT	O
effect	NN	O
of	IN	O
clonazepam	NN	D
on	IN	O
the	DT	O
metabolism	NN	O
of	IN	O
other	JJ	O
drugs	NNS	D
has	VBZ	O
not	RB	O
been	VBN	O
investigated	VBN	O
.	.	.
		
effect	NN	O
of	IN	O
other	JJ	O
drugs	NNS	O
on	IN	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
clonazepam	NNP	D
:	:	O
literature	NNP	O
reports	NNS	O
suggest	VBP	O
that	IN	O
ranitidine	NN	D
","	","	O
an	DT	O
agent	NN	O
that	WDT	O
decreases	VBZ	O
stomach	NN	O
acidity	NN	O
","	","	O
does	VBZ	O
not	RB	O
greatly	RB	O
alter	VB	O
clonazepam	NN	D
pharmacokinetics	NNS	O
.	.	.
		
in	IN	O
a	DT	O
study	NN	O
in	IN	O
which	WDT	O
the	DT	O
2	CD	O
mg	NN	O
clonazepam	NN	D
orally	RB	O
disintegrating	VBG	O
tablet	NN	O
was	VBD	O
administered	VBN	O
with	IN	O
and	CC	O
without	IN	O
propantheline	NN	D
-lrb-	-LRB-	O
an	DT	O
anticholinergic	JJ	G
agent	NN	O
with	IN	O
multiple	JJ	O
effects	NNS	O
on	IN	O
the	DT	O
gi	NN	O
tract	NN	O
-rrb-	-RRB-	O
to	TO	O
healthy	JJ	O
volunteers	NNS	O
","	","	O
the	DT	O
auc	NN	O
of	IN	O
clonazepam	NN	D
was	VBD	O
10	CD	O
%	NN	O
lower	JJR	O
and	CC	O
the	DT	O
cmax	NN	O
of	IN	O
clonazepam	NN	D
was	VBD	O
20	CD	O
%	NN	O
lower	JJR	O
when	WRB	O
the	DT	O
orally	RB	O
disintegrating	VBG	O
tablet	NN	O
was	VBD	O
given	VBN	O
with	IN	O
propantheline	NN	D
compared	VBN	O
to	TO	O
when	WRB	O
it	PRP	O
was	VBD	O
given	VBN	O
alone	RB	O
.	.	.
		
fluoxetine	NN	D
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
clonazepam	NN	D
.	.	.
		
cytochrome	NN	O
p-450	NN	O
inducers	NNS	O
","	","	O
such	JJ	O
as	IN	O
phenytoin	NN	D
","	","	O
carbamazepine	NN	D
and	CC	O
phenobarbital	NN	D
","	","	O
induce	VBP	O
clonazepam	NN	D
metabolism	NN	O
","	","	O
causing	VBG	O
an	DT	O
approximately	RB	O
30	CD	O
%	NN	O
decrease	NN	O
in	IN	O
plasma	NN	O
clonazepam	NN	D
levels	NNS	O
.	.	.
		
although	IN	O
clinical	JJ	O
studies	NNS	O
have	VBP	O
not	RB	O
been	VBN	O
performed	VBN	O
","	","	O
based	VBN	O
on	IN	O
the	DT	O
involvement	NN	O
of	IN	O
the	DT	O
cytochrome	NN	O
p-450	NN	O
3a	NN	O
family	NN	O
in	IN	O
clonazepam	NN	D
metabolism	NN	O
","	","	O
inhibitors	NNS	O
of	IN	O
this	DT	O
enzyme	NN	O
system	NN	O
","	","	O
notably	RB	O
oral	JJ	O
antifungal	JJ	O
agents	NNS	O
","	","	O
should	MD	O
be	VB	O
used	VBN	O
cautiously	RB	O
in	IN	O
patients	NNS	O
receiving	VBG	O
clonazepam	NN	D
.	.	.
		
pharmacodynamic	JJ	O
interactions	NNS	O
:	:	O
the	DT	O
cns-depressant	JJ	O
action	NN	O
of	IN	O
the	DT	O
benzodiazepine	NN	G
class	NN	O
of	IN	O
drugs	NNS	D
may	MD	O
be	VB	O
potentiated	VBN	O
by	IN	O
alcohol	NN	D
","	","	O
narcotics	NNS	G
","	","	O
barbiturates	NNS	G
","	","	O
nonbarbiturate	JJ	O
hypnotics	NNS	O
","	","	O
antianxiety	JJ	O
agents	NNS	O
","	","	O
the	DT	O
phenothiazines	NNS	G
","	","	O
thioxanthene	NN	O
and	CC	O
butyrophenone	NN	O
classes	NNS	O
of	IN	O
antipsychotic	JJ	O
agents	NNS	O
","	","	O
monoamine	NN	O
oxidase	NN	O
inhibitors	NNS	O
and	CC	O
the	DT	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
and	CC	O
by	IN	O
other	JJ	O
anticonvulsant	JJ	O
drugs	NNS	D
.	.	.
		
tablet	NNP	O
if	IN	O
a	DT	O
patient	NN	O
receiving	VBG	O
clonidine	NN	D
hydrochloride	NN	O
is	VBZ	O
also	RB	O
taking	VBG	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
the	DT	O
effect	NN	O
of	IN	O
clonidine	NN	D
may	MD	O
be	VB	O
reduced	VBN	O
","	","	O
thus	RB	O
necessitating	VBG	O
an	DT	O
increase	NN	O
in	IN	O
dosage	NN	O
.	.	.
		
clonidine	NN	D
hydrochloride	NN	O
may	MD	O
enhance	VB	O
the	DT	O
cns-depressive	JJ	O
effects	NNS	O
of	IN	O
alcohol	NN	D
","	","	O
barbiturates	NNS	G
or	CC	O
other	JJ	O
sedatives	NNS	G
.	.	.
		
amitriptyline	NNP	D
in	IN	O
combination	NN	O
with	IN	O
clonidine	NN	D
enhances	VBZ	O
the	DT	O
manifestation	NN	O
of	IN	O
corneal	NN	O
lesions	NNS	O
in	IN	O
rats	NNS	O
epidural	JJ	O
injection	NN	O
clonidine	NN	D
may	MD	O
potentiate	VB	O
the	DT	O
cns-depressive	JJ	O
effect	NN	O
of	IN	O
alcohol	NN	D
","	","	O
barbiturates	NNS	G
or	CC	O
other	JJ	O
sedating	VBG	O
drugs	NNS	D
.	.	.
		
narcotic	JJ	O
analgesics	NNS	G
may	MD	O
potentiate	VB	O
the	DT	O
hypotensive	JJ	O
effects	NNS	O
of	IN	O
clonidine	NN	D
.	.	.
		
tricyclic	JJ	O
antidepressants	NNS	G
may	MD	O
antagonize	VB	O
the	DT	O
hypotensive	JJ	O
effects	NNS	O
of	IN	O
clonidine	NN	D
.	.	.
		
the	DT	O
effects	NNS	O
of	IN	O
tricyclic	JJ	O
antidepressants	NNS	G
on	IN	O
clonidines	NNS	O
analgesic	JJ	O
actions	NNS	O
are	VBP	O
not	RB	O
known	VBN	O
.	.	.
		
beta	NN	O
blockers	NNS	O
may	MD	O
exacerbate	VB	O
the	DT	O
hypertensive	JJ	O
response	NN	O
seen	VBN	O
with	IN	O
clonidine	NN	D
withdrawl	NN	O
.	.	.
		
also	RB	O
","	","	O
due	JJ	O
to	TO	O
the	DT	O
potential	NN	O
for	IN	O
additive	JJ	O
effects	NNS	O
such	JJ	O
as	IN	O
bradycardia	NN	O
and	CC	O
av	NN	O
block	NN	O
","	","	O
caution	NN	O
is	VBZ	O
warranted	VBN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
clonidine	NN	D
with	IN	O
agents	NNS	O
known	VBN	O
to	TO	O
affect	VB	O
sinus	NN	O
node	NN	O
function	NN	O
or	CC	O
av	NN	O
nodal	JJ	O
conduction	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
digitalis	NN	G
","	","	O
calcium	NN	D
channel	NN	O
blockers	NNS	O
","	","	O
and	CC	O
beta-blockers	NNS	G
.	.	.
		
there	EX	O
is	VBZ	O
one	CD	O
reported	VBD	O
case	NN	O
of	IN	O
a	DT	O
patient	NN	O
with	IN	O
acute	JJ	O
delirium	NN	O
associated	VBN	O
with	IN	O
the	DT	O
simultaneous	JJ	O
use	NN	O
of	IN	O
fluphenazine	NN	D
and	CC	O
oral	JJ	O
clonidine	NN	D
.	.	.
		
symptoms	NNS	O
resolved	VBN	O
when	WRB	O
clonidine	NN	D
was	VBD	O
withdrawn	VBN	O
and	CC	O
recurred	VBN	O
when	WRB	O
the	DT	O
patient	NN	O
was	VBD	O
rechallenged	VBN	O
with	IN	O
clonidine	NN	D
.	.	.
		
epidural	JJ	O
clonidine	NN	D
may	MD	O
prolong	VB	O
the	DT	O
duration	NN	O
of	IN	O
pharmacologic	JJ	O
effects	NNS	O
of	IN	O
epidural	JJ	O
local	JJ	O
anesthetics	NNS	G
","	","	O
including	VBG	O
both	DT	O
sensory	JJ	O
and	CC	O
motor	NN	O
blockade	NN	O
.	.	.
		
aspirin	NN	B
","	","	O
warfarin	NN	D
","	","	O
heparin	NN	D
","	","	O
nsaid	NN	O
if	IN	O
tranxene	NN	B
is	VBZ	O
to	TO	O
be	VB	O
combined	VBN	O
with	IN	O
other	JJ	O
drugs	NNS	D
acting	VBG	O
on	IN	O
the	DT	O
central	JJ	O
nervous	JJ	O
system	NN	O
","	","	O
careful	JJ	O
consideration	NN	O
should	MD	O
be	VB	O
given	VBN	O
to	TO	O
the	DT	O
pharmacology	NN	O
of	IN	O
the	DT	O
agents	NNS	O
to	TO	O
be	VB	O
employed	VBN	O
.	.	.
		
animal	NN	O
experience	NN	O
indicates	VBZ	O
that	IN	O
clorazepate	NN	O
dipotassium	NN	O
prolongs	VBZ	O
the	DT	O
sleeping	VBG	O
time	NN	O
after	IN	O
hexobarbital	JJ	D
or	CC	O
after	IN	O
ethyl	NN	O
alcohol	NN	D
","	","	O
increases	VBZ	O
the	DT	O
inhibitory	JJ	O
effects	NNS	O
of	IN	O
chlorpromazine	NN	D
","	","	O
but	CC	O
does	VBZ	O
not	RB	O
exhibit	VB	O
monoamine	NN	O
oxidase	NN	O
inhibition	NN	O
.	.	.
		
clinical	JJ	O
studies	NNS	O
have	VBP	O
shown	VBN	O
increased	VBN	O
sedation	NN	O
with	IN	O
concurrent	JJ	O
hypnotic	JJ	O
medications	NNS	O
.	.	.
		
the	DT	O
actions	NNS	O
of	IN	O
the	DT	O
benzodiazepines	NNS	G
may	MD	O
be	VB	O
potentiated	VBN	O
by	IN	O
barbiturates	NNS	G
","	","	O
narcotics	NNS	G
","	","	O
phenothiazines	NNS	G
","	","	O
monoamine	NN	O
oxidase	NN	O
inhibitors	NNS	O
or	CC	O
other	JJ	O
antidepressants	NNS	G
.	.	.
		
if	IN	O
tranxene	NN	B
tablets	NNS	O
are	VBP	O
used	VBN	O
to	TO	O
treat	VB	O
anxiety	NN	O
associated	VBN	O
with	IN	O
somatic	JJ	O
disease	NN	O
states	NNS	O
","	","	O
careful	JJ	O
attention	NN	O
must	MD	O
be	VB	O
paid	VBN	O
to	TO	O
possible	JJ	O
drug	NN	D
interaction	NN	O
with	IN	O
concomitant	JJ	O
medication	NN	O
.	.	.
		
in	IN	O
bioavailability	NN	O
studies	NNS	O
with	IN	O
normal	JJ	O
subjects	NNS	O
","	","	O
the	DT	O
concurrent	JJ	O
administration	NN	O
of	IN	O
antacids	NNS	G
at	IN	O
therapeutic	JJ	O
levels	NNS	O
did	VBD	O
not	RB	O
significantly	RB	O
influence	VB	O
the	DT	O
bioavailability	NN	O
of	IN	O
tranxene	NNP	B
tablets	NNS	O
.	.	.
		
the	DT	O
risks	NNS	O
of	IN	O
using	VBG	O
clozapine	NNP	D
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
drugs	NNS	D
have	VBP	O
not	RB	O
been	VBN	O
systematically	RB	O
evaluated	VBN	O
.	.	.
		
pharmacodynamic-related	JJ	O
interactions	NNS	O
:	:	O
the	DT	O
mechanism	NN	O
of	IN	O
clozapine	NN	D
induced	VBD	O
agranulocytosis	NN	O
is	VBZ	O
unknown	JJ	O
.	.	.
		
nonetheless	RB	O
","	","	O
the	DT	O
possibility	NN	O
that	IN	O
causative	JJ	O
factors	NNS	O
may	MD	O
interact	VB	O
synergistically	RB	O
to	TO	O
increase	VB	O
the	DT	O
risk	NN	O
and/or	CC	O
severity	NN	O
of	IN	O
bone	NN	O
marrow	NN	O
suppression	NN	O
warrants	NNS	O
consideration	NN	O
.	.	.
		
therefore	RB	O
","	","	O
clozapine	NNP	D
should	MD	O
not	RB	O
be	VB	O
used	VBN	O
with	IN	O
other	JJ	O
agents	NNS	O
having	VBG	O
a	DT	O
well-known	JJ	O
potential	NN	O
to	TO	O
suppress	VB	O
bone	NN	O
marrow	NN	O
function	NN	O
.	.	.
		
given	VBN	O
the	DT	O
primary	JJ	O
cns	NN	O
effects	NNS	O
of	IN	O
clozapine	NNP	D
","	","	O
caution	NN	O
is	VBZ	O
advised	VBN	O
in	IN	O
using	VBG	O
it	PRP	O
concomitantly	RB	O
with	IN	O
other	JJ	O
cns-active	JJ	O
drugs	NNS	D
or	CC	O
alcohol	NN	D
.	.	.
		
orthostatic	JJ	O
hypotension	NN	O
in	IN	O
patients	NNS	O
taking	VBG	O
clozapine	NN	D
can	MD	O
","	","	O
in	IN	O
rare	JJ	O
cases	NNS	O
-lrb-	-LRB-	O
approximately	RB	O
1	CD	O
case	NN	O
per	IN	O
"3,000"	CD	O
patients	NNS	O
-rrb-	-RRB-	O
","	","	O
be	VB	O
accompanied	VBN	O
by	IN	O
profound	JJ	O
collapse	NN	O
and	CC	O
respiratory	JJ	O
and/or	CC	O
cardiac	JJ	O
arrest	NN	O
.	.	.
		
some	DT	O
of	IN	O
the	DT	O
cases	NNS	O
of	IN	O
collapse/respiratory	JJ	O
arrest/cardiac	JJ	O
arrest	NN	O
during	IN	O
initial	JJ	O
treatment	NN	O
occurred	VBD	O
in	IN	O
patients	NNS	O
who	WP	O
were	VBD	O
being	VBG	O
administered	VBN	O
benzodiazepines	NNS	G
.	.	.
		
similar	JJ	O
events	NNS	O
have	VBP	O
been	VBN	O
reported	VBN	O
in	IN	O
patients	NNS	O
taking	VBG	O
other	JJ	O
psychotropic	JJ	O
drugs	NNS	D
or	CC	O
even	RB	O
clozapine	NNP	D
by	IN	O
itself	PRP	O
.	.	.
		
although	IN	O
it	PRP	O
has	VBZ	O
not	RB	O
been	VBN	O
established	VBN	O
that	IN	O
there	EX	O
is	VBZ	O
an	DT	O
interaction	NN	O
between	IN	O
clozapine	NNP	D
and	CC	O
benzodiazepines	NNS	G
or	CC	O
other	JJ	O
psychotropics	NNS	G
","	","	O
caution	NN	O
is	VBZ	O
advised	VBN	O
when	WRB	O
clozapine	NN	D
is	VBZ	O
initiated	VBN	O
in	IN	O
patients	NNS	O
taking	VBG	O
a	DT	O
benzodiazepine	NN	G
or	CC	O
any	DT	O
other	JJ	O
psychotropic	JJ	O
drug	NN	D
.	.	.
		
clozapine	NNP	D
may	MD	O
potentiate	VB	O
the	DT	O
hypotensive	JJ	O
effects	NNS	O
of	IN	O
antihypertensive	JJ	O
drugs	NNS	D
and	CC	O
the	DT	O
anticholinergic	JJ	G
effects	NNS	O
of	IN	O
atropine-type	JJ	O
drugs	NNS	D
.	.	.
		
the	DT	O
administration	NN	O
of	IN	O
epinephrine	NN	D
should	MD	O
be	VB	O
avoided	VBN	O
in	IN	O
the	DT	O
treatment	NN	O
of	IN	O
drug	NN	D
induced	VBD	O
hypotension	NN	O
because	IN	O
of	IN	O
a	DT	O
possible	JJ	O
reverse	JJ	O
epinephrine	NN	D
effect	NN	O
.	.	.
		
pharmacokinetic-related	JJ	O
interactions	NNS	O
:	:	O
clozapine	NNP	D
is	VBZ	O
a	DT	O
substrate	NN	O
for	IN	O
many	JJ	O
cyp	NN	O
450	CD	O
isozymes	NNS	O
","	","	O
in	IN	O
particular	JJ	O
1a2	NN	O
","	","	O
2d6	NN	O
","	","	O
and	CC	O
3a4	NN	O
.	.	.
		
the	DT	O
risk	NN	O
of	IN	O
metabolic	JJ	O
interactions	NNS	O
caused	VBN	O
by	IN	O
an	DT	O
effect	NN	O
on	IN	O
an	DT	O
individual	JJ	O
isoform	NN	O
is	VBZ	O
therefore	RB	O
minimized	VBN	O
.	.	.
		
nevertheless	RB	O
","	","	O
caution	NN	O
should	MD	O
be	VB	O
used	VBN	O
in	IN	O
patients	NNS	O
receiving	VBG	O
concomitant	JJ	O
treatment	NN	O
with	IN	O
other	JJ	O
drugs	NNS	D
that	WDT	O
are	VBP	O
either	DT	O
inhibitors	NNS	O
or	CC	O
inducers	NNS	O
of	IN	O
these	DT	O
enzymes	NNS	O
.	.	.
		
concomitant	JJ	O
administration	NN	O
of	IN	O
drugs	NNS	D
known	VBN	O
to	TO	O
induce	VB	O
cytochrome	NN	O
p450	NN	O
enzymes	NNS	O
may	MD	O
decrease	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
clozapine	NN	D
.	.	.
		
phenytoin	NNP	D
","	","	O
nicotine	NN	D
","	","	O
and	CC	O
rifampin	NN	D
may	MD	O
decrease	VB	O
clozapine	NNP	D
plasma	NN	O
levels	NNS	O
","	","	O
resulting	VBG	O
in	IN	O
a	DT	O
decrease	NN	O
in	IN	O
effectiveness	NN	O
of	IN	O
a	DT	O
previously	RB	O
effective	JJ	O
clozapine	NNP	D
dose	NN	O
.	.	.
		
concomitant	JJ	O
administration	NN	O
of	IN	O
drugs	NNS	D
known	VBN	O
to	TO	O
inhibit	VB	O
the	DT	O
activity	NN	O
of	IN	O
cytochrome	NN	O
p450	NN	O
isozymes	NNS	O
may	MD	O
increase	VB	O
the	DT	O
plasma	NN	O
levels	NNS	O
of	IN	O
clozapine	NN	D
.	.	.
		
cimetidine	NNP	D
","	","	O
caffeine	NN	D
","	","	O
and	CC	O
erythromycin	NN	D
may	MD	O
increase	VB	O
plasma	NN	O
levels	NNS	O
of	IN	O
clozapine	NNP	D
","	","	O
potentially	RB	O
resulting	VBG	O
in	IN	O
adverse	JJ	O
effects	NNS	O
.	.	.
		
although	IN	O
concomitant	JJ	O
use	NN	O
of	IN	O
clozapine	NNP	D
and	CC	O
carbamazepine	NN	D
is	VBZ	O
not	RB	O
recommended	VBN	O
","	","	O
it	PRP	O
should	MD	O
be	VB	O
noted	VBN	O
that	IN	O
discontinuation	NN	O
of	IN	O
concomitant	JJ	O
carbamazepine	NN	D
administration	NN	O
may	MD	O
result	VB	O
in	IN	O
an	DT	O
increase	NN	O
in	IN	O
clozapine	NNP	D
plasma	NN	O
levels	NNS	O
.	.	.
		
in	IN	O
a	DT	O
study	NN	O
of	IN	O
schizophrenic	JJ	O
patients	NNS	O
who	WP	O
received	VBD	O
clozapine	NN	D
under	IN	O
steady	JJ	O
state	NN	O
conditions	NNS	O
","	","	O
fluvoxamine	NN	D
or	CC	O
paroxetine	NN	D
was	VBD	O
added	VBN	O
in	IN	O
16	CD	O
and	CC	O
14	CD	O
patients	NNS	O
","	","	O
respectively	RB	O
.	.	.
		
after	IN	O
14	CD	O
days	NNS	O
of	IN	O
co-administration	NN	O
","	","	O
mean	VB	O
trough	NN	O
concentrations	NNS	O
of	IN	O
clozapine	NN	D
and	CC	O
its	PRP$	O
metabolites	NNS	O
","	","	O
n-desmethylclozapine	NN	D_n
and	CC	O
clozapine	NN	D
n-oxide	NN	O
","	","	O
were	VBD	O
elevated	JJ	O
with	IN	O
fluvoxamine	NN	D
by	IN	O
about	IN	O
three-fold	JJ	O
compared	VBN	O
to	TO	O
baseline	NN	O
concentrations	NNS	O
.	.	.
		
paroxetine	NNP	D
produced	VBD	O
only	RB	O
minor	JJ	O
changes	NNS	O
in	IN	O
the	DT	O
levels	NNS	O
of	IN	O
clozapine	NN	D
and	CC	O
its	PRP$	O
metabolites	NNS	O
.	.	.
		
however	RB	O
","	","	O
other	JJ	O
published	VBN	O
reports	NNS	O
describe	VBP	O
modest	JJ	O
elevations	NNS	O
-lrb-	-LRB-	O
less	JJR	O
than	IN	O
two-fold	JJ	O
-rrb-	-RRB-	O
of	IN	O
clozapine	NN	D
and	CC	O
metabolite	NN	O
concentrations	NNS	O
when	WRB	O
clozapine	NN	D
was	VBD	O
taken	VBN	O
with	IN	O
paroxetine	NN	D
","	","	O
fluoxetine	NN	D
","	","	O
and	CC	O
sertraline	NN	D
.	.	.
		
therefore	RB	O
","	","	O
such	JJ	O
combined	JJ	O
treatment	NN	O
should	MD	O
be	VB	O
approached	VBN	O
with	IN	O
caution	NN	O
and	CC	O
patients	NNS	O
should	MD	O
be	VB	O
monitored	VBN	O
closely	RB	O
when	WRB	O
clozapine	NNP	D
is	VBZ	O
combined	VBN	O
with	IN	O
these	DT	O
drugs	NNS	D
","	","	O
particularly	RB	O
with	IN	O
fluvoxamine	NN	D
.	.	.
		
a	DT	O
reduced	VBN	O
clozapine	NNP	D
dose	NN	O
should	MD	O
be	VB	O
considered	VBN	O
.	.	.
		
a	DT	O
subset	NN	O
-lrb-	-LRB-	O
3	CD	O
%	NN	O
-10	CD	O
%	NN	O
-rrb-	-RRB-	O
of	IN	O
the	DT	O
population	NN	O
has	VBZ	O
reduced	VBN	O
activity	NN	O
of	IN	O
certain	JJ	O
drug	NN	D
metabolizing	VBG	O
enzymes	NNS	O
such	JJ	O
as	IN	O
the	DT	O
cytochrome	NN	O
p450	NN	O
isozyme	NN	O
p450	NN	O
2d6	NN	O
.	.	.
		
such	JJ	O
individuals	NNS	O
are	VBP	O
referred	VBN	O
to	TO	O
as	IN	O
poor	JJ	O
metabolizers	NNS	O
of	IN	O
drugs	NNS	D
such	JJ	O
as	IN	O
debrisoquin	NN	D
","	","	O
dextromethorphan	NN	D
","	","	O
the	DT	O
tricyclic	JJ	O
antidepressants	NNS	G
","	","	O
and	CC	O
clozapine	NN	D
.	.	.
		
these	DT	O
individuals	NNS	O
may	MD	O
develop	VB	O
higher	JJR	O
than	IN	O
expected	VBN	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
clozapine	NN	D
when	WRB	O
given	VBN	O
usual	JJ	O
doses	NNS	O
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
certain	JJ	O
drugs	NNS	D
that	WDT	O
are	VBP	O
metabolized	VBN	O
by	IN	O
this	DT	O
isozyme	NN	O
","	","	O
including	VBG	O
many	JJ	O
antidepressants	NNS	G
-lrb-	-LRB-	O
clozapine	NN	D
","	","	O
selective	JJ	O
serotonin	NN	O
reuptake	NN	O
inhibitors	NNS	O
","	","	O
and	CC	O
others	NNS	O
-rrb-	-RRB-	O
","	","	O
may	MD	O
inhibit	VB	O
the	DT	O
activity	NN	O
of	IN	O
this	DT	O
isozyme	NN	O
","	","	O
and	CC	O
thus	RB	O
may	MD	O
make	VB	O
normal	JJ	O
metabolizers	NNS	O
resemble	VBP	O
poor	JJ	O
metabolizers	NNS	O
with	IN	O
regard	NN	O
to	TO	O
concomitant	JJ	O
therapy	NN	O
with	IN	O
other	JJ	O
drugs	NNS	D
metabolized	VBN	O
by	IN	O
this	DT	O
enzyme	NN	O
system	NN	O
","	","	O
leading	VBG	O
to	TO	O
drug	NN	D
interaction	NN	O
.	.	.
		
concomitant	JJ	O
use	NN	O
of	IN	O
clozapine	NN	D
with	IN	O
other	JJ	O
drugs	NNS	D
metabolized	VBN	O
by	IN	O
cytochrome	NN	O
p450	NN	O
2d6	NN	O
may	MD	O
require	VB	O
lower	JJR	O
doses	NNS	O
than	IN	O
usually	RB	O
prescribed	VBN	O
for	IN	O
either	CC	O
clozapine	NN	D
or	CC	O
the	DT	O
other	JJ	O
drug	NN	D
.	.	.
		
therefore	RB	O
","	","	O
co-administration	NN	O
of	IN	O
clozapine	NN	D
with	IN	O
other	JJ	O
drugs	NNS	D
that	WDT	O
are	VBP	O
metabolized	VBN	O
by	IN	O
this	DT	O
isozyme	NN	O
","	","	O
including	VBG	O
antidepressants	NNS	G
","	","	O
phenothiazines	NNS	G
","	","	O
carbamazepine	NN	D
","	","	O
and	CC	O
type	NN	O
1c	NN	O
antiarrhythmics	NNS	G
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
propafenone	NN	D
","	","	O
flecainide	NN	D
and	CC	O
encainide	NN	D
-rrb-	-RRB-	O
","	","	O
or	CC	O
that	IN	O
inhibit	VBP	O
this	DT	O
enzyme	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
quinidine	NN	D
-rrb-	-RRB-	O
","	","	O
should	MD	O
be	VB	O
approached	VBN	O
with	IN	O
caution	NN	O
.	.	.
		
the	DT	O
risk	NN	O
of	IN	O
a	DT	O
potential	JJ	O
interaction	NN	O
between	IN	O
novoseven	NNP	B
and	CC	O
coagulation	NN	O
factor	NN	O
concentrates	VBZ	O
has	VBZ	O
not	RB	O
been	VBN	O
adequately	RB	O
evaluated	VBN	O
in	IN	O
preclinical	JJ	O
or	CC	O
clinical	JJ	O
studies	NNS	O
.	.	.
		
simultaneous	JJ	O
use	NN	O
of	IN	O
activated	VBN	O
prothrombin	NN	O
complex	NN	O
concentrates	VBZ	O
or	CC	O
prothrombin	NN	O
complex	NN	O
concentrates	VBZ	O
should	MD	O
be	VB	O
avoided	VBN	O
.	.	.
		
although	IN	O
the	DT	O
specific	JJ	O
drug	NN	D
interaction	NN	O
was	VBD	O
not	RB	O
studied	VBN	O
in	IN	O
a	DT	O
clinical	JJ	O
trial	NN	O
","	","	O
there	EX	O
have	VBP	O
been	VBN	O
more	JJR	O
than	IN	O
50	CD	O
episodes	NNS	O
of	IN	O
concomitant	JJ	O
use	NN	O
of	IN	O
antifibrinolytic	JJ	O
therapies	NNS	O
-lrb-	-LRB-	O
i.e.	FW	O
","	","	O
tranexamic	JJ	O
acid	NN	O
","	","	O
aminocaproic	JJ	O
acid	NN	O
-rrb-	-RRB-	O
and	CC	O
novoseven	NNP	B
.	.	.
		
novoseven	NNP	B
should	MD	O
not	RB	O
be	VB	O
mixed	VBN	O
with	IN	O
infusion	NN	O
solutions	NNS	O
until	IN	O
clinical	JJ	O
data	NNS	O
are	VBP	O
available	JJ	O
to	TO	O
direct	VB	O
this	DT	O
use	NN	O
.	.	.
		
codeine	NNP	D
in	IN	O
combination	NN	O
with	IN	O
other	JJ	O
narcotic	JJ	G
analgesics	NNS	G
","	","	O
general	JJ	O
anesthetics	NNS	G
","	","	O
phenothiazines	NNS	G
","	","	O
tranquilizers	NNS	G
","	","	O
sedative-hypnotics	NNS	G
","	","	O
or	CC	O
other	JJ	O
cns	NN	O
depressants	NNS	O
-lrb-	-LRB-	O
including	VBG	O
alcohol	NN	D
-rrb-	-RRB-	O
has	VBZ	O
additive	JJ	O
depressant	NN	O
effects	NNS	O
.	.	.
		
when	WRB	O
s.c.	NN	O
combination	NN	O
therapy	NN	O
is	VBZ	O
contemplated	VBN	O
","	","	O
the	DT	O
dosage	NN	O
of	IN	O
one	CD	O
or	CC	O
both	DT	O
agents	NNS	O
should	MD	O
be	VB	O
reduced	VBN	O
.	.	.
		
colchicine	NNP	D
is	VBZ	O
inhibited	VBN	O
by	IN	O
acidifying	VBG	O
agents	NNS	O
.	.	.
		
the	DT	O
action	NN	O
of	IN	O
colchicine	NN	D
is	VBZ	O
potentiated	VBN	O
by	IN	O
alkalinizing	VBG	O
agents	NNS	O
.	.	.
		
colchicine	NNP	D
may	MD	O
increase	VB	O
sensitivity	NN	O
to	TO	O
the	DT	O
cns	NN	O
depressants	NNS	O
.	.	.
		
response	NN	O
to	TO	O
sympathomimetic	JJ	D
agents	NNS	O
may	MD	O
be	VB	O
enhanced	VBN	O
by	IN	O
colchicine	NN	D
.	.	.
		
welchol	NNP	B
has	VBZ	O
been	VBN	O
studied	VBN	O
in	IN	O
several	JJ	O
human	JJ	O
drug	NN	D
interaction	NN	O
studies	NNS	O
in	IN	O
which	WDT	O
it	PRP	O
was	VBD	O
administered	VBN	O
with	IN	O
a	DT	O
meal	NN	O
and	CC	O
the	DT	O
test	NN	O
drug	NN	D
.	.	.
		
welchol	NNP	B
was	VBD	O
found	VBN	O
to	TO	O
have	VB	O
no	DT	O
significant	JJ	O
effect	NN	O
on	IN	O
the	DT	O
bioavailability	NN	O
of	IN	O
digoxin	NN	D
","	","	O
lovastatin	NN	D
","	","	O
metoprolol	NN	D
","	","	O
quinidine	NN	D
","	","	O
valproic	JJ	O
acid	NN	O
","	","	O
and	CC	O
warfarin	NN	D
.	.	.
		
welchol	NNP	B
decreased	VBD	O
the	DT	O
cmax	NN	O
and	CC	O
auc	NN	O
of	IN	O
sustained-release	JJ	O
verapamil	NN	D
-lrb-	-LRB-	O
calan	JJ	O
sr	NN	O
-rrb-	-RRB-	O
by	IN	O
approximately	RB	O
31	CD	O
%	NN	O
and	CC	O
11	CD	O
%	NN	O
","	","	O
respectively	RB	O
.	.	.
		
since	IN	O
there	EX	O
is	VBZ	O
a	DT	O
high	JJ	O
degree	NN	O
of	IN	O
variability	NN	O
in	IN	O
the	DT	O
bioavailability	NN	O
of	IN	O
verapamil	NN	D
","	","	O
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
this	DT	O
finding	NN	O
is	VBZ	O
unclear	JJ	O
.	.	.
		
increased	VBN	O
phenytoin	NNP	D
levels	NNP	O
should	MD	O
be	VB	O
treated	VBN	O
with	IN	O
appropriate	JJ	O
dosage	NN	O
adjustment	NN	O
.	.	.
		
it	PRP	O
may	MD	O
be	VB	O
necessary	JJ	O
to	TO	O
adjust	VB	O
the	DT	O
dosage	NN	O
of	IN	O
oral	JJ	O
anticoagulants	NNS	G
upon	IN	O
beginning	VBG	O
or	CC	O
stopping	VBG	O
disulfiram	NN	D
.	.	.
		
since	IN	O
disulfiram	NN	D
may	MD	O
prolong	VB	O
prothrombin	NN	O
time	NN	O
.	.	.
		
patients	NNS	O
taking	VBG	O
isoniazid	NN	D
when	WRB	O
disulfiram	NN	D
is	VBZ	O
given	VBN	O
should	MD	O
be	VB	O
observed	VBN	O
for	IN	O
the	DT	O
appearance	NN	O
of	IN	O
unsteady	JJ	O
gait	NN	O
or	CC	O
marked	JJ	O
changes	NNS	O
in	IN	O
mental	JJ	O
status	NN	O
.	.	.
		
the	DT	O
disulfiram	NN	D
should	MD	O
be	VB	O
discontinued	VBN	O
if	IN	O
such	JJ	O
signs	NNS	O
appear	VBP	O
.	.	.
		
in	IN	O
rats	NNS	O
","	","	O
simultaneous	JJ	O
ingestion	NN	O
of	IN	O
disulfiram	NN	D
and	CC	O
nitrite	NN	D
in	IN	O
the	DT	O
diet	NN	O
for	IN	O
78	CD	O
weeks	NNS	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
cause	VB	O
tumors	NNS	O
","	","	O
and	CC	O
it	PRP	O
has	VBZ	O
been	VBN	O
suggested	VBN	O
that	IN	O
disulfiram	NN	D
may	MD	O
react	VB	O
with	IN	O
nitrites	NNS	G
in	IN	O
the	DT	O
rat	NN	O
stomach	NN	O
to	TO	O
form	VB	O
a	DT	O
nitrosamine	NN	O
","	","	O
which	WDT	O
is	VBZ	O
tumorigenic	JJ	O
.	.	.
		
disulfiram	NNP	D
alone	RB	O
in	IN	O
the	DT	O
rat	NN	O
s	VBZ	O
diet	NN	O
did	VBD	O
not	RB	O
lead	VB	O
to	TO	O
such	JJ	O
tumors	NNS	O
.	.	.
		
the	DT	O
relevance	NN	O
of	IN	O
this	DT	O
finding	NN	O
to	TO	O
humans	NNS	O
is	VBZ	O
not	RB	O
known	VBN	O
at	IN	O
this	DT	O
time	NN	O
.	.	.
		
animal	NN	O
studies	NNS	O
indicate	VBP	O
that	IN	O
dobutamine	NN	D
may	MD	O
be	VB	O
ineffective	JJ	O
if	IN	O
the	DT	O
patient	NN	O
has	VBZ	O
recently	RB	O
received	VBN	O
a	DT	O
b-blocking	NN	O
drug	NN	D
.	.	.
		
in	IN	O
such	PDT	O
a	DT	O
case	NN	O
","	","	O
the	DT	O
peripheral	JJ	O
vascular	JJ	O
resistance	NN	O
may	MD	O
increase	VB	O
.	.	.
		
preliminary	JJ	O
studies	NNS	O
indicate	VBP	O
that	IN	O
the	DT	O
concomitant	JJ	O
use	NN	O
of	IN	O
dobutamine	NN	D
and	CC	O
nitroprusside	JJ	D
results	NNS	O
in	IN	O
a	DT	O
higher	JJR	O
cardiac	JJ	O
output	NN	O
and	CC	O
","	","	O
usually	RB	O
","	","	O
a	DT	O
lower	JJR	O
pulmonary	JJ	O
wedge	NN	O
pressure	NN	O
than	IN	O
when	WRB	O
either	CC	O
drug	NN	D
is	VBZ	O
used	VBN	O
alone	RB	O
.	.	.
		
there	EX	O
was	VBD	O
no	DT	O
evidence	NN	O
of	IN	O
drug	NN	D
interactions	NNS	O
in	IN	O
clinical	JJ	O
studies	NNS	O
in	IN	O
which	WDT	O
dobutamine	NN	D
was	VBD	O
administered	VBN	O
concurrently	RB	O
with	IN	O
other	JJ	O
drugs	NNS	D
","	","	O
including	VBG	O
digitalis	NN	G
preparations	NNS	O
","	","	O
furosemide	NN	D
","	","	O
spironolactone	NN	D
","	","	O
lidocaine	NN	D
","	","	O
glyceryl	NN	O
trinitrate	NN	O
","	","	O
isosorbide	NN	O
dinitrate	NN	O
","	","	O
morphine	NN	D
","	","	O
atropine	NN	D
","	","	O
heparin	NN	D
","	","	O
protamine	NN	D
","	","	O
potassium	NN	D
chloride	NN	O
","	","	O
folic	JJ	O
acid	NN	O
","	","	O
and	CC	O
acetaminophen	NN	D
.	.	.
		
there	EX	O
have	VBP	O
been	VBN	O
no	DT	O
formal	JJ	O
clinical	JJ	O
studies	NNS	O
to	TO	O
evaluate	VB	O
the	DT	O
drug	NN	D
interactions	NNS	O
of	IN	O
taxotere	NN	B
with	IN	O
other	JJ	O
medications	NNS	O
.	.	.
		
in	FW	O
vitro	FW	O
studies	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
the	DT	O
metabolism	NN	O
of	IN	O
docetaxel	NN	D
may	MD	O
be	VB	O
modified	VBN	O
by	IN	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
compounds	NNS	O
that	WDT	O
induce	VBP	O
","	","	O
inhibit	VBP	O
","	","	O
or	CC	O
are	VBP	O
metabolized	VBN	O
by	IN	O
cytochrome	NN	O
p450	NN	O
3a4	NN	O
","	","	O
such	JJ	O
as	IN	O
cyclosporine	NN	D
","	","	O
terfenadine	NN	D
","	","	O
ketoconazole	NN	D
","	","	O
erythromycin	NN	D
","	","	O
and	CC	O
troleandomycin	NN	D
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
with	IN	O
these	DT	O
drugs	NNS	D
when	WRB	O
treating	VBG	O
patients	NNS	O
receiving	VBG	O
taxotere	NN	B
as	IN	O
there	EX	O
is	VBZ	O
a	DT	O
potential	NN	O
for	IN	O
a	DT	O
significant	JJ	O
interaction	NN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
none	NN	O
known	VBN	O
.	.	.
		
drug-drug	NNP	O
interactions	NNS	O
cimetidine	NNP	D
:	:	O
concomitant	JJ	O
use	NN	O
of	IN	O
cimetidine	NN	D
is	VBZ	O
contraindicated	VBN	O
.	.	.
		
cimetidine	NN	D
at	IN	O
400	CD	O
mg	NN	O
bid	NNP	O
-lrb-	-LRB-	O
the	DT	O
usual	JJ	O
prescription	NN	O
dose	NN	O
-rrb-	-RRB-	O
co-administered	JJ	O
with	IN	O
tikosyn	NN	B
-lrb-	-LRB-	O
500	CD	O
mcg	NN	O
bid	NNP	O
-rrb-	-RRB-	O
for	IN	O
7	CD	O
days	NNS	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
dofetilide	NN	D
plasma	NN	O
levels	NNS	O
by	IN	O
58	CD	O
%	NN	O
.	.	.
		
cimetidine	NN	D
at	IN	O
doses	NNS	O
of	IN	O
100	CD	O
mg	NN	O
bid	NNP	O
-lrb-	-LRB-	O
otc	NNP	O
dose	NN	O
-rrb-	-RRB-	O
resulted	VBD	O
in	IN	O
a	DT	O
13	CD	O
%	NN	O
increase	NN	O
in	IN	O
dofetilide	NN	D
plasma	NN	O
levels	NNS	O
-lrb-	-LRB-	O
500	CD	O
mcg	NN	O
single	JJ	O
dose	NN	O
-rrb-	-RRB-	O
.	.	.
		
no	DT	O
studies	NNS	O
have	VBP	O
been	VBN	O
conducted	VBN	O
at	IN	O
intermediate	JJ	O
doses	NNS	O
of	IN	O
cimetidine	NN	D
.	.	.
		
if	IN	O
a	DT	O
patient	NN	O
requires	VBZ	O
tikosyn	NNP	B
and	CC	O
anti-ulcer	JJ	G
therapy	NN	O
","	","	O
it	PRP	O
is	VBZ	O
suggested	VBN	O
that	IN	O
omeprazole	NN	D
","	","	O
ranitidine	NN	D
","	","	O
or	CC	O
antacids	NNS	G
-lrb-	-LRB-	O
aluminum	NN	D
and	CC	O
magnesium	NN	D
hydroxides	NNS	O
-rrb-	-RRB-	O
be	VB	O
used	VBN	O
as	IN	O
alternatives	NNS	O
to	TO	O
cimetidine	NN	D
","	","	O
as	IN	O
these	DT	O
agents	NNS	O
have	VBP	O
no	DT	O
effect	NN	O
on	IN	O
the	DT	O
pharmacokinetic	JJ	O
profile	NN	O
of	IN	O
tikosyn	NNP	B
.	.	.
		
verapamil	NNP	D
:	:	O
concomitant	JJ	O
use	NN	O
of	IN	O
verapamil	NN	D
is	VBZ	O
contraindicated	VBN	O
.	.	.
		
co-administration	NN	O
of	IN	O
tikosyn	NN	B
with	IN	O
verapamil	NN	D
resulted	VBD	O
in	IN	O
increases	NNS	O
in	IN	O
dofetilide	NN	D
peak	NN	O
plasma	NN	O
levels	NNS	O
of	IN	O
42	CD	O
%	NN	O
","	","	O
although	IN	O
overall	JJ	O
exposure	NN	O
to	TO	O
dofetilide	NN	D
was	VBD	O
not	RB	O
significantly	RB	O
increased	VBN	O
.	.	.
		
in	IN	O
an	DT	O
analysis	NN	O
of	IN	O
the	DT	O
supraventricular	JJ	O
arrhythmia	NN	O
and	CC	O
diamond	NN	O
patient	NN	O
populations	NNS	O
","	","	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
verapamil	NN	D
with	IN	O
dofetilide	NN	D
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
occurrence	NN	O
of	IN	O
torsade	FW	O
de	FW	O
pointes	FW	O
.	.	.
		
ketoconazole	NN	D
:	:	O
concomitant	JJ	O
use	NN	O
of	IN	O
ketoconazole	NN	D
is	VBZ	O
contraindicated	VBN	O
.	.	.
		
ketoconazole	NN	D
at	IN	O
400	CD	O
mg	NN	O
daily	JJ	O
-lrb-	-LRB-	O
the	DT	O
maximum	NN	O
approved	VBD	O
prescription	NN	O
dose	NN	O
-rrb-	-RRB-	O
co-administered	JJ	O
with	IN	O
tikosyn	NN	B
-lrb-	-LRB-	O
500	CD	O
mcg	NN	O
bid	NNP	O
-rrb-	-RRB-	O
for	IN	O
7	CD	O
days	NNS	O
has	VBZ	O
been	VBN	O
shown	VBN	O
to	TO	O
increase	VB	O
dofetilide	NN	D
cmax	NN	O
by	IN	O
53	CD	O
%	NN	O
in	IN	O
males	NNS	O
and	CC	O
97	CD	O
%	NN	O
in	IN	O
females	NNS	O
","	","	O
and	CC	O
auc	NN	O
by	IN	O
41	CD	O
%	NN	O
in	IN	O
males	NNS	O
and	CC	O
69	CD	O
%	NN	O
in	IN	O
females	NNS	O
.	.	.
		
trimethoprim	NNP	D
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
sulfamethoxazole	NNP	D
:	:	O
concomitant	JJ	O
use	NN	O
of	IN	O
trimethoprim	NN	D
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
sulfamethoxazole	NN	D
is	VBZ	O
contraindicated	VBN	O
.	.	.
		
hydrochlorothiazide	NN	D
-lrb-	-LRB-	O
hctz	NN	D
-rrb-	-RRB-	O
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
triamterene	NN	D
:	:	O
concomitant	JJ	O
use	NN	O
of	IN	O
hctz	NN	D
alone	RB	O
or	CC	O
in	IN	O
combination	NN	O
with	IN	O
triamterene	NN	D
is	VBZ	O
contraindicated	VBN	O
.	.	.
		
hctz	NN	D
50	CD	O
mg	NN	O
qd	NN	O
or	CC	O
hctz/triamterene	NN	O
50/100	CD	O
mg	NN	O
qd	NN	O
was	VBD	O
co-administered	VBN	O
with	IN	O
tikosyn	NN	B
-lrb-	-LRB-	O
500	CD	O
mcg	NN	O
bid	NNP	O
-rrb-	-RRB-	O
for	IN	O
5	CD	O
days	NNS	O
-lrb-	-LRB-	O
following	VBG	O
2	CD	O
days	NNS	O
of	IN	O
diuretic	JJ	G
use	NN	O
at	IN	O
half	NN	O
dose	NN	O
-rrb-	-RRB-	O
.	.	.
		
in	IN	O
patients	NNS	O
receiving	VBG	O
hctz	NN	D
alone	RB	O
","	","	O
dofetilide	NN	D
auc	NN	O
increased	VBN	O
by	IN	O
27	CD	O
%	NN	O
and	CC	O
cmax	NN	O
by	IN	O
21	CD	O
%	NN	O
.	.	.
		
however	RB	O
","	","	O
the	DT	O
pharmacodynamic	JJ	O
effect	NN	O
increased	VBN	O
by	IN	O
197	CD	O
%	NN	O
-lrb-	-LRB-	O
qtc	NN	O
increase	NN	O
over	IN	O
time	NN	O
-rrb-	-RRB-	O
and	CC	O
by	IN	O
95	CD	O
%	NN	O
-lrb-	-LRB-	O
maximum	NN	O
qtc	NN	O
increase	NN	O
-rrb-	-RRB-	O
.	.	.
		
however	RB	O
","	","	O
the	DT	O
pharmacodynamic	JJ	O
effect	NN	O
increased	VBN	O
by	IN	O
190	CD	O
%	NN	O
-lrb-	-LRB-	O
qtc	NN	O
increase	NN	O
over	IN	O
time	NN	O
-rrb-	-RRB-	O
and	CC	O
by	IN	O
84	CD	O
%	NN	O
-lrb-	-LRB-	O
maximum	NNP	O
qtc	NNP	O
increase	NN	O
-rrb-	-RRB-	O
.	.	.
		
the	DT	O
pharmacodynamic	JJ	O
effects	NNS	O
can	MD	O
be	VB	O
explained	VBN	O
by	IN	O
a	DT	O
combination	NN	O
of	IN	O
the	DT	O
increase	NN	O
in	IN	O
dofetilide	NN	D
exposure	NN	O
and	CC	O
the	DT	O
reductions	NNS	O
in	IN	O
serum	NN	O
potassium	NN	D
.	.	.
		
in	IN	O
the	DT	O
diamond	NN	O
trials	NNS	O
","	","	O
1252	CD	O
patients	NNS	O
were	VBD	O
treated	VBN	O
with	IN	O
tikosyn	NN	B
and	CC	O
diuretics	NNS	G
concomitantly	RB	O
of	IN	O
whom	WP	O
493	CD	O
died	VBD	O
compared	VBN	O
to	TO	O
508	CD	O
deaths	NNS	O
among	IN	O
the	DT	O
1248	CD	O
patients	NNS	O
receiving	VBG	O
placebo	NN	O
and	CC	O
diuretics	NNS	G
.	.	.
		
of	IN	O
the	DT	O
229	CD	O
patients	NNS	O
who	WP	O
had	VBD	O
potassium	NN	D
depleting	VBG	O
diuretics	NNS	G
added	VBD	O
to	TO	O
their	PRP$	O
concomitant	JJ	O
medications	NNS	O
in	IN	O
the	DT	O
diamond	NN	O
trials	NNS	O
","	","	O
the	DT	O
patients	NNS	O
on	IN	O
tikosyn	NNP	B
had	VBD	O
a	DT	O
non-significantly	JJ	O
reduced	VBN	O
relative	JJ	O
risk	NN	O
for	IN	O
death	NN	O
of	IN	O
0.68	CD	O
-lrb-	-LRB-	O
95	CD	O
%	NN	O
ci	NN	O
0.376	CD	O
","	","	O
1.23	CD	O
-rrb-	-RRB-	O
.	.	.
		
potential	JJ	O
drug	NN	O
interactions	NNS	O
dofetilide	NNP	D
is	VBZ	O
eliminated	VBN	O
in	IN	O
the	DT	O
kidney	NN	O
by	IN	O
cationic	JJ	O
secretion	NN	O
.	.	.
		
inhibitors	NNS	O
of	IN	O
renal	JJ	O
cationic	JJ	O
secretion	NN	O
are	VBP	O
contraindicated	VBN	O
with	IN	O
tikosyn	NN	B
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
drugs	NNS	D
that	WDT	O
are	VBP	O
actively	RB	O
secreted	VBN	O
via	IN	O
this	DT	O
route	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
triamterene	NN	D
","	","	O
metformin	NN	D
and	CC	O
amiloride	NN	D
-rrb-	-RRB-	O
should	MD	O
be	VB	O
co-administered	VBN	O
with	IN	O
care	NN	O
as	IN	O
they	PRP	O
might	MD	O
increase	VB	O
dofetilide	NN	D
levels	NNS	O
.	.	.
		
dofetilide	NNP	D
is	VBZ	O
metabolized	VBN	O
to	TO	O
a	DT	O
small	JJ	O
extent	NN	O
by	IN	O
the	DT	O
cyp3a4	NN	D
isoenzyme	NN	O
of	IN	O
the	DT	O
cytochrome	NN	O
p450	NN	O
system	NN	O
.	.	.
		
inhibitors	NNS	O
of	IN	O
the	DT	O
cyp3a4	NN	D
isoenzyme	NN	O
could	MD	O
increase	VB	O
systemic	JJ	O
dofetilide	NN	D
exposure	NN	O
.	.	.
		
inhibitors	NNS	O
of	IN	O
this	DT	O
isoenzyme	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
macrolide	NN	O
antibiotics	NNS	G
","	","	O
azole	JJ	O
antifungal	JJ	O
agents	NNS	O
","	","	O
protease	NN	O
inhibitors	NNS	O
","	","	O
serotonin	NN	O
reuptake	NN	O
inhibitors	NNS	O
","	","	O
amiodarone	NN	D
","	","	O
cannabinoids	NNS	G
","	","	O
diltiazem	NN	D
","	","	O
grapefruit	NN	O
juice	NN	O
","	","	O
nefazadone	NN	D
","	","	O
norfloxacin	NN	D
","	","	O
quinine	NN	D
","	","	O
zafirlukast	NN	D
-rrb-	-RRB-	O
should	MD	O
be	VB	O
cautiously	RB	O
coadministered	VBN	O
with	IN	O
tikosyn	NN	B
as	IN	O
they	PRP	O
can	MD	O
potentially	RB	O
increase	VB	O
dofetilide	NN	D
levels	NNS	O
.	.	.
		
dofetilide	NNP	D
is	VBZ	O
not	RB	O
an	DT	O
inhibitor	NN	O
of	IN	O
cyp3a4	NN	D
nor	CC	O
of	IN	O
other	JJ	O
cytochrome	NN	O
p450	NN	O
isoenzymes	NNS	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
cyp2c9	NN	D
","	","	O
cyp2d6	NN	D
-rrb-	-RRB-	O
and	CC	O
is	VBZ	O
not	RB	O
expected	VBN	O
to	TO	O
increase	VB	O
levels	NNS	O
of	IN	O
drugs	NNS	D
metabolized	VBN	O
by	IN	O
cyp3a4	NN	D
.	.	.
		
other	JJ	O
drug	NN	O
interaction	NN	O
information	NN	O
digoxin	NNP	D
:	:	O
studies	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
tikosyn	NN	B
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
digoxin	NN	D
.	.	.
		
in	IN	O
patients	NNS	O
","	","	O
the	DT	O
concomitant	JJ	O
administration	NN	O
of	IN	O
digoxin	NN	D
with	IN	O
dofetilide	NN	D
was	VBD	O
associated	VBN	O
with	IN	O
a	DT	O
higher	JJR	O
occurrence	NN	O
of	IN	O
torsade	FW	O
de	FW	O
pointes	FW	O
.	.	.
		
it	PRP	O
is	VBZ	O
not	RB	O
clear	JJ	O
whether	IN	O
this	DT	O
represents	VBZ	O
an	DT	O
interaction	NN	O
with	IN	O
tikosyn	NN	B
or	CC	O
the	DT	O
presence	NN	O
of	IN	O
more	RBR	O
severe	JJ	O
structural	JJ	O
heart	NN	O
disease	NN	O
in	IN	O
patients	NNS	O
on	IN	O
digoxin	NN	D
.	.	.
		
structural	JJ	O
heart	NN	O
disease	NN	O
is	VBZ	O
a	DT	O
known	JJ	O
risk	NN	O
factor	NN	O
for	IN	O
arrhythmia	NN	O
.	.	.
		
no	DT	O
increase	NN	O
in	IN	O
mortality	NN	O
was	VBD	O
observed	VBN	O
in	IN	O
patients	NNS	O
taking	VBG	O
digoxin	NN	D
as	IN	O
concomitant	JJ	O
medication	NN	O
.	.	.
		
other	JJ	O
drugs	NNS	O
:	:	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
","	","	O
amlodipine	NN	D
","	","	O
phenytoin	NN	D
","	","	O
glyburide	NN	D
","	","	O
ranitidine	NN	D
","	","	O
omeprazole	NN	D
","	","	O
hormone	NN	O
replacement	NN	O
therapy	NN	O
-lrb-	-LRB-	O
a	DT	O
combination	NN	O
of	IN	O
conjugated	VBN	O
estrogens	NNS	G
and	CC	O
medroxyprogesterone	NN	D
-rrb-	-RRB-	O
","	","	O
antacid	NN	G
-lrb-	-LRB-	O
aluminum	NN	D
and	CC	O
magnesium	NN	D
hydroxides	NNS	O
-rrb-	-RRB-	O
and	CC	O
theophylline	NN	D
did	VBD	O
not	RB	O
affect	VB	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
tikosyn	NN	B
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
studies	NNS	O
in	IN	O
healthy	JJ	O
volunteers	NNS	O
have	VBP	O
shown	VBN	O
that	IN	O
tikosyn	NN	B
does	VBZ	O
not	RB	O
affect	VB	O
the	DT	O
pharmacokinetics	NNS	O
or	CC	O
pharmacodynamics	NNS	O
of	IN	O
warfarin	NN	D
","	","	O
or	CC	O
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
propranolol	NN	D
-lrb-	-LRB-	O
40	CD	O
mg	NN	O
twice	RB	O
daily	RB	O
-rrb-	-RRB-	O
","	","	O
phenytoin	NN	D
","	","	O
theophylline	NN	D
","	","	O
or	CC	O
oral	JJ	O
contraceptives	NNS	G
.	.	.
		
population	NNP	O
pharmacokinetic	JJ	O
analyses	NNS	O
were	VBD	O
conducted	VBN	O
on	IN	O
plasma	NN	O
concentration	NN	O
data	NNS	O
from	IN	O
1445	CD	O
patients	NNS	O
in	IN	O
clinical	JJ	O
trials	NNS	O
to	TO	O
examine	VB	O
the	DT	O
effects	NNS	O
of	IN	O
concomitant	JJ	O
medications	NNS	O
on	IN	O
clearance	NN	O
or	CC	O
volume	NN	O
of	IN	O
distribution	NN	O
of	IN	O
dofetilide	NN	D
.	.	.
		
concomitant	JJ	O
medications	NNS	O
were	VBD	O
grouped	VBN	O
as	IN	O
ace	NN	O
inhibitors	NNS	O
","	","	O
oral	JJ	O
anticoagulants	NNS	G
","	","	O
calcium	NN	D
channel	NN	O
blockers	NNS	O
","	","	O
beta	NN	O
blockers	NNS	O
","	","	O
cardiac	JJ	O
glycosides	NNS	O
","	","	O
inducers	NNS	O
of	IN	O
cyp3a4	NN	D
","	","	O
substrates	NNS	O
and	CC	O
inhibitors	NNS	O
of	IN	O
cyp3a4	NN	D
","	","	O
substrates	NNS	O
and	CC	O
inhibitors	NNS	O
of	IN	O
p-glycoprotein	NN	O
","	","	O
nitrates	NNS	G
","	","	O
sulphonylureas	NNS	G
","	","	O
loop	NN	O
diuretics	NNS	G
","	","	O
potassium	NN	D
sparing	VBG	O
diuretics	NNS	G
","	","	O
thiazide	JJ	O
diuretics	NNS	G
","	","	O
substrates	NNS	O
and	CC	O
inhibitors	NNS	O
of	IN	O
tubular	JJ	O
organic	JJ	O
cation	NN	O
transport	NN	O
","	","	O
and	CC	O
qtc-prolonging	JJ	O
drugs	NNS	D
.	.	.
		
differences	NNS	O
in	IN	O
clearance	NN	O
between	IN	O
patients	NNS	O
on	IN	O
these	DT	O
medications	NNS	O
-lrb-	-LRB-	O
at	IN	O
any	DT	O
occasion	NN	O
in	IN	O
the	DT	O
study	NN	O
-rrb-	-RRB-	O
and	CC	O
those	DT	O
off	IN	O
medications	NNS	O
varied	VBD	O
between	IN	O
-16	CD	O
%	NN	O
and	CC	O
3	CD	O
%	NN	O
.	.	.
		
the	DT	O
mean	NN	O
clearances	NNS	O
of	IN	O
dofetilide	NN	D
were	VBD	O
16	CD	O
%	NN	O
and	CC	O
15	CD	O
%	NN	O
lower	JJR	O
in	IN	O
patients	NNS	O
on	IN	O
thiazide	JJ	O
diuretics	NNS	G
and	CC	O
inhibitors	NNS	O
of	IN	O
tubular	JJ	O
organic	JJ	O
cation	NN	O
transport	NN	O
","	","	O
respectively	RB	O
.	.	.
		
the	DT	O
potential	NN	O
for	IN	O
clinically	RB	O
significant	JJ	O
drug-drug	JJ	O
interactions	NNS	O
posed	VBN	O
by	IN	O
dolasetron	NN	D
and	CC	O
hydrodolasetron	NN	D_n
appears	VBZ	O
to	TO	O
be	VB	O
low	JJ	O
for	IN	O
drugs	NNS	D
commonly	RB	O
used	VBN	O
in	IN	O
chemotherapy	NN	O
or	CC	O
surgery	NN	O
","	","	O
because	IN	O
hydrodolasetron	NN	D_n
is	VBZ	O
eliminated	VBN	O
by	IN	O
multiple	JJ	O
routes	NNS	O
.	.	.
		
blood	NN	O
levels	NNS	O
of	IN	O
hydrodolasetron	NN	D_n
increased	VBD	O
24	CD	O
%	NN	O
when	WRB	O
dolasetron	NN	D
was	VBD	O
coadministered	VBN	O
with	IN	O
cimetidine	NN	D
-lrb-	-LRB-	O
nonselective	JJ	O
inhibitor	NN	O
of	IN	O
cytochrome	NN	O
p-450	NN	O
-rrb-	-RRB-	O
for	IN	O
7	CD	O
days	NNS	O
","	","	O
and	CC	O
decreased	VBD	O
28	CD	O
%	NN	O
with	IN	O
coadministration	NN	O
of	IN	O
rifampin	NN	D
-lrb-	-LRB-	O
potent	JJ	O
inducer	NN	O
of	IN	O
cytochrome	NN	O
p-450	NN	O
-rrb-	-RRB-	O
for	IN	O
7	CD	O
days	NNS	O
.	.	.
		
dolasetron	NNP	D
has	VBZ	O
been	VBN	O
safely	RB	O
coadministered	VBN	O
with	IN	O
drugs	NNS	D
used	VBN	O
in	IN	O
chemotherapy	NN	O
and	CC	O
surgery	NN	O
.	.	.
		
this	DT	O
observed	VBN	O
increase	NN	O
in	IN	O
the	DT	O
bioavailability	NN	O
of	IN	O
fexofenadine	NN	D
may	MD	O
be	VB	O
due	JJ	O
to	TO	O
transport-related	JJ	O
effects	NNS	O
","	","	O
such	JJ	O
as	IN	O
p-glycoprotein	NN	O
.	.	.
		
in	FW	O
vivo	FW	O
animal	NN	O
studies	NNS	O
also	RB	O
suggest	VBP	O
that	IN	O
in	IN	O
addition	NN	O
to	TO	O
enhancing	VBG	O
absorption	NN	O
","	","	O
ketoconazole	NN	D
decreases	VBZ	O
fexofenadine	NN	D
gastrointestinal	JJ	O
secretion	NN	O
","	","	O
while	IN	O
erythromycin	NN	D
may	MD	O
also	RB	O
decrease	VB	O
biliary	JJ	O
excretion	NN	O
.	.	.
		
drug	NN	O
interactions	NNS	O
with	IN	O
antacids	NNPS	G
administration	NNP	O
of	IN	O
120	CD	O
mg	NN	O
of	IN	O
fexofenadine	NN	D
hydrochloride	NN	O
-lrb-	-LRB-	O
2	CD	O
x	CC	O
60	CD	O
mg	NN	O
capsule	NN	O
-rrb-	-RRB-	O
within	IN	O
15	CD	O
minutes	NNS	O
of	IN	O
an	DT	O
aluminum	NN	D
and	CC	O
magnesium	NN	D
containing	VBG	O
antacid	NN	G
-lrb-	-LRB-	O
maalox	NNP	B
-rrb-	-RRB-	O
decreased	VBD	O
fexofenadine	NN	D
auc	NN	O
by	IN	O
41	CD	O
%	NN	O
and	CC	O
cmax	NN	O
by	IN	O
43	CD	O
%	NN	O
.	.	.
		
allegra	NNP	B
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
closely	RB	O
in	IN	O
time	NN	O
with	IN	O
aluminum	NN	D
and	CC	O
magnesium	NN	D
containing	VBG	O
antacids	NNS	G
.	.	.
		
interactions	NNS	O
with	IN	O
fruit	NNP	O
juices	NNP	O
fruit	NNP	O
juices	NNS	O
such	JJ	O
as	IN	O
grapefruit	NN	O
","	","	O
orange	NN	O
and	CC	O
apple	NN	O
may	MD	O
reduce	VB	O
the	DT	O
bioavailability	NN	O
and	CC	O
exposure	NN	O
of	IN	O
fexofenadine	NN	D
.	.	.
		
this	DT	O
is	VBZ	O
based	VBN	O
on	IN	O
the	DT	O
results	NNS	O
from	IN	O
3	CD	O
clinical	JJ	O
studies	NNS	O
using	VBG	O
histamine	NN	D
induced	VBD	O
skin	NN	O
wheals	NNS	O
and	CC	O
flares	NNS	O
coupled	VBN	O
with	IN	O
population	NN	O
pharmacokinetic	JJ	O
analysis	NN	O
.	.	.
		
the	DT	O
size	NN	O
of	IN	O
wheal	NN	O
and	CC	O
flare	NN	O
were	VBD	O
significantly	RB	O
larger	JJR	O
when	WRB	O
fexofenadine	NN	D
hydrochloride	NN	O
was	VBD	O
administered	VBN	O
with	IN	O
either	CC	O
grapefruit	NN	O
or	CC	O
orange	JJ	O
juices	NNS	O
compared	VBN	O
to	TO	O
water	NN	O
.	.	.
		
based	VBN	O
on	IN	O
the	DT	O
literature	NN	O
reports	NNS	O
","	","	O
the	DT	O
same	JJ	O
effects	NNS	O
may	MD	O
be	VB	O
extrapolated	VBN	O
to	TO	O
other	JJ	O
fruit	NN	O
juices	NNS	O
such	JJ	O
as	IN	O
apple	NN	O
juice	NN	O
.	.	.
		
the	DT	O
clinical	JJ	O
significance	NN	O
of	IN	O
these	DT	O
observations	NNS	O
is	VBZ	O
unknown	JJ	O
.	.	.
		
in	IN	O
addition	NN	O
","	","	O
based	VBN	O
on	IN	O
the	DT	O
population	NN	O
pharmacokinetics	NNS	O
analysis	NN	O
of	IN	O
the	DT	O
combined	JJ	O
data	NNS	O
from	IN	O
grapefruit	NN	O
and	CC	O
orange	JJ	O
juices	NNS	O
studies	NNS	O
with	IN	O
the	DT	O
data	NNS	O
from	IN	O
a	DT	O
bioequivalence	NN	O
study	NN	O
","	","	O
the	DT	O
bioavailability	NN	O
of	IN	O
fexofenadine	NN	D
was	VBD	O
reduced	VBN	O
by	IN	O
36	CD	O
%	NN	O
.	.	.
		
therefore	RB	O
","	","	O
to	TO	O
maximize	VB	O
the	DT	O
effects	NNS	O
of	IN	O
fexofenadine	NN	D
","	","	O
it	PRP	O
is	VBZ	O
recommended	VBN	O
that	IN	O
allegra	NNP	B
should	MD	O
be	VB	O
taken	VBN	O
with	IN	O
wate	NN	O
.	.	.
		
drug	NN	O
interactions	NNS	O
between	IN	O
neupogen	NNP	B
and	CC	O
other	JJ	O
drugs	NNS	D
have	VBP	O
not	RB	O
been	VBN	O
fully	RB	O
evaluated	VBN	O
.	.	.
		
drugs	NNS	O
which	WDT	O
may	MD	O
potentiate	VB	O
the	DT	O
release	NN	O
of	IN	O
neutrophils	NNS	O
","	","	O
such	JJ	O
as	IN	O
lithium	NN	D
","	","	O
should	MD	O
be	VB	O
used	VBN	O
with	IN	O
caution	NN	O
.	.	.
		
no	DT	O
drug	NN	D
interactions	NNS	O
of	IN	O
clinical	JJ	O
importance	NN	O
have	VBP	O
been	VBN	O
identified	VBN	O
.	.	.
		
finasteride	NN	D
does	VBZ	O
not	RB	O
appear	VB	O
to	TO	O
affect	VB	O
the	DT	O
cytochrome	NN	O
p450-linked	JJ	O
drug-metabolizing	JJ	O
enzyme	NN	O
system	NN	O
.	.	.
		
compounds	NNS	O
that	WDT	O
have	VBP	O
been	VBN	O
tested	VBN	O
in	IN	O
man	NN	O
include	VBP	O
antipyrine	NN	D
","	","	O
digoxin	NN	D
","	","	O
propranolol	NN	D
","	","	O
theophylline	NN	D
","	","	O
and	CC	O
warfarin	NN	D
and	CC	O
no	DT	O
clinically	RB	O
meaningful	JJ	O
interactions	NNS	O
were	VBD	O
found	VBN	O
.	.	.
		
other	JJ	O
concomitant	JJ	O
therapy	NN	O
although	IN	O
specific	JJ	O
interaction	NN	O
studies	NNS	O
were	VBD	O
not	RB	O
performed	VBN	O
","	","	O
finasteride	NN	D
doses	NNS	O
of	IN	O
1	CD	O
mg	NN	O
or	CC	O
more	JJR	O
were	VBD	O
concomitantly	RB	O
used	VBN	O
in	IN	O
clinical	JJ	O
studies	NNS	O
with	IN	O
acetaminophen	NN	D
","	","	O
acetylsalicylic	JJ	O
acid	NN	O
","	","	O
a-blockers	NNS	O
","	","	O
analgesics	NNS	G
","	","	O
angiotensin-converting	JJ	O
enzyme	NN	O
-lrb-	-LRB-	O
ace	NN	O
-rrb-	-RRB-	O
inhibitors	NNS	O
","	","	O
anticonvulsants	NNS	G
","	","	O
benzodiazepines	NNS	G
","	","	O
beta	NN	O
blockers	NNS	O
","	","	O
calcium-channel	JJ	O
blockers	NNS	O
","	","	O
cardiac	JJ	O
nitrates	NNS	G
","	","	O
diuretics	NNS	G
","	","	O
h2	NN	O
antagonists	NNS	O
","	","	O
hmg-coa	NN	O
reductase	NN	O
inhibitors	NNS	O
","	","	O
prostaglandin	NN	O
synthetase	NN	O
inhibitors	NNS	O
-lrb-	-LRB-	O
also	RB	O
referred	VBN	O
to	TO	O
as	IN	O
nsaids	NNS	G
-rrb-	-RRB-	O
","	","	O
and	CC	O
quinolone	NN	G
anti-infectives	NNS	O
without	IN	O
evidence	NN	O
of	IN	O
clinically	RB	O
significant	JJ	O
adverse	JJ	O
interactions	NNS	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
finasteride	NNP	D
had	VBD	O
no	DT	O
effect	NN	O
on	IN	O
circulating	VBG	O
levels	NNS	O
of	IN	O
cortisol	NN	O
","	","	O
thyroid-stimulating	JJ	O
hormone	NN	O
","	","	O
or	CC	O
thyroxine	NN	D
","	","	O
nor	CC	O
did	VBD	O
it	PRP	O
affect	VB	O
the	DT	O
plasma	NN	O
lipid	NN	O
profile	NN	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
total	JJ	O
cholesterol	NN	O
","	","	O
low-density	JJ	O
lipoproteins	NNS	O
","	","	O
high-density	JJ	O
lipoproteins	NNS	O
and	CC	O
triglycerides	NNS	O
-rrb-	-RRB-	O
or	CC	O
bone	NN	O
mineral	NN	O
density	NN	O
.	.	.
		
in	IN	O
studies	NNS	O
with	IN	O
finasteride	NN	D
","	","	O
no	DT	O
clinically	RB	O
meaningful	JJ	O
changes	NNS	O
in	IN	O
luteinizing	VBG	O
hormone	NN	O
-lrb-	-LRB-	O
lh	NN	O
-rrb-	-RRB-	O
","	","	O
follicle-stimulating	JJ	O
hormone	NN	O
-lrb-	-LRB-	O
fsh	NN	O
-rrb-	-RRB-	O
or	CC	O
prolactin	NN	O
were	VBD	O
detected	VBN	O
.	.	.
		
in	IN	O
healthy	JJ	O
volunteers	NNS	O
","	","	O
treatment	NN	O
with	IN	O
finasteride	NN	D
did	VBD	O
not	RB	O
alter	VB	O
the	DT	O
response	NN	O
of	IN	O
lh	NN	O
and	CC	O
fsh	NN	O
to	TO	O
gonadotropin-releasing	NN	O
hormone	NN	O
indicating	VBG	O
that	IN	O
the	DT	O
hypothalamic-pituitary-testicular	JJ	O
axis	NN	O
was	VBD	O
not	RB	O
affected	VBN	O
.	.	.
		
in	IN	O
clinical	JJ	O
studies	NNS	O
with	IN	O
propecia	NN	B
-lrb-	-LRB-	O
finasteride	NN	D
","	","	O
1	CD	O
mg	NN	O
-rrb-	-RRB-	O
in	IN	O
men	NNS	O
18-41	CD	O
years	NNS	O
of	IN	O
age	NN	O
","	","	O
the	DT	O
mean	JJ	O
value	NN	O
of	IN	O
serum	NN	O
prostate-specific	JJ	O
antigen	NN	O
-lrb-	-LRB-	O
psa	NN	O
-rrb-	-RRB-	O
decreased	VBD	O
from	IN	O
0.7	CD	O
ng/ml	NN	O
at	IN	O
baseline	NN	O
to	TO	O
0.5	CD	O
ng/ml	NN	O
at	IN	O
month	NNP	O
12	CD	O
.	.	.
		
further	RB	O
","	","	O
in	IN	O
clinical	JJ	O
studies	NNS	O
with	IN	O
proscar	NN	B
-lrb-	-LRB-	O
finasteride	NN	D
","	","	O
5	CD	O
mg	NN	O
-rrb-	-RRB-	O
when	WRB	O
used	VBN	O
in	IN	O
older	JJR	O
men	NNS	O
who	WP	O
have	VBP	O
benign	JJ	O
prostatic	JJ	O
hyperplasia	NN	O
-lrb-	-LRB-	O
bph	NNP	O
-rrb-	-RRB-	O
","	","	O
psa	NN	O
levels	NNS	O
are	VBP	O
decreased	VBN	O
by	IN	O
approximately	RB	O
50	CD	O
%	NN	O
.	.	.
		
these	DT	O
findings	NNS	O
should	MD	O
be	VB	O
taken	VBN	O
into	IN	O
account	NN	O
for	IN	O
proper	JJ	O
interpretation	NN	O
of	IN	O
serum	NN	O
psa	NN	O
when	WRB	O
evaluating	VBG	O
men	NNS	O
treated	VBN	O
with	IN	O
finasteride	NN	D
.	.	.
		
drug	NN	O
interactions	NNS	O
.	.	.
		
tambocor	NN	B
has	VBZ	O
been	VBN	O
administered	VBN	O
to	TO	O
patients	NNS	O
receiving	VBG	O
digitalis	NN	G
preparations	NNS	O
or	CC	O
beta-adrenergic	JJ	O
blocking	VBG	O
agents	NNS	O
without	IN	O
adverse	JJ	O
effects	NNS	O
.	.	.
		
during	IN	O
administration	NN	O
of	IN	O
multiple	JJ	O
oral	JJ	O
doses	NNS	O
of	IN	O
tambocor	NN	B
to	TO	O
healthy	JJ	O
subjects	NNS	O
stabilized	VBD	O
on	IN	O
a	DT	O
maintenance	NN	O
dose	NN	O
of	IN	O
digoxin	NN	D
","	","	O
a	DT	O
13	CD	O
%	NN	O
-19	CD	O
%	NN	O
increase	NN	O
in	IN	O
plasma	NN	O
digoxin	NN	D
levels	NNS	O
occurred	VBD	O
at	IN	O
six	CD	O
hours	NNS	O
postdose	NN	O
.	.	.
		
in	IN	O
a	DT	O
study	NN	O
involving	VBG	O
healthy	JJ	O
subjects	NNS	O
receiving	VBG	O
tambocor	NN	B
and	CC	O
propranolol	NN	D
concurrently	RB	O
","	","	O
plasma	NN	O
flecainide	NN	D
levels	NNS	O
were	VBD	O
increased	VBN	O
about	RB	O
20	CD	O
%	NN	O
and	CC	O
propranolol	NN	D
levels	NNS	O
were	VBD	O
increased	VBN	O
about	IN	O
30	CD	O
%	NN	O
compared	VBN	O
to	TO	O
control	VB	O
values	NNS	O
.	.	.
		
in	IN	O
this	DT	O
formal	JJ	O
interaction	NN	O
study	NN	O
","	","	O
tambocor	NN	B
and	CC	O
propranolol	NN	D
were	VBD	O
each	DT	O
found	VBN	O
to	TO	O
have	VB	O
negative	JJ	O
inotropic	JJ	O
effects	NNS	O
.	.	.
		
when	WRB	O
the	DT	O
drugs	NNS	D
were	VBD	O
administered	VBN	O
together	RB	O
","	","	O
the	DT	O
effects	NNS	O
were	VBD	O
additive	JJ	O
.	.	.
		
the	DT	O
effects	NNS	O
of	IN	O
concomitant	JJ	O
administration	NN	O
of	IN	O
tambocor	NN	B
and	CC	O
propranolol	NN	D
on	IN	O
the	DT	O
pr	NN	O
interval	NN	O
were	VBD	O
less	JJR	O
than	IN	O
additive	JJ	O
.	.	.
		
in	IN	O
tambocor	NN	B
clinical	JJ	O
trials	NNS	O
","	","	O
patients	NNS	O
who	WP	O
were	VBD	O
receiving	VBG	O
beta	NN	O
blockers	NNS	O
concurrently	RB	O
did	VBD	O
not	RB	O
experience	VB	O
an	DT	O
increased	VBN	O
incidence	NN	O
of	IN	O
side	JJ	O
effects	NNS	O
.	.	.
		
nevertheless	RB	O
","	","	O
the	DT	O
possibility	NN	O
of	IN	O
additive	JJ	O
negative	JJ	O
inotropic	JJ	O
effects	NNS	O
of	IN	O
beta	NN	O
blockers	NNS	O
and	CC	O
flecainide	NN	D
should	MD	O
be	VB	O
recognized	VBN	O
.	.	.
		
flecainide	NNP	D
is	VBZ	O
not	RB	O
extensively	RB	O
bound	VBN	O
to	TO	O
plasma	NN	O
proteins	NNS	O
.	.	.
		
in	FW	O
vitro	FW	O
studies	NNS	O
with	IN	O
several	JJ	O
drugs	NNS	D
which	WDT	O
may	MD	O
be	VB	O
administered	VBN	O
concomitantly	RB	O
showed	VBD	O
that	IN	O
the	DT	O
extent	NN	O
of	IN	O
flecainide	NN	D
binding	NN	O
to	TO	O
human	JJ	O
plasma	NN	O
proteins	NNS	O
is	VBZ	O
either	CC	O
unchanged	JJ	O
or	CC	O
only	RB	O
slightly	RB	O
less	RBR	O
.	.	.
		
consequently	RB	O
","	","	O
interactions	NNS	O
with	IN	O
other	JJ	O
drugs	NNS	D
which	WDT	O
are	VBP	O
highly	RB	O
protein	NN	O
bound	VBD	O
-lrb-	-LRB-	O
e.g.	FW	O
","	","	O
anticoagulants	NNS	G
-rrb-	-RRB-	O
would	MD	O
not	RB	O
be	VB	O
expected	VBN	O
.	.	.
		
tambocor	NN	B
has	VBZ	O
been	VBN	O
used	VBN	O
in	IN	O
a	DT	O
large	JJ	O
number	NN	O
of	IN	O
patients	NNS	O
receiving	VBG	O
diuretics	NNS	G
without	IN	O
apparent	JJ	O
interaction	NN	O
.	.	.
		
limited	JJ	O
data	NNS	O
in	IN	O
patients	NNS	O
receiving	VBG	O
known	JJ	O
enzyme	NN	O
inducers	NNS	O
-lrb-	-LRB-	O
phenytoin	NN	D
","	","	O
phenobarbital	NN	D
","	","	O
carbamazepine	NN	D
-rrb-	-RRB-	O
indicate	VBP	O
only	RB	O
a	DT	O
30	CD	O
%	NN	O
increase	NN	O
in	IN	O
the	DT	O
rate	NN	O
of	IN	O
flecainide	NN	D
elimination	NN	O
.	.	.
		
in	IN	O
healthy	JJ	O
subjects	NNS	O
receiving	VBG	O
cimetidine	NN	D
-lrb-	-LRB-	O
1	CD	O
gm	NN	O
daily	JJ	O
-rrb-	-RRB-	O
for	IN	O
one	CD	O
week	NN	O
","	","	O
plasma	NN	O
flecainide	NN	D
levels	NNS	O
increased	VBN	O
by	IN	O
about	IN	O
30	CD	O
%	NN	O
and	CC	O
half-life	NN	O
increased	VBN	O
by	IN	O
about	RB	O
10	CD	O
%	NN	O
.	.	.
		
when	WRB	O
amiodarone	NN	D
is	VBZ	O
added	VBN	O
to	TO	O
flecainide	NN	D
therapy	NN	O
","	","	O
plasma	NN	O
flecainide	NN	D
levels	NNS	O
may	MD	O
increase	VB	O
two-fold	RB	O
or	CC	O
more	RBR	O
in	IN	O
some	DT	O
patients	NNS	O
","	","	O
if	IN	O
flecainide	NN	D
dosage	NN	O
is	VBZ	O
not	RB	O
reduced	VBN	O
.	.	.
		
drugs	NNS	O
that	WDT	O
inhibit	VBP	O
cytochrome	NN	O
p450iid6	NN	O
","	","	O
such	JJ	O
as	IN	O
quinidine	NN	D
","	","	O
might	MD	O
increase	VB	O
the	DT	O
plasma	NN	O
concentrations	NNS	O
of	IN	O
flecainide	NN	D
in	IN	O
patients	NNS	O
that	WDT	O
are	VBP	O
on	IN	O
chronic	JJ	O
flecainide	NN	D
therapy	NN	O
.	.	.
		
especially	RB	O
if	IN	O
these	DT	O
patients	NNS	O
are	VBP	O
extensive	JJ	O
metabolizers	NNS	O
.	.	.
		
there	EX	O
has	VBZ	O
been	VBN	O
little	JJ	O
experience	NN	O
with	IN	O
the	DT	O
coadministration	NN	O
of	IN	O
tambocor	NN	B
and	CC	O
either	CC	O
disopyramide	NN	D
or	CC	O
verapamil	NN	D
.	.	.
		
because	IN	O
both	DT	O
of	IN	O
these	DT	O
drugs	NNS	D
have	VBP	O
negative	JJ	O
inotropic	JJ	O
properties	NNS	O
and	CC	O
the	DT	O
effects	NNS	O
of	IN	O
coadministration	NN	O
with	IN	O
tambocor	NN	B
are	VBP	O
unknown	JJ	O
","	","	O
neither	CC	O
disopyramide	NN	D
nor	CC	O
verapamil	NN	D
should	MD	O
be	VB	O
administered	VBN	O
concurrently	RB	O
with	IN	O
tambocor	NN	B
unless	IN	O
","	","	O
in	IN	O
the	DT	O
judgment	NN	O
of	IN	O
the	DT	O
physician	NN	O
","	","	O
the	DT	O
benefits	NNS	O
of	IN	O
this	DT	O
combination	NN	O
outweigh	VBP	O
the	DT	O
risks	NNS	O
.	.	.
		
there	EX	O
has	VBZ	O
been	VBN	O
too	RB	O
little	JJ	O
experience	NN	O
with	IN	O
the	DT	O
coadministration	NN	O
of	IN	O
tambocor	NN	B
with	IN	O
nifedipine	NN	D
or	CC	O
diltiazem	NN	D
to	TO	O
recommend	VB	O
concomitant	JJ	O
use	NN	O
.	.	.
		
combination	NN	O
therapy	NN	O
:	:	O
any	DT	O
form	NN	O
of	IN	O
therapy	NN	O
which	WDT	O
adds	VBZ	O
to	TO	O
the	DT	O
stress	NN	O
of	IN	O
the	DT	O
patient	NN	O
","	","	O
interferes	VBZ	O
with	IN	O
nutrition	NN	O
or	CC	O
depresses	VBZ	O
bone	NN	O
marrow	NN	O
function	NN	O
will	MD	O
increase	VB	O
the	DT	O
toxicity	NN	O
of	IN	O
floxuridine	NN	D
.	.	.
		
cytosine	NN	O
arabinoside	NN	O
","	","	O
a	DT	O
cytostatic	JJ	O
agent	NN	O
","	","	O
has	VBZ	O
been	VBN	O
reported	VBN	O
to	TO	O
inactivate	VB	O
the	DT	O
antifungal	JJ	O
activity	NN	O
of	IN	O
flucytosine	NN	D
by	IN	O
competitive	JJ	O
inhibition	NN	O
.	.	.
		
drugs	NNS	O
which	WDT	O
impair	VBP	O
glomerular	JJ	O
filtration	NN	O
may	MD	O
prolong	VB	O
the	DT	O
biological	JJ	O
half-life	NN	O
of	IN	O
flucytosine	NN	D
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
:	:	O
measurement	NN	O
of	IN	O
serum	NN	O
creatinine	NN	O
levels	NNS	O
should	MD	O
be	VB	O
determined	VBN	O
by	IN	O
the	DT	O
jaffe	NNP	O
reaction	NN	O
","	","	O
since	IN	O
ancobon	NNP	B
does	VBZ	O
not	RB	O
interfere	VB	O
with	IN	O
the	DT	O
determination	NN	O
of	IN	O
creatinine	NN	O
values	NNS	O
by	IN	O
this	DT	O
method	NN	O
.	.	.
		
most	JJS	O
automated	JJ	O
equipment	NN	O
for	IN	O
measurement	NN	O
of	IN	O
creatinine	NN	O
makes	VBZ	O
use	NN	O
of	IN	O
the	DT	O
jaffe	NNP	O
reaction	NN	O
.	.	.
		
the	DT	O
use	NN	O
of	IN	O
fludara	NNP	B
for	IN	O
injection	NNP	O
in	IN	O
combination	NN	O
with	IN	O
pentostatin	NN	D
is	VBZ	O
not	RB	O
recommended	VBN	O
due	JJ	O
to	TO	O
the	DT	O
risk	NN	O
of	IN	O
severe	JJ	O
pulmonary	JJ	O
toxicity	NN	O
.	.	.
		
when	WRB	O
administered	VBN	O
concurrently	RB	O
","	","	O
the	DT	O
following	VBG	O
drugs	NNS	D
may	MD	O
interact	VB	O
with	IN	O
adrenal	JJ	O
corticosteroids	NNS	G
.	.	.
		
amphotericin	NN	O
b	NN	O
or	CC	O
potassium-depleting	JJ	O
diuretics	NNS	G
-lrb-	-LRB-	O
benzothiadiazines	NNS	G
and	CC	O
related	JJ	O
drugs	NNS	D
","	","	O
ethacrynic	JJ	O
acid	NN	O
and	CC	O
furosemide	NN	D
-rrb-	-RRB-	O
enhanced	VBD	O
hypokalemia	NN	O
.	.	.
		
check	VB	O
serum	NN	O
potassium	NN	D
levels	NNS	O
at	IN	O
frequent	JJ	O
intervals	NNS	O
;	:	O
.	.	.
		
use	NN	O
potassium	NN	D
supplements	NNS	O
if	IN	O
necessary	JJ	O
.	.	.
		
digitalis	NN	G
glycosides	NNS	O
enhanced	VBD	O
possibility	NN	O
of	IN	O
arrhythmias	NNS	O
or	CC	O
digitalis	NN	G
toxicity	NN	O
associated	VBN	O
with	IN	O
hypokalemia	NN	O
.	.	.
		
monitor	NNP	O
serum	NN	O
potassium	NN	D
levels	NNS	O
;	:	O
.	.	.
		
use	NN	O
potassium	NN	D
supplements	NNS	O
if	IN	O
necessary	JJ	O
.	.	.
		
oral	JJ	O
anticoagulants	NNS	G
decreased	VBD	O
prothrombin	NN	O
time	NN	O
response	NN	O
.	.	.
		
monitor	NNP	O
prothrombin	NN	O
levels	NNS	O
and	CC	O
adjust	VBP	O
anticoagulant	JJ	G
dosage	NN	O
accordingly	RB	O
.	.	.
		
antidiabetic	JJ	O
drugs	NNS	D
-lrb-	-LRB-	O
oral	JJ	O
agents	NNS	O
and	CC	O
insulin	NN	D
-rrb-	-RRB-	O
diminished	VBD	O
antidiabetic	JJ	O
effect	NN	O
.	.	.
		
monitor	NNP	O
for	IN	O
symptoms	NNS	O
of	IN	O
hyperglycemia	NN	O
;	:	O
.	.	.
		
adjust	VBP	O
dosage	NN	O
of	IN	O
antidiabetic	JJ	O
drug	NN	D
upward	RB	O
if	IN	O
necessary	JJ	O
.	.	.
		
aspirin	NN	B
increased	VBD	O
ulcerogenic	JJ	O
effect	NN	O
.	.	.
		
decreased	VBN	O
pharmacologic	JJ	O
effect	NN	O
of	IN	O
aspirin	NN	B
.	.	.
		
rarely	RB	O
salicylate	NN	G
toxicity	NN	O
may	MD	O
occur	VB	O
in	IN	O
patients	NNS	O
who	WP	O
discontinue	VBP	O
steroids	NNS	G
after	IN	O
concurrent	JJ	O
high-dose	JJ	O
aspirin	NN	B
therapy	NN	O
.	.	.
		
monitor	NNP	O
salicylate	NN	G
levels	NNS	O
or	CC	O
the	DT	O
therapeutic	JJ	O
effect	NN	O
for	IN	O
which	WDT	O
aspirin	NN	B
is	VBZ	O
given	VBN	O
.	.	.
		
adjust	VBP	O
salicylate	NN	G
dosage	NN	O
accordingly	RB	O
if	IN	O
effect	NN	O
is	VBZ	O
altered	VBN	O
.	.	.
		
barbiturates	NNP	G
","	","	O
phenytoin	NN	D
","	","	O
or	CC	O
rifampin	NN	D
increased	VBD	O
metabolic	JJ	O
clearance	NN	O
of	IN	O
fludrocortisone	NN	O
acetate	NN	O
because	IN	O
of	IN	O
the	DT	O
induction	NN	O
of	IN	O
hepatic	JJ	O
enzymes	NNS	O
.	.	.
		
observe	VB	O
the	DT	O
patient	NN	O
for	IN	O
possible	JJ	O
diminished	JJ	O
effect	NN	O
of	IN	O
steroid	NN	G
and	CC	O
increase	VB	O
the	DT	O
steroid	NN	G
dosage	NN	O
accordingly	RB	O
.	.	.
		
anabolic	JJ	O
steroids	NNS	G
-lrb-	-LRB-	O
particularly	RB	O
c-17	JJ	O
alkylated	VBN	O
androgens	NNS	G
such	JJ	O
as	IN	O
oxymetholone	NN	D
","	","	O
methandrostenolone	NN	D
","	","	O
norethandrolone	NN	D
","	","	O
and	CC	O
similar	JJ	O
compounds	NNS	O
-rrb-	-RRB-	O
enhanced	VBD	O
tendency	NN	O
toward	IN	O
edema	NN	O
.	.	.
		
use	NNP	O
caution	NN	O
when	WRB	O
giving	VBG	O
these	DT	O
drugs	NNS	D
together	RB	O
","	","	O
especially	RB	O
in	IN	O
patients	NNS	O
with	IN	O
hepatic	JJ	O
or	CC	O
cardiac	JJ	O
disease	NN	O
.	.	.
		
vaccines	NNS	G
neurological	JJ	O
complications	NNS	O
and	CC	O
lack	NN	O
of	IN	O
antibody	NN	O
response	NN	O
.	.	.
		
estrogen	NN	G
increased	VBD	O
levels	NNS	O
of	IN	O
corticosteroid-binding	JJ	O
globulin	NN	O
","	","	O
thereby	RB	O
increasing	VBG	O
the	DT	O
bound	VBN	O
-lrb-	-LRB-	O
inactive	JJ	O
-rrb-	-RRB-	O
fraction	NN	O
.	.	.
		
this	DT	O
effect	NN	O
is	VBZ	O
at	IN	O
least	JJS	O
balanced	VBN	O
by	IN	O
decreased	VBN	O
metabolism	NN	O
of	IN	O
corticosteroids	NNS	G
.	.	.
		
when	WRB	O
estrogen	NN	G
therapy	NN	O
is	VBZ	O
initiated	VBN	O
","	","	O
a	DT	O
reduction	NN	O
in	IN	O
corticosteroid	NN	G
dosage	NN	O
may	MD	O
be	VB	O
required	VBN	O
","	","	O
and	CC	O
increased	VBD	O
amounts	NNS	O
may	MD	O
be	VB	O
required	VBN	O
when	WRB	O
estrogen	NN	G
is	VBZ	O
terminated	VBN	O
.	.	.
		
drug/laboratory	JJ	O
test	NN	O
interactions	NNS	O
corticosteroids	NNS	G
may	MD	O
affect	VB	O
the	DT	O
nitrobluetetrazolium	JJ	O
test	NN	O
for	IN	O
bacterial	JJ	O
infection	NN	O
and	CC	O
produce	VBP	O
false-negative	JJ	O
result	NN	O
.	.	.
		
interaction	NN	O
with	IN	O
central	JJ	O
nervous	JJ	O
system	NN	O
depressants	NNS	O
other	JJ	O
than	IN	O
benzodiazepines	NNS	G
has	VBZ	O
not	RB	O
been	VBN	O
specifically	RB	O
studied	VBN	O
.	.	.
		
however	RB	O
","	","	O
no	DT	O
deleterious	JJ	O
interactions	NNS	O
were	VBD	O
seen	VBN	O
when	WRB	O
romazicon	NNP	B
was	VBD	O
administered	VBN	O
after	IN	O
narcotics	NNS	G
","	","	O
inhalational	JJ	O
anesthetics	NNS	G
","	","	O
muscle	NN	O
relaxants	NNS	O
and	CC	O
muscle	NN	O
relaxant	NN	O
antagonists	NNS	O
administered	VBN	O
in	IN	O
conjunction	NN	O
with	IN	O
sedation	NN	O
or	CC	O
anesthesia	NN	D
.	.	.
		
particular	JJ	O
caution	NN	O
is	VBZ	O
necessary	JJ	O
when	WRB	O
using	VBG	O
romazicon	NNP	B
in	IN	O
cases	NNS	O
of	IN	O
mixed	JJ	O
drug	NN	D
overdosage	NN	O
since	IN	O
the	DT	O
toxic	JJ	O
effects	NNS	O
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
convulsions	NNS	O
and	CC	O
cardiac	JJ	O
dysrhythmias	NNS	O
-rrb-	-RRB-	O
of	IN	O
other	JJ	O
drugs	NNS	D
taken	VBN	O
in	IN	O
overdose	NN	O
-lrb-	-LRB-	O
especially	RB	O
cyclic	JJ	O
antidepressants	NNS	G
-rrb-	-RRB-	O
may	MD	O
emerge	VB	O
with	IN	O
the	DT	O
reversal	NN	O
of	IN	O
the	DT	O
benzodiazepine	NN	G
effect	NN	O
by	IN	O
flumazenil	NN	D
.	.	.
		
the	DT	O
use	NN	O
of	IN	O
romazicon	NNP	B
is	VBZ	O
not	RB	O
recommended	VBN	O
in	IN	O
epileptic	JJ	O
patients	NNS	O
who	WP	O
have	VBP	O
been	VBN	O
receiving	VBG	O
benzodiazepine	NN	G
treatment	NN	O
for	IN	O
a	DT	O
prolonged	JJ	O
period	NN	O
.	.	.
		
although	IN	O
romazicon	NN	B
exerts	VBZ	O
a	DT	O
slight	JJ	O
intrinsic	JJ	O
anticonvulsant	JJ	O
effect	NN	O
","	","	O
its	PRP$	O
abrupt	JJ	O
suppression	NN	O
of	IN	O
the	DT	O
protective	JJ	O
effect	NN	O
of	IN	O
a	DT	O
benzodiazepine	NN	G
agonist	NN	O
can	MD	O
give	VB	O
rise	VB	O
to	TO	O
convulsions	NNS	O
in	IN	O
epileptic	JJ	O
patients	NNS	O
.	.	.
		
romazicon	NN	B
blocks	VBZ	O
the	DT	O
central	JJ	O
effects	NNS	O
of	IN	O
benzodiazepines	NNS	G
by	IN	O
competitive	JJ	O
interaction	NN	O
at	IN	O
the	DT	O
receptor	NN	D
level	NN	O
.	.	.
		
the	DT	O
effects	NNS	O
of	IN	O
nonbenzodiazepine	JJ	O
agonists	NNS	O
at	IN	O
benzodiazepine	NN	G
receptors	NNS	O
","	","	O
such	JJ	O
as	IN	O
zopiclone	NN	D
","	","	O
triazolopyridazines	NNS	O
and	CC	O
others	NNS	O
","	","	O
are	VBP	O
also	RB	O
blocked	VBN	O
by	IN	O
romazicon	NN	B
.	.	.
		
the	DT	O
pharmacokinetics	NNS	O
of	IN	O
benzodiazepines	NNS	G
are	VBP	O
unaltered	JJ	O
in	IN	O
the	DT	O
presence	NN	O
of	IN	O
flumazenil	NN	D
and	CC	O
vice	NN	O
versa	RB	O
.	.	.
		
there	EX	O
is	VBZ	O
no	DT	O
pharmacokinetic	JJ	O
interaction	NN	O
between	IN	O
ethanol	NN	D
and	CC	O
flumazenil	NN	D
.	.	.
		
use	NN	O
in	IN	O
ambulatory	JJ	O
patients	NNS	O
the	DT	O
effects	NNS	O
of	IN	O
romazicon	NN	B
may	MD	O
wear	VB	O
off	RP	O
before	IN	O
a	DT	O
long-acting	JJ	O
benzodiazepine	NN	G
is	VBZ	O
completely	RB	O
cleared	VBN	O
from	IN	O
the	DT	O
body	NN	O
.	.	.
		
in	IN	O
general	JJ	O
","	","	O
if	IN	O
a	DT	O
patient	NN	O
shows	VBZ	O
no	DT	O
signs	NNS	O
of	IN	O
sedation	NN	O
within	IN	O
2	CD	O
hours	NNS	O
after	IN	O
a	DT	O
1-mg	JJ	O
dose	NN	O
of	IN	O
flumazenil	NN	D
","	","	O
serious	JJ	O
resedation	NN	O
at	IN	O
a	DT	O
later	JJ	O
time	NN	O
is	VBZ	O
unlikely	JJ	O
.	.	.
		
an	DT	O
adequate	JJ	O
period	NN	O
of	IN	O
observation	NN	O
must	MD	O
be	VB	O
provided	VBN	O
for	IN	O
any	DT	O
patient	NN	O
in	IN	O
whom	WP	O
either	CC	O
long-acting	JJ	O
benzodiazepines	NNS	G
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
diazepam	NN	D
-rrb-	-RRB-	O
or	CC	O
large	JJ	O
doses	NNS	O
of	IN	O
short-acting	JJ	O
benzodiazepines	NNS	G
-lrb-	-LRB-	O
such	JJ	O
as	IN	O
10	CD	O
mg	NN	O
of	IN	O
midazolam	NN	D
-rrb-	-RRB-	O
have	VBP	O
been	VBN	O
used	VBN	O
.	.	.
		
because	IN	O
of	IN	O
the	DT	O
increased	VBN	O
risk	NN	O
of	IN	O
adverse	JJ	O
reactions	NNS	O
in	IN	O
patients	NNS	O
who	WP	O
have	VBP	O
been	VBN	O
taking	VBG	O
benzodiazepines	NNS	G
on	IN	O
a	DT	O
regular	JJ	O
basis	NN	O
","	","	O
it	PRP	O
is	VBZ	O
particularly	RB	O
important	JJ	O
that	IN	O
physicians	NNS	O
query	NN	O
patients	NNS	O
or	CC	O
their	PRP$	O
guardians	NNS	O
carefully	RB	O
about	IN	O
benzodiazepine	NN	G
","	","	O
alcohol	NN	D
and	CC	O
sedative	NN	G
use	VBP	O
as	IN	O
part	NN	O
of	IN	O
the	DT	O
history	NN	O
prior	RB	O
to	TO	O
any	DT	O
procedure	NN	O
in	IN	O
which	WDT	O
the	DT	O
use	NN	O
of	IN	O
romazicon	NNP	B
is	VBZ	O
planned	VBN	O
.	.	.
		
no	DT	O
information	NN	O
available	JJ	O
.	.	.
		
do	VB	O
not	RB	O
take	VB	O
this	DT	O
medicine	NN	O
with	IN	O
thioridizine	NN	O
","	","	O
or	CC	O
within	IN	O
5	CD	O
weeks	NNS	O
of	IN	O
taking	VBG	O
fluoxetine	NN	D
.	.	.
		
talk	NN	O
to	TO	O
your	PRP$	O
doctor	NN	O
if	IN	O
you	PRP	O
are	VBP	O
taking	VBG	O
certain	JJ	O
antibiotics	NNS	G
such	JJ	O
as	IN	O
erythromycin	NN	D
","	","	O
clarithromycin	NN	D
or	CC	O
azithromycin	NN	D
.	.	.
		
this	DT	O
medicine	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
with	IN	O
mao	NN	O
inhibitors	NNS	O
.	.	.
		
caution	NN	O
should	MD	O
be	VB	O
exercised	VBN	O
when	WRB	O
taking	VBG	O
this	DT	O
medicine	NN	O
certain	JJ	O
antibiotics	NNS	G
","	","	O
such	JJ	O
as	IN	O
erythromycin	NN	D
","	","	O
clarithromycin	NN	D
","	","	O
or	CC	O
azithromycin	NN	D
.	.	.
		
this	DT	O
medicine	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
with	IN	O
mao	NN	O
inhibitors	NNS	O
.	.	.
		
if	IN	O
you	PRP	O
think	VBP	O
you	PRP	O
are	VBP	O
taking	VBG	O
an	DT	O
mao	NNP	O
inhibitor	NN	O
talk	NN	O
to	TO	O
your	PRP$	O
doctor	NN	O
or	CC	O
pharmacist	NN	O
.	.	.
		
do	VB	O
not	RB	O
take	VB	O
this	DT	O
medicine	NN	O
with	IN	O
st.	NNP	O
johns	NNP	O
wort	NNP	O
because	IN	O
of	IN	O
the	DT	O
additive	JJ	O
effects	NNS	O
of	IN	O
sertonin	NN	O
.	.	.
		
this	DT	O
medication	NN	O
should	MD	O
not	RB	O
be	VB	O
taken	VBN	O
with	IN	O
mao	NN	O
inhibitors	NNS	O
.	.	.
		
your	PRP$	O
doctor	NN	O
or	CC	O
pharmacist	NN	O
can	MD	O
give	VB	O
you	PRP	O
more	JJR	O
information	NN	O
on	IN	O
mao	NN	O
inhibitors	NNS	O
.	.	.
		
wait	VB	O
5	CD	O
weeks	NNS	O
after	IN	O
stopping	VBG	O
escitalopram	NN	D
before	IN	O
starting	VBG	O
a	DT	O
non-selective	JJ	O
mao	NNP	O
inhibitor	NN	O
.	.	.
		
wait	VB	O
2	CD	O
weeks	NNS	O
after	IN	O
stopping	VBG	O
an	DT	O
mao	NNP	O
inhibitor	NN	O
before	IN	O
starting	VBG	O
escitalopram	NN	D
